⚠️ Current Drug Shortages
The FDA drug-shortage list in one searchable place. See what's in shortage, why, and which NDCs are affected — open any drug for the full detail. Resolved shortages are kept on file too.
Ask about a drug shortage in plain English
Type a brand or generic, or ask a plain-English question — like “Is amoxicillin on backorder?” — and get a clear answer from the FDA drug-shortage list.
Where does this data come from?
Key stats
Biggest shortage impact right now Why?
High supply-risk drugs, ranked by how many patients rely on them (Medicaid prescriptions/yr).
- 1 Ketorolac Tromethamine Injection
- 2 Guanfacine Hydrochloride Tablet, Extended Re...
- 3 Lidocaine Hydrochloride Injection
- 4 Metoprolol Succinate Tablet, Extended Releas...
- 5 Morphine Sulfate Injection
Utilization shown is Medicaid only (CMS State Drug Utilization Data). It has reporting gaps and under-represents drugs used mainly outside Medicaid — treat it as a relative signal, not total U.S. use.
What changed
Between the FDA refresh on Sep 20, 2026 and Sep 21, 2026.
No drugs were added to or cleared from the FDA shortage list between these two refreshes.
Compared against our previously saved copy of the FDA list. “Resolved or cleared” means the FDA no longer lists it as a current shortage.
Newly reported shortages per month
The shortage landscape — tap a tile to filter the list below
Shortage insights — tap to expand
Most-used drugs in shortageby Medicaid Rx/yr, where we have data
Utilization shown is Medicaid only (CMS State Drug Utilization Data). It has reporting gaps and under-represents drugs used mainly outside Medicaid — treat it as a relative signal, not total U.S. use. Counts are annual prescriptions across each drug’s matched NDCs — a proxy for how many patients a shortage touches.
Longest-running active shortageshow long each has dragged on
Measured from the FDA’s first posting date to today. Tap a bar to jump to that drug.
Shortage list — 242 drugs, active first · newest shortages first
Rivastigmine Film, Extended Release View full page →
Key facts about the Rivastigmine Film, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Rivastigmine Film, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Rivastigmine Film, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Rivastigmine extended-release film (the 4.6 mg/24 h patch) is currently on the FDA shortage list. This applies to the 4.6 mg/24 h strength, which is the only strength on this record, and it does not have an available source right now.
The reason listed is that the manufacturer, Mylan Pharmaceuticals, is discontinuing this product. Because it is being discontinued, this supply problem may be permanent rather than temporary. This report reflects only Mylan's filing, so it does not mean every company has stopped making this medicine. The same medicine — rivastigmine 4.6 mg/24 h — is still listed from other makers, including Novartis (Exelon), Sandoz, and Breckenridge.
Here is what I suggest, in order:
- Do not stop, skip, or change your patch on your own. Keep using it as prescribed while you sort out supply.
- Ask your pharmacy whether they can source rivastigmine 4.6 mg/24 h from another maker (such as those listed above). It may not be in local stock, but they can check wholesalers and other manufacturers.
- If your exact patch cannot be found, ask your prescriber or pharmacist about a suitable option for you.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Exelon — RIVASTIGMINE 4.6 mg/24h
- Exelon — RIVASTIGMINE 9.5 mg/24h
- Exelon — RIVASTIGMINE 13.3 mg/24h
- Rivastigmine — RIVASTIGMINE 9.5 mg/24h
- Rivastigmine — RIVASTIGMINE 13.3 mg/24h
- Rivastigmine — RIVASTIGMINE 4.6 mg/24h
- Rivastigmine — RIVASTIGMINE 9.5 mg/24h
- Rivastigmine — RIVASTIGMINE 13.3 mg/24h
- Rivastigmine — RIVASTIGMINE 9.5 mg/24h
- Rivastigmine — RIVASTIGMINE 13.3 mg/24h
- Rivastigmine Transdermal System — RIVASTIGMINE 4.6 mg/24h
- Rivastigmine Transdermal System — RIVASTIGMINE 9.5 mg/24h
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 4.6 mg/24 h Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 800-796-9526 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rivastigmine, Film, Extended Release, 4.6 mg/24 h (NDC 0378-9070-93) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Rivastigmine Film, Extended Release →
View Rivastigmine Film, Extended Release on the FDA drug-shortage database →
Melphalan Hydrochloride Injection View full page →
Key facts about the Melphalan Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Melphalan Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Melphalan Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Melphalan Hydrochloride Injection is currently on the FDA drug-shortage list. This note reflects a report from one manufacturer, Fresenius Kabi USA, so it does not mean the medicine is gone from every source.
The affected product is the injectable kit (NDC 63323-760-20) from Fresenius Kabi. This record does not list any strengths that still have supply from this maker, because the company reports it is discontinuing manufacture of this product. Since this is listed as "to be discontinued," this particular supply may not return, which makes a conversation with your care team the right next step.
The reported reason is simply that this one manufacturer is stopping production. Importantly, the same medicine — melphalan hydrochloride injection kit — is still listed from several other makers, including Avet, Sagent, Dr. Reddy's, BPI Labs, Mylan Institutional, Meitheal, Fosun, Avenacy, and Delcath (Hepzato Kit).
Here is what I suggest:
- Do not stop or change your treatment on your own — this medicine is usually given in a clinical setting under close supervision.
- Ask your pharmacy or treatment center to source the same medicine from another maker on the list above; it may not be in local stock immediately.
- Ask your prescriber or pharmacist about a clinician-chosen option if your product cannot be found.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- All / unspecified Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Melphalan Hydrochloride, Injection, Kit (NDC 63323-760-20) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Melphalan Hydrochloride Injection →
View Melphalan Hydrochloride Injection on the FDA drug-shortage database →
Micafungin Sodium Injection View full page →
Key facts about the Micafungin Sodium Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Micafungin Sodium Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Micafungin Sodium Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Micafungin Sodium Injection is currently on the FDA shortage list, and I want to walk you through what that means for you.
Both strengths on this report — the 10 mg/1 mL and the 20 mg/1 mL — have no available source from the reporting manufacturer right now. This particular record comes from one company, Par Health, USA LLC, which has marked both strengths as being discontinued.
The reason given is a business decision to stop making these two products. Because they are listed as "to be discontinued," this supply problem may be permanent for these specific items from this maker. That said, this report reflects only one manufacturer — other companies still make micafungin, so a lasting solution is very possible with your care team's help.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own. This is an important medicine and any change should be guided by your care team.
- Because these two strengths are being discontinued, talk with your prescriber or pharmacist about next steps soon.
- The same medicine, micafungin, is made by several other companies (for example Hikma, Astellas, Sagent, Fresenius Kabi, Glenmark, Hisun, and Biocon). Your pharmacy may be able to source one of these, though it may not be in local stock.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Micafungin — MICAFUNGIN 50 mg/1
- Micafungin — MICAFUNGIN 100 mg/1
- Mycamine — MICAFUNGIN SODIUM 10 mg/mL
- Micafungin — MICAFUNGIN SODIUM 50 mg/5mL
- Micafungin — MICAFUNGIN SODIUM 100 mg/5mL
- Micafungin — MICAFUNGIN SODIUM 50 mg/1
- Micafungin — MICAFUNGIN SODIUM 100 mg/1
- Micafungin — MICAFUNGIN SODIUM 50 mg/1
- Micafungin — MICAFUNGIN SODIUM 100 mg/1
- Micafungin — MICAFUNGIN 10 mg/mL
- Micafungin — MICAFUNGIN 20 mg/mL
- Micafungin — MICAFUNGIN SODIUM 10 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg/1 mL A business decision was made to discontinue manufacture of the drug.
- 20 mg/1 mL A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Par Health, USA LLC 📞 800-828-9393 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Micafungin Sodium, Injection, 20 mg/1 mL (NDC 42023-230-10) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Micafungin Sodium, Injection, 10 mg/1 mL (NDC 42023-229-10) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Micafungin Sodium Injection →
View Micafungin Sodium Injection on the FDA drug-shortage database →
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution View full page →
Key facts about the Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution may not appear here at all, so this is not a picture of every available option. See the full Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
The combination solution you take — dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, and magnesium chloride (DELFLEX) — is currently on the FDA drug-shortage list. I want to walk you through what this means so you can plan your next steps calmly.
This shortage covers all reported strengths of this product: 18.4 mg/100 mL, 4.25 g/100 mL, 5.08 mg/100 mL, 538 mg/100 mL, and 448 mg/100 mL. None of these currently has an available source. The reason reported is a business decision by the manufacturer to discontinue making the drug, which means this supply problem may be permanent rather than temporary.
Because this product is being discontinued, a conversation with your prescriber is the most important next step. Please do not stop or change how you use this solution on your own.
- Do not skip or adjust your treatment without professional guidance.
- Ask your pharmacy to check wholesalers and other suppliers for any remaining stock.
- Talk with your prescriber or pharmacist soon about a clinician-chosen alternative, since this product is being discontinued.
- A manufacturer contact number is listed on this page for reference; pharmacies usually handle these calls.
This is general, national information and may not match your local pharmacy's stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 18.4 mg/100 mL; 4.25 g/100 mL;... A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Medical Care North America 📞 800-323-5188 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| DELFLEX, Solution, 18.4 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 46163-212-95) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution →
View Dextrose Monohydrate, Sodium Chloride, S... on the FDA drug-shortage database →
Imipenem Anhydrous, Cilastatin, And Relebactam Anhydrous Injection View full page →
Key facts about the Imipenem Anhydrous, Cilastatin, And Relebactam Anhydrous Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Imipenem Anhydrous, Cilastatin, And Relebactam Anhydrous Injection may not appear here at all, so this is not a picture of every available option. See the full Imipenem Anhydrous, Cilastatin, And Relebactam Anhydrous Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
The combination injection imipenem, cilastatin, and relebactam — sold as RECARBRIO — is currently on the FDA shortage list, and the manufacturer has reported it as being discontinued.
The affected product is the 250 mg/100 mL and 500 mg/100 mL combination injection. Based on the data I have, none of these strengths currently show an available source. The manufacturer, Merck Sharp & Dohme LLC, has reported this product is set to be discontinued on or near late September 2026. Because this is a planned discontinuation, the supply problem may be permanent rather than temporary. I do not have any other same-medicine makers listed in my records, so I cannot point you to an alternate source at this time.
This is a medicine given in a clinical setting, so please rely on your care team to manage it. Still, here is how to approach it:
- Do not stop or change this medicine on your own — keep working with your prescriber.
- Ask your pharmacy or care team to check wholesalers and other manufacturers for current stock.
- Because this product is being discontinued, talk with your prescriber about a clinician-chosen alternative that fits your treatment.
A manufacturer contact number is listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match local stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500 mg/100 mL; 500 mg/100 mL;... To be discontinued on or near late September 2026.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Merck Sharp & Dohme LLC 📞 800-672-6372 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02) | — | To be discontinued on or near late September 2026. | — | To Be Discontinued |
Full shortage page: Imipenem Anhydrous, Cilastatin, And Relebactam Anhydrous Injection →
View Imipenem Anhydrous, Cilastatin, And Rele... on the FDA drug-shortage database →
Glycerol Phenylbutyrate Oral Liquid View full page →
Key facts about the Glycerol Phenylbutyrate Oral Liquid shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Glycerol Phenylbutyrate Oral Liquid may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Glycerol Phenylbutyrate Oral Liquid shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Glycerol phenylbutyrate oral liquid is currently on the FDA drug-shortage list. This applies to the medicine you may know by the brand name RAVICTI.
The only strength involved is the 1.1 g/1 mL oral liquid, and right now there is no available source reported for it from the manufacturer that filed this record. The reason given is a discontinuation in the manufacturing of this product. Because this is listed as "to be discontinued," this particular supply problem may be permanent for that manufacturer. Keep in mind, though, this report reflects only the one company that filed it — other makers of the same medicine may still supply it.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — this medicine is important, and any change should be guided by your care team.
- Ask your pharmacy to check with wholesalers and other manufacturers. Several companies — including Teva, Camber, Par, Aurobindo, Lupin, and Novadoz — are listed as making the same 1.1 g/mL liquid, so your pharmacy may be able to source one, though it may not be in local stock.
- If your product cannot be found, talk with your prescriber or pharmacist about the best next step.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Glycerol Phenylbutyrate — GLYCEROL PHENYLBUTYRATE 1.1 g/mL
- Glycerol Phenylbutyrate — GLYCEROL PHENYLBUTYRATE 1.1 g/mL
- Glycerol Phenylbutyrate — GLYCEROL PHENYLBUTYRATE 1.1 g/mL
- Glycerol Phenylbutyrate — GLYCEROL PHENYLBUTYRATE 1.1 g/mL
- Glycerol Phenylbutyrate — GLYCEROL PHENYLBUTYRATE 1.1 g/mL
- Glycerol Phenylbutyrate — GLYCEROL PHENYLBUTYRATE 1.1 g/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1.1 g/1 mL Discontinuation in the manufacturing of the drug product
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amgen Inc. 📞 800-772-6436 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-07) | — | Discontinuation in the manufacturing of the drug product | — | To Be Discontinued |
| RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-06) | — | Discontinuation in the manufacturing of the drug product | — | To Be Discontinued |
Full shortage page: Glycerol Phenylbutyrate Oral Liquid →
View Glycerol Phenylbutyrate Oral Liquid on the FDA drug-shortage database →
Insulin Glargine-Aglr Injection View full page →
Key facts about the Insulin Glargine-Aglr Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Insulin Glargine-Aglr Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Insulin Glargine-Aglr Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Insulin glargine-aglr injection (the brand Rezvoglar) is currently on the FDA shortage list.
The affected product is the 100 [iU]/1 mL strength. Right now, there is no available source reported for this strength from the manufacturer that filed this record. The manufacturer, Eli Lilly and Co., has reported that this is a planned discontinuation rather than a temporary supply problem: a business decision was made to stop making it, and distribution is projected to end in June 2027. Because this may be a permanent change, planning ahead with your care team is the right next step.
Please keep taking your insulin exactly as prescribed. Do not stop, skip, or change doses on your own. Here are a few steps to consider:
- Talk with your prescriber or pharmacist soon about a longer-term plan, since this product is being discontinued.
- Ask your pharmacy whether the same medicine is available from another maker — our records show Rezvoglar Kwikpen (insulin glargine 100 [iU]/mL) from A-S Medication Solutions, though it may not be in local stock.
- If your exact product cannot be found, ask about a clinician-chosen alternative.
The manufacturer contact number is listed on this page for reference; pharmacies usually make these calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 [iU]/1 mL A business decision was made to discontinue manufacture of the drug. Distribution projecte...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05) | — | A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance. | — | To Be Discontinued |
Full shortage page: Insulin Glargine-Aglr Injection →
View Insulin Glargine-Aglr Injection on the FDA drug-shortage database →
Insulin Lispro Protamine And Insulin Lispro Injection View full page →
Key facts about the Insulin Lispro Protamine And Insulin Lispro Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Insulin Lispro Protamine And Insulin Lispro Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Insulin Lispro Protamine And Insulin Lispro Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Insulin lispro protamine and insulin lispro injection (the mix product) is currently on the FDA shortage list. I want to walk you through what this means so you can plan calmly.
The affected strength is 100 units/mL, and right now this strength has no available source reported. The reason is not a manufacturing problem — the maker, Eli Lilly, has made a business decision to discontinue this product. Distribution is projected to end in June 2027, so supply may still be available for a while but is expected to stop over time. Because this is a discontinuation, this supply change is likely permanent, which makes a conversation with your prescriber the right next step.
Here is what I suggest, in order:
- Do not stop, skip, or change your insulin doses on your own — changes to insulin need a clinician's guidance.
- While supply lasts, ask your pharmacy to check wholesalers and order what they can find.
- The same medicine (Humalog Mix 75/25, 100 units/mL) is still listed from Eli Lilly, so your pharmacy may be able to source it, though it may not be in local stock.
- Ask your prescriber or pharmacist about a suitable alternative before your current supply runs out.
A manufacturer contact number is listed on this page for reference; pharmacies usually handle these calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 [iU]/1 mL A business decision was made to discontinue manufacture of the drug. Distribution projecte...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05) | — | A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance. | — | To Be Discontinued |
Full shortage page: Insulin Lispro Protamine And Insulin Lispro Injection →
View Insulin Lispro Protamine And Insulin Lis... on the FDA drug-shortage database →
Medroxyprogesterone Acetate Tablet View full page →
Key facts about the Medroxyprogesterone Acetate Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Medroxyprogesterone Acetate Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Medroxyprogesterone Acetate Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Medroxyprogesterone acetate tablets are currently listed on the FDA drug-shortage list. The record for this listing comes from Pfizer, whose brand product (Provera) in both the 2.5 mg and 10 mg strengths is being discontinued. Neither of these two strengths has an available source from Pfizer at this time.
The reported reason is that Pfizer is stopping manufacture of these tablets. Withdrawal from sale is expected around September 2026 for the 10 mg and early October 2026 for the 2.5 mg. Because this is a planned discontinuation, this particular supply may not return. It's important to know that this report covers only Pfizer — the same medicine is still made by other companies, so the ingredient itself is not gone from the market.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy whether they can source medroxyprogesterone acetate in your strength from another maker — the same medicine is listed from companies such as Teva and Mylan (including 2.5 mg and 10 mg), though it may not be in local stock.
- If your exact tablet can't be found, ask your prescriber or pharmacist about options, such as a different strength or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually makes these calls. This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Provera — MEDROXYPROGESTERONE ACETATE 5 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 10 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 2.5 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 5 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 10 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 2.5 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 5 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 10 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 2.5 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 10 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 5 mg/1
- Medroxyprogesterone Acetate — MEDROXYPROGESTERONE ACETATE 10 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2.5 mg Discontinuation of the manufacture of the drug; Withdrawal from sale expected early Octobe...
- 10 mg Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 20...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| PROVERA, Tablet, 10 mg (NDC 0009-0051-01) | — | Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026. | — | To Be Discontinued |
| PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01) | — | Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026. | — | To Be Discontinued |
Full shortage page: Medroxyprogesterone Acetate Tablet →
View Medroxyprogesterone Acetate Tablet on the FDA drug-shortage database →
Metoprolol Succinate Tablet, Extended Release View full page →
Key facts about the Metoprolol Succinate Tablet, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Metoprolol Succinate Tablet, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Metoprolol Succinate Tablet, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Metoprolol succinate extended-release tablets are currently listed on the FDA drug-shortage list. This note reflects national, manufacturer-reported data, so it may not match what your local pharmacy actually has on its shelves.
The shortage record here comes from one manufacturer, Teva, who has reported all four strengths — 25 mg, 50 mg, 100 mg, and 200 mg — with no available source from them right now. Teva lists these tablets as "to be discontinued," based on a business decision. Because this is a discontinuation rather than a temporary delay, Teva's supply problem may be permanent. Please keep in mind, though, that this record covers only Teva; other companies still make this same medicine.
That last point matters, so here is how to move forward:
- Do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed.
- Ask your pharmacy to check wholesalers and other manufacturers; the same medicine, metoprolol succinate ER, is also listed from Major Pharmaceuticals, Cranbury, Camber, and Epic (depending on strength). It may not be in local stock, but your pharmacy may be able to order it.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Metoprolol Succinate — METOPROLOL SUCCINATE 25 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 50 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 100 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 25 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 50 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 100 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 200 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 25 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 50 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 100 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 200 mg/1
- Metoprolol Succinate — METOPROLOL SUCCINATE 25 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 25 mg A business decision was made to discontinue manufacture of the drug.
- 100 mg A business decision was made to discontinue manufacture of the drug.
- 50 mg A business decision was made to discontinue manufacture of the drug.
- 200 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Metoprolol Succinate, Tablet, Extended Release, 200 mg (NDC 45963-678-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-96) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-96) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-96) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Metoprolol Succinate Tablet, Extended Release →
View Metoprolol Succinate Tablet, Extended Re... on the FDA drug-shortage database →
Palovarotene Capsule View full page →
Key facts about the Palovarotene Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Palovarotene Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Palovarotene Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Palovarotene capsules (brand name Sohonos) are currently on the FDA shortage list, and I want to walk you through what this means.
The 2.5 mg strength is the one affected here, and it has no available source right now. The manufacturer, Ipsen Biopharmaceuticals, has reported this as a discontinuation — meaning they are stopping production of the 2.5 mg capsule. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, so a conversation with your prescriber is the right next step.
I do want to note that the same medicine, Sohonos, is still listed in other strengths (1 mg, 1.5 mg, 5 mg, and 10 mg). This matters because your care team may be able to use a different strength to reach your prescribed dose.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your prescriber or pharmacist about options — for example, combining other available Sohonos strengths to make up your usual dose, or another clinician-chosen plan.
- Your pharmacy can check wholesalers and confirm what is currently in stock.
Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls.
This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2.5 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Ipsen Biopharmaceuticals, Inc. 📞 (855)-463-5127 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| SOHONOS, Capsule, 2.5 mg (NDC 15054-0025-1) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Palovarotene Capsule →
View Palovarotene Capsule on the FDA drug-shortage database →
Potassium Chloride, Sodium Chloride, Calcium Chloride, And Magnesium Chloride Injection, Solution View full page →
Key facts about the Potassium Chloride, Sodium Chloride, Calcium Chloride, And Magnesium Chloride Injection, Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Potassium Chloride, Sodium Chloride, Calcium Chloride, And Magnesium Chloride Injection, Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Potassium Chloride, Sodium Chloride, Calcium Chloride, And Magnesium Chloride Injection, Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
The combination cardioplegic solution containing potassium chloride, sodium chloride, calcium chloride, and magnesium chloride injection is currently on the FDA shortage list. I want to walk you through what this means so you know your options.
The affected product comes as a single combined strength (potassium chloride 119.3 mg/100 mL, sodium chloride 643 mg/100 mL, calcium chloride 17.6 mg/100 mL, and magnesium chloride 325.3 mg/100 mL). Right now, this strength has no available source reported.
The reason listed is that the manufacturer, Fresenius Kabi USA, is discontinuing production. Because the status is to be discontinued, this supply problem may be permanent, so a conversation with your prescriber or pharmacist is the right next step.
Here is what I suggest:
- Do not stop, skip, or change how this is used on your own — talk with your prescriber or pharmacist first.
- Ask your pharmacy to check wholesalers and other manufacturers; a same-medicine version (Plegisol, from Hospira) may be available, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about a suitable alternative.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 17.6 mg/100 mL; 325.3 mg/100 m... Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cardioplegic Solution, Injection, Solution, 17.6 mg/100 mL; 325.3 mg/100 mL; 119.3 mg/100 mL; 643 mg/100 mL (NDC 65219-258-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Potassium Chloride, Sodium Chloride, Calcium Chloride, And Magnesium Chloride Injection, Solution →
View Potassium Chloride, Sodium Chloride, Cal... on the FDA drug-shortage database →
Pentostatin Injection View full page →
Key facts about the Pentostatin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Pentostatin Injection may not appear here at all, so this is not a picture of every available option. See the full Pentostatin Injection shortage page → for the still-marketed options we could find.
- Other
Do you take this medicine? What Should I Do?!
Pentostatin injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
There is only one strength involved here, the 10 mg single-dose vial, and it is the strength that is affected. Right now that strength has no reported available source from the manufacturer on this record. The reason given is listed simply as "Other," with the maker also noting manufacturing delays. The manufacturer's timeline points to a next delivery in the second quarter of 2027 and an estimated recovery in the third quarter of 2027, so this may take some time to resolve.
Please keep in mind this report reflects only the manufacturer that filed it, and it may not match what your own pharmacy or treatment center actually has in stock.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own. Pentostatin is given as part of a care plan, so any change should come from your care team.
- Ask your pharmacy or infusion center to check with wholesalers and other suppliers for the 10 mg vial.
- Because the same medicine isn't listed from another maker in our records, talk with your prescriber about how to manage your treatment schedule if the vial cannot be found.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg Next delivery: Q2 2027; Estimated recovery: Q3 2027; Shortage per manufacturer: manufactur...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01) | Unavailable | Next delivery: Q2 2027; Estimated recovery: Q3 2027; Shortage per manufacturer: manufacturing delays | Other | Current |
Full shortage page: Pentostatin Injection →
View Pentostatin Injection on the FDA drug-shortage database →
Mesalamine Capsule, Extended Release View full page →
Key facts about the Mesalamine Capsule, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Mesalamine Capsule, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Mesalamine Capsule, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Mesalamine Extended Release Capsules are currently on the FDA drug-shortage list, and the record shows this product is marked "To Be Discontinued." I want to walk you through what that means so you can plan ahead calmly.
Right now, none of the three strengths on this record — .375 g, 250 mg, and 500 mg — have an available source reported from the two manufacturers who filed. The 250 mg and 500 mg strengths (Pentasa, from Takeda) are anticipated to remain available until December 31, 2027, while the .375 g strength (from Mylan) is listed as a discontinuation of manufacture. Because this involves planned discontinuation, the supply issue for these specific products may be lasting rather than temporary.
Please keep in mind this is national, manufacturer-reported data and may not match your local pharmacy's actual stock. Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other makers for your strength — supply can vary locally.
- The same medicine (mesalamine extended-release capsules) is listed from other makers, including Teva, Upsher-Smith, Aurobindo, Alembic, Sun, Ascend, and Salix (Apriso); your pharmacy may be able to source one, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Mesalamine — MESALAMINE 400 mg/1
- Mesalamine — MESALAMINE 375 mg/1
- Mesalamine — MESALAMINE .375 g/1
- Mesalamine — MESALAMINE .375 g/1
- Mesalamine — MESALAMINE .375 g/1
- Mesalamine — MESALAMINE .375 g/1
- Mesalamine — MESALAMINE 400 mg/1
- Mesalamine — MESALAMINE .375 g/1
- Mesalamine — MESALAMINE .375 g/1
- Mesalamine — MESALAMINE 500 mg/1
- Apriso — MESALAMINE 375 mg/1
- Mesalamine — MESALAMINE .375 g/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .375 g Discontinuation of the manufacture of the drug
- 250 mg Product is anticipated to be available until December 31, 2027
- 500 mg Product is anticipated to be available until December 31, 2027
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 800-796-9526 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Mesalamine, Capsule, Extended Release, .375 g (NDC 0378-1375-78) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Takeda Pharmaceuticals USA Inc. 📞 877 825 3327 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Pentasa, Capsule, Extended Release, 500 mg (NDC 54092-191-12) | — | Product is anticipated to be available until December 31, 2027 | — | To Be Discontinued |
| Pentasa, Capsule, Extended Release, 250 mg (NDC 54092-189-81) | — | Product is anticipated to be available until December 31, 2027 | — | To Be Discontinued |
Full shortage page: Mesalamine Capsule, Extended Release →
View Mesalamine Capsule, Extended Release on the FDA drug-shortage database →
Disopyramide Phosphate Capsule, Extended Release View full page →
Key facts about the Disopyramide Phosphate Capsule, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Disopyramide Phosphate Capsule, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Disopyramide Phosphate Capsule, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Disopyramide phosphate extended-release capsules (the brand Norpace CR) are currently on the FDA shortage list, so I want to walk you through what this means for you.
Both strengths of the extended-release capsule are affected. The 100 mg and 150 mg extended-release capsules have no available source right now, and neither strength has a manufacturer reporting supply. The reason listed is that the manufacturer, Pfizer, is discontinuing production. Because this is a planned discontinuation rather than a temporary delay, this supply problem for the extended-release form may be permanent, so a conversation with your prescriber is the right next step.
Please keep in mind this is national, manufacturer-reported information and may not match what your local pharmacy actually has in stock.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check with wholesalers and other makers — the same medicine, disopyramide phosphate, is also made in capsule form by Teva, Mayne, Mylan, and Dr. Reddy's, so your pharmacy may be able to source one of those, though it may not be in local stock.
- Ask your prescriber or pharmacist about the best option for you, since the extended-release version is being discontinued.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Norpace — DISOPYRAMIDE PHOSPHATE 100 mg/1
- Norpace — DISOPYRAMIDE PHOSPHATE 150 mg/1
- Disopyramide Phosphate — DISOPYRAMIDE PHOSPHATE 100 mg/1
- Disopyramide Phosphate — DISOPYRAMIDE PHOSPHATE 150 mg/1
- Disopyramide Phosphate — DISOPYRAMIDE PHOSPHATE 100 mg/1
- Disopyramide Phosphate — DISOPYRAMIDE PHOSPHATE 100 mg/1
- Disopyramide Phosphate — DISOPYRAMIDE PHOSPHATE 150 mg/1
- Disopyramide Phosphate — DISOPYRAMIDE PHOSPHATE 150 mg/1
- Disopyramide Phosphate — DISOPYRAMIDE PHOSPHATE 100 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg Discontinuation of the manufacture of the drug
- 150 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Norpace CR, Capsule, Extended Release, 150 mg (NDC 0025-2742-31) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Norpace CR, Capsule, Extended Release, 100 mg (NDC 0025-2732-31) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Disopyramide Phosphate Capsule, Extended Release →
View Disopyramide Phosphate Capsule, Extended... on the FDA drug-shortage database →
Fulvestrant Injection View full page →
Key facts about the Fulvestrant Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Fulvestrant Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Fulvestrant Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Fulvestrant injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The affected strength is the 250 mg per 5 mL injection. Right now that strength has no available source from the manufacturer on this record. The reason reported is that this maker, Fresenius Kabi USA, is discontinuing production of the drug. Because this is listed as a discontinuation rather than a temporary delay, this particular supply may not return. That said, this report reflects only the one manufacturer who filed it — other companies still make the same medicine, so it is not gone from the market everywhere.
Here is how I would approach it:
- Do not stop, skip, or change your doses on your own. Keep your current schedule while your supply is sorted out.
- Ask your pharmacy to check wholesalers and other manufacturers. The same medicine, fulvestrant injection, is made by several other companies, including some that supply the same 250 mg/5 mL strength. Your pharmacy may be able to source one of these, though it may not be in local stock.
- Because this product is being discontinued, talk with your prescriber or pharmacist soon about a suitable next step.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Fulvestrant — FULVESTRANT 50 mg/mL
- Faslodex — FULVESTRANT 50 mg/mL
- Fulvestrant — FULVESTRANT 50 mg/mL
- Fulvestrant — FULVESTRANT 50 mg/mL
- Fulvestrant — FULVESTRANT 250 mg/5mL
- Fulvestrant — FULVESTRANT 50 mg/mL
- Fulvestrant — FULVESTRANT 50 mg/mL
- Fulvestrant — FULVESTRANT 50 mg/mL
- Fulvestrant — FULVESTRANT 250 mg/5mL
- Fulvestrant — FULVESTRANT 250 mg/5mL
- Fulvestrant — FULVESTRANT 50 mg/mL
- Fulvestrant — FULVESTRANT 50 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 250 mg per 5mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Fulvestrant, Injection, 250 mg per 5mL (NDC 63323-715-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Fulvestrant Injection →
View Fulvestrant Injection on the FDA drug-shortage database →
Diclofenac Sodium Tablet, Delayed Release View full page →
Key facts about the Diclofenac Sodium Tablet, Delayed Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Diclofenac Sodium Tablet, Delayed Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Diclofenac Sodium Tablet, Delayed Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Diclofenac Sodium delayed-release tablets are currently on the FDA shortage list, and I want to walk you through what this means for you.
Both the 50 mg and 75 mg strengths are affected, and neither has an available source right now from the manufacturer on this record. The reason reported is a business decision by Teva Pharmaceuticals to discontinue making the drug. Because this is a discontinuation rather than a temporary delay, this particular supply may not return. That said, this report reflects only one manufacturer — other companies may still make the same medicine.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own. Keep taking your medicine as prescribed.
- Because your exact strength shows no supply from this maker, this same medicine may still be available from another company. Both 50 mg and 75 mg diclofenac sodium delayed-release tablets are listed from makers such as Rising Pharma, AvKARE, and Golden State Medical Supply. Your pharmacy may be able to source one of these, though it may not be in local stock.
- Since this is a discontinuation, please speak with your prescriber or pharmacist about your options.
- For reference, the manufacturer's phone number is listed on this page, though pharmacies usually handle those calls.
This is national, manufacturer-reported data and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Diclofenac Sodium — DICLOFENAC SODIUM 75 mg/1
- Diclofenac Sodium — DICLOFENAC SODIUM 50 mg/1
- Diclofenac Sodium — DICLOFENAC SODIUM 25 mg/1
- Diclofenac Sodium — DICLOFENAC SODIUM 50 mg/1
- Diclofenac Sodium — DICLOFENAC SODIUM 75 mg/1
- Diclofenac Sodium — DICLOFENAC SODIUM 100 mg/1
- Diclofenac Sodium — DICLOFENAC SODIUM 50 mg/1
- Diclofenac Sodium — DICLOFENAC SODIUM 50 mg/1
- Diclofenac Sodium Delayed Release — DICLOFENAC SODIUM 75 mg/1
- Diclofenac Sodium — DICLOFENAC SODIUM 100 mg/1
- Diclofenac Sodium Delayed Release — DICLOFENAC SODIUM 25 mg/1
- Diclofenac Sodium Delayed Release — DICLOFENAC SODIUM 50 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg A business decision was made to discontinue manufacture of the drug.
- 75 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-06) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-96) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-06) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-96) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Diclofenac Sodium Tablet, Delayed Release →
View Diclofenac Sodium Tablet, Delayed Releas... on the FDA drug-shortage database →
Polyethylene Glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, And Potassium Chloride Oral Solution View full page →
Key facts about the Polyethylene Glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, And Potassium Chloride Oral Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Polyethylene Glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, And Potassium Chloride Oral Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Polyethylene Glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, And Potassium Chloride Oral Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Plenvu, the bowel-prep oral solution, is currently on the FDA shortage list. This report comes from Salix Pharmaceuticals, and the record shows the product is being discontinued.
The reason is straightforward: the manufacturer made a business decision to stop making this particular product. Because this is a discontinuation rather than a temporary delay, the supply problem for Salix's Plenvu kit may be permanent. That said, this record reflects only one manufacturer — the same type of bowel-prep kit is still listed from other makers, so your pharmacy may be able to find an equivalent option.
Here is what I suggest, in order:
- Do not stop, skip, or change how you use your prep without checking with your prescriber or pharmacist first.
- Ask your pharmacy to check wholesalers and other manufacturers — this same medicine (the same ingredients, kit, and route) is listed from Teva, Oceanside, and Salix under other product names, though it may not be in local stock.
- If your exact kit cannot be found, ask your prescriber or pharmacist about a suitable alternative prep.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- All / unspecified A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Salix Pharmaceuticals, a division of Bausch Health US, LLC 📞 800-321-4576 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Plenvu, Oral Solution, KIT (NDC 65649-400-01) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Polyethylene Glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, And Potassium Chloride Oral Solution →
View Polyethylene Glycol 3350, Sodium Ascorba... on the FDA drug-shortage database →
Glyburide Tablet View full page →
Key facts about the Glyburide Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Glyburide Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Glyburide Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Glyburide tablets are currently on the FDA drug-shortage list, so I want to walk you through what this means for you.
This shortage report comes from Sanofi-Aventis, the maker of the brand DiaBeta. It affects all three strengths they make — 1.25 mg, 2.5 mg, and 5 mg — and none of these currently have an available source from this manufacturer. The reason given is a business decision to discontinue making the product. Because this is listed as a discontinuation rather than a temporary delay, this particular supply may not be coming back, which makes a conversation with your prescriber or pharmacist the right next step.
The important thing to know is that this report reflects only one manufacturer. Glyburide is the same medicine no matter who makes it, and other companies are still listed as making all three strengths.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine (glyburide) is reported from makers such as Teva, Avet, and Chartwell, though it may not be in local stock right away.
- If your strength cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Glyburide — GLYBURIDE 1.25 mg/1
- Glyburide — GLYBURIDE 2.5 mg/1
- Glyburide — GLYBURIDE 5 mg/1
- Glyburide — GLYBURIDE 5 mg/1
- Glyburide — GLYBURIDE 2.5 mg/1
- Glyburide — GLYBURIDE 1.25 mg/1
- Glyburide — GLYBURIDE 2.5 mg/1
- Glyburide — GLYBURIDE 5 mg/1
- Glyburide — GLYBURIDE 2.5 mg/1
- Glyburide — GLYBURIDE 5 mg/1
- Glyburide — GLYBURIDE 1.25 mg/1
- Glyburide — GLYBURIDE 2.5 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg A business decision was made to discontinue manufacture of the drug.
- 1.25 mg A business decision was made to discontinue manufacture of the drug.
- 2.5 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Sanofi-Aventis U.S. LLC 📞 800-633-1610 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Diabeta, Tablet, 5 mg (NDC 0093-9364-01) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Diabeta, Tablet, 5 mg (NDC 0093-9364-10) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Glyburide Tablet →
Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution View full page →
Key facts about the Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Your peritoneal dialysis solution — the Dianeal family of Dextrose/Sodium Chloride/Sodium Lactate solutions used for at-home dialysis — is currently on the FDA shortage list. I know this fluid is part of your daily routine, so let me walk you through what the reports show and what to do next.
All of the strengths on this record are listed with no available source right now. This includes the various Dianeal Low Calcium and Dianeal PD-2 concentrations (such as the 1.5 g, 2.5 g, and 4.25 g dextrose versions). The reason given is a business decision by the manufacturer to discontinue making these products. Because this is a planned discontinuation, this supply problem may be permanent — which makes an early conversation with your care team especially important.
Please take these steps:
- Do not stop, skip, or change your dialysis fluid or schedule on your own.
- Ask your pharmacy or dialysis supplier to check wholesalers and other manufacturers for your exact strength — local stock can differ from national reports.
- Talk with your prescriber or dialysis team soon about a plan, such as a clinician-chosen alternative solution suited to your treatment.
Manufacturer contact information is listed on this page for reference, though pharmacies and suppliers usually make these calls for you. This is general information and may not match your local supply.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 1.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Dianeal Pd-2 With Dextrose — DEXTROSE MONOHYDRATE 1.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Dianeal Pd-2 With Dextrose — DEXTROSE MONOHYDRATE 2.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Dianeal Pd-2 With Dextrose — DEXTROSE MONOHYDRATE 4.25 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 2.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 4.25 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 1.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 2.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 4.25 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 1.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 2.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Dianeal Low Calcium With Dextrose — DEXTROSE MONOHYDRATE 4.25 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 18.3 mg/100 mL; 2.5 g/100 mL;... A business decision was made to discontinue manufacture of the drug.
- 25.7 mg/100 mL; 2.5 g/100 mL;... A business decision was made to discontinue manufacture of the drug.
- 25.7 mg/100 mL; 1.5 g/100 mL;... A business decision was made to discontinue manufacture of the drug.
- 18.3 mg/100 mL; 4.25 g/100 mL;... A business decision was made to discontinue manufacture of the drug.
- 25.7 mg/100 mL; 4.25 g/100 mL;... A business decision was made to discontinue manufacture of the drug.
- 18.3 mg/100 mL; 1.5 g/100 mL;... A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Vantive US Healthcare LLC 📞 800-284-4060 18 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0409-07) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0459-05) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0429-52) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0424-51) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-52) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0415-06) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0415-07) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0411-06) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0430-51) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0429-53) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-52) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0433-51) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0413-07) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0413-06) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0411-07) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-53) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-53) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0457-05) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution →
View Calcium Chloride; Dextrose; Magnesium Ch... on the FDA drug-shortage database →
Doxycycline Hyclate Tablet, Delayed Release View full page →
Key facts about the Doxycycline Hyclate Tablet, Delayed Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Doxycycline Hyclate Tablet, Delayed Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Doxycycline Hyclate Tablet, Delayed Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Doxycycline hyclate delayed-release tablets are currently on the FDA shortage list. I want to walk you through what this means and the practical steps you can take.
Both strengths on this record — the 50 mg and the 200 mg delayed-release tablets — have no available source reported right now. The reason listed for both is that the manufacturer (Teva) is discontinuing production. Because this is a discontinuation rather than a temporary supply gap, this particular product may not return, so a conversation with your prescriber is the right next step.
It's worth knowing that this report reflects only the manufacturer who filed it. The same medicine, doxycycline hyclate delayed-release, is still on the market from another maker (Heritage/Avet) in several strengths, including a 200 mg delayed-release tablet. Your pharmacy may be able to source one of these, though it may not be in local stock.
Here is what I suggest:
- Do not stop or change your dose on your own — keep taking it as prescribed while you sort this out.
- Ask your pharmacy to check wholesalers and other manufacturers for the same medicine.
- Ask your prescriber or pharmacist about a clinician-chosen option or a strength that matches your dose.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate Delayed Release — DOXYCYCLINE HYCLATE 75 mg/1
- Doxycycline Hyclate Delayed Release — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate Delayed Release — DOXYCYCLINE HYCLATE 150 mg/1
- Doxycycline Hyclate Delayed Release — DOXYCYCLINE HYCLATE 200 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 75 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 150 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline — DOXYCYCLINE HYCLATE 100 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg Discontinuation of the manufacture of the drug
- 200 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Doxycycline Hyclate, Tablet, Delayed Release, 200 mg (NDC 0591-4575-60) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Doxycycline Hyclate, Tablet, Delayed Release, 50 mg (NDC 0591-4550-22) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Doxycycline Hyclate Tablet, Delayed Release →
View Doxycycline Hyclate Tablet, Delayed Rele... on the FDA drug-shortage database →
Glycopyrrolate Injection View full page →
Key facts about the Glycopyrrolate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Glycopyrrolate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Glycopyrrolate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Glycopyrrolate Injection is currently listed on the FDA drug-shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The manufacturer that filed this report, Fresenius Kabi USA, is discontinuing all of its listed strengths: 0.2 mg/1 mL, 0.4 mg per 2 mL, and 1 mg per 5 mL. None of these currently have an available source from that maker, and the reason given is that they are ending production. Because this is a discontinuation rather than a temporary delay, this particular supply may be permanent. That said, this report reflects only one manufacturer — other companies still make the same medicine, so it is not gone from the market entirely.
Please do not stop, skip, or change your doses on your own. Here is how to move forward:
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine (same ingredient, form, and route) is listed as available from makers such as Hikma, American Regent, Sandoz, Accord, Sagent, and others, though it may not be in local stock right away.
- If your exact strength cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Glycopyrrolate — GLYCOPYRROLATE .2 mg/mL
- Glycopyrrolate — GLYCOPYRROLATE .2 mg/mL
- Glycopyrrolate — GLYCOPYRROLATE .2 mg/mL
- Glycopyrrolate — GLYCOPYRROLATE .4 mg/2mL
- Glycopyrrolate — GLYCOPYRROLATE 1 mg/5mL
- Glycopyrrolate — GLYCOPYRROLATE 4 mg/20mL
- Glycopyrrolate — GLYCOPYRROLATE .2 mg/mL
- Glycopyrrolate — GLYCOPYRROLATE .2 mg/mL
- Glycopyrrolate — GLYCOPYRROLATE .2 mg/mL
- Glycopyrrolate — GLYCOPYRROLATE .4 mg/2mL
- Glycopyrrolate — GLYCOPYRROLATE .2 mg/mL
- Glycopyrrolate — GLYCOPYRROLATE .2 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .2 mg/1 mL Discontinuation of the manufacture of the drug
- 1 mg per 5 mL Discontinuation of the manufacture of the drug
- 0.4 mg per 2 mL Discontinuation of the manufacture of the drug
- 0.2 mg per 1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Glycopyrrolate, Injection, 0.2 mg per 1 mL (NDC 65219-801-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Glycopyrrolate, Injection, 0.4 mg per 2 mL (NDC 63323-578-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Glycopyrrolate, Injection, 1 mg per 5 mL (NDC 63323-578-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Glycopyrrolate, Injection, .2 mg/1 mL (NDC 63323-578-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Glycopyrrolate Injection →
View Glycopyrrolate Injection on the FDA drug-shortage database →
Fluticasone Propionate And Salmeterol Xinafoate Aerosol, Metered View full page →
Key facts about the Fluticasone Propionate And Salmeterol Xinafoate Aerosol, Metered shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Fluticasone Propionate And Salmeterol Xinafoate Aerosol, Metered may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Fluticasone Propionate And Salmeterol Xinafoate Aerosol, Metered shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Advair HFA (fluticasone propionate and salmeterol) inhalers are currently listed on the FDA drug-shortage list. This affects the metered aerosol inhaler you may know by the numbers on the box.
All three strengths reported here have no available source right now: 45/21 mcg, 115/21 mcg, and 230/21 mcg. There are no strengths from this maker with reported supply at this time.
The reason listed is that GlaxoSmithKline plans to stop distributing these specific presentations around December 31, 2026, so this is described as a planned discontinuation rather than a temporary manufacturing delay. GSK does note that the 120-dose presentation of this product is still expected to be available. Because this may become a permanent change, a conversation with your prescriber is the right next step.
Here is what I suggest:
- Do not stop, skip, or change how you use your inhaler on your own — keep using it as prescribed.
- Ask your pharmacy to check wholesalers and other suppliers; the same medicine may still be available from another maker (for example, Prasco Laboratories or A-S Medication Solutions list the same strengths), though it may not be in local stock.
- If your exact inhaler cannot be found, ask your prescriber or pharmacist about a suitable alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Advair Hfa — FLUTICASONE PROPIONATE 45 ug/1; SALMETEROL XINAFOATE 21 ug/1
- Advair Hfa — FLUTICASONE PROPIONATE 115 ug/1; SALMETEROL XINAFOATE 21 ug/1
- Advair Hfa — FLUTICASONE PROPIONATE 230 ug/1; SALMETEROL XINAFOATE 21 ug/1
- Advair Hfa — FLUTICASONE PROPIONATE 115 ug/1; SALMETEROL XINAFOATE 21 ug/1
- Fluticasone Propionate And Salmeterol Hfa — FLUTICASONE PROPIONATE 45 ug/1; SALMETEROL XINAFOATE 21 ug/1
- Fluticasone Propionate And Salmeterol Hfa — FLUTICASONE PROPIONATE 115 ug/1; SALMETEROL XINAFOATE 21 ug/1
- Fluticasone Propionate And Salmeterol Hfa — FLUTICASONE PROPIONATE 230 ug/1; SALMETEROL XINAFOATE 21 ug/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 115 ug; 21 ug The anticipated date that GSK will cease distribution of the presentation is approximately...
- 45 ug; 21 ug The anticipated date that GSK will cease distribution of the presentation is approximately...
- 230 ug; 21 ug The anticipated date that GSK will cease distribution of the presentation is approximately...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: GlaxoSmithKline 📞 888-825-5249 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22) | — | The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available. | — | To Be Discontinued |
| Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22) | — | The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available. | — | To Be Discontinued |
| Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22) | — | The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available. | — | To Be Discontinued |
Full shortage page: Fluticasone Propionate And Salmeterol Xinafoate Aerosol, Metered →
View Fluticasone Propionate And Salmeterol Xi... on the FDA drug-shortage database →
Aspirin Suppository View full page →
Key facts about the Aspirin Suppository shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Aspirin Suppository may not appear here at all, so this is not a picture of every available option. See the full Aspirin Suppository shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Aspirin suppositories, 300 mg, are currently listed on the FDA drug-shortage report. I want to walk you through what this means so you can plan your next steps calmly.
The only strength on this record is the 300 mg suppository, and it does not have an available source right now. The manufacturer that filed this report, Padagis US LLC, lists the reason as a discontinuation of the manufacture of the drug. Because this is marked "to be discontinued," this supply problem may be permanent rather than temporary. No other maker is listed on this record, so I don't have a same-medicine option to point you to here.
Please keep in mind this information comes from national, manufacturer-reported data and may not match what any single pharmacy has on its shelves.
Here is what I suggest, in order:
- Do not stop, skip, or change how you use this medicine on your own.
- Because this strength is being discontinued, ask your prescriber or pharmacist about options — for example a clinician-chosen alternative that fits your needs.
- Your pharmacy can also check wholesalers and other manufacturers to see whether any supply remains.
- The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls.
A short conversation with your prescriber is the right next step.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 300 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 (800) 775-2054 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Aspirin, Suppository, 300 mg (NDC 0574-7034-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Aspirin Suppository →
View Aspirin Suppository on the FDA drug-shortage database →
Belladonna And Opium Suppository View full page →
Key facts about the Belladonna And Opium Suppository shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Belladonna And Opium Suppository may not appear here at all, so this is not a picture of every available option. See the full Belladonna And Opium Suppository shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Belladonna and Opium suppositories are currently on the FDA shortage list, and I want to walk you through what that means for you.
Both strengths of this medicine — the 16.2 mg / 30 mg suppository and the 16.2 mg / 60 mg suppository — have no available source reported right now. The manufacturer on this record has listed this product as to be discontinued, which means the supply problem may be permanent rather than a short-term gap.
Because the reason given is discontinuation of manufacturing, this is a situation where planning ahead with your care team matters. Please don't feel you need to make any changes on your own.
Here are the steps I'd suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort out next steps.
- Ask your pharmacy to check with their wholesalers; local stock sometimes remains even after a discontinuation notice.
- Since this product is being discontinued, contact your prescriber or pharmacist to discuss a clinician-chosen alternative that fits your needs.
- A manufacturer contact number is listed on this page for reference, though your pharmacy usually handles those calls.
This is general, national information and may not match your local pharmacy's actual stock, so please confirm details with your pharmacist.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 16.2 mg; 60 mg Discontinuation of the manufacture of the drug
- 16.2 mg; 30 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 (800) 775-2054 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-04) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-04) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Belladonna And Opium Suppository →
View Belladonna And Opium Suppository on the FDA drug-shortage database →
Bendamustine Hydrochloride Injection, Solution View full page →
Key facts about the Bendamustine Hydrochloride Injection, Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Bendamustine Hydrochloride Injection, Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Bendamustine Hydrochloride Injection, Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Bendamustine Hydrochloride Injection is currently on the FDA drug-shortage list. This note reflects national, manufacturer-reported data, so it may not match what your local pharmacy actually has on hand.
The affected strength here is the 25 mg/5 mL solution, made as Treanda by Cephalon, LLC (a Teva subsidiary). No manufacturer is reporting available supply of this exact product right now. The reported reason is a business decision to discontinue making it, which means this particular product's supply problem may be permanent rather than temporary.
Because this is a discontinuation, the most important step is a conversation with your care team. Please do not change or skip any dose on your own.
- Do not stop or adjust your treatment on your own — this medicine is used under close supervision.
- Ask your prescriber or pharmacist about options, since this exact product is being discontinued.
- The same medicine, bendamustine hydrochloride, is still listed from several other makers — including Baxter, Accord, Eugia, Apotex, Azurity, Eagle, BluePoint, Slayback, and Teva (Bendeka). Your pharmacy or clinic may be able to source one of these, though it may not be in local stock and your clinician chooses what fits your care.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general information, not individualized medical advice.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Bendamustine Hydrochloride — BENDAMUSTINE HYDROCHLORIDE 100 mg/1
- Bendamustine Hydrochloride — BENDAMUSTINE HYDROCHLORIDE 25 mg/5mL
- Bendamustine Hydrochloride — BENDAMUSTINE HYDROCHLORIDE 100 mg/20mL
- Vivimusta — BENDAMUSTINE HYDROCHLORIDE 25 mg/mL
- Belrapzo — BENDAMUSTINE HYDROCHLORIDE 100 mg/4mL
- Bendamustine Hydrochloride — BENDAMUSTINE HYDROCHLORIDE 25 mg/5mL
- Bendamustine Hydrochloride — BENDAMUSTINE HYDROCHLORIDE 100 mg/20mL
- Bendamustine Hydrochloride — BENDAMUSTINE HYDROCHLORIDE 25 mg/mL
- Bendeka — BENDAMUSTINE HYDROCHLORIDE 25 mg/mL
- Treanda — BENDAMUSTINE HYDROCHLORIDE 100 mg/20mL
- Bendamustine Hydrochloride — BENDAMUSTINE HYDROCHLORIDE 100 mg/20mL
- Vivimusta — BENDAMUSTINE HYDROCHLORIDE 25 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 25 mg/5 mL A business decision has been made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) 📞 (610) 344-0200 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08) | — | A business decision has been made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Bendamustine Hydrochloride Injection, Solution →
View Bendamustine Hydrochloride Injection, So... on the FDA drug-shortage database →
Hydrocortisone Acetate Suppository View full page →
Key facts about the Hydrocortisone Acetate Suppository shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Hydrocortisone Acetate Suppository may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Hydrocortisone Acetate Suppository shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Hydrocortisone acetate suppositories are currently listed on the FDA shortage report. This record covers one manufacturer, Padagis US LLC, and both of its strengths — the 25 mg and the 30 mg — are affected. Neither strength has an available source from this maker right now.
The reason listed for both strengths is that the manufacturer is discontinuing production. This means the supply problem from Padagis may be permanent rather than temporary. That said, this report reflects only one company, and the same medicine is made by several other manufacturers, so it may still be available from a different source through your pharmacy.
Here is how I would approach it:
- Please do not stop or change how you use your suppositories on your own.
- Ask your pharmacy to check whether the same medicine (hydrocortisone acetate suppository, in your 25 mg or 30 mg strength) is available from another maker. Companies such as Cosette, Major, Marlex, Laser, Rising, APNAR, Patrin, and others make the same product, though it may not be in local stock.
- Since Padagis is discontinuing this item, talk with your prescriber or pharmacist about your options if a replacement cannot be found.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 30 mg/1
- Anucort-Hc — HYDROCORTISONE ACETATE 25 mg/1
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 25 mg/1
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 25 mg/1
- Hemmorex-Hc — HYDROCORTISONE ACETATE 25 mg/1
- Hemmorex-Hc — HYDROCORTISONE ACETATE 30 mg/1
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 25 mg/1
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 25 mg/1
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 30 mg/1
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 25 mg/1
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 30 mg/1
- Hydrocortisone Acetate — HYDROCORTISONE ACETATE 25 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 30 mg Discontinuation of the manufacture of the drug
- 25 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 (800) 775-2054 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hydrocortisone Acetate, Suppository, 25 mg (NDC 0574-7090-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Hydrocortisone Acetate, Suppository, 30 mg (NDC 0574-7093-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Hydrocortisone Acetate Suppository →
View Hydrocortisone Acetate Suppository on the FDA drug-shortage database →
Hydromorphone Hydrochloride Suppository View full page →
Key facts about the Hydromorphone Hydrochloride Suppository shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Hydromorphone Hydrochloride Suppository may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Hydromorphone Hydrochloride Suppository shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Hydromorphone Hydrochloride suppositories (3 mg) are currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The one strength this medicine comes in — 3 mg — has no available source right now from the manufacturer that filed this report. There are no other strengths involved, so this affects the exact product many people rely on. The reason listed is that the manufacturer, Padagis US LLC, is discontinuing production of the drug. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, which makes a conversation with your prescriber the right next step.
Please do not stop, skip, or adjust your doses on your own while this is being sorted out. Here is how I would approach it:
- Talk with your prescriber or pharmacist soon about your options, since this product is being discontinued.
- The same medicine — hydromorphone 3 mg suppository — may be available from another maker (Bryant Ranch Prepack). Your pharmacy may be able to source it, though it may not be in local stock, so ask them to check with wholesalers and other manufacturers.
- If it cannot be found, your prescriber or pharmacist can help choose a suitable alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 3 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 (800) 775-2054 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hydromorphone Hydrochloride, Suppository, 3 mg (NDC 0574-7224-06) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Hydromorphone Hydrochloride Suppository →
View Hydromorphone Hydrochloride Suppository on the FDA drug-shortage database →
Morphine Sulfate Suppository View full page →
Key facts about the Morphine Sulfate Suppository shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Morphine Sulfate Suppository may not appear here at all, so this is not a picture of every available option. See the full Morphine Sulfate Suppository shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Morphine Sulfate Suppository is currently on the FDA drug-shortage list, and the manufacturer that filed this report has listed it as being discontinued.
All four strengths are affected: the 5 mg, 10 mg, 20 mg, and 30 mg suppositories currently have no available source reported. None of these strengths shows available supply right now. The reason given for each one is discontinuation of the manufacture of the drug, and this report reflects a single manufacturer (Padagis US LLC). Because the product is marked "to be discontinued," this supply problem may be permanent rather than a short-term gap, so planning ahead with your care team is the right next step.
Please keep this in mind:
- Do not stop, skip, or change your dose on your own — talk with your prescriber or pharmacist first.
- Ask your pharmacist to check wholesalers and other manufacturers, since local stock can differ from this national report.
- Because this form is being discontinued, ask your prescriber about options — for example, a clinician-chosen alternative that fits your needs.
- The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls.
This is general, manufacturer-reported information and may not match your local pharmacy's actual stock, so please rely on your pharmacist and prescriber for advice specific to you.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 30 mg Discontinuation of the manufacture of the drug
- 5 mg Discontinuation of the manufacture of the drug
- 10 mg Discontinuation of the manufacture of the drug
- 20 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 (800) 775-2054 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Morphine Sulfate, Suppository, 20 mg (NDC 0574-7114-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Morphine Sulfate, Suppository, 10 mg (NDC 0574-7112-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Morphine Sulfate, Suppository, 5 mg (NDC 0574-7110-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Morphine Sulfate, Suppository, 30 mg (NDC 0574-7116-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Morphine Sulfate Suppository →
View Morphine Sulfate Suppository on the FDA drug-shortage database →
Podophyllum Resin Topical Tincture View full page →
Key facts about the Podophyllum Resin Topical Tincture shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Podophyllum Resin Topical Tincture may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Podophyllum Resin Topical Tincture shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Podophyllum Resin Topical Tincture is currently listed on the FDA drug-shortage report. I want to walk you through what this means so you know what to expect.
There is only one strength involved here: the 1 mg/4 mL topical tincture (Podocon 25). That strength does not have an available source right now. The reason reported is that the manufacturer, Padagis US LLC, is discontinuing production of this product. Because the record shows it is being discontinued, this supply problem may be a lasting one rather than a short-term gap — which makes a conversation with your prescriber the right next step.
Here is what I suggest:
- Do not stop or change how you use this medicine on your own. Keep following your current directions.
- Ask your pharmacy to check with wholesalers and other suppliers. Our records show the same medicine and strength (Podocon 25, podophyllum resin 1 mg/4 mL) listed from another maker, Bryant Ranch Prepack — your pharmacy may be able to source it, though it may not be sitting in local stock.
- Since this product is being discontinued, ask your prescriber or pharmacist about a clinician-chosen alternative for your situation.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls. This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mg/4 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 (800) 775-2054 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Podocon 25, Topical Tincture, 1 mg/4 mL (NDC 0574-0601-15) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Podophyllum Resin Topical Tincture →
View Podophyllum Resin Topical Tincture on the FDA drug-shortage database →
Succinylcholine Chloride Injection View full page →
Key facts about the Succinylcholine Chloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Succinylcholine Chloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Succinylcholine Chloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Succinylcholine Chloride Injection is currently on the FDA drug-shortage list. I want to walk you through what this means so you have a clear picture.
This shortage record covers the 20 mg/1 mL strength, and that strength has no available source from the manufacturer who filed this report. This is a medicine given during medical procedures, so it is handled in a hospital or clinical setting rather than picked up at a retail pharmacy.
The reported reason is that the manufacturer (Fresenius Kabi USA) is discontinuing its production of the drug. Because this is a discontinuation rather than a temporary supply gap, this particular company's supply problem may be permanent. Importantly, though, several other manufacturers make the same medicine in this same strength, so it may still be available through other sources.
Here is what I suggest:
- Do not stop, skip, or change any medicine on your own.
- Because this is a hospital-administered medicine, your care team and their pharmacy are the ones who source it — they can check wholesalers and other manufacturers who still make the same 20 mg/mL product, such as Hikma, Hospira (Quelicin), Camber, and others.
- If your care team cannot obtain it, ask them about a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match a specific facility's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE DIHYDRATE 20 mg/mL
- Quelicin — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
- Succinylcholine Chloride — SUCCINYLCHOLINE CHLORIDE 20 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Succinylcholine Chloride, Injection, 20 mg/1 mL (NDC 63323-943-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Succinylcholine Chloride Injection →
View Succinylcholine Chloride Injection on the FDA drug-shortage database →
Tobramycin Sulfate Injection View full page →
Key facts about the Tobramycin Sulfate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Tobramycin Sulfate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Tobramycin Sulfate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Tobramycin Sulfate Injection is currently on the FDA shortage list. I want to walk you through what this means so you know your next steps.
The affected product is the 80 mg/2 mL (40 mg/mL) 2 mL Multiple Dose Glass Fliptop Vial, which has no available source reported right now. This is the only strength on this record, and it is listed as to be discontinued. That means the manufacturer, Hospira (a Pfizer company), has decided to stop making this specific vial. Because this reflects only the manufacturer who filed the report, other companies may still supply this same medicine.
Please do not let this worry you into changing anything on your own. Here is what I suggest:
- Do not stop, skip, or change your dose without talking to your pharmacist or prescriber.
- Because this vial is being discontinued, this supply problem may be permanent, so a conversation with your prescriber is the right next step.
- The same medicine, tobramycin sulfate injection, is also listed from Baxter, Fresenius Kabi, and Mylan. Your pharmacy may be able to source one of these, though it may not be in local stock.
- The manufacturer's contact number is listed on this page for reference; pharmacies usually handle these calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 80 mg/2 mL (40 mg/mL); 2 mL Mu... Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Tobramycin Sulfate Injection →
View Tobramycin Sulfate Injection on the FDA drug-shortage database →
Travoprost Ophthalmic Solution View full page →
Key facts about the Travoprost Ophthalmic Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Travoprost Ophthalmic Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Travoprost Ophthalmic Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Travoprost ophthalmic solution, the eye drop used to lower eye pressure, is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next step calmly.
The shortage record here comes from one manufacturer, Mylan Pharmaceuticals (a Viatris company), and both of its strengths are affected: the 5 mL and the 2.5 mL both have no available source right now. Neither strength currently shows supply from this maker. The reason given is that Mylan is discontinuing its manufacture of the drug, so for this particular product the supply problem may be permanent.
Please keep in mind that this report reflects only Mylan. Travoprost 0.004% is still made by several other companies, so the medicine itself remains on the market — this is a good reason to talk with your pharmacist or prescriber soon.
Here is what I suggest, in order:
- Do not stop, skip, or change your drops on your own — keep using them as prescribed.
- Ask your pharmacy to check wholesalers and other manufacturers; the same medicine (travoprost 0.004%) is available from makers such as Novartis, Sagent, Apotex, Sandoz, Glenmark, and others, though it may not be in local stock.
- Because Mylan's version is being discontinued, ask your prescriber or pharmacist which option is right for you.
The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Travatan Z — TRAVOPROST .04 mg/mL
- Travoprost Ophthalmic Soluton — TRAVOPROST .04 mg/mL
- Travoprost Ophthalmic — TRAVOPROST .04 mg/mL
- Travoprost — TRAVOPROST .04 mg/mL
- Travoprost — TRAVOPROST .04 mg/mL
- Travatan Z — TRAVOPROST .04 mg/mL
- Travoprost Ophthalmic Solution — TRAVOPROST .04 mg/mL
- Travoprost — TRAVOPROST .04 mg/mL
- Travoprost Ophthalmic — TRAVOPROST .04 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mL Discontinuation of the manufacture of the drug
- 2.5 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 877-446-3679 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Travoprost, Ophthalmic Solution, 0.004%, 5 mL (NDC 0378-9651-50) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Travoprost Ophthalmic Solution →
View Travoprost Ophthalmic Solution on the FDA drug-shortage database →
Desflurane Liquid For Inhalation View full page →
Key facts about the Desflurane Liquid For Inhalation shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Desflurane Liquid For Inhalation may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Desflurane Liquid For Inhalation shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Desflurane Liquid for Inhalation is currently listed on the FDA drug-shortage list. Because this is an inhaled anesthetic used during surgery, this is a product your care team manages rather than something you keep at home — so I want to give you the facts clearly.
The one strength on this record, 240 mL/240 mL, has no available source right now from the manufacturer that filed this report. The reason given is that the maker (distributed by Sandoz) is discontinuing manufacture of the drug. Because the status is listed as "to be discontinued," this particular supply may not return. However, this report reflects only that one manufacturer — the same medicine may still be available from another maker.
Here is what to keep in mind:
- Do not change any part of your care plan on your own — this medicine is given by your surgical or anesthesia team, who will select what is appropriate.
- The same medicine, desflurane, is also listed on the market as Suprane (240 mL/240 mL) from Baxter Healthcare Corporation, so your facility may be able to source it, though it may not always be in local stock.
- Your anesthesia provider can choose a suitable alternative if desflurane cannot be obtained.
Manufacturer contact numbers are listed on this page for reference. This information comes from national, manufacturer-reported FDA data and may not match a specific facility's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 240 mL/240 mL Discontinuation of the manufacture of the drug; Distributed by Sandoz, Inc.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 Sandoz: 800-525-8747 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Desflurane, Liquid for Inhalation, 240 mL/240 mL (NDC 0781-6172-86) | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz, Inc. | — | To Be Discontinued |
Full shortage page: Desflurane Liquid For Inhalation →
View Desflurane Liquid For Inhalation on the FDA drug-shortage database →
Daptomycin Injection View full page →
Key facts about the Daptomycin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Daptomycin Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Daptomycin Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Daptomycin injection is currently on the FDA shortage list, and I want to walk you through what that means for the strength you or your loved one may be receiving.
The affected strength is the 500 mg/10 mL injection, which has no available source reported right now. This shortage record covers one manufacturer, Jiangsu Hengrui Pharmaceuticals (with product marketed by Hikma Pharmaceuticals USA), and the reason listed is that this maker is discontinuing production of the drug. Because it is being discontinued, this particular supply may not return, so a conversation with your prescriber or pharmacist is the right next step.
It is important to know this report reflects only the manufacturer that filed it. Daptomycin is the same medicine no matter who makes it, and several other companies still list it on the market — so your pharmacy may be able to source it from another supplier, though it may not be sitting in local stock.
Here is what I suggest, in order:
- Do not stop or change your treatment on your own — daptomycin is given for an active infection.
- Ask your pharmacy to check wholesalers and other manufacturers who may still supply the same medicine.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Daptomycin — DAPTOMYCIN 500 mg/10mL
- Daptomycin — DAPTOMYCIN 350 mg/7mL
- Daptomycin — DAPTOMYCIN 350 mg/7mL
- Daptomycin — DAPTOMYCIN 500 mg/10mL
- Daptomycin — DAPTOMYCIN 350 mg/7mL
- Daptomycin — DAPTOMYCIN 500 mg/10mL
- Daptomycin — DAPTOMYCIN 50 mg/mL
- Daptomycin — DAPTOMYCIN 350 mg/7mL
- Daptomycin — DAPTOMYCIN 350 mg/7mL
- Daptomycin — DAPTOMYCIN 500 mg/10mL
- Daptomycin — DAPTOMYCIN 500 mg/1
- Daptomycin — DAPTOMYCIN 500 mg/10mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500 mg/10 mL Discontinuation of the manufacture of the drug · Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 609-395-8625 ext. 203 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Daptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01) | — | Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc. | — | To Be Discontinued |
| Daptomycin, Injection, 500 mg/10 mL (NDC 57884-3151-1) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Daptomycin Injection →
View Daptomycin Injection on the FDA drug-shortage database →
Gadobutrol Injection View full page →
Key facts about the Gadobutrol Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Gadobutrol Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Gadobutrol Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Gadobutrol Injection, a contrast agent used for certain MRI scans, is currently on the FDA drug-shortage list. This is a medicine given by a healthcare team during imaging, not one you take at home, so I want to walk you through what this report means.
The single-strength product listed here is the 604.72 mg/mL injection, and the shortage record shows the single-dose vials are being discontinued. That means this particular packaging may not return. The note also states that two larger Imaging Bulk Package sizes (18.1416 g/30 mL and 39.3068 g/65 mL) are set to remain in supply. This report reflects one filer, so other makers of the same medicine may still have it.
Do not change or delay any scheduled imaging on your own. A few practical steps:
- Ask your imaging center or pharmacy to check wholesalers and other manufacturers for available supply.
- The same medicine, gadobutrol 604.72 mg/mL, is also listed from other makers (including Bayer's Gadavist, Fresenius Kabi, and Slate Run) — your facility may be able to source one of these, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber about a suitable alternative.
Manufacturer contact numbers are listed on this page for reference; facilities usually handle those calls. This is general national data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 604.72 mg/mL Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co., Ltd. 📞 888-386-1300 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-07) | — | Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA | — | To Be Discontinued |
| Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-10) | — | Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA | — | To Be Discontinued |
| Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-02) | — | Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA | — | To Be Discontinued |
| Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-15) | — | Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA | — | To Be Discontinued |
Full shortage page: Gadobutrol Injection →
View Gadobutrol Injection on the FDA drug-shortage database →
Emtricitabine Capsule View full page →
Key facts about the Emtricitabine Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Emtricitabine Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Emtricitabine Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Emtricitabine 200 mg capsules are currently on the FDA drug-shortage list, and the record notes this product is being discontinued.
The only strength listed here, 200 mg, has no available source reported at this time. The manufacturer on this record, Gilead Sciences (Emtriva), reports that its supply is expected to last until March 2027. Because the product is marked "to be discontinued," this supply change may be permanent, so a conversation with your prescriber is the right next step to plan ahead.
Please keep taking your medicine as prescribed while this is sorted out. Here is how to approach it:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for the 200 mg capsule — local stock can differ from national reports.
- The same medicine, emtricitabine 200 mg capsules, is also listed from Aurobindo Pharma and Cipla USA. Your pharmacy may be able to source one of these, though it may not be on the shelf right away.
- If your exact capsule cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 200 mg Product expected to be available until March 2027
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Gilead Sciences, Inc. 📞 800-445-3235 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Emtriva, Capsule, 200 mg (NDC 61958-0601-1) | — | Product expected to be available until March 2027 | — | To Be Discontinued |
Full shortage page: Emtricitabine Capsule →
View Emtricitabine Capsule on the FDA drug-shortage database →
Emtricitabine Oral Solution View full page →
Key facts about the Emtricitabine Oral Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Emtricitabine Oral Solution may not appear here at all, so this is not a picture of every available option. See the full Emtricitabine Oral Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Emtricitabine oral solution (10 mg/1 mL) is currently on the FDA drug-shortage list. I want to walk you through what this means so you can plan ahead with confidence.
The one strength of this product — 10 mg/1 mL — is listed with no available source on this report, and the status shows it is set to be discontinued. The maker reports it is expected to remain available until March 2027. Because this is a planned discontinuation, the supply problem may eventually be permanent, which makes a conversation with your prescriber the right next step before that date arrives.
Please keep in mind this information comes from national, manufacturer-reported FDA data, so it may not match what your local pharmacy actually has on its shelves today.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers to see whether your strength can still be ordered while supply lasts.
- Because this product is planned for discontinuation, talk with your prescriber or pharmacist about a clinician-chosen plan for the future.
A manufacturer contact number is listed on this page for reference, though pharmacies usually make these calls for you. You have time to plan this thoughtfully.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg/1 mL Product expected to be available until March 2027
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Gilead Sciences, Inc. 📞 800-445-3235 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Emtriva, Oral Solution, 10 mg/1 mL (NDC 61958-0602-1) | — | Product expected to be available until March 2027 | — | To Be Discontinued |
Full shortage page: Emtricitabine Oral Solution →
View Emtricitabine Oral Solution on the FDA drug-shortage database →
Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release View full page →
Key facts about the Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
The combination medicine donepezil and memantine (an extended-release capsule) is currently on the FDA shortage list. I know this news can feel unsettling, so let me walk you through what it means for you.
This report covers the two strengths that combine 10 mg donepezil with either 14 mg or 28 mg memantine. Neither strength has an available source from the manufacturer that filed this report (Amneal Pharmaceuticals). The reason given is that this maker is discontinuing the product. Because this is listed as a discontinuation rather than a temporary delay, this particular supply may not return — so a conversation with your prescriber is the right next step. Keep in mind this report reflects only one manufacturer; the same medicine is still made by other companies.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same donepezil-memantine combination is also made by companies such as Macleods, ANI, Vitruvias, AvKARE, and others, though it may not be in local stock right away.
- If your exact product cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls. This is general national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Namzaric — MEMANTINE HYDROCHLORIDE 7 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Namzaric — MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Namzaric — MEMANTINE HYDROCHLORIDE 21 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Namzaric — MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Memantine And Donepezil — MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Memantine And Donepezil — MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Memantine And Donepezil Hydrochlorides — MEMANTINE HYDROCHLORIDE 21 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Memantine And Donepezil Hydrochlorides Extended-Release — MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Memantine And Donepezil Hydrochlorides Extended-Release — MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Memantine Hydrochloride And Donepezil Hydrochloride — MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Memantine Hydrochloride And Donepezil Hydrochloride — MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
- Memantine And Donepezil Hydrochlorides Extended-Release — MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg; 14 mg Discontinuation of the manufacture of the drug
- 10 mg; 28 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 28 mg (NDC 69238-1247-3) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release →
View Donepezil Hydrochloride; Memantine Hydro... on the FDA drug-shortage database →
Lorlatinib Tablet View full page →
Key facts about the Lorlatinib Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Lorlatinib Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Lorlatinib Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Lorlatinib (brand name Lorbrena) tablets are currently on the FDA shortage list, so I want to walk you through what this means for you.
The affected item is the 25 mg strength sold in the 120-tablet bottle with a child-resistant closure. That specific package has no available source right now and is listed as being discontinued, with existing supply expected to run out by June 30, 2026. The important detail is that this affects only that one bottle size. The same 25 mg tablet packaged in a 30-tablet bottle is reported to continue being made, and the same medicine (Lorbrena) is also listed in a 100 mg tablet. So the medicine itself remains on the market — it is the larger bottle that is going away.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy whether they can order the same medicine in the 30-tablet bottle, or another available package, through their wholesalers — though it may not be in local stock.
- Because this bottle size is being discontinued, talk with your prescriber or pharmacist about a steady plan going forward, such as a different package or strength to make up your dose.
The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 25 mg; 120 tablets bottle with... Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a chi...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03) | — | Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation | — | To Be Discontinued |
Full shortage page: Lorlatinib Tablet →
Ifosfamide Injection View full page →
Key facts about the Ifosfamide Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ifosfamide Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ifosfamide Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug (3 NDCs)
- Requirements related to complying with good manufacturing practices (2 NDCs)
Do you take this medicine? What Should I Do?!
Ifosfamide injection is currently on the FDA shortage list. This is a chemotherapy medicine, and it is typically handled by your care team rather than a retail pharmacy, so treatment planning here usually happens with your oncology providers.
Here is how the strengths break down. The 50 mg/1 mL strength currently has no available source, with additional lots expected around September 2026. Three strengths still have a reported source: the 1 g/20 mL, the 1 g/1, and the 3 g/60 mL — though supply of the 1 g/1 from one maker is limited.
The reported reasons are a rise in demand and steps tied to good manufacturing practices. Three of four listed manufacturers still report available supply, so this is a partial shortage, not a full one. Some products carry recovery estimates in September or October 2026.
A few things you can do:
- Do not stop, skip, or change any dose on your own.
- If your strength still has supply, ask your care team or pharmacy to order it — they can check wholesalers and other makers.
- The same medicine (ifosfamide 1 g/1) is also listed from another maker, so your pharmacy may be able to source it, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber about options.
Manufacturer contact numbers are listed on this page for reference. This reflects national data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg/1 mL Additional lots will be available in the September 2026 timeframe. Product will be made av...
- 1 g/20 mL Estimated recovery: September 2026
- 1 g/1 To place an order, please contact GlobalRX at [email protected] or (919) 245-8418 · Check wholesalers for inventory
- 3 g/60 mL Estimated recovery: October 2026
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Baxter Healthcare 📞 888-229-0001 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01) | Unavailable | Estimated recovery: October 2026 | Requirements related to complying with good manufacturing pr... | Current |
| Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02) | Available | — | — | Current |
| IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01) | Unavailable | Estimated recovery: September 2026 | Requirements related to complying with good manufacturing pr... | Current |
| Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01) | Available | — | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ifosfamide, Injection, 1 g/1 (NDC 63323-142-10) | Limited Availability | Check wholesalers for inventory | Demand increase for the drug | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01) | Unavailable | Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug | Current |
| Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01) | Unavailable | Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug | Current |
Manufacturer: SteriMax, Inc. 📞 877-373-4657 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02) | Available | To place an order, please contact GlobalRX at [email protected] or (919) 245-8418 | — | Current |
Full shortage page: Ifosfamide Injection →
View Ifosfamide Injection on the FDA drug-shortage database →
Dacomitinib Tablet View full page →
Key facts about the Dacomitinib Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dacomitinib Tablet may not appear here at all, so this is not a picture of every available option. See the full Dacomitinib Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Dacomitinib (also sold as Vizimpro) is currently listed on the FDA drug-shortage list, and I want to walk you through what that means for you.
All three tablet strengths are affected. The 45 mg, 30 mg, and 15 mg tablets each have no available source reported right now. The reason given is that the manufacturer, Pfizer Inc., is discontinuing production of this medicine. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent. Our records do not list another maker for dacomitinib at this time, though this report reflects only the manufacturer that filed it.
Here is what I suggest you do:
- Please do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort out your supply.
- Ask your pharmacy to check with their wholesalers and other suppliers; local stock can differ from national reports.
- Because this medicine is being discontinued, reach out to your prescriber or pharmacist soon to discuss your options, such as a clinician-chosen alternative that fits your treatment.
For reference, the manufacturer's contact number is listed on this page, though pharmacies usually handle those calls. This is general information from national FDA data and may not match your local pharmacy's actual stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 45 mg Discontinuation of the manufacture of the drug
- 15 mg Discontinuation of the manufacture of the drug
- 30 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vizimpro, Tablet, 30 mg (NDC 0069-1198-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Vizimpro, Tablet, 15 mg (NDC 0069-0197-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Vizimpro, Tablet, 45 mg (NDC 0069-2299-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Dacomitinib Tablet →
Leflunomide Tablet View full page →
Key facts about the Leflunomide Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Leflunomide Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Leflunomide Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Leflunomide tablets are currently on the FDA shortage list. This report comes from one manufacturer, Sanofi-Aventis U.S. LLC, which has listed all three strengths — 10 mg, 20 mg, and 100 mg — as being discontinued. That means none of these strengths have an available source from this maker right now.
The reason given is straightforward: this company is stopping production of the drug. Because it is marked "to be discontinued," this particular supply problem may be permanent. Importantly, this reflects only one manufacturer. Other companies still make leflunomide, so the medicine itself is not gone from the market.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed.
- Ask your pharmacy about the same medicine, leflunomide, from another maker. Options such as KVK-Tech, Avet, Burel, AvKARE, AvPAK, and Aurobindo make the 10 mg and 20 mg tablets; your pharmacy can check wholesalers, though these may not be in local stock.
- If your exact strength or dose cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Leflunomide — LEFLUNOMIDE 10 mg/1
- Leflunomide — LEFLUNOMIDE 20 mg/1
- Leflunomide — LEFLUNOMIDE 10 mg/1
- Leflunomide — LEFLUNOMIDE 20 mg/1
- Leflunomide — LEFLUNOMIDE 10 mg/1
- Leflunomide — LEFLUNOMIDE 20 mg/1
- Leflunomide — LEFLUNOMIDE 10 mg/1
- Leflunomide — LEFLUNOMIDE 20 mg/1
- Leflunomide — LEFLUNOMIDE 20 mg/1
- Leflunomide — LEFLUNOMIDE 10 mg/1
- Leflunomide — LEFLUNOMIDE 20 mg/1
- Leflunomide — LEFLUNOMIDE 10 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg Discontinuation of the manufacture of the drug
- 10 mg Discontinuation of the manufacture of the drug
- 100 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Sanofi-Aventis U.S. LLC 📞 800-981-2491 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Arava, Tablet, 100 mg (NDC 0088-2162-33) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Leflunomide, Tablet, 10 mg (NDC 0955-1735-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Arava, Tablet, 10 mg (NDC 0088-2160-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Arava, Tablet, 20 mg (NDC 0088-2161-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Leflunomide, Tablet, 20 mg (NDC 0955-1737-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Leflunomide Tablet →
Semaglutide Tablet View full page →
Key facts about the Semaglutide Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Semaglutide Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Semaglutide Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Semaglutide tablets (Rybelsus) are currently on the FDA shortage list, and I want to walk you through what this means for you.
All three strengths are affected — the 3 mg, 7 mg, and 14 mg tablets. None of these strengths have a currently available source in this report, so there is no unaffected strength I can point you to right now.
The reason listed is that the manufacturer is discontinuing production of these tablets, and the record notes they are to be replaced by Ozempic (semaglutide) tablets. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, and a conversation with your prescriber is the right next step.
Please do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed while you sort out a plan.
- Talk with your prescriber or pharmacist soon about what to do next, since your current tablets are being discontinued.
- Ask whether an alternative form of semaglutide, such as Ozempic, is right for you — the same ingredient is still made by the manufacturer, though your pharmacy may need to check availability.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 3 mg Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic...
- 14 mg Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic...
- 7 mg Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Novo Nordisk, Inc. 📞 833-493-4689 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rybelsus, Tablet, 7 mg (NDC 0169-4307-30) | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | — | To Be Discontinued |
| Rybelsus, Tablet, 14 mg (NDC 0169-4314-30) | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | — | To Be Discontinued |
| Rybelsus, Tablet, 3 mg (NDC 0169-4303-30) | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | — | To Be Discontinued |
Full shortage page: Semaglutide Tablet →
Dehydrated Alcohol Injection, Solution View full page →
Key facts about the Dehydrated Alcohol Injection, Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dehydrated Alcohol Injection, Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dehydrated Alcohol Injection, Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Dehydrated Alcohol Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The specific product affected is the 1 mL/1 mL, 10-pack configuration, which has no available source reported right now. This is the only strength listed on this record, so there is no separate "still available" version of the same package to point you to.
The reason given is that the manufacturer, Accord Healthcare, is transitioning from the 10-pack to a 5-pack configuration. Because this record is marked "to be discontinued," this particular 10-pack may not return, so a conversation with your prescriber or pharmacist about next steps is the right move. Keep in mind this report reflects only Accord; other companies may still supply this same medicine.
Here is what I suggest:
- Do not stop, skip, or change how this medicine is used on your own.
- Ask your pharmacy to check with wholesalers and other makers — the same medicine (dehydrated alcohol injection) is also listed from XGen, A-S Medication Solutions, BPI Labs, Ajenat, and Avenacy, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mL/1 mL (10 pack) Accord is transitioning to the 5-pack configuration (NDC 16729-710-53).
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dehydrated Alcohol, Injection, Solution, 1 mL/1 mL (10 pack) (NDC 16729-710-45) | — | Accord is transitioning to the 5-pack configuration (NDC 16729-710-53). | — | To Be Discontinued |
Full shortage page: Dehydrated Alcohol Injection, Solution →
View Dehydrated Alcohol Injection, Solution on the FDA drug-shortage database →
Gadoterate Meglumine Injection View full page →
Key facts about the Gadoterate Meglumine Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Gadoterate Meglumine Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Gadoterate Meglumine Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Gadoterate Meglumine Injection is currently on the FDA shortage list. This is a contrast dye used during MRI scans, so it is given at an imaging center rather than taken at home.
This product comes in one strength, 376.9 mg/1 mL, and that strength currently has no available source from the manufacturer that filed this report. The reason listed is a discontinuation of manufacturing by the company marketed as Fresenius Kabi, USA. Because this is a planned discontinuation, this particular supply may not return. That said, this report reflects only one manufacturer, and the same medicine is made by other companies.
Here is what you can do:
- Do not skip or delay a scheduled scan on your own — talk with your imaging center or ordering provider first.
- Ask your imaging facility whether they can source the same medicine from another maker. Same-ingredient options in our records include Clariscan (GE Healthcare), Dotarem (Guerbet), and gadoterate meglumine from Fresenius Kabi USA and Slate Run Pharmaceuticals. These may not be in local stock everywhere.
- Since this product is being discontinued, ask your provider or radiologist about a clinician-chosen alternative contrast agent.
- Manufacturer contact numbers are listed on this page for reference; facilities usually handle those calls.
This is general, national information and may not match your local supply.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 376.9 mg/1 mL Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug · Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co., Ltd. 📞 888-386-1800 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05) | — | Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20) | — | Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15) | — | Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10) | — | Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Gadoterate Meglumine Injection →
View Gadoterate Meglumine Injection on the FDA drug-shortage database →
Alteplase Injection View full page →
Key facts about the Alteplase Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Alteplase Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Alteplase Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Alteplase Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The affected product is the single-use 100 mL vial (the 100 mg configuration). Right now, this strength has no available source reported. There are no other strengths listed as still supplied on this record.
The reason given is a discontinuation of the 100 mg vial configuration. When a product is marked "to be discontinued," the supply problem may be permanent rather than temporary. Because of that, a conversation with your prescriber or pharmacist is the right next step to plan ahead.
Here is what I suggest, in order:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check with wholesalers and other manufacturers — local stock does not always match national reports.
- The same medicine, Activase from Genentech, appears in our records as a same-ingredient option; your pharmacy may be able to source it, though it may not be in local stock.
- Since this vial is being discontinued, ask your prescriber or pharmacist about clinician-chosen options that fit your care.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not reflect your local pharmacy's supply.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- SINGLE-USE * 100 mL in 1 VIAL Discontinuation of the 100mg vial configuration
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Genentech, Inc 📞 800-551-2231 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Activase, Injection, 1 KIT in 1 CARTON (50242-085-27) * 100 mL in 1 VIAL, SINGLE-USE * 100 mL in 1 VIAL, SINGLE USE (NDC 50242-085-27) | — | Discontinuation of the 100mg vial configuration | — | To Be Discontinued |
Full shortage page: Alteplase Injection →
View Alteplase Injection on the FDA drug-shortage database →
Iron Sucrose Injection View full page →
Key facts about the Iron Sucrose Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Iron Sucrose Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Iron Sucrose Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Iron Sucrose Injection is currently on the FDA shortage list. I want to walk you through what this means for the strength you may receive.
The strength affected is the 50 mg/2.5 mL presentation, which has no available source reported right now. According to the manufacturer, Mylan Institutional (a Viatris company), this is the result of a business decision to discontinue the 2.5 mL size specifically. Because this is a discontinuation, the supply problem with this particular presentation may be permanent — so a conversation with your prescriber or pharmacist is the right next step.
Importantly, this report reflects one manufacturer's decision about one size. The same medicine, iron sucrose, is still made in other presentations and by other makers.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — iron sucrose is still listed from makers such as American Regent, Sandoz, Fresenius, and others, though it may not be in local stock.
- If your exact size cannot be found, ask your prescriber or pharmacist about a clinician-chosen option, such as a different presentation to make up the dose.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This is general national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg/2.5 mL A business decision has been made to discontinue of 2.5mL presentation only. Continuity of...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Iron Sucrose, Injection, 50 mg/2.5 mL (NDC 67457-957-99) | — | A business decision has been made to discontinue of 2.5mL presentation only. Continuity of supply is forecasted across all other presentations of Iron Sucrose: 67457-639-10 Iron Sucrose 20mg/mL 10mL SDV 5PK 67457-638-10 Iron Sucrose 20mg/mL 5mL SDV 10PK 67457-638-25 Iron Sucrose 20mg/mL 5mL SDV 25PK. | — | To Be Discontinued |
Full shortage page: Iron Sucrose Injection →
View Iron Sucrose Injection on the FDA drug-shortage database →
Activated Charcoal Oral Suspension View full page →
Key facts about the Activated Charcoal Oral Suspension shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Activated Charcoal Oral Suspension may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Activated Charcoal Oral Suspension shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Activated Charcoal Oral Suspension is currently on the FDA drug-shortage list, and I want to walk you through what that means.
The one strength involved, 208 mg/1 mL, has no available source reported right now. The manufacturer that filed this report, Padagis US LLC, has listed this product (including Actidose and Actidose Aqua) as being discontinued. Because the reason is discontinuation rather than a temporary delay, this supply problem may be permanent for that maker, and no estimated-recovery date applies.
Since this is a discontinuation, the most important next step is a conversation with your prescriber or pharmacist. Please do not adjust or stop anything on your own first.
- Do not skip or change how you use this medicine without talking to a professional first.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine may still be available from another maker. Our records list Actidose (Padagis) and Insta-Char Aqueous (VistaPharm) as the same ingredient and form, though these may not be in local stock.
- Ask your prescriber or pharmacist about a suitable option if your product cannot be found.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This national data may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 208 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 866-634-9120 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Activated Charcoal Oral Suspension →
View Activated Charcoal Oral Suspension on the FDA drug-shortage database →
Sulconazole Nitrate Solution View full page →
Key facts about the Sulconazole Nitrate Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Sulconazole Nitrate Solution may not appear here at all, so this is not a picture of every available option. See the full Sulconazole Nitrate Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Sulconazole nitrate solution (also sold under the brand name Exelderm) is currently on the FDA shortage list. I want to walk you through what this means for the version you use.
At this time, none of the reported strengths have an available source. This includes the 1.0% 30 mL, the 1.0% 5 mL, and the 30 mL solution. The reason listed for all three is that the manufacturer is discontinuing production of this product. Because the status is "to be discontinued," this supply problem may be permanent rather than temporary.
Since this involves a discontinuation, the most important next step is a conversation with the person who prescribed it. Here is what I suggest:
- Do not stop or change how you use your medicine on your own. Keep following your current directions while you sort out next steps.
- Ask your pharmacy to check their wholesalers and other suppliers — a store may still have some on hand even after a discontinuation is announced.
- Talk with your prescriber or pharmacist about a suitable alternative, since this product is being discontinued.
The manufacturer's contact number is listed on this page for reference, though your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's actual stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1.0% 30 mL Discontinuation of the manufacture of the drug
- 1.0% 5 mL Discontinuation of the manufacture of the drug
- 30 mL Discontinuation of the manufacture of the drug. Manufactured for JG Pharma
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Journey Medical Corporation 📞 480-434-6670 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sulconazole Nitrate, Solution, 30 mL (NDC 72143-321-30) | — | Discontinuation of the manufacture of the drug. Manufactured for JG Pharma | — | To Be Discontinued |
| Exelderm, Solution, 1.0% 5 mL (NDC 69489-721-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Exelderm, Solution, 1.0% 30 mL (NDC 69489-721-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Sulconazole Nitrate Solution →
View Sulconazole Nitrate Solution on the FDA drug-shortage database →
Icatibant Acetate Injection View full page →
Key facts about the Icatibant Acetate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Icatibant Acetate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Icatibant Acetate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Icatibant Acetate Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The only strength covered by this report is the 10 mg/1 mL injection, and it does not have an available source right now. The reason listed is that the manufacturer who filed this report, Fresenius Kabi USA, is discontinuing this product. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent for that maker, and no estimated-recovery date is given.
Even so, this report reflects only one manufacturer. The same medicine, icatibant acetate, is still on the market from other companies, so it is not gone everywhere. Here is what I suggest:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine is available from makers such as Teva, Hikma, Takeda (Firazyr), Eugia, Alembic, Cipla, and Cycle (Sajazir), though these may not be in local stock.
- Because your current product is being discontinued, talk with your prescriber or pharmacist about a suitable alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg/1 mL Discontinuation of the manufacturer of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 847-550-2300 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93) | — | Discontinuation of the manufacturer of the drug | — | To Be Discontinued |
| Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86) | — | Discontinuation of the manufacturer of the drug | — | To Be Discontinued |
Full shortage page: Icatibant Acetate Injection →
View Icatibant Acetate Injection on the FDA drug-shortage database →
Cisatracurium Besylate Injection View full page →
Key facts about the Cisatracurium Besylate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Cisatracurium Besylate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Cisatracurium Besylate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Cisatracurium Besylate Injection is currently on the FDA drug-shortage list. This is a hospital medicine given during procedures, so any supply planning is usually handled by your care team rather than something you manage at home.
The shortage record here comes from one manufacturer, Hospira (a Pfizer company), and it lists all three strengths as having no available source at this time: the 200 mg/20 mL (10 mg/mL) single-dose vial, the 20 mg/10 mL (2 mg/mL) multidose vial, and the 10 mg/5 mL (2 mg/mL) single-dose vial. This maker has marked the product to be discontinued, with supply expected to run out around late June 2026 for the first two strengths and November 2026 for the third. Because this is a discontinuation, this particular supply problem may be permanent.
Importantly, other companies still list this same medicine, so it is not gone from the market overall.
- Do not stop or change any medicine on your own.
- Ask your pharmacy or care team to check wholesalers and other manufacturers.
- The same medicine is listed by other makers — including Hikma, Sandoz, Camber, Eugia, Fresenius Kabi, Caplin Steriles, and Somerset — so your team may be able to source one, though it may not be in local stock.
- Because this maker is discontinuing it, talk with your prescriber about the right long-term plan.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 10 mg/mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 2 mg/mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 2 mg/mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 10 mg/mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 10 mg/mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 2 mg/mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 10 mg/5mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 20 mg/10mL
- Cisatracurium — CISATRACURIUM BESYLATE 2 mg/mL
- Cisatracurium — CISATRACURIUM BESYLATE 10 mg/mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 10 mg/mL
- Cisatracurium Besylate — CISATRACURIUM BESYLATE 2 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 200 mg/20ml (10 mg/mL) Single... Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug
- 20 mg/10 mL (2 mg/mL) Multidos... Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug
- 10 mg/5ml (2 mg/mL) Single Dos... Supply expected to exhaust November 2026; Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cisatracurium Besylate, Injection, 10 mg/5ml (2 mg/mL) Single Dose Vial (NDC 0409-1098-02) | — | Supply expected to exhaust November 2026; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01) | — | Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01) | — | Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Cisatracurium Besylate Injection →
View Cisatracurium Besylate Injection on the FDA drug-shortage database →
Lamotrigine Tablet, Extended Release View full page →
Key facts about the Lamotrigine Tablet, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Lamotrigine Tablet, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Lamotrigine Tablet, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Lamotrigine extended-release tablets are currently on the FDA shortage list. This report comes from one manufacturer, Par Health, Inc., who has marked all of its strengths for discontinuation.
The affected strengths are the 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg extended-release tablets. Right now, none of these strengths have an available source from this manufacturer, and each is listed as a discontinued product. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent for this maker — which makes a conversation with your prescriber the right next step. Please keep in mind this reflects national, manufacturer-reported data and may not match what your local pharmacy actually has on its shelf.
Most importantly, do not stop, skip, or change your dose on your own — lamotrigine is a medicine that needs to be managed carefully.
Here are your next steps:
- Ask your pharmacy to check wholesalers and other manufacturers for your strength.
- The same medicine, lamotrigine, is still made by other companies (for example, Amneal and GlaxoSmithKline) in certain forms and strengths; your pharmacy may be able to source one of these, though it may not be in local stock.
- Ask your prescriber or pharmacist about options, such as a different strength or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Lamotrigine — LAMOTRIGINE 25 mg/1
- Lamotrigine — LAMOTRIGINE 50 mg/1
- Lamotrigine — LAMOTRIGINE 100 mg/1
- Lamotrigine — LAMOTRIGINE 200 mg/1
- Lamictal — LAMOTRIGINE 5 mg/1
- Lamictal — LAMOTRIGINE 25 mg/1
- Lamictal — LAMOTRIGINE 25 mg/1
- Lamictal — LAMOTRIGINE 100 mg/1
- Lamictal — LAMOTRIGINE 150 mg/1
- Lamictal — LAMOTRIGINE 200 mg/1
- Lamictal — LAMOTRIGINE 2 mg/1
- Lamictal Xr — LAMOTRIGINE 25 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg Discontinuation of the manufacture of the drug
- 50 mg Discontinuation of the manufacture of the drug
- 250 mg Discontinuation of the manufacture of the drug
- 300 mg Discontinuation of the manufacture of the drug
- 25 mg Discontinuation of the manufacture of the drug
- 200 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Par Health, Inc. 📞 800-828-9393 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Lamotrigine Tablet, Extended Release →
View Lamotrigine Tablet, Extended Release on the FDA drug-shortage database →
Crinecerfont Capsule View full page →
Key facts about the Crinecerfont Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Crinecerfont Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Crinecerfont Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Crinecerfont (brand name Crenessity) is currently listed on the FDA shortage list, and I want to walk you through exactly what that means for the dose you take.
The change affects only the 25 mg soft gel capsule, which the manufacturer, Neurocrine, is discontinuing. The other capsule strengths — 50 mg and 100 mg — along with the 50 mg/mL oral solution are reported to remain on the market. So if you take one of those, your strength is not part of this discontinuation.
Because the 25 mg capsule is being discontinued rather than briefly delayed, this supply problem may be permanent. That is why the most important next step is a conversation with your prescriber, not a change you make on your own.
Here is what I suggest, in order:
- Do not stop, skip, or adjust your dose on your own.
- If you take the 25 mg capsule, ask your prescriber or pharmacist about options — for example, using the 50 mg or 100 mg capsule or the oral solution to reach your prescribed dose.
- Your pharmacy can check wholesalers for any remaining 25 mg stock while you make this plan.
The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 25 mg Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Neurocrine Biosciences, Inc. 📞 858-617-7600 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Crenessity, Capsule, 25 mg (NDC 70370-5025-1) | — | Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1). | — | To Be Discontinued |
Full shortage page: Crinecerfont Capsule →
View Crinecerfont Capsule on the FDA drug-shortage database →
Etravirine Tablet View full page →
Key facts about the Etravirine Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Etravirine Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Etravirine Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Etravirine tablets, sold under the brand name Intelence, are currently on the FDA drug-shortage list. I want to explain what this means for you so you can plan ahead calmly.
The affected strength is the 100 mg tablet. The manufacturer that filed this report, Janssen, has listed both the generic etravirine 100 mg and the brand-name Intelence 100 mg as being discontinued, so those specific products have no available source at this time. The reason given is that this maker is stopping production. Because this is a discontinuation rather than a temporary delay, this supply problem may be a lasting one — which makes a conversation with your prescriber the right next step.
Importantly, this report reflects only one manufacturer. The same medicine, etravirine, is still made by other companies, so it may still be possible to obtain.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own — staying on your HIV therapy consistently matters.
- Ask your pharmacy to source etravirine from another maker; the 100 mg tablet is listed from AvKARE, Amneal, Leading Pharma, and Bionpharma, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber about options, such as a different strength or an alternative they choose.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Etravirine — ETRAVIRINE 200 mg/1
- Etravirine — ETRAVIRINE 100 mg/1
- Etravirine — ETRAVIRINE 200 mg/1
- Intelence — ETRAVIRINE 200 mg/1
- Intelence — ETRAVIRINE 25 mg/1
- Etravirine — ETRAVIRINE 100 mg/1
- Etravirine — ETRAVIRINE 200 mg/1
- Etravirine — ETRAVIRINE 100 mg/1
- Etravirine — ETRAVIRINE 200 mg/1
- Etravirine — ETRAVIRINE 100 mg/1
- Etravirine — ETRAVIRINE 200 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Janssen Research and Development 📞 800-526-7736 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Intelence, Tablet, 100 mg (NDC 59676-570-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Etravirine, Tablet, 100 mg (NDC 10147-0570-1) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Etravirine Tablet →
Palbociclib Capsule View full page →
Key facts about the Palbociclib Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Palbociclib Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Palbociclib Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Palbociclib capsules (brand name Ibrance) are currently on the FDA shortage list, and I want to walk you through what this means for you.
Both capsule strengths on this record — the 75 mg and 100 mg capsules — have no available source reported right now. The manufacturer, Pfizer, has listed these capsules as to be discontinued, so this particular supply problem may be permanent rather than temporary.
The reason given is straightforward: Pfizer is stopping production of the capsule form of these two strengths. Importantly, the company reports it will continue to make the same strengths in tablet form (a 100 mg tablet and a 75 mg tablet). So while the capsule you take may go away, the medicine itself is not disappearing.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Because your capsule strength is being discontinued, the right next step is to talk with your prescriber or pharmacist about moving to the tablet form of the same strength, or another option they choose for you.
- Your pharmacy can also check with wholesalers and other suppliers on your behalf.
For reference, Pfizer's contact number is listed on this page, though your pharmacy usually handles those calls.
This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0...
- 75 mg Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-02...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ibrance, Capsule, 75 mg (NDC 0069-0187-21) | — | Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-0284-03 will continue to be manufactured. | — | To Be Discontinued |
| Ibrance, Capsule, 100 mg (NDC 0069-0188-21) | — | Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured. | — | To Be Discontinued |
Full shortage page: Palbociclib Capsule →
View Palbociclib Capsule on the FDA drug-shortage database →
Ketorolac Tromethamine Tablet View full page →
Key facts about the Ketorolac Tromethamine Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ketorolac Tromethamine Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ketorolac Tromethamine Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Ketorolac tromethamine 10 mg tablets are currently on the FDA drug-shortage list. I want to walk you through what this means so you can plan your next step calmly.
The 10 mg tablet is the only strength listed, and right now it does not have an available source from the manufacturer on this record. The reason given is that this manufacturer, Mylan Pharmaceuticals (a Viatris company), is discontinuing production of this product. Because this is a discontinuation rather than a temporary delay, the interruption from this maker may be permanent. That said, this report reflects only one manufacturer — other companies still make the same 10 mg tablet.
Please do not stop, skip, or change your dose on your own. Here is what to do instead:
- Ask your pharmacy to check whether the same 10 mg ketorolac tablet is available from another maker — several companies still list it, including Teva, Major, Ajanta, Camber, Dr. Reddy's, and others. Your pharmacy can order through wholesalers, though a given brand may not be in local stock right away.
- If your exact tablet cannot be found, ask your prescriber or pharmacist about clinician-chosen options.
The manufacturer contact number is listed on this page for reference; pharmacies usually make these calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 10 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 877-446-3679 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketorolac Tromethamine, Tablet, 10 mg (NDC 0378-1134-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Ketorolac Tromethamine Tablet →
View Ketorolac Tromethamine Tablet on the FDA drug-shortage database →
Isocarboxazid Tablet View full page →
Key facts about the Isocarboxazid Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Isocarboxazid Tablet may not appear here at all, so this is not a picture of every available option. See the full Isocarboxazid Tablet shortage page → for the still-marketed options we could find.
- Other
Do you take this medicine? What Should I Do?!
Isocarboxazid tablets are currently on the FDA drug-shortage list. If you take this medicine, please keep taking it as prescribed while supply steadies.
This medicine comes in one strength, 10 mg, and that strength still has an available source. The manufacturer on this record, Lifsa Drugs LLC, reports it as limited availability, so your pharmacy may need a little extra time to order it. No strength is listed as completely unavailable right now.
The reported reason is listed only as "Other," and an estimated recovery date has not yet been set. One manufacturer is currently supplying this medicine, so it has not stopped being made — it is simply harder to get in the short term.
Here are practical steps you can take:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order the 10 mg tablets; they can check wholesalers and manufacturers for available stock.
- If your pharmacy cannot locate it soon, ask your prescriber or pharmacist about your options rather than going without.
- Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls.
This is general, national information from FDA data and may not match your local pharmacy's stock, so please check with them directly.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Lifsa Drugs LLC 📞 833.627.0070 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01) | Limited Availability | Estimated recovery: TBD | Other | Current |
Full shortage page: Isocarboxazid Tablet →
View Isocarboxazid Tablet on the FDA drug-shortage database →
Tiagabine Hydrochloride Tablet View full page →
Key facts about the Tiagabine Hydrochloride Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Tiagabine Hydrochloride Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Tiagabine Hydrochloride Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Tiagabine Hydrochloride tablets are currently on the FDA drug-shortage list, and I want to walk you through what this means so you can plan calmly.
This report covers all four strengths — 2 mg, 4 mg, 12 mg, and 16 mg (30-count bottles). Right now none of these strengths have an available source from the manufacturer that filed this report, Teva Pharmaceuticals. The reason given is that Teva is discontinuing manufacture of the drug. Because this is a discontinuation rather than a temporary delay, this particular supply may not return, so a conversation with your prescriber is a sensible next step. Keep in mind this report reflects only Teva — other makers may still supply this same medicine.
Please do not stop, skip, or change your dose on your own. Here is how to approach it:
- Ask your pharmacy to check wholesalers and other manufacturers for your strength.
- This same medicine (tiagabine) is also listed from Sun Pharmaceutical, Cephalon, and Novadoz. Your pharmacy may be able to source one of these, though it may not be in local stock right away.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general information from national FDA data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 2 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 4 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 2 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 4 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 12 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 16 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 2 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 4 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 12 mg/1
- Tiagabine Hydrochloride — TIAGABINE HYDROCHLORIDE 16 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2mg 30 count Discontinuation of the manufacture of the drug
- 12mg 30 count Discontinuation of the manufacture of the drug
- 4mg 30 count Discontinuation of the manufacture of the drug
- 16mg 30 count Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 888-838-2872 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Tiagabine Hydrochloride Tablet →
View Tiagabine Hydrochloride Tablet on the FDA drug-shortage database →
Nitroglycerin Ointment View full page →
Key facts about the Nitroglycerin Ointment shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Nitroglycerin Ointment may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Nitroglycerin Ointment shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Nitroglycerin ointment (0.4%) is currently listed on the FDA drug-shortage list. I want to walk you through what this means so you can plan calmly.
The strength involved here is the 0.4% ointment, and right now there is no available source reported for it. The manufacturer on this record, AbbVie (the brand Rectiv), has reported that this product is being discontinued — meaning they are stopping its manufacture. Because this is a discontinuation, this particular supply problem may be permanent rather than temporary. That makes a conversation with your prescriber the right next step.
At the same time, this report reflects only that one manufacturer. The same medicine — nitroglycerin 4 mg/g ointment — is still made by other companies, so it may still be possible to obtain.
Here is what I suggest, in order:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check whether the same nitroglycerin ointment is available from another maker, such as Cosette, Encube, Trupharma, Bryant Ranch, or Solaris — though it may not be in local stock right away.
- If it cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 0.4% Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: AbbVie Inc. 📞 800-678-1605 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rectiv, Ointment, 0.4% (NDC 58914-301-80) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Nitroglycerin Ointment →
View Nitroglycerin Ointment on the FDA drug-shortage database →
Nitrofurantoin Oral Suspension View full page →
Key facts about the Nitrofurantoin Oral Suspension shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Nitrofurantoin Oral Suspension may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Nitrofurantoin Oral Suspension shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Nitrofurantoin oral suspension is currently on the FDA shortage list. This applies to the liquid form, which is often used for children or for people who have trouble swallowing pills.
The one strength on this record, 25 mg/5 mL, has no available source right now. There are no other strengths of the suspension listed to compare it against here. The reason reported is that Amneal Pharmaceuticals is discontinuing its manufacture of this product. Because this is a discontinuation rather than a temporary delay, this particular supply may not return, so it's worth planning your next step early — but this record reflects only one manufacturer, and other companies still make the same medicine.
Here is what I'd suggest, in order:
- Do not stop or change the dose on your own. Keep taking it as prescribed while you sort out supply.
- Ask your pharmacy to check other makers — the same medicine (nitrofurantoin suspension) is listed from Lupin, Aurobindo, Rising Pharma, Biocon, ANI, and NorthStar. Your pharmacy may be able to source one, though it may not be in local stock.
- If it can't be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
- Manufacturer contact numbers are listed on this page; pharmacies usually make these calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Nitrofurantoin — NITROFURANTOIN 50 mg/5mL
- Nitrofurantoin — NITROFURANTOIN 25 mg/5mL
- Nitrofurantoin — NITROFURANTOIN MONOHYDRATE 25 mg/5mL
- Nitrofurantoin — NITROFURANTOIN MONOHYDRATE 25 mg/5mL
- Nitrofurantoin — NITROFURANTOIN 25 mg/5mL
- Nitrofurantoin — NITROFURANTOIN 25 mg/5mL
- Nitrofurantoin — NITROFURANTOIN 25 mg/5mL
- Nitrofurantoin — NITROFURANTOIN 25 mg/5mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 25 mg/5 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Nitrofurantoin, Oral Suspension, 25 mg/5 mL (NDC 69238-2512-9) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Nitrofurantoin Oral Suspension →
View Nitrofurantoin Oral Suspension on the FDA drug-shortage database →
Azithromycin Tablet View full page →
Key facts about the Azithromycin Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Azithromycin Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Azithromycin Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Azithromycin tablets are currently listed on the FDA drug-shortage list. I know that can feel unsettling, so let me walk you through what this report actually shows.
The record filed here comes from Pfizer, the maker of the brand Zithromax, and it covers both the 250 mg and 500 mg tablets. Neither strength has an available source from this manufacturer right now. The reason listed is that Pfizer is discontinuing manufacture of these tablets, so for this maker the supply problem may be permanent rather than short-term. No estimated recovery date is given because the product is being discontinued.
It is important to know that this report reflects only Pfizer's filing. Azithromycin is the same medicine whether it comes from one company or another, and other makers still hold records for the same tablets — including Lannett, Sandoz, Major Pharmaceuticals, and AvKARE.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order azithromycin from another manufacturer, such as those listed above; your pharmacy can check wholesalers, though a given brand may not be in local stock.
- If your exact tablet cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers appear on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Zithromax — AZITHROMYCIN DIHYDRATE 250 mg/1
- Zithromax — AZITHROMYCIN DIHYDRATE 500 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 250 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 500 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 250 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 500 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 600 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 250 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 500 mg/1
- Azithromycin — AZITHROMYCIN MONOHYDRATE 600 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 250 mg/1
- Azithromycin — AZITHROMYCIN DIHYDRATE 500 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 250 mg Discontinuation of the manufacture of the drug
- 500 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Zithromax, Tablet, 500 mg (NDC 0069-3070-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Zithromax, Tablet, 250 mg (NDC 0069-4061-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Azithromycin Tablet →
View Azithromycin Tablet on the FDA drug-shortage database →
Aprepitant Oral Powder For Suspension View full page →
Key facts about the Aprepitant Oral Powder For Suspension shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Aprepitant Oral Powder For Suspension may not appear here at all, so this is not a picture of every available option. See the full Aprepitant Oral Powder For Suspension shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Aprepitant Oral Powder for Suspension is currently on the FDA shortage list. I want to walk you through what this means for the strength you may be taking.
The 125 mg strength is the one affected, and right now no available source is reported for it. According to the manufacturer's filing, this product (sold as Emend, Oral Powder for Suspension) is set to be discontinued in approximately early-September 2026. Because it is being discontinued rather than temporarily out of stock, this supply problem may be permanent, so a conversation with your prescriber is the right next step.
This report reflects only the one manufacturer who filed it, so please do not assume the medicine is gone everywhere. Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check with wholesalers and other manufacturers, since local stock can differ from national data.
- Talk with your prescriber or pharmacist about options — for example, another form of aprepitant or a clinician-chosen alternative that fits your needs.
The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls. This is general information from national data and is not individualized medical advice.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 125 mg To be discontinued in approximately early-September 2026.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Merck Sharp & Dohme LLC 📞 800-672-6372 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03) | — | To be discontinued in approximately early-September 2026. | — | To Be Discontinued |
Full shortage page: Aprepitant Oral Powder For Suspension →
View Aprepitant Oral Powder For Suspension on the FDA drug-shortage database →
Fosaprepitant Dimeglumine Injection View full page →
Key facts about the Fosaprepitant Dimeglumine Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Fosaprepitant Dimeglumine Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Fosaprepitant Dimeglumine Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Fosaprepitant dimeglumine injection — the medicine used to help prevent nausea and vomiting from chemotherapy — is currently on the FDA shortage list. I want to explain what this means for you in plain terms.
This shortage record covers the single strength, 150 mg/5 mL, which has no available source from the reporting manufacturer right now. The reason listed is that Fresenius Kabi USA is discontinuing its manufacture of this product. Because this is a discontinuation rather than a temporary delay, this particular supply may not return. Importantly, though, this report reflects only that one manufacturer — the same medicine is still listed as available from several other makers, so your pharmacy may be able to find it elsewhere.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own — keep your scheduled doses as planned with your care team.
- Ask your pharmacy to check wholesalers and other manufacturers; the same medicine (150 mg/5 mL) is listed from makers such as Merck, Hikma, Baxter, and others, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Emend — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Fosaprepitant Dimeglumine — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Fosaprepitant — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Fosaprepitant — FOSAPREPITANT DIMEGLUMINE 150 mg/1
- Fosaprepitant — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Fosaprepitant — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Fosaprepitant — FOSAPREPITANT DIMEGLUMINE 150 mg/1
- Fosaprepitant — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Fosaprepitant Dimeglumine — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Fosaprepitant — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Fosaprepitant — FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
- Focinvez — FOSAPREPITANT DIMEGLUMINE 150 mg/50mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 150 mg/5 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Fosaprepitant Dimeglumine Injection →
View Fosaprepitant Dimeglumine Injection on the FDA drug-shortage database →
Idelalisib Tablet View full page →
Key facts about the Idelalisib Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Idelalisib Tablet may not appear here at all, so this is not a picture of every available option. See the full Idelalisib Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Idelalisib tablets (brand name Zydelig) are currently on the FDA shortage list, and I want to walk you through what that means for you.
Both strengths of this medicine are affected. Neither the 100 mg nor the 150 mg tablet has an available source right now, and the manufacturer on this record has reported that the product is being discontinued.
Because the reason listed is a discontinuation in manufacturing, this supply problem may be permanent rather than a short-term gap. Our records do not show another maker supplying the same medicine at this time, so the most important next step is a conversation with your care team.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort out next steps.
- Ask your pharmacy to check with wholesalers and other manufacturers; local stock can differ from national reports.
- Contact your prescriber soon to discuss options, since this medicine is being discontinued and a clinician-chosen plan is the right path forward.
- The manufacturer's contact number is listed on this page for reference, though pharmacies usually handle those calls.
This is general information from national, manufacturer-reported data and may not match your pharmacy's actual stock. Your prescriber and pharmacist can guide the choice that fits you best.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg Discontinuation in the manufacturing of the drug
- 150 mg Discontinuation in the manufacturing of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Gilead Sciences, Inc. 📞 800-445-3235 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Zydelig, Tablet, 150 mg (NDC 61958-1702-1) | — | Discontinuation in the manufacturing of the drug | — | To Be Discontinued |
| Zydelig, Tablet, 100 mg (NDC 61958-1701-1) | — | Discontinuation in the manufacturing of the drug | — | To Be Discontinued |
Full shortage page: Idelalisib Tablet →
Ursodiol Capsule View full page →
Key facts about the Ursodiol Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ursodiol Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ursodiol Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Ursodiol 300 mg capsules are currently on the FDA shortage list, and I want to walk you through what this means so you can plan ahead calmly.
The one strength involved here is the 300 mg capsule. The manufacturer that filed this report, Strides Pharma, has listed it as being discontinued — meaning they are stopping production of this product. Because this is a discontinuation rather than a temporary delay, this particular company's supply problem may be permanent rather than short-term. That said, this report reflects only Strides Pharma. Several other companies make the same ursodiol 300 mg capsule, so the medicine itself can still be available.
Here is how to approach it:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort out supply.
- Ask your pharmacy to check wholesalers and other manufacturers. The same ursodiol 300 mg capsule is made by companies including Lannett, Actavis, Major, KVK-Tech, PuraCap, AvKARE, Laurus, Epic, Aurobindo, and others. Your pharmacy may be able to source one, though it may not be in local stock right away.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSADIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSADIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
- Ursodiol — URSODIOL 300 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 300 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Strides Pharma Inc. 📞 877-244-9825 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ursodiol, Capsule, 300 mg (NDC 64380-844-06) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Ursodiol Capsule →
Icosapent Ethyl Capsule View full page →
Key facts about the Icosapent Ethyl Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Icosapent Ethyl Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Icosapent Ethyl Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Icosapent ethyl capsules are currently on the FDA shortage list, and I want to walk you through what that means for you.
The affected strength is the 1 g capsule, which one manufacturer, Apotex, has reported as having no available source right now. The reason listed is that this manufacturer is discontinuing its production of the drug. Because this is a discontinuation rather than a temporary delay, this particular supply may not return. That said, this report reflects only Apotex — other companies still make icosapent ethyl, so the medicine itself is not off the market.
Here is what I'd suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort out supply.
- Ask your pharmacy to check wholesalers and other manufacturers; the same 1 g capsule is made by several other companies, including Hikma, Teva, Northstar, Camber, AvKARE, Epic Pharma, Dr. Reddy's, and Amarin (Vascepa). Your pharmacy may be able to source one of these, though it may not be in local stock.
- If your exact capsule can't be found, ask your prescriber or pharmacist about options that fit your needs.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Icosapent Ethyl — ICOSAPENT ETHYL 1 g/1
- Icosapent Ethyl — ICOSAPENT ETHYL .5 g/1
- Icosapent Ethyl — ICOSAPENT ETHYL 500 mg/1
- Icosapent Ethyl — ICOSAPENT ETHYL 1 g/1
- Icosapent Ethyl — ICOSAPENT ETHYL 1 g/1
- Icosapent Ethyl — ICOSAPENT ETHYL .5 g/1
- Icosapent Ethyl — ICOSAPENT ETHYL 1 g/1
- Icosapent Ethyl — ICOSAPENT ETHYL 1 g/1
- Icosapent Ethyl — ICOSAPENT ETHYL 1 g/1
- Icosapent — ICOSAPENT ETHYL 1000 mg/1
- Icosapent Ethyl — ICOSAPENT ETHYL 500 mg/1
- Vascepa — ICOSAPENT ETHYL 1000 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 g Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Apotex Corp. 📞 800-706-5575 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Icosapent Ethyl, Capsule, 1 g (NDC 61474-9711-1) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Icosapent Ethyl, Capsule, 1 g (NDC 60429-005-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Icosapent Ethyl Capsule →
View Icosapent Ethyl Capsule on the FDA drug-shortage database →
Furosemide Oral Solution View full page →
Key facts about the Furosemide Oral Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Furosemide Oral Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Furosemide Oral Solution shortage page → for the still-marketed options we could find.
- Shortage of an inactive ingredient component (3 NDCs)
Do you take this medicine? What Should I Do?!
Furosemide oral solution is currently on the FDA shortage list. If you or someone you care for takes this liquid form of furosemide, here is what that means in practical terms.
Both strengths of this product remain available from the reporting manufacturer, so neither strength is completely without a source right now. The 10 mg/1 mL and the 40 mg/5 mL solutions are both listed as available, though on a limited "allocation" basis. This means supply is being released in measured amounts rather than freely, which can make it harder for your pharmacy to order large quantities at once. The reason given by the manufacturer is a shortage of one of the inactive ingredients used to make the solution. There is no estimated recovery date listed beyond these allocation notes.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — this medicine helps control fluid, and consistency matters.
- Ask your pharmacy to order your strength, since both are still reportedly available; pharmacies can check wholesalers and manufacturers.
- The same medicine is also listed from another maker (Precision Dose), so your pharmacy may be able to source it, though it may not be in local stock.
- If your exact product cannot be found, ask your pharmacist or prescriber about options.
A manufacturer contact number appears on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg/1 mL Available on allocation
- 40 mg/5 mL Available on allocation
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63) | Limited Availability | Available on allocation | Shortage of an inactive ingredient component | Current |
| Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46) | Limited Availability | Available on allocation | Shortage of an inactive ingredient component | Current |
| Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50) | Limited Availability | Available on allocation | Shortage of an inactive ingredient component | Current |
Full shortage page: Furosemide Oral Solution →
View Furosemide Oral Solution on the FDA drug-shortage database →
Dapsone Gel View full page →
Key facts about the Dapsone Gel shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dapsone Gel may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dapsone Gel shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Dapsone gel is currently listed on the FDA drug-shortage report. I want to walk you through what this means so you can plan your next refill with confidence.
The affected product is the 7.5% strength, made by Amneal Pharmaceuticals. Right now, this strength has no available source reported, and the reason listed is that the manufacturer is discontinuing this product. Because this is marked "to be discontinued," the supply problem for Amneal's 7.5% gel may be permanent rather than temporary. That said, this report reflects only the one manufacturer who filed it, and dapsone gel is still made by other companies.
Please do not stop or change how you use your gel on your own. Here is a sensible way to move forward:
- Talk with your prescriber or pharmacist before your next refill runs low, since your exact 7.5% product is being discontinued.
- Ask your pharmacy whether they can source dapsone gel from another maker — the same medicine is listed as available in 5% (50 mg/g) and 7.5% (75 mg/g) forms from several manufacturers, though these may not sit on your local shelf.
- Ask your prescriber which option is right for you before switching.
Manufacturer contact numbers appear on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Aczone — DAPSONE 50 mg/g
- Dapsone — DAPSONE 75 mg/g
- Dapsone — DAPSONE 50 mg/g
- Dapsone — DAPSONE 75 mg/g
- Aczone — DAPSONE 75 mg/g
- Dapsone — DAPSONE 50 mg/g
- Dapsone — DAPSONE 75 mg/g
- Dapsone — DAPSONE 50 mg/g
- Dapsone — DAPSONE 50 mg/g
- Dapsone — DAPSONE 75 mg/g
- Dapsone — DAPSONE 50 mg/g
- Dapsone — DAPSONE 50 mg/g
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 7.5% Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dapsone, Gel, 7.5% (NDC 69238-1627-6) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Dapsone Gel →
Progesterone Vaginal Gel View full page →
Key facts about the Progesterone Vaginal Gel shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Progesterone Vaginal Gel may not appear here at all, so this is not a picture of every available option. See the full Progesterone Vaginal Gel shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Progesterone vaginal gel (4%) is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
This shortage affects the 4% strength, which is the only strength on this record. There is no available source reported for it right now. The manufacturer, AbbVie, has listed the product (Crinone, 4%) as being discontinued, which means this supply problem may be permanent rather than a short-term gap. Because the reason given is discontinuation of manufacture, a conversation with your prescriber is the right next step.
Please keep this in mind, in order:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check with their wholesalers, since local stock can differ from national reports and some supply may still be found.
- If your pharmacy cannot locate the 4% gel, talk with your prescriber or pharmacist about a clinician-chosen option that fits your needs.
- Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls.
This information comes from national, manufacturer-reported FDA data and is general, not personal medical advice. Your care team can help you decide what is best for you.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 4% Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: AbbVie Inc. 📞 800-678-1605 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Crinone, Vaginal Gel, 4% (NDC 0023-6150-04) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Progesterone Vaginal Gel →
View Progesterone Vaginal Gel on the FDA drug-shortage database →
Tazemetostat Hydrobromide Tablet View full page →
Key facts about the Tazemetostat Hydrobromide Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Tazemetostat Hydrobromide Tablet may not appear here at all, so this is not a picture of every available option. See the full Tazemetostat Hydrobromide Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Tazemetostat (brand name Tazverik) is currently listed on the FDA drug-shortage list. I want to walk you through what this means so you know your next step.
This medicine comes in one strength, 200 mg, and that strength has no available source reported right now. The manufacturer, Epizyme (an Ipsen Company), has reported that it is discontinuing the manufacture of this product. Because the record shows the product is being discontinued rather than temporarily short, this supply problem may be permanent. No other maker of this exact medicine appears in our records at this time.
Please keep taking your medicine as prescribed while this is sorted out. Do not stop or change your dose on your own.
Here is what I suggest:
- Contact your prescriber or pharmacist soon to discuss your options, since this medicine is being discontinued and a plan for what comes next is the right step.
- Ask your pharmacy to check whether any stock remains at wholesalers, though supply may be limited.
- For reference, the manufacturer's contact number is listed on this page; pharmacies usually handle those calls.
This information comes from national, manufacturer-reported FDA data and may not match what your local pharmacy has on hand. It is general information, not personal medical advice.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 200 mg Discontinuation of the manufacture of the drug product
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Epizyme, Inc. (An Ipsen Company) 📞 (855)-463-5127 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Tazverik, Tablet, 200 mg (NDC 72607-100-00) | — | Discontinuation of the manufacture of the drug product | — | To Be Discontinued |
Full shortage page: Tazemetostat Hydrobromide Tablet →
View Tazemetostat Hydrobromide Tablet on the FDA drug-shortage database →
Nebivolol Hydrochloride Tablet View full page →
Key facts about the Nebivolol Hydrochloride Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Nebivolol Hydrochloride Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Nebivolol Hydrochloride Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Nebivolol hydrochloride tablets are currently on the FDA drug-shortage list. This medicine is used to help manage blood pressure, so I want to walk you through what this report means and the steps you can take.
The report comes from one manufacturer, Torrent Pharmaceuticals, and covers all four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg — none of these have an available source from Torrent right now. The listed reason is that Torrent is discontinuing its production of the drug. Because this is a discontinuation rather than a temporary delay, this particular supply may not return. That said, this record reflects only Torrent, and other companies still make nebivolol.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed.
- Ask your pharmacy to check wholesalers and other makers; the same medicine is also listed from Allergan (Bystolic), Major Pharmaceuticals, Apnar Pharma, and Unichem, though these may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as a different strength or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Bystolic — NEBIVOLOL HYDROCHLORIDE 2.5 mg/1
- Bystolic — NEBIVOLOL HYDROCHLORIDE 5 mg/1
- Bystolic — NEBIVOLOL HYDROCHLORIDE 10 mg/1
- Bystolic — NEBIVOLOL HYDROCHLORIDE 20 mg/1
- Nebivolol — NEBIVOLOL 2.5 mg/1
- Nebivolol — NEBIVOLOL 5 mg/1
- Nebivolol — NEBIVOLOL 10 mg/1
- Nebivolol — NEBIVOLOL HYDROCHLORIDE 2.5 mg/1
- Nebivolol — NEBIVOLOL HYDROCHLORIDE 5 mg/1
- Nebivolol — NEBIVOLOL HYDROCHLORIDE 10 mg/1
- Nebivolol — NEBIVOLOL HYDROCHLORIDE 20 mg/1
- Nebivolol Hydrochloride — NEBIVOLOL HYDROCHLORIDE 2.5 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg Discontinuation of the manufacture of the drug
- 2.5 mg Discontinuation of the manufacture of the drug
- 5 mg Discontinuation of the manufacture of the drug
- 10 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Torrent Pharmaceuticals Limited 📞 908-280-3333 16 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-90) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-90) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-90) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-90) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Nebivolol Hydrochloride Tablet →
View Nebivolol Hydrochloride Tablet on the FDA drug-shortage database →
Ivabradine Hydrochloride Tablet View full page →
Key facts about the Ivabradine Hydrochloride Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ivabradine Hydrochloride Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ivabradine Hydrochloride Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Ivabradine hydrochloride tablets are currently listed on the FDA drug-shortage list, and I want to walk you through what this means for you.
Both strengths of the branded product on this record — the 5 mg and the 7.5 mg tablets — currently have no available source. Neither is reported as available right now. The reason listed is that the manufacturer of this branded product (Corlanor, made by Amgen) has chosen to stop making it. Because this is a discontinuation, the supply problem with that particular product may be permanent rather than temporary.
Here is the important part: this notice reflects only the manufacturer that filed it. The same medicine, ivabradine, is still made by several other companies, so this is not the end of the road.
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other makers — ivabradine tablets in both 5 mg and 7.5 mg are listed from several other manufacturers, though they may not be in local stock right away.
- If your exact product cannot be found, talk with your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Ivabradine — IVABRADINE HYDROCHLORIDE 5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 7.5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 7.5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 7.5 mg/1
- Corlanor — IVABRADINE HYDROCHLORIDE 5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 7.5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 5 mg/1
- Ivabradine — IVABRADINE HYDROCHLORIDE 7.5 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- eq. 7.5 mg base Discontinuation of the manufacture of the drug product
- eq. 5 mg base Discontinuation of the manufacture of the drug product
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amgen Inc. 📞 1-800-772-6436 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60) | — | Discontinuation of the manufacture of the drug product | — | To Be Discontinued |
| Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60) | — | Discontinuation of the manufacture of the drug product | — | To Be Discontinued |
Full shortage page: Ivabradine Hydrochloride Tablet →
View Ivabradine Hydrochloride Tablet on the FDA drug-shortage database →
Ivabradine Solution View full page →
Key facts about the Ivabradine Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ivabradine Solution may not appear here at all, so this is not a picture of every available option. See the full Ivabradine Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Ivabradine oral solution (5 mg/5 mL) is currently on the FDA drug-shortage list, and the manufacturer that filed this report has listed it as being discontinued.
The one strength covered here — 5 mg/5 mL — has no available source reported right now. The reason given is a discontinuation of the manufacture of the drug product, filed by Amgen (for Corlanor solution). Because this is a discontinuation rather than a short-term delay, this supply problem may be permanent, so a conversation with your prescriber is the right next step. No other maker of this oral solution is listed in our records, though this report reflects only the manufacturer who filed it.
What you can do:
- Do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed while you sort this out.
- Ask your pharmacy to check with wholesalers and other suppliers, since local stock can differ from national reports.
- Because this strength is listed as discontinued, ask your prescriber or pharmacist about options — for example a clinician-chosen alternative that fits your needs.
The manufacturer contact number is listed on this page for reference; pharmacies usually handle those calls. This is general information from national data and is not individualized medical advice.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg/5 mL Discontinuation of the manufacture of the drug product
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amgen Inc. 📞 1-800-772-6436 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28) | — | Discontinuation of the manufacture of the drug product | — | To Be Discontinued |
Full shortage page: Ivabradine Solution →
View Ivabradine Solution on the FDA drug-shortage database →
Pilocarpine Hydrochloride Ophthalmic Solution View full page →
Key facts about the Pilocarpine Hydrochloride Ophthalmic Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Pilocarpine Hydrochloride Ophthalmic Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Pilocarpine Hydrochloride Ophthalmic Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Pilocarpine hydrochloride ophthalmic solution (the brand Vuity) is currently on the FDA shortage list. I want to walk you through what this means and the practical steps that can help.
The affected strength is 12.5 mg/1 mL, and right now there is no available source reported for it. The reason is that the maker on this record, AbbVie, is discontinuing its manufacture of this product. Because this is listed as a discontinuation rather than a temporary supply gap, this particular product may not return. That makes a conversation with your prescriber the right next step.
It is important to know this report reflects only one manufacturer's decision. The same active medicine, pilocarpine hydrochloride eye drops, is still listed from other makers — including Amneal, Sandoz, Somerset, and a low-concentration product called Qlosi from Orasis — though these come in different concentrations and may not be in local stock.
- Do not stop or change how you use your drops on your own.
- Ask your pharmacy whether they can source the same medicine from another maker; it may need to be ordered.
- Since your exact product is being discontinued, ask your prescriber or pharmacist which option fits you.
- Manufacturer contact numbers are listed on this page; pharmacies usually make these calls.
This is national, manufacturer-reported information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Pilocarpine Hydrochloride Ophthalmic — PILOCARPINE HYDROCHLORIDE 12.5 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 10 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 20 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 40 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 10 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 20 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 40 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 10 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 20 mg/mL
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 40 mg/mL
- Qlosi — PILOCARPINE HYDROCHLORIDE 4 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 12.5 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: AbbVie Inc. 📞 800-633-9110 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-03) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-04) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-06) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Pilocarpine Hydrochloride Ophthalmic Solution →
View Pilocarpine Hydrochloride Ophthalmic Sol... on the FDA drug-shortage database →
Pentamidine Isethionate Injection View full page →
Key facts about the Pentamidine Isethionate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Pentamidine Isethionate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Pentamidine Isethionate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Pentamidine Isethionate Injection is currently on the FDA shortage list, and I want to walk you through what that means for you.
The one strength on this report, 300 mg/3 mL, has no available source from the manufacturer that filed this report. There are no other strengths to separate out here — this record covers a single strength.
The reason given is straightforward: the manufacturer, XGen Pharmaceuticals, made a business decision to stop making this product. Because the status is listed as "to be discontinued," this particular supply problem may be permanent rather than temporary. That makes a conversation with your prescriber or pharmacist the right next step. Importantly, this report reflects only that one manufacturer — the same medicine may still be available from other makers.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own.
- Ask your pharmacy to check wholesalers and other suppliers, since the same medicine (pentamidine isethionate injection) is still listed from other makers, including PAI Pharma, Seton Pharmaceuticals, Avet Pharmaceuticals, and Fresenius Kabi (Pentam 300). Your pharmacy may be able to source one of these, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
A manufacturer contact number is listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 300 mg/3 mL A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: XGen Pharmaceuticals DJB, Inc. 📞 866-390-4411 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Pentamidine Isethionate, Injection, 300 mg/3 mL (NDC 39822-3050-2) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Pentamidine Isethionate Injection →
View Pentamidine Isethionate Injection on the FDA drug-shortage database →
Ramelteon Tablet View full page →
Key facts about the Ramelteon Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ramelteon Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ramelteon Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Ramelteon (the brand version is called Rozerem) is currently on the FDA shortage list. This affects the 8 mg tablet, which is the only strength for this product, and the record lists it as to be discontinued.
Here is what that means. The manufacturer on this record, Takeda, reports the 8 mg tablet as having no available source right now, though it is expected to remain available through sometime in 2027 depending on the package. Because this product is being discontinued, this supply problem may be permanent for the branded version. That said, ramelteon is a widely prescribed medicine, and the same medicine is still made by several other companies — so this does not mean ramelteon itself is going away.
What you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to try ordering the 8 mg tablet — they can check wholesalers and other makers. Generic ramelteon 8 mg is listed from several manufacturers (for example Actavis, Upsher-Smith, Aurobindo, Granules, and others), so your pharmacy may be able to source one, though it may not be in local stock.
- If it cannot be found, talk with your prescriber or pharmacist about the best next step.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
- Ramelteon — RAMELTEON 8 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 8 mg Product is expected to be available through February 2027. · Product is expected to be available through June 2027.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Takeda Pharmaceuticals USA Inc. 📞 877-825-3327 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rozerem, Tablet, 8 mg (NDC 64764-805-30) | — | Product is expected to be available through June 2027. | — | To Be Discontinued |
| Rozerem, Tablet, 8 mg (NDC 64764-805-10) | — | Product is expected to be available through February 2027. | — | To Be Discontinued |
Full shortage page: Ramelteon Tablet →
Plerixafor Injection View full page →
Key facts about the Plerixafor Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Plerixafor Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Plerixafor Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Plerixafor injection is currently on the FDA shortage list, so I want to walk you through what that means and what comes next.
The strength affected is the 24 mg per 1.2 mL (20 mg per mL) injection. Right now this is the only strength on this record, and it has no available source from the manufacturer who filed this report. The reason given is that the maker, Fresenius Kabi USA, made a business decision to discontinue making this product. Because this is a discontinuation rather than a temporary delay, the supply problem from this particular manufacturer may be permanent.
I want to be clear, though: this report reflects only the one manufacturer that filed it. The same medicine is still listed from other makers, so it may still be possible to obtain.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine (plerixafor 24 mg/1.2 mL) is also made by Sanofi-Aventis (Mozobil), Sagent, Camber, Amneal, Zydus, Bryant Ranch Prepack, and Novadoz, though these may not be in local stock.
- Since this product is being discontinued, talk with your prescriber or pharmacist about a clinician-chosen plan.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles these calls. This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 24 mg per 1.2 mL (20 mg per mL... A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-391-6300 www.fresenius-kabi.com 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Plerixafor Injection →
View Plerixafor Injection on the FDA drug-shortage database →
Peritoneal Dialysis Solution View full page →
Key facts about the Peritoneal Dialysis Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Peritoneal Dialysis Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Peritoneal Dialysis Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Peritoneal Dialysis Solution (the DELFLEX brand with dextrose) is currently on the FDA shortage list. Because your dialysis is so important, I want to walk you through what this means and what to do next.
All six reported strengths are affected right now, with no available source listed: 4.25%, 2.5%, and 1.5% Low Mg/Low Ca in both the 2L and 2.5L/3L sizes. The manufacturer, Fresenius Medical Care North America, has marked these products "to be discontinued" — the older product codes (NDC numbers) are being retired and replaced with a new labeler code. In practical terms, this supply change may be permanent, so a conversation with your dialysis team or prescriber is the right next step rather than waiting.
Here is how I'd approach it:
- Do not stop, skip, or change your dialysis solution on your own — keep following your current plan.
- Ask your pharmacy or dialysis provider to check wholesalers for your exact product; the replacement code may be reaching them.
- The same medicine is made by related Fresenius suppliers, so your provider may be able to source an equivalent DELFLEX solution, though it may not be in local stock.
- Talk with your prescriber about the best equivalent for your prescription.
Manufacturer contact numbers are listed on this page for reference; your provider usually handles these calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Delflex — DEXTROSE MONOHYDRATE 1.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Delflex — SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 448 mg/100mL; CALCIUM CHLORIDE 18.4
- Delflex — DEXTROSE MONOHYDRATE 1.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
- Delflex — DEXTROSE MONOHYDRATE 2.5 g/100mL; SODIUM CHLORIDE 538 mg/100mL; SODIUM LACTATE 4
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 4.25% Low Mg/Low Ca 2L The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- 1.5% Low Mg/Low Ca 2L The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- 4.25% Low Mg/Low Ca 2.5L/3L The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- 2.5% Low Mg/Low Ca 2.5L/3L The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- 1.5% Low Mg/Low Ca 2.5L/3L The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- 2.5% Low Mg/Low Ca 2L The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Medical Care North America 📞 800-323-5188 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92) | — | The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. | — | To Be Discontinued |
| DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-206-94) | — | The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. | — | To Be Discontinued |
| DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94) | — | The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. | — | To Be Discontinued |
| DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94) | — | The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. | — | To Be Discontinued |
| DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92) | — | The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. | — | To Be Discontinued |
| DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92) | — | The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. | — | To Be Discontinued |
Full shortage page: Peritoneal Dialysis Solution →
View Peritoneal Dialysis Solution on the FDA drug-shortage database →
Clindamycin Palmitate Hydrochloride Injection View full page →
Key facts about the Clindamycin Palmitate Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Clindamycin Palmitate Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Clindamycin Palmitate Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Clindamycin Palmitate Hydrochloride Injection is currently listed on the FDA drug-shortage report, so I want to walk you through what that means for you.
This medicine comes in one strength on this record, 75 mg/5 mL, and right now that strength has no available source. The reason given is that the manufacturer, Amneal Pharmaceuticals, is discontinuing production of this product. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent — so a conversation with your prescriber is the right next step to plan ahead.
Please keep taking your medicine as prescribed while you sort this out. Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check with wholesalers and other manufacturers — local stock can differ from national reports.
- The same medicine (Clindamycin Palmitate Hydrochloride, 75 mg/5 mL, in a powder-for-solution form) may still be available from another maker; your pharmacy may be able to source it, though it may not be on the shelf locally.
- Ask your prescriber or pharmacist about options if it cannot be found.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 75 mg/5 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Clindamycin Palmitate Hydrochloride Injection →
View Clindamycin Palmitate Hydrochloride Inje... on the FDA drug-shortage database →
Itraconazole Capsule View full page →
Key facts about the Itraconazole Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Itraconazole Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Itraconazole Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Itraconazole capsules are currently on the FDA shortage list, and I want to walk you through what that means for you.
The strength involved here is the 100 mg capsule. Right now, no available source is being reported for this strength, and the reason listed is a discontinuation of manufacturing. This report comes from Janssen Pharmaceuticals (the maker of the brand Sporanox), whose 100 mg capsules are marked "to be discontinued." Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent — which makes a conversation with your prescriber or pharmacist the right next step.
Please keep in mind that this reflects only the manufacturer who filed the report. Other companies still make itraconazole 100 mg capsules, so your pharmacy may be able to source the same medicine from a different maker, though it may not be sitting on the local shelf.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check whether the same medicine is available from another manufacturer — for example, Torrent, Rising Pharma, Amneal, Alembic, Ascend, or NorthStar all list itraconazole 100 mg capsules.
- If your exact capsule cannot be found, ask your prescriber or pharmacist about a suitable alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Itraconazole — ITRACONAZOLE 100 mg/1
- Itraconazole — ITRACONAZOLE 100 mg/1
- Itraconazole — ITRACONAZOLE 100 mg/1
- Itraconazole — ITRACONAZOLE 100 mg/1
- Tolsura — ITRACONAZOLE 65 mg/1
- Itraconazole — ITRACONAZOLE 100 mg/1
- Itraconazole — ITRACONAZOLE 100 mg/1
- Itraconazole — ITRACONAZOLE 100 mg/1
- Itraconazole — ITRACONAZOLE 100 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Janssen Pharmaceuticals 📞 800-JANSSEN (1-800-526-7736) 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sporanox, Capsule, 100 mg (NDC 50458-290-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Sporanox, Capsule, 100 mg (NDC 50458-290-04) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Sporanox, Capsule, 100 mg (NDC 10147-1700-3) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Itraconazole Capsule →
View Itraconazole Capsule on the FDA drug-shortage database →
Lincomycin Hydrochloride Injection View full page →
Key facts about the Lincomycin Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Lincomycin Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Lincomycin Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Lincomycin Hydrochloride Injection is currently on the FDA shortage list, and I want to walk you through what that means for you.
Right now, none of the strengths on this record have an available source. The two manufacturers who filed this report list all three affected sizes — the 600 mg/2 mL vial (10 count), the 3 grams/10 mL vial (10 count), and the 2 mL multiple dose vial — as having no supply available at this time.
The reported reason is a business decision by the manufacturers to stop making these products, and the status is listed as "to be discontinued." This means the supply problem for these specific products may be permanent, so talking with your prescriber is the right next step. Keep in mind this report reflects only these two manufacturers — other companies may still supply the same medicine.
Here is what I suggest:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check wholesalers and other makers — the same medicine (lincomycin hydrochloride injection, 300 mg/mL) is listed from Pharmacia & Upjohn and Sagent, though it may not be in local stock.
- Because these products are being discontinued, ask your prescriber or pharmacist about the best option for you.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 600 mg/2 mL vial x 10 count A business decision was made to discontinue manufacture of the drug.
- 3 grams/10 mL vial x 10 count A business decision was made to discontinue manufacture of the drug.
- 2 mL multiple dose vial Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: XGen Pharmaceuticals DJB, Inc. 📞 866-390-4411 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Lincomycin Hydrochloride Injection →
View Lincomycin Hydrochloride Injection on the FDA drug-shortage database →
Clindamycin Hydrochloride Capsule View full page →
Key facts about the Clindamycin Hydrochloride Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Clindamycin Hydrochloride Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Clindamycin Hydrochloride Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Clindamycin hydrochloride capsules are currently on the FDA shortage list, and I want to walk you through what that means for the strength you take.
This report covers all three capsule strengths — 75 mg, 150 mg, and 300 mg — and none of them have an available source from the manufacturer that filed this notice. The reason listed for each strength is that this maker (Pfizer, which sells the brand Cleocin Hydrochloride) is discontinuing the product. Because this is a discontinuation rather than a temporary supply gap, this particular product's shortage may be permanent. That said, this report reflects only one manufacturer. Clindamycin hydrochloride capsules in the same strengths are still made by other companies, so this medicine is not gone from the market.
Here is how I'd suggest handling it:
- Do not stop, skip, or change your dose on your own.
- Because the same medicine is made by other companies (for example Major Pharmaceuticals, Micro Labs, and others in these strengths), ask your pharmacy whether they can source one of those. It may not be on the local shelf right now.
- If your capsule can't be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually makes these calls. This is general, national data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 150 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 300 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 75 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 150 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 300 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 150 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 300 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 300 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 150 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 150 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 300 mg/1
- Clindamycin Hydrochloride — CLINDAMYCIN HYDROCHLORIDE 75 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 75 mg Discontinuation of the manufacture of the drug
- 300 mg Discontinuation of the manufacture of the drug
- 150 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 844-646-4398 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Clindamycin Hydrochloride Capsule →
View Clindamycin Hydrochloride Capsule on the FDA drug-shortage database →
Arsenic Trioxide Injection View full page →
Key facts about the Arsenic Trioxide Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Arsenic Trioxide Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Arsenic Trioxide Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Arsenic Trioxide Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The affected strength is the 1 mg/1 mL injection. Right now, that strength has no available source from the manufacturer that filed this report, Ingenus Pharmaceuticals. The reason listed is a business decision to discontinue making the product. Because it is being discontinued rather than temporarily delayed, this particular supply may not return, so a conversation with your care team is the right next step.
I want to be clear that this report reflects only one manufacturer. Arsenic Trioxide is still made by several other companies, so the medicine itself is not gone from the market.
Here is what I suggest, in order:
- Do not stop, skip, or change your treatment on your own — this medicine is given by your care team, and continuity matters.
- Ask your pharmacy or infusion provider to check wholesalers and other makers; the same medicine (1 mg/mL and 2 mg/mL) is listed from suppliers such as Fresenius Kabi, Sandoz, Sagent, and others, though it may not be in local stock.
- Ask your prescriber or pharmacist about a clinician-chosen option if your source cannot be found.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Arsenic Trioxide — ARSENIC TRIOXIDE 2 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 1 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 1 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 2 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 1 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 2 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 2 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 1 mg/mL
- Trisenox — ARSENIC TRIOXIDE 2 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 1 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 1 mg/mL
- Arsenic Trioxide — ARSENIC TRIOXIDE 1 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mg/1 mL A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Ingenus Pharmaceuticals LLC 📞 866-321-5031 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Arsenic Trioxide Injection →
View Arsenic Trioxide Injection on the FDA drug-shortage database →
Decitabine Injection View full page →
Key facts about the Decitabine Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Decitabine Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Decitabine Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Decitabine Injection is currently on the FDA shortage list, and I want to walk you through what this means for you.
The only strength on this report is the 50 mg injection, and it does not have an available source right now. The manufacturer listed here, Ingenus Pharmaceuticals (also labeled BluePoint Laboratories), has reported this product as to be discontinued — meaning they are stopping production. Because this is a discontinuation rather than a temporary delay, this particular supply may not return. That said, this report reflects only one manufacturer, and decitabine 50 mg injection is still made by several other companies.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own — this medicine is part of a carefully planned regimen.
- Ask your pharmacy or infusion center to check wholesalers and other manufacturers; the same medicine, decitabine 50 mg injection, is listed from makers such as Hikma, Accord, Sagent, Camber, Dr. Reddy's, Eugia, Mylan, Amneal, and Meitheal. It may not be in local stock, but it can often be sourced.
- If your exact product cannot be found, talk with your prescriber about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually make these calls. Local stock may differ from this national data.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Decitabine — DECITABINE 50 mg/1
- Decitabine — DECITABINE 50 mg/20mL
- Decitabine — DECITABINE 50 mg/20mL
- Decitabine — DECITABINE 50 mg/10mL
- Decitabine — DECITABINE 50 mg/10mL
- Decitabine — DECITABINE 50 mg/10mL
- Decitabine — DECITABINE 50 mg/26mL
- Decitabine — DECITABINE 50 mg/20mL
- Decitabine — DECITABINE 50 mg/20mL
- Decitabine — DECITABINE 50 mg/10mL
- Decitabine — DECITABINE 50 mg/20mL
- Decitabine — DECITABINE 50 mg/20mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg Discontinuation of the manufacture of the drug · Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Ingenus Pharmaceuticals LLC 📞 866-321-5031 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Decitabine, Injection, 50 mg (NDC 68001-573-41) | — | Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Decitabine, Injection, 50 mg (NDC 50742-430-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Decitabine Injection →
View Decitabine Injection on the FDA drug-shortage database →
Docetaxel Injection View full page →
Key facts about the Docetaxel Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Docetaxel Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Docetaxel Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Docetaxel Injection is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The affected strength is the 10 mg/1 mL injection, and right now there is no available source reported for it. The manufacturer that filed this report, Ingenus Pharmaceuticals, states this is a business decision to discontinue making the drug. Because this product is listed "to be discontinued," this particular supply problem may be permanent. That said, this report reflects only one manufacturer — docetaxel is made by other companies too, so the medicine itself is still on the market in various forms and strengths.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own — this medicine is part of a carefully planned regimen.
- Since your exact strength is being discontinued, talk with your prescriber or pharmacist soon. They can look into the same medicine from another maker (for example, docetaxel is also produced by Hospira, Sagent, Hikma, Sanofi-Aventis, Accord, and Avet), though it may not sit in local stock and may come in a different concentration.
- Your care team can choose the right option for your treatment plan.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is national, manufacturer-reported data and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Docetaxel — DOCETAXEL 20 mg/mL
- Docetaxel — DOCETAXEL ANHYDROUS 10 mg/mL
- Docetaxel — DOCETAXEL 20 mg/mL
- Docetaxel — DOCETAXEL 20 mg/mL
- Docetaxel — DOCETAXEL 80 mg/4mL
- Docetaxel — DOCETAXEL 160 mg/8mL
- Docetaxel — DOCETAXEL ANHYDROUS 20 mg/mL
- Docetaxel — DOCETAXEL 20 mg/mL
- Docetaxel — DOCETAXEL 80 mg/4mL
- Docetaxel — DOCETAXEL 160 mg/8mL
- Docetaxel — DOCETAXEL ANHYDROUS 20 mg/mL
- Docetaxel — DOCETAXEL ANHYDROUS 10 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg/1 mL A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Ingenus Pharmaceuticals LLC 📞 866-321-5031 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Docetaxel Injection →
View Docetaxel Injection on the FDA drug-shortage database →
Allopurinol Tablet View full page →
Key facts about the Allopurinol Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Allopurinol Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Allopurinol Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Allopurinol tablets are currently on the FDA drug-shortage list. This report comes from one manufacturer, Teva Pharmaceuticals, and reflects only their supply — not every company that makes this medicine.
For the manufacturer on this record, both the 100 mg and 300 mg tablets have no available source right now. The reason given is that the maker is discontinuing production of the drug, and this record is marked "to be discontinued." That means, for this manufacturer, the supply problem may be permanent rather than temporary.
The important point: allopurinol is still made by several other companies. Because your dose helps control uric acid over time, keeping steady treatment matters.
Here is how to move forward:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same allopurinol tablets (100 mg and 300 mg) are listed from other makers, such as Mylan, Actavis, Par, Major, Rising, and NorthStar. Your pharmacy may be able to source one, though it may not be in local stock right away.
- If your exact tablet cannot be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Allopurinol — ALLOPURINOL 100 mg/1
- Allopurinol — ALLOPURINOL 300 mg/1
- Allopurinol — ALLOPURINOL 100 mg/1
- Allopurinol — ALLOPURINOL 300 mg/1
- Allopurinol — ALLOPURINOL 100 mg/1
- Allopurinol — ALLOPURINOL 300 mg/1
- Allopurinol — ALLOPURINOL 300 mg/1
- Allopurinol — ALLOPURINOL 100 mg/1
- Allopurinol — ALLOPURINOL 100 mg/1
- Allopurinol — ALLOPURINOL 200 mg/1
- Allopurinol — ALLOPURINOL 300 mg/1
- Allopurinol — ALLOPURINOL 100 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 300 mg Discontinuation of the manufacture of the drug
- 100 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Allopurinol, Tablet, 100 mg (NDC 0591-5543-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Allopurinol, Tablet, 300 mg (NDC 0591-5544-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Allopurinol, Tablet, 100 mg (NDC 0591-5543-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Allopurinol, Tablet, 300 mg (NDC 0591-5544-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Allopurinol Tablet →
Cefepime Hydrochloride Injection View full page →
Key facts about the Cefepime Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Cefepime Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Cefepime Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Cefepime Hydrochloride Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
This shortage record covers both strengths — the 1 g and 2 g — and neither has an available source from the reporting manufacturer right now. The reason listed for both is that this manufacturer, Fresenius Kabi USA, is discontinuing its production of the drug. Because this is a discontinuation rather than a temporary delay, this particular supply may not be coming back from that maker. Please know, though, that this report reflects only the manufacturer who filed it — other companies still make the same medicine.
Here is what I suggest, in order:
- Do not stop, skip, or change your treatment on your own. This is a prescriber-managed injection, and your care team should guide any change.
- Ask your pharmacy or care team about sourcing the same medicine from another maker. Cefepime is also listed from Hikma, Hospira, Sagent, WG Critical Care, and Apotex — though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about the best option for you.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Cefepime Hydrochloride — CEFEPIME HYDROCHLORIDE 1 g/1
- Cefepime Hydrochloride — CEFEPIME HYDROCHLORIDE 2 g/1
- Cefepime — CEFEPIME HYDROCHLORIDE 1 g/1
- Cefepime — CEFEPIME HYDROCHLORIDE 2 g/1
- Cefepime — CEFEPIME HYDROCHLORIDE 1 g/20mL
- Cefepime — CEFEPIME HYDROCHLORIDE 2 g/20mL
- Cefepime — CEFEPIME HYDROCHLORIDE 1 g/1
- Cefepime — CEFEPIME HYDROCHLORIDE 2 g/1
- Cefepime — CEFEPIME HYDROCHLORIDE 1 g/1
- Cefepime — CEFEPIME HYDROCHLORIDE 2 g/1
- Cefepime — CEFEPIME HYDROCHLORIDE 100 g/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 g Discontinuation of the manufacture of the drug.
- 2 g Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cefepime Hydrochloride, Injection, 2 g (NDC 63323-340-20) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
| Cefepime Hydrochloride, Injection, 1 g (NDC 63323-326-20) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Cefepime Hydrochloride Injection →
View Cefepime Hydrochloride Injection on the FDA drug-shortage database →
Chlorothiazide Oral Suspension View full page →
Key facts about the Chlorothiazide Oral Suspension shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Chlorothiazide Oral Suspension may not appear here at all, so this is not a picture of every available option. See the full Chlorothiazide Oral Suspension shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Chlorothiazide oral suspension (also sold as Diuril) is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The one strength on this record, 250 mg/5mL, does not have an available source reported right now. This is the strength most people take as the liquid form, so it is likely the one that affects you.
This product is listed as to be discontinued by the manufacturer that filed this report (Salix Pharmaceuticals). That means the supply problem may be permanent rather than a short-term gap, so a conversation with your prescriber is the right next step. No estimated-recovery date is given in the data.
Here is what I suggest:
- Do not stop, skip, or change your doses on your own — keep taking it as prescribed while you sort out a plan.
- Because this liquid is being discontinued, talk with your prescriber or pharmacist soon about options, such as a clinician-chosen alternative that fits your needs.
- Manufacturer contact numbers are listed on this page for reference, though pharmacies usually make these calls.
Please remember this comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock. Your pharmacist and prescriber can guide you to the safest choice for you.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Salix Pharmaceuticals, a division of Bausch Health US, LLC 📞 800-321-4576 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12) | — | — | — | To Be Discontinued |
Full shortage page: Chlorothiazide Oral Suspension →
View Chlorothiazide Oral Suspension on the FDA drug-shortage database →
Gemfibrozil Tablet View full page →
Key facts about the Gemfibrozil Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Gemfibrozil Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Gemfibrozil Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Gemfibrozil 600 mg tablets are currently listed on the FDA drug-shortage list. The medicine you take comes in one strength, 600 mg, and that strength has no available source from the manufacturer on this record.
The reason reported here is a discontinuation. Pfizer Inc., the maker on this shortage record, has listed its Lopid 600 mg tablet as being discontinued. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent, so a conversation with your prescriber is the right next step. That said, this record reflects only one manufacturer — gemfibrozil 600 mg is still made by several other companies, so the medicine itself may still be available.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers; the same medicine, gemfibrozil 600 mg, is still on the market from makers such as Rising Pharma, Northstar Rx, Camber, Aurobindo, and Chartwell RX, though it may not be in local stock.
- If your pharmacy cannot find it, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
This is general, national information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Lopid — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
- Gemfibrozil — GEMFIBROZIL 600 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 600 mg Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lopid, Tablet, 600 mg (NDC 0071-0737-20) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Gemfibrozil Tablet →
Pindolol Tablet View full page →
Key facts about the Pindolol Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Pindolol Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Pindolol Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Pindolol tablets are currently listed on the FDA drug-shortage list. I know that can feel unsettling, so let me walk you through what the report actually shows and the steps you can take.
Both strengths are affected. Neither the 5 mg nor the 10 mg tablet has an available source from the manufacturer on this record right now. The reason listed is that this manufacturer (Sun Pharmaceutical Industries) is discontinuing its production of pindolol. The last distributed batches carry expiry dates of October 2026 for the 10 mg and January 2027 for the 5 mg. Because this is a discontinuation rather than a temporary delay, the supply problem from this maker may be permanent — which makes a conversation with your prescriber the right next step.
Please keep in mind that this report reflects only one manufacturer. Other companies still make pindolol in both strengths, so your pharmacy may be able to source the same medicine elsewhere.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other makers — the same medicine in both 5 mg and 10 mg is listed from makers such as ANI, Unichem, Marlex, and Westminster, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This is general information from national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Pindolol — PINDOLOL 5 mg/1
- Pindolol — PINDOLOL 10 mg/1
- Pindolol — PINDOLOL 5 mg/1
- Pindolol — PINDOLOL 10 mg/1
- Pindolol — PINDOLOL 5 mg/1
- Pindolol — PINDOLOL 10 mg/1
- Pindolol — PINDOLOL 5 mg/1
- Pindolol — PINDOLOL 10 mg/1
- Pindolol — PINDOLOL 10 mg/1
- Pindolol — PINDOLOL 5 mg/1
- Pindolol — PINDOLOL 5 mg/1
- Pindolol — PINDOLOL 10 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg Discontinuation of the manufacture of the drug; Expiry date of last distributed batch Octo...
- 5 mg Discontinuation of the manufacture of the drug; Expiry date of last distributed batch Janu...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Sun Pharmaceutical Industries, Inc. 📞 800-818-4555 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Pindolol, Tablet, 5 mg (NDC 57664-655-88) | — | Discontinuation of the manufacture of the drug; Expiry date of last distributed batch January 2027 | — | To Be Discontinued |
| Pindolol, Tablet, 10 mg (NDC 57664-656-88) | — | Discontinuation of the manufacture of the drug; Expiry date of last distributed batch October 2026 | — | To Be Discontinued |
Full shortage page: Pindolol Tablet →
Podofilox Topical Gel View full page →
Key facts about the Podofilox Topical Gel shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Podofilox Topical Gel may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Podofilox Topical Gel shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Podofilox topical gel (0.5%) is currently listed on the FDA drug-shortage report. I want to walk you through what this means so you know what to do next.
The one strength covered by this report — 0.5% — has no available source from the manufacturer that filed it, AbbVie (the maker of Condylox). There are no other strengths in this record, so the 0.5% gel is the one affected. The reason given is a discontinuation of manufacture, which means this particular supply problem may be permanent rather than temporary.
Please keep in mind this reflects only the manufacturer that filed the report — it does not mean every company has stopped making this medicine. Our records show the same medicine, podofilox gel, is also listed from another maker, Padagis US LLC. Your pharmacy may be able to source it, though it may not be sitting on the local shelf.
Here is what I suggest:
- Do not stop or change how you use your medicine on your own.
- Ask your pharmacy to check wholesalers and other manufacturers, including the Padagis version of podofilox gel.
- Because AbbVie's product is being discontinued, talk with your prescriber or pharmacist about the right next step.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 0.5% Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: AbbVie Inc. 📞 800-633-9110 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Condylox , Topical Gel, 0.5% (NDC 0023-6118-03) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Podofilox Topical Gel →
View Podofilox Topical Gel on the FDA drug-shortage database →
Benztropine Mesylate Injection View full page →
Key facts about the Benztropine Mesylate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Benztropine Mesylate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Benztropine Mesylate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Benztropine mesylate injection is currently on the FDA shortage list, so I want to walk you through what that means for you.
The affected strength is the 1 mg/1 mL injection. Right now, this strength has no available source from the manufacturer that filed this report, Fresenius Kabi. They have noted that they are discontinuing this product, which means this particular supply problem may be permanent rather than temporary.
That said, this report reflects only one manufacturer. The same medicine — benztropine mesylate 1 mg/mL injection — is still listed from other makers, so it has not left the market entirely. Your pharmacy may be able to source it through one of those companies, though it may not be sitting on the local shelf.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers; the same medicine is also made by Hikma Pharmaceuticals and Zydus Pharmaceuticals.
- Because the Fresenius Kabi product is being discontinued, talk with your prescriber or pharmacist about your options going forward.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle these calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Benztropine Mesylate, Injection, 1 mg/1 mL (NDC 63323-970-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Benztropine Mesylate Injection →
View Benztropine Mesylate Injection on the FDA drug-shortage database →
Fluvastatin Sodium Tablet, Extended Release View full page →
Key facts about the Fluvastatin Sodium Tablet, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Fluvastatin Sodium Tablet, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Fluvastatin Sodium Tablet, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Fluvastatin sodium extended-release tablets are currently on the FDA drug-shortage list. I want to walk you through what this means for the strength you take so you know what to do next.
The only strength on this report is the 80 mg extended-release tablet, and right now it has no available source from the manufacturer that filed this report. Sandoz Inc. has listed both its generic fluvastatin 80 mg and the brand Lescol XL 80 mg as being discontinued. Because the reason given is discontinuation of manufacture, this particular supply problem may be permanent for that maker, which makes a conversation with your prescriber the right next step.
Please keep this in mind, in order:
- Do not stop, skip, or change your dose on your own.
- Because the 80 mg is discontinued by this manufacturer, ask your prescriber or pharmacist about your options soon.
- The same medicine, fluvastatin 80 mg extended-release, is also made by Teva Pharmaceuticals and Lannett Company. Your pharmacy may be able to source one of these, though it may not be in local stock.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 80 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Sandoz Inc. 📞 800-525-8747 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Fluvastatin Sodium Tablet, Extended Release →
View Fluvastatin Sodium Tablet, Extended Rele... on the FDA drug-shortage database →
Azithromycin Injection View full page →
Key facts about the Azithromycin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Azithromycin Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Azithromycin Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Azithromycin injection (500 mg/5 mL) is currently on the FDA drug-shortage list. I want to walk you through what this means for you.
The one strength covered by this report, 500 mg/5 mL, has no available source right now. The reason listed is that the manufacturer, Pfizer Inc., is discontinuing its version of this product (Zithromax IV). Because this is a discontinuation rather than a short-term delay, this particular supply problem may be permanent. That makes a conversation with your prescriber or pharmacist the right next step.
Please keep in mind that this report reflects only the one manufacturer that filed it. The same medicine — azithromycin injection, 500 mg/5 mL — is still listed from several other makers, so your pharmacy may be able to source one of those, though it may not be sitting in local stock.
Here is what I suggest:
- Do not stop, skip, or change how you receive this medicine on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for the same medicine from a different maker.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Zithromax — AZITHROMYCIN DIHYDRATE 500 mg/5mL
- Azithromycin — AZITHROMYCIN MONOHYDRATE 500 mg/5mL
- Azithromycin — AZITHROMYCIN MONOHYDRATE 500 mg/1
- Azithromycin — AZITHROMYCIN MONOHYDRATE 500 mg/5mL
- Azithromycin — AZITHROMYCIN MONOHYDRATE 500 mg/5mL
- Azithromycin Monohydrate — AZITHROMYCIN MONOHYDRATE 500 mg/10mL
- Azithromycin — AZITHROMYCIN DIHYDRATE 500 mg/5mL
- Azithromycin — AZITHROMYCIN MONOHYDRATE 500 mg/5mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500 mg/5 mL Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Azithromycin Injection →
View Azithromycin Injection on the FDA drug-shortage database →
Maraviroc Solution View full page →
Key facts about the Maraviroc Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Maraviroc Solution may not appear here at all, so this is not a picture of every available option. See the full Maraviroc Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Maraviroc oral solution (20 mg/mL, sold as Selzentry) is currently on the FDA shortage list. I'm sharing this so you know what's happening and what steps make sense next.
The one strength on this record — the 20 mg/mL Oral Solution Kit (a 230 mL bottle, one bottle per carton) — has no available source reported right now. There are no other strengths of this product still listed with supply. This record was filed by one manufacturer, ViiV Healthcare, and the product is marked "to be discontinued," with distribution expected to stop around August 1, 2026. Because this looks permanent for this maker, a conversation with your prescriber is the right next step.
Please keep these steps in mind:
- Do not stop, skip, or change doses on your own — keeping your treatment steady matters.
- Ask your pharmacy to check wholesalers and other suppliers; local stock can differ from national reports.
- Talk with your prescriber or pharmacist soon about a clinician-chosen plan, since this product is being discontinued.
- The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls.
This is general information from national, manufacturer-reported FDA data and may not match your local pharmacy's stock. It isn't individual medical advice, so please let your care team guide your next move.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg/mL Oral Solution Kit | 2... The anticipated date that GSK will cease distribution of the product is approximately Augu...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: ViiV Healthcare Company 📞 877-844-8872 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55) | — | The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026. | — | To Be Discontinued |
Full shortage page: Maraviroc Solution →
Piperacillin And Tazobactam Injection View full page →
Key facts about the Piperacillin And Tazobactam Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Piperacillin And Tazobactam Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Piperacillin And Tazobactam Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Piperacillin and tazobactam injection is currently on the FDA shortage list, and I want to walk you through what this means for the strength you may be using.
The affected strength is the 2.25 g vial, which right now has no available source. The manufacturer that filed this report, Fresenius Kabi USA, has listed this vial as being discontinued. Because this is a discontinuation rather than a temporary delay, the supply problem for this specific product may be permanent.
It's important to know that this report reflects only the one manufacturer that filed it. The same medicine — piperacillin and tazobactam — is still listed by several other makers, including B. Braun Medical, Sagent, WG Critical Care, Eugia US, and Apotex, in various strengths and forms. These are the same active ingredients from a different maker, though they may not be sitting in local stock.
Here is what I suggest, in order:
- Do not stop, skip, or change your treatment on your own.
- Ask your pharmacy to check wholesalers and other manufacturers, since this same medicine is still made by other companies.
- Because your exact vial is being discontinued, talk with your prescriber or pharmacist about a suitable option, such as another strength or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Piperacillin And Tazobactam And Sodium Chloride — TAZOBACTAM SODIUM 250 mg/50mL; PIPERACILLIN SODIUM 2 g/50mL
- Piperacillin And Tazobactam And Sodium Chloride — TAZOBACTAM SODIUM 375 mg/50mL; PIPERACILLIN SODIUM 3 g/50mL
- Piperacillin And Tazobactam And Sodium Chloride — TAZOBACTAM SODIUM 500 mg/100mL; PIPERACILLIN SODIUM 4 g/100mL
- Piperacillin, Tazobactam — PIPERACILLIN SODIUM 36 g/152mL; TAZOBACTAM SODIUM 4.5 g/152mL
- Piperacillin And Tazobactam — PIPERACILLIN SODIUM 2 g/1; TAZOBACTAM SODIUM .25 g/1
- Piperacillin And Tazobactam — PIPERACILLIN SODIUM 3 g/1; TAZOBACTAM SODIUM .375 g/1
- Piperacillin And Tazobactam — PIPERACILLIN SODIUM 4 g/1; TAZOBACTAM SODIUM .5 g/1
- Piperacillin And Tazobactam — PIPERACILLIN SODIUM 36 g/1; TAZOBACTAM SODIUM 4.5 g/1
- Piperacillin And Tazobactam — PIPERACILLIN SODIUM 2 g/1; TAZOBACTAM SODIUM .25 g/1
- Piperacillin And Tazobactam — PIPERACILLIN SODIUM 3 g/1; TAZOBACTAM SODIUM .375 g/1
- Piperacillin And Tazobactam — PIPERACILLIN SODIUM 4 g/1; TAZOBACTAM SODIUM .5 g/1
- Piperacillin And Tazobactam — PIPERACILLIN SODIUM 2 g/10mL; TAZOBACTAM SODIUM .25 g/10mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2.25 g vial Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Piperacillin And Tazobactam Injection →
View Piperacillin And Tazobactam Injection on the FDA drug-shortage database →
Riboflavin 5-Phosphate Ophthalmic Solution View full page →
Key facts about the Riboflavin 5-Phosphate Ophthalmic Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Riboflavin 5-Phosphate Ophthalmic Solution may not appear here at all, so this is not a picture of every available option. See the full Riboflavin 5-Phosphate Ophthalmic Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Riboflavin 5-Phosphate ophthalmic solution is currently on the FDA shortage list, and the reason listed is important to understand.
According to the manufacturer report, Glaukos Corporation plans to discontinue making this product (the Photrexa Cross-linking Kit) as of July 2026. Because this is a planned discontinuation rather than a temporary manufacturing delay, this supply problem may become permanent. Only one manufacturer is on this record, and no other same-medicine sources appear in our records at this time.
Even so, please know that a discontinuation date in the future does not mean the product is gone today. Supply may still be available now, and your care team can help you plan ahead.
Here is what I suggest:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check whether stock is still available through wholesalers or the manufacturer.
- Because this product is set to be discontinued, talk with your prescriber or eye specialist about the right next step for your treatment plan.
- The manufacturer's phone number is listed on this page for reference; pharmacies usually handle these calls.
This is general information from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- All / unspecified Discontinuing manufacture of the product as of July 2026.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Glaukos Corporation 📞 949-367-9600 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03) | — | Discontinuing manufacture of the product as of July 2026. | — | To Be Discontinued |
Full shortage page: Riboflavin 5-Phosphate Ophthalmic Solution →
View Riboflavin 5-Phosphate Ophthalmic Solut... on the FDA drug-shortage database →
Adalimumab-Adaz Injection View full page →
Key facts about the Adalimumab-Adaz Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Adalimumab-Adaz Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Adalimumab-Adaz Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Adalimumab-Adaz Injection is currently on the FDA drug-shortage list. This report has been filed as to be discontinued, which means this supply problem may be permanent, so I want to walk you through what that means and what steps make sense.
Both strengths in this record are affected right now, with no available source reported: the 80 mg/0.8 mL and the 40 mg/0.4 mL. The reason listed is that the manufacturer plans to discontinue this format, and the notes indicate an equivalent Sandoz format is available. Because this record covers only the one manufacturer who filed it, other makers of the same medicine may still be able to supply it.
Here is how to handle this:
- Do not stop, skip, or change your doses on your own. Keep taking it as prescribed while you sort out a supply.
- Ask your pharmacy whether the same medicine (adalimumab) can be sourced from another maker — for example, Sandoz or Cordavis formats appear in our records — though it may not be in local stock right away.
- Because this product is being discontinued, talk with your prescriber or pharmacist about a suitable long-term option.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 80 mg/.8 mL Equivalent Sandoz format is available.
- 40 mg/.4 mL Equivalent Sandoz format is available.
- All / unspecified Equivalent Sandoz format is available.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Sandoz Inc. 📞 800-525-8747 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36) | — | Equivalent Sandoz format is available. | — | To Be Discontinued |
| Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64) | — | Equivalent Sandoz format is available. | — | To Be Discontinued |
| Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68) | — | Equivalent Sandoz format is available. | — | To Be Discontinued |
| Hyrimoz, Injection, Kit (NDC 61314-517-36) | — | Equivalent Sandoz format is available. | — | To Be Discontinued |
| Hyrimoz, Injection, Kit (NDC 61314-531-64) | — | Equivalent Sandoz format is available. | — | To Be Discontinued |
Full shortage page: Adalimumab-Adaz Injection →
View Adalimumab-Adaz Injection on the FDA drug-shortage database →
Caspofungin Acetate Injection View full page →
Key facts about the Caspofungin Acetate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Caspofungin Acetate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Caspofungin Acetate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Caspofungin Acetate Injection is currently on the FDA shortage list. This is an antifungal medicine given by injection, and I want to walk you through what the current report shows.
Both strengths on this record — the 5 mg/1 mL and the 7 mg/1 mL — have no available source from the manufacturers who filed this report. The reason listed for both is that the maker is discontinuing production, so for these specific products the supply problem may be permanent rather than temporary. Because this is a discontinuation, talking with your prescriber or pharmacist is the right next step.
Keep in mind this report reflects only the manufacturer(s) who filed it. The same medicine is still listed as available from other makers, so this does not mean caspofungin is gone everywhere.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own — this medicine is used for serious infections.
- Ask your pharmacy whether the same medicine from another maker can be sourced. Options in our records include Cancidas (Merck), and caspofungin acetate from Sagent, Fresenius Kabi, and Fosun Pharma — though these may not be in local stock.
- Ask your prescriber or pharmacist about a clinician-chosen alternative if your product cannot be found.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This is general national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Cancidas — CASPOFUNGIN ACETATE 5 mg/mL
- Cancidas — CASPOFUNGIN ACETATE 7 mg/mL
- Caspofungin Acetate — CASPOFUNGIN ACETATE 5 mg/mL
- Caspofungin Acetate — CASPOFUNGIN ACETATE 7 mg/mL
- Caspofungin Acetate — CASPOFUNGIN ACETATE 5 mg/mL
- Caspofungin Acetate — CASPOFUNGIN ACETATE 5 mg/mL
- Caspofungin Acetate — CASPOFUNGIN ACETATE 7 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg/1 mL Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
- 7 mg/1 mL Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug · Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 Sandoz: 800-525-8747 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94) | — | Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94) | — | Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Caspofungin Acetate Injection →
View Caspofungin Acetate Injection on the FDA drug-shortage database →
Doxycycline Hyclate Tablet View full page →
Key facts about the Doxycycline Hyclate Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Doxycycline Hyclate Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Doxycycline Hyclate Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Doxycycline Hyclate 100 mg tablets are currently listed on the FDA drug-shortage list. The listing covers the 100 mg tablet, and right now that strength has no available source from the manufacturer who filed this report.
The reason listed is a discontinuation — Mylan Pharmaceuticals (a Viatris Company) has reported it is stopping the manufacture of its 100 mg doxycycline hyclate tablet. Because this is a discontinuation, this particular supply may not return. That said, this report reflects only one manufacturer, and the same medicine may still be available from other makers.
Please keep taking your medicine as prescribed while your pharmacy sorts out supply. Here is how I suggest you proceed:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check wholesalers and other manufacturers; the same medicine (doxycycline hyclate) is made by companies such as Hikma, Actavis, and Major Pharmaceuticals, though it may not be in your local stock.
- Because the Mylan version is being discontinued, talk with your prescriber or pharmacist about your options — such as a product from another maker or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 50 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 50 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 200 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate Delayed Release — DOXYCYCLINE HYCLATE 75 mg/1
- Doxycycline Hyclate Delayed Release — DOXYCYCLINE HYCLATE 100 mg/1
- Doxycycline Hyclate Delayed Release — DOXYCYCLINE HYCLATE 150 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 800-796-9526 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-13) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Doxycycline Hyclate Tablet →
View Doxycycline Hyclate Tablet on the FDA drug-shortage database →
Doxylamine Succinate And Pyridoxine Hydrochloride Tablet, Delayed Release View full page →
Key facts about the Doxylamine Succinate And Pyridoxine Hydrochloride Tablet, Delayed Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Doxylamine Succinate And Pyridoxine Hydrochloride Tablet, Delayed Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Doxylamine Succinate And Pyridoxine Hydrochloride Tablet, Delayed Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Doxylamine succinate and pyridoxine (the delayed-release combination tablet, often used for nausea in pregnancy) is currently on the FDA shortage list. Please know that this affects one manufacturer's product — it does not mean the medicine has disappeared from every maker.
The strength involved is the 10 mg / 10 mg delayed-release tablet made by Mylan (a Viatris company). This specific product has no available source right now. The company reports this is because of a business decision to discontinue manufacturing it, which means this particular version is being permanently stopped rather than temporarily out of stock.
Because this is a discontinuation, the most important step is to plan ahead calmly with your care team. Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- The same medicine (doxylamine 10 mg / pyridoxine 10 mg, delayed-release) is still made by other companies, including Actavis, Par Health, Bionpharma, Analog Pharma, and Bryant Ranch. Ask your pharmacy whether they can order one of these — though it may not be in local stock today.
- Talk with your prescriber or pharmacist about the best path forward for you.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Doxylamine Succinate And Pyridoxine Hydrochloride — DOXYLAMINE SUCCINATE 10 mg/1; PYRIDOXINE HYDROCHLORIDE 10 mg/1
- Doxylamine Succinate And Pyridoxine Hydrochloride — DOXYLAMINE SUCCINATE 10 mg/1; PYRIDOXINE HYDROCHLORIDE 10 mg/1
- Diclegis — DOXYLAMINE SUCCINATE 10 mg/1; PYRIDOXINE HYDROCHLORIDE 10 mg/1
- Bonjesta — DOXYLAMINE SUCCINATE 20 mg/1; PYRIDOXINE HYDROCHLORIDE 20 mg/1
- Doxylamine Succinate And Pyridoxine Hydrochloride — DOXYLAMINE SUCCINATE 10 mg/1; PYRIDOXINE HYDROCHLORIDE 10 mg/1
- Doxylamine Succinate And Pyridoxine Hydrochloride — DOXYLAMINE SUCCINATE 10 mg/1; PYRIDOXINE HYDROCHLORIDE 10 mg/1
- Doxylamine Succinate And Pyridoxine Hydrochloride — DOXYLAMINE SUCCINATE 10 mg/1; PYRIDOXINE HYDROCHLORIDE 10 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg; 10 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 800-796-9526 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Doxylamine Succinate and Pyridoxine Hydrochloride, Tablet, Delayed Release, 10 mg; 10 mg (NDC 0378-4615-01) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Doxylamine Succinate And Pyridoxine Hydrochloride Tablet, Delayed Release →
View Doxylamine Succinate And Pyridoxine Hyd... on the FDA drug-shortage database →
Neostigmine Methylsulfate Injection View full page →
Key facts about the Neostigmine Methylsulfate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Neostigmine Methylsulfate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Neostigmine Methylsulfate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Neostigmine Methylsulfate Injection is currently on the FDA shortage list, and I want to walk you through what this means for you.
The one strength on this record, 0.5 mg/1 mL, has no available source from the manufacturer that filed this report (Fresenius Kabi). Their reason is straightforward: they are discontinuing the manufacture of this product. Because this is a planned discontinuation rather than a temporary delay, this particular supply problem may be permanent for that maker. It's important to know this report reflects only Fresenius Kabi — other companies make this same medicine and may still be supplying it.
Here is what I suggest, in order:
- Do not stop, skip, or change how this medicine is used on your own. Because this is an injection typically given by a clinician, your care team manages dosing and supply.
- Ask your pharmacy or care team to check wholesalers and other manufacturers — several companies (such as Amphastar, Hikma, Sagent, Par Health, and others) are listed as making the same medicine, though it may not be in local stock right now.
- If your exact product cannot be found, ask your prescriber or pharmacist about an equivalent option from another maker.
The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE .5 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE 1 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE 1 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE .5 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE .5 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE 1 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE .5 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE 1 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE 1 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE .5 mg/mL
- Neostigmine Methylsulfate — NEOSTIGMINE METHYLSULFATE 1 mg/mL
- Neostigmine — NEOSTIGMINE METHYLSULFATE .5 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .5 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Neostigmine Methylsulfate Injection →
View Neostigmine Methylsulfate Injection on the FDA drug-shortage database →
Haloperidol Decanoate Injection View full page →
Key facts about the Haloperidol Decanoate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Haloperidol Decanoate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Haloperidol Decanoate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Haloperidol Decanoate Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The affected strength is the 50 mg/1 mL injection. Right now, that strength has no available source from the manufacturer that filed this report (Fresenius Kabi). The reason listed is that this manufacturer is discontinuing production, so for this particular product the supply problem may be permanent rather than a short delay.
This report reflects only one manufacturer, so it does not mean the medicine is gone everywhere. The same medicine — haloperidol decanoate injection — is still listed as available from several other makers, including Hikma, Patriot, Sagent, Janssen (Haldol Decanoate), Caplin Steriles, Mylan, and other Fresenius Kabi products. Because this maker is stopping production, a conversation with your prescriber is the right next step.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own. This medicine works best when given on schedule.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine may be sourced from another maker, though it may not be in local stock.
- Ask your prescriber or pharmacist about options, such as a clinician-chosen alternative product.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls. This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 100 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 50 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 100 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 50 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 100 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 500 mg/5mL
- Haldol Decanoate — HALOPERIDOL DECANOATE 50 mg/mL
- Haldol Decanoate — HALOPERIDOL DECANOATE 100 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 100 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 100 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 50 mg/mL
- Haloperidol Decanoate — HALOPERIDOL DECANOATE 100 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Haloperidol Decanoate Injection →
View Haloperidol Decanoate Injection on the FDA drug-shortage database →
Imipenem And Cilastatin Injection View full page →
Key facts about the Imipenem And Cilastatin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Imipenem And Cilastatin Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Imipenem And Cilastatin Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Imipenem and cilastatin injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
This shortage record covers the 500mg strength, which is the one form listed here. Right now that strength has no available source from the manufacturer who filed this report. The record shows this product is being discontinued, planned for approximately the fourth quarter of 2026.
Because a discontinuation is reported, this supply problem may be a lasting one for this particular maker (Merck Sharp & Dohme Corp.). The good part is that this report reflects only that one manufacturer — other companies still make the same imipenem and cilastatin injection. A conversation with your prescriber is the right next step to plan ahead.
Here is what I suggest, in order:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check whether the same medicine is available from another maker — records show imipenem and cilastatin injection from WG Critical Care and Fresenius Kabi, though these may not be in local stock.
- Because your strength is being discontinued, ask your prescriber or pharmacist about the best option for you.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500mg To be discontinued in approximately Q4 2026.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Merck Sharp & Dohme Corp. 📞 800-672-6372 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Primaxin, Injection, 500mg (NDC 0006-3516-59) | — | To be discontinued in approximately Q4 2026. | — | To Be Discontinued |
Full shortage page: Imipenem And Cilastatin Injection →
View Imipenem And Cilastatin Injection on the FDA drug-shortage database →
Diltiazem Hydrochloride Injection View full page →
Key facts about the Diltiazem Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Diltiazem Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Diltiazem Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Diltiazem Hydrochloride Injection is currently on the FDA drug-shortage list. I want to walk you through what this means so you know what to expect.
The strength affected is the 100 mg Single Dose ADD-Vantage® Glass Vial, which has no available source reported right now. This is the only strength listed on this record, and the manufacturer that filed it, Hospira (a Pfizer Company), has reported it as to be discontinued — meaning they are stopping production of this particular vial. Because that decision is a discontinuation, this supply problem may be permanent for this specific product, so a conversation with your prescriber is the right next step.
Please keep in mind this is national, manufacturer-reported data and may not match what your local pharmacy actually has. Here is what I suggest:
- Do not stop, skip, or change your doses on your own.
- Ask your prescriber or pharmacist about options, since your exact vial is being discontinued. The same medicine, diltiazem injection, is still made by other companies (Hikma, Sagent, and Eugia); your care team can decide whether one of those fits your treatment.
- Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls.
You and your care team can sort out the best path forward.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg Single Dose ADD-Vantage... Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-4350-03) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Diltiazem Hydrochloride Injection →
View Diltiazem Hydrochloride Injection on the FDA drug-shortage database →
Hydroxychloroquine Sulfate Tablet View full page →
Key facts about the Hydroxychloroquine Sulfate Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Hydroxychloroquine Sulfate Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Hydroxychloroquine Sulfate Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Hydroxychloroquine sulfate tablets are currently on the FDA drug-shortage list, and I want to explain what that means for you in a clear, calm way.
This report covers the 200 mg tablet, which has no available source from the manufacturer that filed it, Teva Pharmaceuticals. Teva has listed this product as to be discontinued, meaning they are ending its manufacture. This particular supply problem may be permanent. It is important to know, though, that this report reflects only Teva — other companies still make the same 200 mg medicine, so a conversation with your pharmacy is the right next step rather than a reason to worry.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for the same 200 mg hydroxychloroquine tablet.
- The same medicine is listed as available from other makers, including Major Pharmaceuticals, Rising Pharma, Northstar Rx, Accord Healthcare, Dr. Reddy's, and A-S Medication Solutions. Your pharmacy may be able to source one of these, though it may not be in local stock right away.
- If your tablet cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 200 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 200 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 200 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 200 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 100 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 300 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 400 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 400 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 300 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 100 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 200 mg/1
- Hydroxychloroquine Sulfate — HYDROXYCHLOROQUINE SULFATE 200 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 200 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate, Tablet, 200 mg (NDC 0093-2401-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Hydroxychloroquine Sulfate Tablet →
View Hydroxychloroquine Sulfate Tablet on the FDA drug-shortage database →
Sodium Oxybate Solution View full page →
Key facts about the Sodium Oxybate Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Sodium Oxybate Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Sodium Oxybate Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Sodium oxybate oral solution is currently on the FDA shortage list, and I want to walk you through what that means for you.
The strength involved is the 0.5 g/mL solution. Right now, this strength has no available source from the manufacturer that filed this report (Amneal Pharmaceuticals). Because no other strength of this product is on the record, there isn't a separate strength still in supply to point you toward here.
The reason listed is that the maker is discontinuing manufacture of this product. That means this particular supply problem may be permanent rather than temporary. Importantly, this report reflects only one manufacturer — other companies may still make the same medicine, so this does not mean sodium oxybate is gone everywhere.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Because Amneal's product is being discontinued, ask your prescriber or pharmacist about next steps soon, rather than waiting.
- The same medicine (sodium oxybate solution, 0.5 g/mL) may be available from other makers — Hikma, Camber, or as Xyrem from Jazz. Your pharmacy can try to source one, though it may not be on the local shelf.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This is general, national information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .5 g/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amneal Pharmaceuticals 📞 800-525-7270 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Oxybate, Solution, .5 g/1 mL (NDC 69238-2391-1) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Sodium Oxybate Solution →
View Sodium Oxybate Solution on the FDA drug-shortage database →
Mirikizumab-Mrkz Injection View full page →
Key facts about the Mirikizumab-Mrkz Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Mirikizumab-Mrkz Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Mirikizumab-Mrkz Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Mirikizumab-Mrkz injection (brand name Omvoh) is currently listed on the FDA drug-shortage list, and I want to walk you through what that means for you.
The affected strength is the 100 mg/1 mL injection. According to the report, this strength has no available source right now and is set to be discontinued, with distribution ending in April 2026. The manufacturer, Eli Lilly and Co., notes that the 200 mg/2 mL injection presentation will remain on the market. Because this is a business decision to discontinue the 100 mg/1 mL form, this supply change may be permanent — which makes a conversation with your prescriber the right next step.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own. Keeping your treatment steady matters.
- Ask your pharmacy to check wholesalers and other manufacturers, though supply for the 100 mg/1 mL is not currently reported.
- Talk with your prescriber or pharmacist about options — for example, the 200 mg/2 mL presentation of the same medicine that will remain available, which they can help arrange safely.
- The manufacturer's contact number is listed on this page for reference; pharmacies usually handle these calls.
This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg/1 mL A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/... · A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27) | — | A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain. | — | To Be Discontinued |
| Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27) | — | A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain. | — | To Be Discontinued |
Full shortage page: Mirikizumab-Mrkz Injection →
View Mirikizumab-Mrkz Injection on the FDA drug-shortage database →
Morphine Sulfate Tablet View full page →
Key facts about the Morphine Sulfate Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Morphine Sulfate Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Morphine Sulfate Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Morphine Sulfate tablets are currently on the FDA drug-shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The report covers two strengths: the 15 mg and 30 mg tablets, and both are affected right now with no available source reported. This shortage record reflects one manufacturer, Upsher-Smith Laboratories, and the reason listed for both strengths is that the company is discontinuing the manufacture of the drug. Because this is a discontinuation rather than a temporary delay, the supply problem from this maker may be permanent, so a conversation with your prescriber is the right next step.
It's important to know this report reflects only one manufacturer. The same medicine — morphine sulfate tablets in both 15 mg and 30 mg — is still on the market from other makers, including Hikma Pharmaceuticals and SpecGx.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy whether they can source the same medicine from another maker (such as Hikma or SpecGx); it may not be in local stock but can often be ordered.
- If it cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Morphine Sulfate — MORPHINE SULFATE 15 mg/1
- Morphine Sulfate — MORPHINE SULFATE 30 mg/1
- Morphine Sulfate — MORPHINE SULFATE 15 mg/1
- Morphine Sulfate — MORPHINE SULFATE 30 mg/1
- Morphine Sulfate — MORPHINE SULFATE 15 mg/1
- Morphine Sulfate — MORPHINE SULFATE 200 mg/1
- Morphine Sulfate — MORPHINE SULFATE 30 mg/1
- Morphine Sulfate — MORPHINE SULFATE 60 mg/1
- Morphine Sulfate — MORPHINE SULFATE 100 mg/1
- Morphine Sulfate Extended Release — MORPHINE SULFATE 15 mg/1
- Morphine Sulfate Extended Release — MORPHINE SULFATE 30 mg/1
- Morphine Sulfate Extended Release — MORPHINE SULFATE 60 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 30 mg Discontinuation of the manufacture of the drug
- 15 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Upsher-Smith Laboratories, LLC 📞 763-315-2000 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Morphine Sulfate Tablet →
View Morphine Sulfate Tablet on the FDA drug-shortage database →
Carbamazepine Capsule, Extended Release View full page →
Key facts about the Carbamazepine Capsule, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Carbamazepine Capsule, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Carbamazepine Capsule, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Carbamazepine extended-release capsules are currently on the FDA shortage list. This report comes from Takeda, the maker of the brand Carbatrol, which lists all three strengths — 100 mg, 200 mg, and 300 mg — as being discontinued. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent for the Carbatrol brand.
I want to be clear that this record reflects only one manufacturer. Other companies still make the same medicine — carbamazepine extended-release capsules — in these same strengths, so this does not mean the medicine has disappeared. Please do not stop, skip, or change your doses on your own, as this medicine needs to be taken steadily.
Here is what I suggest:
- Talk with your pharmacist or prescriber soon, since the brand you take is being discontinued and you will likely need a plan.
- Ask your pharmacy about the same medicine from another maker — options in our records include Major Pharmaceuticals, AvPAK, Apotex, ANI Pharmaceuticals, and Bryant Ranch Prepack. These are the same medicine and form, though your pharmacy may not have them in local stock and can check wholesalers.
- If your exact product cannot be found, your prescriber can help choose the right next step for you.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Carbamazepine — CARBAMAZEPINE 200 mg/1
- Carbamazepine — CARBAMAZEPINE 100 mg/1
- Carbamazepine — CARBAMAZEPINE 200 mg/1
- Carbamazepine — CARBAMAZEPINE 300 mg/1
- Carbamazepine — CARBAMAZEPINE 100 mg/1
- Carbamazepine — CARBAMAZEPINE 200 mg/1
- Carbamazepine — CARBAMAZEPINE 300 mg/1
- Carbamazepine — CARBAMAZEPINE 100 mg/1
- Carbamazepine — CARBAMAZEPINE 200 mg/1
- Carbamazepine — CARBAMAZEPINE 300 mg/1
- Carbamazepine — CARBAMAZEPINE 200 mg/1
- Carbamazepine — CARBAMAZEPINE 300 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 200 mg Discontinuation of the manufacture of the drug
- 100 mg Discontinuation of the manufacture of the drug
- 300 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Takeda Pharmaceuticals USA Inc. 📞 855-268-1825 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Carbamazepine Capsule, Extended Release →
View Carbamazepine Capsule, Extended Release on the FDA drug-shortage database →
Doxercalciferol Injection View full page →
Key facts about the Doxercalciferol Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Doxercalciferol Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Doxercalciferol Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Doxercalciferol injection is currently on the FDA drug-shortage list, and I want to walk you through what this means for you.
All three reported strengths are affected, and none currently have an available source from the manufacturer on this record: the 4 mcg/2 mL single-dose vials, the 2 mcg/mL single-dose vials, and the 4 mcg/2 mL multiple-dose vials. The reason listed for each is that the manufacturer (Sanofi-Aventis) is discontinuing production of these products. Because this is a discontinuation rather than a temporary delay, the supply problem from this maker may be permanent, and no estimated-recovery date applies.
That said, this report reflects only one manufacturer. The same medicine — doxercalciferol injection — is still listed on the market from other makers, including Dr. Reddy's, Eugia, Alembic, and Meitheal.
Here is how I would approach it:
- Do not stop, skip, or change your doses on your own. This medicine is given by a clinician, so keep your appointments.
- Ask your pharmacy or infusion center to source the same medicine from one of the other makers listed above; it may not be in local stock, but they can check wholesalers.
- Because your product is being discontinued, talk with your prescriber about a clinician-chosen plan going forward.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 4 mcg/2 mL injection 50 single... Discontinuation of the manufacture of the drug
- 2 mcg/mL injection 50 single-d... Discontinuation of the manufacture of the drug
- 4 mcg/2 mL injection 50 multip... Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Sanofi-Aventis U.S. LLC 📞 800-633-1610 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Doxercalciferol Injection →
View Doxercalciferol Injection on the FDA drug-shortage database →
Spironolactone Tablet View full page →
Key facts about the Spironolactone Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Spironolactone Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Spironolactone Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Spironolactone tablets are currently listed on the FDA drug-shortage list, so I want to walk you through what this means for you.
This shortage record covers the 25 mg and 100 mg tablets, and right now neither of these strengths has an available source from the manufacturer that filed the report. The reason given is a discontinuation of the manufacture of the drug (the brand Aldactone from Pfizer Inc.). Because this is a discontinuation rather than a temporary delay, the supply problem may be permanent for that manufacturer's product. Importantly, this report reflects only that one company — other makers may still supply spironolactone, so this does not mean the medicine is gone everywhere.
Please do not stop, skip, or change your dose on your own. Here is how I would approach next steps:
- Ask your pharmacy to check whether the same medicine is available from another maker. The same-ingredient spironolactone tablet (25 mg and 100 mg) is made by several other companies, though it may not be in local stock right away.
- If your exact tablet cannot be found, talk with your prescriber or pharmacist about options, such as a different strength to make up your dose or another clinician-chosen plan.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Aldactone — SPIRONOLACTONE 50 mg/1
- Spironolactone — SPIRONOLACTONE 50 mg/1
- Spironolactone — SPIRONOLACTONE 100 mg/1
- Spironolactone — SPIRONOLACTONE 25 mg/1
- Spironolactone — SPIRONOLACTONE 25 mg/1
- Spironolactone — SPIRONOLACTONE 25 mg/1
- Spironolactone — SPIRONOLACTONE 50 mg/1
- Spironolactone — SPIRONOLACTONE 100 mg/1
- Spironolactone — SPIRONOLACTONE 25 mg/1
- Spironolactone — SPIRONOLACTONE 50 mg/1
- Spironolactone — SPIRONOLACTONE 100 mg/1
- Spironolactone — SPIRONOLACTONE 25 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 25 mg Discontinuation of the manufacture of the drug.
- 100 mg Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Aldactone, Tablet, 100 mg (NDC 0025-1031-31) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
| Aldactone, Tablet, 25 mg (NDC 0025-1001-31) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Spironolactone Tablet →
View Spironolactone Tablet on the FDA drug-shortage database →
Ampicillin Sodium Injection View full page →
Key facts about the Ampicillin Sodium Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ampicillin Sodium Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ampicillin Sodium Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Ampicillin Sodium Injection is currently on the FDA drug-shortage list. I want to walk you through what this means so you can plan your next step calmly.
The report covers three strengths — the 1 g, 2 g, and 10 g — and at this time none of these has an available source from the manufacturer on this record. The status is listed as "to be discontinued," specifically the discontinuation of a private-label product. Because this may be a permanent change from this maker rather than a short delay, a conversation with your prescriber or pharmacist is the right next step. Keep in mind this record reflects only one manufacturer's filing, and the same medicine is still made by other companies.
Here is how I'd suggest approaching it:
- Do not stop, skip, or change how the injection is given on your own.
- Ask your pharmacy to check wholesalers and other manufacturers; the same medicine (Ampicillin Sodium Injection) is listed from Sagent Pharmaceuticals and WG Critical Care as well, though it may not be in local stock.
- Since your exact strength is being discontinued from this maker, ask your prescriber or pharmacist about options they can source.
- Manufacturer contact numbers appear on this page for reference; pharmacies usually make these calls.
This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Ampicillin — AMPICILLIN SODIUM 125 mg/1
- Ampicillin — AMPICILLIN SODIUM 250 mg/1
- Ampicillin — AMPICILLIN SODIUM 1 g/1
- Ampicillin — AMPICILLIN SODIUM 500 mg/1
- Ampicillin — AMPICILLIN SODIUM 2 g/1
- Ampicillin — AMPICILLIN SODIUM 10 g/1
- Ampicillin — AMPICILLIN SODIUM 1 g/1
- Ampicillin — AMPICILLIN SODIUM 2 g/1
- Ampicillin Sodium — AMPICILLIN SODIUM 10 g/100mL
- Ampicillin — AMPICILLIN SODIUM 250 mg/1
- Ampicillin — AMPICILLIN SODIUM 500 mg/1
- Ampicillin — AMPICILLIN SODIUM 1 g/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 g Discontinuation of private label only
- 1 g Discontinuation of private label only
- 2 g Discontinuation of private label only
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Sandoz Inc. 📞 800-525-8747 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92) | — | Discontinuation of private label only | — | To Be Discontinued |
| Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92) | — | Discontinuation of private label only | — | To Be Discontinued |
| Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95) | — | Discontinuation of private label only | — | To Be Discontinued |
| Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95) | — | Discontinuation of private label only | — | To Be Discontinued |
| Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95) | — | Discontinuation of private label only | — | To Be Discontinued |
Full shortage page: Ampicillin Sodium Injection →
View Ampicillin Sodium Injection on the FDA drug-shortage database →
Calcitriol Capsule View full page →
Key facts about the Calcitriol Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Calcitriol Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Calcitriol Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Calcitriol capsules are currently on the FDA drug-shortage list. I know that news can feel unsettling, so let me walk you through what the report actually says and what it means for you.
Both strengths are affected: the 0.25 mcg and 0.5 mcg capsules each have no available source right now. The reason listed is a business decision by the manufacturer (Teva) to discontinue making the drug. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent for Teva's product. This report reflects only that one manufacturer, though — other companies still make the same medicine.
That last point matters, so here is how to move forward:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers. The same medicine — calcitriol capsules in both your 0.25 mcg and 0.5 mcg strengths — is listed as available from other makers, including Hikma, Avet (Heritage), Sun, Chartwell, and others. Your pharmacy may be able to source one, though it may not be in local stock today.
- If your exact capsule cannot be found, ask your prescriber or pharmacist about options that fit your dose.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Calcitriol — CALCITRIOL .25 ug/1
- Calcitriol — CALCITRIOL .25 ug/1
- Calcitriol — CALCITRIOL .5 ug/1
- Calcitriol — CALCITRIOL .25 ug/1
- Calcitriol — CALCITRIOL .25 ug/1
- Calcitriol — CALCITRIOL .25 ug/1
- Calcitriol — CALCITRIOL .5 ug/1
- Calcitriol — CALCITRIOL .25 ug/1
- Calcitriol — CALCITRIOL .25 ug/1
- Calcitriol — CALCITRIOL .5 ug/1
- Calcitriol — CALCITRIOL .25 ug/1
- Calcitriol — CALCITRIOL .5 ug/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .5 ug A business decision was made to discontinue manufacture of the drug
- .25 ug A business decision was made to discontinue manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Calcitriol, Capsule, .25 ug (NDC 0093-7352-01) | — | A business decision was made to discontinue manufacture of the drug | — | To Be Discontinued |
| Calcitriol, Capsule, .5 ug (NDC 0093-7353-01) | — | A business decision was made to discontinue manufacture of the drug | — | To Be Discontinued |
Full shortage page: Calcitriol Capsule →
Sodium Chloride 0.9% Injection View full page →
Key facts about the Sodium Chloride 0.9% Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Sodium Chloride 0.9% Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Sodium Chloride 0.9% Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Sodium Chloride 0.9% Injection is currently on the FDA drug-shortage list. This report covers the ADD-Vantage® Flexible Container form made by Hospira, Inc., a Pfizer Company, and their record shows this product is being discontinued.
All three sizes on this record — the 50 mL, 100 mL, and 250 mL ADD-Vantage® Flexible Containers — have no available source right now from this manufacturer. The reported reason is that the maker is discontinuing production of these items. Because this is a discontinuation rather than a temporary delay, the supply problem for these specific containers may be permanent. It's worth noting that this report reflects only one manufacturer, and the same medicine is still made by other companies.
Here is what I suggest:
- Do not stop or change how you use this medicine on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine (Sodium Chloride 0.9% Injection) is listed as available from makers such as B. Braun, Baxter, ICU Medical, and others, though it may not be in local stock.
- Since these containers are being discontinued, talk with your prescriber or pharmacist about a suitable option for your situation.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls.
This is general, manufacturer-reported national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Sodium Chloride — SODIUM CHLORIDE 9 mg/mL
- Sodium Chloride — SODIUM CHLORIDE .9 g/100mL
- Sodium Chloride — SODIUM CHLORIDE 9 mg/mL
- Sodium Chloride — SODIUM CHLORIDE 9 g/1000mL
- Sodium Chloride — SODIUM CHLORIDE 900 mg/100mL
- Sodium Chloride — SODIUM CHLORIDE 450 mg/50mL
- Sodium Chloride — SODIUM CHLORIDE 9 mg/mL
- Sodium Chloride — SODIUM CHLORIDE 900 mg/100mL
- Sodium Chloride — SODIUM CHLORIDE 9 mg/mL
- Sodium Chloride — SODIUM CHLORIDE 900 mg/100mL
- Sodium Chloride — SODIUM CHLORIDE 900 mg/100mL
- 0.9% Sodium Chloride — SODIUM CHLORIDE 9 g/1000mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mL ADD-Vantage® Flexible C... Discontinuation of the manufacture of the drug
- 100 mL ADD-Vantage® Flexible... Discontinuation of the manufacture of the drug
- 250 mL ADD-Vantage® Flexible... Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Sodium Chloride 0.9% Injection →
View Sodium Chloride 0.9% Injection on the FDA drug-shortage database →
Posaconazole Injection View full page →
Key facts about the Posaconazole Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Posaconazole Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Posaconazole Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Posaconazole injection (18 mg/mL) is currently on the FDA drug-shortage list. I want to explain what this means for you clearly and calmly.
Only one strength exists on this record — the 18 mg/mL injection — and it is the strength affected. The manufacturer that filed this report, Merck Sharp & Dohme (its Noxafil injection), lists this product as to be discontinued. The reported reason is that the maker is stopping production of the drug. Because this is a discontinuation rather than a temporary delay, the supply problem for that specific product may be permanent, and no recovery date is given.
Please do not stop, skip, or change how you use this medicine on your own. Here is a sensible order of steps:
- Talk with your prescriber or pharmacist about next steps, since this product is being discontinued.
- Ask your pharmacy whether the same medicine — posaconazole 18 mg/mL — is available from another maker. Our records show it from Camber Pharmaceuticals and Mylan Institutional. Your pharmacy may be able to source one of these, though it may not be in local stock.
- For reference, the manufacturer's contact number is listed on this page; pharmacies usually handle those calls.
This is national, manufacturer-reported information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 18 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Merck Sharp & Dohme Corp. 📞 800-672-6372 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Posaconazole Injection →
View Posaconazole Injection on the FDA drug-shortage database →
Nilutamide Tablet View full page →
Key facts about the Nilutamide Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Nilutamide Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Nilutamide Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Nilutamide 150 mg tablets are currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps with confidence.
The one strength made under this report — 150 mg — has no available source at this time. The manufacturer that filed this report, Advanz Pharma, has listed the product (sold as Nilandron) as being discontinued, with remaining supply set to expire in March 2026. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent for that maker. That makes a conversation with your prescriber the right next step so you have a plan in place.
The important thing is not to make changes on your own.
- Do not stop, skip, or adjust your doses without talking to a pharmacist or prescriber.
- Ask your pharmacy to check wholesalers and other makers — the same medicine, nilutamide 150 mg, is also listed from ANI Pharmaceuticals. Your pharmacy may be able to source it, though it may not be in local stock.
- Because the reporting manufacturer is discontinuing this product, ask your prescriber about your options going forward.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 150 mg Product to expire in March 2026; Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Advanz Pharma (US) Corp. 📞 847-283-7921 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Nilandron, Tablet, 150 mg (NDC 59212-111-14) | — | Product to expire in March 2026; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Nilandron, Tablet, 150 mg (NDC 66993-212-38) | — | Product to expire in March 2026; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Nilutamide Tablet →
Phenoxybenzamine Hydrochloride Capsule View full page →
Key facts about the Phenoxybenzamine Hydrochloride Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Phenoxybenzamine Hydrochloride Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Phenoxybenzamine Hydrochloride Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Phenoxybenzamine hydrochloride 10 mg capsules are currently listed on the FDA drug-shortage list. I know seeing this can be unsettling, so let me walk you through what it means and the steps that can help.
The affected strength is the 10 mg capsule, and there is no available source reported for it from the manufacturer on this record. The reason given is that the maker (Advanz Pharma, which sold it as Dibenzyline) is discontinuing manufacture of this product. Because this is a discontinuation rather than a temporary delay, the supply problem from this manufacturer may be permanent — which makes a conversation with your prescriber an important next step.
Please keep this in mind, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine, phenoxybenzamine hydrochloride 10 mg capsule, is also made by Burel, Amneal, Novitium, and NorthStar Rx. Your pharmacy may be able to source one of these, though it may not be in local stock.
- If your pharmacy cannot find it, ask your prescriber or pharmacist about your options.
This information comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock. Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Advanz Pharma (US) Corp. 📞 847-283-7921 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dibenzyline, Capsule, 10 mg (NDC 66993-066-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Dibenzyline, Capsule, 10 mg (NDC 59212-001-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Dibenzyline, Capsule, 10 mg (NDC 59212-001-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Phenoxybenzamine Hydrochloride Capsule →
View Phenoxybenzamine Hydrochloride Capsule on the FDA drug-shortage database →
Potassium Chloride Tablet, Extended Release View full page →
Key facts about the Potassium Chloride Tablet, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Potassium Chloride Tablet, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Potassium Chloride Tablet, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Potassium Chloride Extended-Release Tablets are currently on the FDA shortage list. I want to walk you through what this means so you can plan your next step calmly.
Both strengths on this record — the 10 meq and the 20 meq — have no available source from the manufacturer that filed this report. Neither strength is currently being supplied by that maker. The reported reason is that this manufacturer is discontinuing production of the drug. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent, which makes a conversation with your prescriber the right next step.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own — steady potassium levels matter.
- Ask your pharmacy to check wholesalers and other manufacturers, since this report reflects only one maker.
- The same medicine (potassium chloride extended-release) is still marketed by other companies, including Upsher-Smith (Klor-Con), Mylan, and Major Pharmaceuticals. Your pharmacy may be able to source one of these, though it may not be in local stock right now.
- Ask your prescriber or pharmacist about a suitable option chosen for you, such as a different strength to match your dose.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This information comes from national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Klor-Con — POTASSIUM CHLORIDE 600 mg/1
- Klor-Con — POTASSIUM CHLORIDE 750 mg/1
- Klor-Con M — POTASSIUM CHLORIDE 750 mg/1
- Klor-Con M — POTASSIUM CHLORIDE 1125 mg/1
- Klor-Con M — POTASSIUM CHLORIDE 1500 mg/1
- Potassium Chloride — POTASSIUM CHLORIDE 8 meq/1
- Potassium Chloride — POTASSIUM CHLORIDE 10 meq/1
- Potassium Chloride — POTASSIUM CHLORIDE 750 mg/1
- Potassium Chloride — POTASSIUM CHLORIDE 1500 mg/1
- Potassium Chloride — POTASSIUM CHLORIDE 750 mg/1
- Potassium Chloride — POTASSIUM CHLORIDE 1500 mg/1
- Potassium Chloride Extended-Release — POTASSIUM CHLORIDE 750 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 meq Discontinuation of the manufacture of the drug
- 10 meq Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Potassium Chloride, Tablet, Extended Release, 10 meq (NDC 62037-710-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Potassium Chloride Tablet, Extended Release →
View Potassium Chloride Tablet, Extended Rele... on the FDA drug-shortage database →
Verapamil Hydrochloride Injection View full page →
Key facts about the Verapamil Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Verapamil Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Verapamil Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Verapamil Hydrochloride Injection is currently on the FDA shortage list. This is a medicine given in a clinical setting, so a care team usually manages its supply, but I want you to understand what is happening.
The only strength on this report is 2.5 mg/1 mL, and it does not have an available source from the manufacturer that filed this notice. That maker, Pfizer Inc., has listed the product as being discontinued — meaning they are stopping production of it. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent for that one manufacturer.
What this report does not mean is that every company has stopped making it. Several other manufacturers are listed as making the same medicine at the same 2.5 mg/mL strength.
Here is what you can do:
- Do not stop or change how this medicine is used on your own.
- Ask your pharmacy or care team to check whether the same medicine is available from another maker — several are listed, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about a suitable option.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
- Verapamil Hydrochloride — VERAPAMIL HYDROCHLORIDE 2.5 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2.5 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Verapamil Hydrochloride Injection →
View Verapamil Hydrochloride Injection on the FDA drug-shortage database →
Anagrelide Hydrochloride Capsule View full page →
Key facts about the Anagrelide Hydrochloride Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Anagrelide Hydrochloride Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Anagrelide Hydrochloride Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Anagrelide hydrochloride capsules are currently on the FDA drug-shortage list. I want to walk you through what this means for the strength you take and the steps that make sense next.
Both available strengths — the 0.5 mg and the 1 mg capsules — are affected, and neither is reported to have an available source right now. The manufacturer that filed this report, Teva Pharmaceuticals USA, has listed both strengths as to be discontinued. The reason given is a business decision to stop making the drug, not a safety problem. Because this is a discontinuation, this particular supply gap may be permanent, so a conversation with your prescriber is the right next step.
Please keep in mind that this report reflects only one manufacturer. Other companies still make the same medicine, so your pharmacy may be able to find it elsewhere.
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other makers — the same medicine (anagrelide capsules, 0.5 mg and 1 mg) is listed from other manufacturers, though it may not be in local stock.
- If your capsules cannot be found, ask your prescriber or pharmacist about your options.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Anagrelide — ANAGRELIDE HYDROCHLORIDE ANHYDROUS .5 mg/1
- Anagrelide — ANAGRELIDE HYDROCHLORIDE ANHYDROUS 1 mg/1
- Agrylin — ANAGRELIDE HYDROCHLORIDE ANHYDROUS .5 mg/1
- Anagrelide — ANAGRELIDE HYDROCHLORIDE ANHYDROUS .5 mg/1
- Anagrelide — ANAGRELIDE HYDROCHLORIDE ANHYDROUS 1 mg/1
- Anagrelide — ANAGRELIDE HYDROCHLORIDE .5 mg/1
- Anagrelide — ANAGRELIDE HYDROCHLORIDE 1 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 0.5 mg A business decision was made to discontinue manufacture of the drug.
- 1 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Anagrelide Hydrochloride Capsule →
View Anagrelide Hydrochloride Capsule on the FDA drug-shortage database →
Hydrochlorothiazide Capsule View full page →
Key facts about the Hydrochlorothiazide Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Hydrochlorothiazide Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Hydrochlorothiazide Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Hydrochlorothiazide capsules are currently on the FDA shortage list, so I want to walk you through what that means for you.
The only strength on this record, the 12.5 mg capsule, has no available source right now from the manufacturer who filed this report (Teva, which makes the brand Microzide). The reason listed is a business decision to discontinue making this product. Because it is marked "to be discontinued," this particular supply problem may be permanent. That said, this report reflects only one manufacturer — the same medicine, hydrochlorothiazide 12.5 mg capsule, is still listed from several other makers.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort this out.
- Ask your pharmacy to source the 12.5 mg capsule from another maker; the same medicine is listed from companies such as Actavis, Unichem, ScieGen, Rising, Aurobindo, and others. It may not be in local stock, but your pharmacy can check wholesalers.
- If your exact capsule cannot be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
- Hydrochlorothiazide — HYDROCHLOROTHIAZIDE 12.5 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 12.5 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Microzide, Capsule, 12.5 mg (NDC 0591-0347-05) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Microzide, Capsule, 12.5 mg (NDC 0591-0347-01) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Hydrochlorothiazide Capsule →
View Hydrochlorothiazide Capsule on the FDA drug-shortage database →
Valsartan Tablet View full page →
Key facts about the Valsartan Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Valsartan Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Valsartan Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Valsartan tablets are currently on the FDA drug-shortage list. This blood-pressure and heart medicine appears here because one manufacturer, Mylan (a Viatris company), reported a business decision to discontinue making it.
All four strengths from this manufacturer are affected — 40 mg, 80 mg, 160 mg, and 320 mg — and none of these are reported as having an available source through Mylan right now. Because this is listed as a discontinuation, this particular supply may not return, so a conversation with your prescriber or pharmacist is the right next step.
An important point: this report reflects only Mylan's supply. Valsartan is the same medicine no matter who makes it, and other companies still list it — including Novartis (brand Diovan) and generic versions from Unichem and Camber. Your pharmacy may be able to source one of these, though a given product may not be in your local stock at any moment.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own — keep taking your valsartan as prescribed.
- Ask your pharmacy to check wholesalers and other manufacturers for the same medicine (Diovan, or generic valsartan from Unichem or Camber).
- If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general information from national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Diovan — VALSARTAN 80 mg/1
- Diovan — VALSARTAN 160 mg/1
- Diovan — VALSARTAN 320 mg/1
- Diovan — VALSARTAN 40 mg/1
- Valsartan — VALSARTAN 40 mg/1
- Valsartan — VALSARTAN 80 mg/1
- Valsartan — VALSARTAN 160 mg/1
- Valsartan — VALSARTAN 320 mg/1
- Valsartan — VALSARTAN 40 mg/1
- Valsartan — VALSARTAN 80 mg/1
- Valsartan — VALSARTAN 160 mg/1
- Valsartan — VALSARTAN 320 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 80 mg A business decision was made to discontinue manufacture of the drug.
- 320 mg A business decision was made to discontinue manufacture of the drug.
- 160 mg A business decision was made to discontinue manufacture of the drug.
- 40 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 800-796-9526 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Valsartan, Tablet, 40 mg (NDC 0378-5807-93) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Valsartan, Tablet, 160 mg (NDC 0378-5814-77) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Valsartan, Tablet, 320 mg (NDC 0378-5815-77) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Valsartan, Tablet, 80 mg (NDC 0378-5813-77) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Valsartan Tablet →
Montelukast Sodium Tablet, Chewable View full page →
Key facts about the Montelukast Sodium Tablet, Chewable shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Montelukast Sodium Tablet, Chewable may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Montelukast Sodium Tablet, Chewable shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Montelukast sodium chewable tablets (the 4 mg strength) are currently on the FDA drug-shortage list. If you or your child take this medicine for asthma or allergies, please read on so you know what this means and what to do next.
The affected strength is the 4 mg chewable tablet. Right now, no source is reported as available for this strength through the manufacturer on this record. The reason listed is that Organon is discontinuing its Singulair 4 mg chewable tablet, so this particular supply problem may be permanent rather than short-term. Because of that, a conversation with your prescriber or pharmacist is the right next step.
Please keep taking your medicine as prescribed. Here is how to move forward:
- Do not stop, skip, or change the dose on your own.
- Ask your pharmacy to check other manufacturers and wholesalers. The same medicine, montelukast sodium 4 mg chewable, is also made by other companies such as Torrent Pharmaceuticals, Ajanta Pharma, and Unichem — your pharmacy may be able to source one of these, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about other options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Montelukast — MONTELUKAST SODIUM 10 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 10 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 4 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 5 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 10 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 10 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 10 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 4 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 5 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 10 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 10 mg/1
- Montelukast Sodium — MONTELUKAST SODIUM 4 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 4 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Organon 📞 844-674-3200 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Montelukast Sodium Tablet, Chewable →
View Montelukast Sodium Tablet, Chewable on the FDA drug-shortage database →
Ceftazidime Injection View full page →
Key facts about the Ceftazidime Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ceftazidime Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ceftazidime Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Ceftazidime injection is currently on the FDA drug-shortage list. I want to explain what this means for you clearly and calmly.
Both strengths on this record — the 1 g and the 2 g — currently have no available source from the manufacturer that filed this report. The reason listed for both is that this maker (Hospira, a Pfizer Company) is discontinuing production of the drug. Because this is a discontinuation, this particular supply problem may be permanent for these products, which makes a conversation with your prescriber the right next step.
That said, this report reflects only one manufacturer. The same medicine — ceftazidime — is also listed as available from other makers, including Sagent Pharmaceuticals and WG Critical Care. Your pharmacy may be able to source one of these, though it may not be sitting in local stock.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for the same medicine from another maker.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2 g Discontinuation of the manufacture of the drug
- 1 g Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Tazicef, Injection, 1 g (NDC 0409-5092-16) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Tazicef, Injection, 2 g (NDC 0409-5093-11) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Ceftazidime Injection →
View Ceftazidime Injection on the FDA drug-shortage database →
Palonosetron Hydrochloride Injection View full page →
Key facts about the Palonosetron Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Palonosetron Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Palonosetron Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Palonosetron Hydrochloride Injection, the anti-nausea medicine often given during chemotherapy, is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The one strength on this record, the .25 mg/5 mL injection, has no available source from the manufacturer that filed this report. The reason listed is that Teva Pharmaceuticals is discontinuing its production of this product. Because this is a discontinuation rather than a short-term delay, this particular supply may not return. That does not mean the medicine has vanished, though — several other companies still make the same palonosetron injection, so your care team has good options.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Because this is a discontinuation, the most important step is to talk with your prescriber or pharmacist about how to continue treatment.
- Ask whether the same medicine can be sourced from another maker — options like Sandoz, Baxter, Fresenius Kabi, and others still list this injection, though it may not be in local stock.
- Your prescriber or pharmacist can also choose a suitable alternative if needed.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. Local stock may differ from this national data.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Palonosetron Hydrochloride — PALONOSETRON HYDROCHLORIDE .25 mg/5mL
- Palonosetron — PALONOSETRON HYDROCHLORIDE .05 mg/mL
- Palonosetron Hydrochloride — PALONOSETRON HYDROCHLORIDE .05 mg/mL
- Palonosetron Hydrochloride — PALONOSETRON HYDROCHLORIDE .25 mg/5mL
- Palonosetron — PALONOSETRON HYDROCHLORIDE .05 mg/mL
- Palonosetron Hydrochloride — PALONOSETRON HYDROCHLORIDE .25 mg/5mL
- Palonosetron — PALONOSETRON HYDROCHLORIDE .25 mg/5mL
- Palonosetron — PALONOSETRON HYDROCHLORIDE .25 mg/5mL
- Palonosetron Hydrochloride — PALONOSETRON HYDROCHLORIDE .25 mg/5mL
- Palonosetron — PALONOSETRON HYDROCHLORIDE .05 mg/mL
- Palonosetron Hydrochloride — PALONOSETRON HYDROCHLORIDE .25 mg/5mL
- Palonosetron Hydrochloride — PALONOSETRON HYDROCHLORIDE .25 mg/5mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .25 mg/5 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Palonosetron Hydrochloride Injection →
View Palonosetron Hydrochloride Injection on the FDA drug-shortage database →
Somatropin Injection View full page →
Key facts about the Somatropin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Somatropin Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Somatropin Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Somatropin injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The strength affected is the 30 mg/3 mL pen (Norditropin), reported by Novo Nordisk. This strength has no available source right now, and the reason given is that the manufacturer is discontinuing production. Because this is listed as "to be discontinued," this particular product's supply problem may be permanent rather than a short-term gap. That makes a conversation with your prescriber the right next step so you can plan ahead.
Please do not let this alarm you — somatropin is still made in other strengths and by another company, and your care team has good options to keep your treatment steady.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Since your exact strength is being discontinued, ask your prescriber or pharmacist about options — for example, a different Norditropin strength (such as 5, 10, or 15 mg/1.5 mL) or Omnitrope (5 or 10 mg/1.5 mL), which are the same medicine from Novo Nordisk or Sandoz.
- Your pharmacy may be able to source one of these, though it may not be in local stock.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual supply.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 30 mg/3 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Novo Nordisk, Inc. 📞 833-493-4689 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Somatropin Injection →
View Somatropin Injection on the FDA drug-shortage database →
Vancomycin Hydrochloride Injection View full page →
Key facts about the Vancomycin Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Vancomycin Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Vancomycin Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Vancomycin Hydrochloride Injection is currently on the FDA shortage list, and I want to walk you through what that means for you.
The specific product affected is the 10 g Vial (NovaPlus) made by Hospira, Inc., a Pfizer Company. This strength has no available source reported right now, and the maker has listed it as being discontinued. In practice, that means this particular supply problem may be permanent rather than a short-term gap. No other strengths are covered by this specific record.
Because this is a discontinuation, the most important next step is a conversation with your prescriber or pharmacist. Here is how I would approach it:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check with wholesalers, since local stock can differ from national reports.
- The same medicine, vancomycin, is still made in several strengths by other manufacturers, including Hikma Pharmaceuticals and Hospira. Your pharmacy may be able to source one of these, though it may not be in local stock and a prescriber's guidance is needed to match your dose.
- Ask your prescriber or pharmacist about a suitable option if this exact vial cannot be found.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is general, national information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 1.25 g/1
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 1.5 g/1
- Vancomycin Hydrochloride — VANCOMYCIN 750 mg/1
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 1 g/1
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 5 g/1
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 10 g/1
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 500 mg/5mL
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 1.5 g/1
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 500 mg/1
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 500 mg/10mL
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 750 mg/1
- Vancomycin Hydrochloride — VANCOMYCIN HYDROCHLORIDE 1 g/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 g Vial NovaPlus Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Vancomycin Hydrochloride Injection →
View Vancomycin Hydrochloride Injection on the FDA drug-shortage database →
Adalimumab-Ryvk Kit View full page →
Key facts about the Adalimumab-Ryvk Kit shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Adalimumab-Ryvk Kit may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Adalimumab-Ryvk Kit shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Adalimumab-Ryvk Kit is currently listed on the FDA drug-shortage list. The maker that filed this report, Teva Pharmaceuticals USA, Inc., has marked its product (Simlandi Kit) as to be discontinued, which means this particular supply problem may be permanent rather than temporary.
The reported reason is the discontinuation of the manufacture of the drug. Because this is a planned discontinuation, the right next step is a conversation with your prescriber or pharmacist so you can plan ahead calmly. Please keep in mind this report reflects only the manufacturer who filed it — the same medicine may still be supplied by other makers.
Here is what I'd suggest, in order:
- Do not stop, skip, or change your doses on your own — keep taking your medicine as prescribed while you sort out supply.
- Ask your pharmacy whether they can source the same medicine from another maker. Our records show the same ingredient is also listed under Simlandi from A-S Medication Solutions, Simlandi from Teva, and Adalimumab-Ryvk from Quallent Pharmaceuticals Health LLC — though these may not be in local stock.
- If your product cannot be found, ask your prescriber or pharmacist about a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- All / unspecified Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Simlandi, Kit, Kit (NDC 51759-523-21) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Adalimumab-Ryvk Kit →
View Adalimumab-Ryvk Kit on the FDA drug-shortage database →
Cetrorelix Acetate Injection View full page →
Key facts about the Cetrorelix Acetate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Cetrorelix Acetate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Cetrorelix Acetate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Cetrorelix Acetate Injection is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next step calmly.
The report on file comes from one manufacturer, Teva Pharmaceuticals USA, and it covers the injection kit (NDC 0480-5795-08). Teva has marked this product as to be discontinued because they are stopping production of the drug. That means this supply problem may be permanent for the Teva product. Importantly, this report reflects only Teva — it does not mean the medicine is gone from every maker. The same medicine is still listed from several other companies.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check whether they can source the same medicine from another maker. The same-ingredient kit is listed from EMD Serono (Cetrotide), Apotex, Fresenius Kabi, and Meitheal — though these may not be in your local stock right away.
- If your pharmacy cannot find it, talk with your prescriber or pharmacist about the best option for you.
For reference, the manufacturer's contact number is listed on this page, though pharmacies usually handle those calls. This is general national information and may not match what your local pharmacy actually has on hand.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- All / unspecified Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cetrorelix Acetate, Injection, Kit (NDC 0480-5795-08) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Cetrorelix Acetate Injection →
View Cetrorelix Acetate Injection on the FDA drug-shortage database →
Guanfacine Hydrochloride Tablet, Extended Release View full page →
Key facts about the Guanfacine Hydrochloride Tablet, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Guanfacine Hydrochloride Tablet, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Guanfacine Hydrochloride Tablet, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Guanfacine extended-release tablets are currently on the FDA shortage list. I want to walk you through what this means so you can plan calmly.
This shortage record covers all four strengths — 1 mg, 2 mg, 3 mg, and 4 mg — and none of these currently has an available source from the manufacturer that filed this report (Actavis Pharma). The reason given is a business decision to discontinue making the drug. Because this is a discontinuation rather than a temporary delay, the supply problem from this maker may be permanent, so a conversation with your prescriber is the right next step.
Please keep in mind this report reflects only one manufacturer. Other companies still make the same medicine, so this does not mean guanfacine ER is gone everywhere.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed.
- Ask your pharmacy whether they can source the same medicine (guanfacine ER) from another maker, such as Northstar Rx, Upsher-Smith, or Unichem. It may not be in local stock right away.
- If your exact strength cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Guanfacine — GUANFACINE HYDROCHLORIDE 1 mg/1
- Guanfacine — GUANFACINE HYDROCHLORIDE 2 mg/1
- Guanfacine — GUANFACINE HYDROCHLORIDE 3 mg/1
- Guanfacine — GUANFACINE HYDROCHLORIDE 4 mg/1
- Guanfacine Extended-Release — GUANFACINE 1 mg/1
- Guanfacine Extended-Release — GUANFACINE 2 mg/1
- Guanfacine Extended-Release — GUANFACINE 3 mg/1
- Guanfacine Extended-Release — GUANFACINE 4 mg/1
- Guanfacine — GUANFACINE HYDROCHLORIDE 1 mg/1
- Guanfacine — GUANFACINE HYDROCHLORIDE 2 mg/1
- Guanfacine — GUANFACINE HYDROCHLORIDE 3 mg/1
- Guanfacine — GUANFACINE HYDROCHLORIDE 4 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 4 mg A business decision was made to discontinue manufacture of the drug.
- 3 mg A business decision was made to discontinue manufacture of the drug.
- 1 mg A business decision was made to discontinue manufacture of the drug.
- 2 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Actavis Pharma, Inc. 📞 800-545-8800 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Guanfacine Hydrochloride, Tablet, Extended Release, 2 mg (NDC 0228-2851-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Guanfacine Hydrochloride, Tablet, Extended Release, 1 mg (NDC 0228-2850-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Guanfacine Hydrochloride, Tablet, Extended Release, 3 mg (NDC 0228-2853-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Guanfacine Hydrochloride, Tablet, Extended Release, 4 mg (NDC 0228-2855-11) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Guanfacine Hydrochloride Tablet, Extended Release →
View Guanfacine Hydrochloride Tablet, Extende... on the FDA drug-shortage database →
Frovatriptan Succinate Tablet View full page →
Key facts about the Frovatriptan Succinate Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Frovatriptan Succinate Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Frovatriptan Succinate Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Frovatriptan succinate 2.5 mg tablets are currently on the FDA drug-shortage list, so I want to walk you through what this means for you.
The affected strength is the 2.5 mg tablet, which is the only strength involved here. At this time, the manufacturer that filed this report—Endo Pharmaceuticals, maker of the brand Frova—has no available supply of the 2.5 mg tablet. This is not because of a production problem; the reported reason is a business decision to discontinue making the drug. Because this is a discontinuation, this particular supply may not come back.
The important point is that other companies still make frovatriptan 2.5 mg tablets, so the medicine itself is not gone from the market.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own. Keep taking your medicine as prescribed.
- Ask your pharmacy whether they can source frovatriptan 2.5 mg from another maker—the same medicine is available from Ingenus, Glenmark, and Amneal. It may not be in local stock, but your pharmacy can check.
- If it cannot be found, talk with your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2.5 mg A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Endo Pharmaceuticals, Inc. 📞 800-828-9393 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Frova, Tablet, 2.5 mg (NDC 63481-025-09) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Frova, Tablet, 2.5 mg (NDC 0603-3718-34) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Frovatriptan Succinate Tablet →
View Frovatriptan Succinate Tablet on the FDA drug-shortage database →
Calcium Chloride Injection View full page →
Key facts about the Calcium Chloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Calcium Chloride Injection may not appear here at all, so this is not a picture of every available option. See the full Calcium Chloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Calcium Chloride Injection (100 mg/1 mL) is currently on the FDA drug-shortage list, and the record shows this product is being discontinued by the manufacturer that filed the report.
The single strength tracked here, 100 mg/1 mL, has no available source reported at this time. There is no other strength listed with active supply, and our records do not show another maker for this same medicine on this report.
The reason given is straightforward: the manufacturer, Hospira, Inc. (a Pfizer Company), has reported discontinuing production of this drug. Because this is a discontinuation rather than a temporary delay, the supply problem may be permanent. That makes a conversation with your prescriber the right next step, since they can plan ahead for your care.
Here is what I suggest, in order:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — local stock can differ from national reports.
- Because this strength is being discontinued, talk with your prescriber or pharmacist about a clinician-chosen option that fits your needs.
A manufacturer contact number is listed on this page for reference, though pharmacies usually handle those calls. This is general information and may not match your pharmacy's actual stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Calcium Chloride Injection →
View Calcium Chloride Injection on the FDA drug-shortage database →
Deferiprone Tablet View full page →
Key facts about the Deferiprone Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Deferiprone Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Deferiprone Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Deferiprone tablets are currently on the FDA drug-shortage list, and I want to walk you through what this means for you.
The strength on this record is the 500 mg tablet, and right now no available source is reported for it from the manufacturer that filed this shortage. There are no other strengths listed as still in supply on this particular record.
The reason given is that the manufacturer (Chiesi USA, maker of the brand Ferriprox) has marked this product as to be discontinued — meaning they are stopping production. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent for that maker, with no estimated recovery date. Importantly, this report reflects only one manufacturer; the same medicine may still be available from other companies.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — deferiprone 500 mg is listed as available from other makers (such as Hikma, Sun Pharmaceutical, and Dr. Reddy's), though it may not be in local stock.
- Because the brand version is being discontinued, talk with your prescriber or pharmacist about your options going forward.
The manufacturer contact number is listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500 mg Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Chiesi USA, Inc. 📞 888-466-6505 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ferriprox, Tablet, 500 mg (NDC 10122-100-10) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Deferiprone Tablet →
Epinephrine Injection View full page →
Key facts about the Epinephrine Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Epinephrine Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Epinephrine Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Epinephrine Injection is currently on the FDA drug-shortage list, and I want to walk you through what this means for you.
The strength involved is the 0.1 mg/1 mL injection. Right now, this strength has no available source from the manufacturer that filed this report. The reason listed is that the maker, Hospira (a Pfizer company), is discontinuing production of this product. Because this is a discontinuation rather than a temporary delay, the supply problem from this manufacturer may be permanent.
It is important to know that this report reflects only that one manufacturer. Other companies make the same 0.1 mg/1 mL epinephrine injection, so it may still be obtainable through your pharmacy.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine at this strength is also listed from A-S Medication Solutions, HealthFirst, and International Medication Systems. Your pharmacy may be able to source one of these, though it may not be in local stock.
- Because this product is being discontinued, talk with your prescriber or pharmacist about your options going forward.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .1 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Epinephrine Injection →
View Epinephrine Injection on the FDA drug-shortage database →
Ketamine Hydrochloride Injection View full page →
Key facts about the Ketamine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ketamine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ketamine Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Ketamine Hydrochloride Injection is currently on the FDA shortage list, so I want to walk you through what that means for you.
The strength involved here is the 500 mg/5mL (100 mg/mL) Multiple Dose Glass Fliptop Vial (Novaplus). This specific product has no available source right now. According to the report, the maker, Pfizer Inc., has listed it as being discontinued — meaning they are stopping production of this particular vial.
Because this is a discontinuation rather than a temporary delay, the supply problem for this exact product may be permanent. That said, this report reflects only one manufacturer's decision. The same medicine — ketamine hydrochloride injection, including the 100 mg/mL strength — is still listed from several other makers, such as Hikma, Hospira, Sagent, Par Health, and Eugia.
Here is what I suggest:
- Do not stop or change how this medicine is used on your own.
- Ask your pharmacy whether they can source the same medicine from one of the other makers above. It may not be in local stock, but they can check wholesalers and other manufacturers.
- If your exact product cannot be found, talk with your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 50 mg/mL
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 100 mg/mL
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 100 mg/mL
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 50 mg/mL
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 10 mg/mL
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 50 mg/mL
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 100 mg/mL
- Ketalar — KETAMINE HYDROCHLORIDE 10 mg/mL
- Ketalar — KETAMINE HYDROCHLORIDE 50 mg/mL
- Ketalar — KETAMINE HYDROCHLORIDE 100 mg/mL
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 10 mg/mL
- Ketamine Hydrochloride — KETAMINE HYDROCHLORIDE 50 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500 mg/5mL (100 mg/mL); Multip... Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Ketamine Hydrochloride Injection →
View Ketamine Hydrochloride Injection on the FDA drug-shortage database →
Everolimus Tablet View full page →
Key facts about the Everolimus Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Everolimus Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Everolimus Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Everolimus tablets are currently on the FDA drug-shortage list. I want to walk you through what this means and the steps that can keep your treatment on track.
This shortage covers every strength on the record — the 2 mg, 2.5 mg, 3 mg, 5 mg, 7.5 mg, and 10 mg tablets. None of these strengths has an available source from the three manufacturers that filed this report. The reason listed for each is that these makers are discontinuing production. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent for these manufacturers. Even so, this report reflects only those three companies — other makers of the same medicine may still supply it.
Please do not stop, skip, or adjust your doses on your own. Here is how to move forward:
- Talk with your pharmacist or prescriber soon about your options, since your usual product is being discontinued.
- Ask your pharmacy whether they can source everolimus from another maker — the same medicine is also listed from Hikma, Novartis (Afinitor and Afinitor Disperz), and Upsher-Smith (Torpenz), though these may not be in local stock.
- Your prescriber can discuss a suitable alternative if needed.
Manufacturer contact numbers are on this page for reference; pharmacies usually make those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Everolimus — EVEROLIMUS 2.5 mg/1
- Everolimus — EVEROLIMUS 5 mg/1
- Everolimus — EVEROLIMUS 10 mg/1
- Everolimus — EVEROLIMUS 7.5 mg/1
- Afinitor — EVEROLIMUS 5 mg/1
- Afinitor — EVEROLIMUS 10 mg/1
- Afinitor — EVEROLIMUS 2.5 mg/1
- Afinitor — EVEROLIMUS 7.5 mg/1
- Afinitor Disperz — EVEROLIMUS 2 mg/1
- Afinitor Disperz — EVEROLIMUS 3 mg/1
- Afinitor Disperz — EVEROLIMUS 5 mg/1
- Torpenz — EVEROLIMUS 2.5 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg Discontinuation of the manufacture of the drug
- 7.5 mg Discontinuation of the manufacture of the drug
- 2.5 mg Discontinuation of the manufacture of the drug
- 2 mg Discontinuation of the manufacture of the drug
- 3 mg Discontinuation of the manufacture of the drug
- 10 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Endo Pharmaceuticals, Inc. 📞 800-828-9393 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Everolimus, Tablet, 2.5 mg (NDC 49884-119-91) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Everolimus, Tablet, 5 mg (NDC 49884-125-91) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Everolimus, Tablet, 10 mg (NDC 49884-128-91) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Everolimus, Tablet, 7.5 mg (NDC 49884-127-91) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 800-796-9526 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Everolimus, Tablet, 3 mg (NDC 0378-0006-85) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Everolimus, Tablet, 2 mg (NDC 0378-0005-85) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Everolimus, Tablet, 5 mg (NDC 0378-0007-85) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Everolimus, Tablet, 10 mg (NDC 0093-7769-24) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Everolimus, Tablet, 5 mg (NDC 0093-7767-24) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Everolimus Tablet →
Acetaminophen; Oxycodone Hydrochloride Tablet View full page →
Key facts about the Acetaminophen; Oxycodone Hydrochloride Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Acetaminophen; Oxycodone Hydrochloride Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Acetaminophen; Oxycodone Hydrochloride Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Acetaminophen with oxycodone (the combination tablet) is currently on the FDA shortage list, so I want to walk you through what this means for the strength you take.
The report covers the 325 mg/2.5 mg, 325 mg/5 mg, 325 mg/7.5 mg, and 325 mg/10 mg tablets. Right now, none of these strengths has an available source from the manufacturer on this record. The reason given is that the maker, Endo Pharmaceuticals, is discontinuing this product. Because a discontinuation is often permanent, it is best to plan for a longer-term solution rather than a short wait.
Importantly, this report reflects only one manufacturer. The same medicine — oxycodone and acetaminophen tablets — is still listed from other makers, including SpecGx, Major Pharmaceuticals, KVK-Tech, and Aurolife, in strengths that match yours.
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check whether the same medicine is available from another maker; they can look through wholesalers, though local stock isn't guaranteed.
- If your exact tablet can't be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
- Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Oxycodone And Acetaminophen — OXYCODONE HYDROCHLORIDE 5 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE HYDROCHLORIDE 7.5 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE HYDROCHLORIDE 10 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE HYDROCHLORIDE 5 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE HYDROCHLORIDE 7.5 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE HYDROCHLORIDE 10 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE 2.5 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE 5 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE 7.5 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE 10 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE HYDROCHLORIDE 5 mg/1; ACETAMINOPHEN 325 mg/1
- Oxycodone And Acetaminophen — OXYCODONE HYDROCHLORIDE 7.5 mg/1; ACETAMINOPHEN 325 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 325 mg; 2.5 mg Discontinuation of the manufacture of the drug
- 325 mg; 5 mg Discontinuation of the manufacture of the drug
- 325 mg; 7.5 mg Discontinuation of the manufacture of the drug
- 325 mg; 10 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Endo Pharmaceuticals, Inc. 📞 800-828-9393 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Acetaminophen; Oxycodone Hydrochloride Tablet →
View Acetaminophen; Oxycodone Hydrochloride T... on the FDA drug-shortage database →
Lasmiditan Succinate Tablet View full page →
Key facts about the Lasmiditan Succinate Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Lasmiditan Succinate Tablet may not appear here at all, so this is not a picture of every available option. See the full Lasmiditan Succinate Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Lasmiditan (brand name Reyvow) is currently on the FDA shortage list, so I want to walk you through what that means for you.
Both available strengths are affected. Neither the 50 mg nor the 100 mg tablet has an available source right now, so this applies no matter which one you take.
The reason listed here is a business decision by the manufacturer, Eli Lilly, to discontinue making both the 50 mg and 100 mg tablets. According to the report, distribution will end on May 31, 2026. This is only the maker on this shortage record; still, because it is a discontinuation rather than a temporary delay, this supply problem may be lasting. That makes a conversation with your prescriber the right next step to plan ahead.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers, since local stock can differ from national reports.
- Because this medicine is being discontinued, talk with your prescriber or pharmacist about a clinician-chosen option that fits you.
- Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls.
This is general, manufacturer-reported information and may not match your local pharmacy's actual stock, so please lean on your care team for advice that fits you.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. D...
- 50 mg A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. D...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Reyvow, Tablet, 100 mg (NDC 0002-4491-61) | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — | To Be Discontinued |
| Reyvow, Tablet, 50 mg (NDC 0002-4312-61) | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — | To Be Discontinued |
| Reyvow, Tablet, 100 mg (NDC 0002-4491-08) | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — | To Be Discontinued |
| Reyvow, Tablet, 50 mg (NDC 0002-4312-62) | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — | To Be Discontinued |
| Reyvow, Tablet, 50 mg (NDC 0002-4312-08) | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — | To Be Discontinued |
| Reyvow, Tablet, 100 mg (NDC 0002-4491-62) | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — | To Be Discontinued |
Full shortage page: Lasmiditan Succinate Tablet →
View Lasmiditan Succinate Tablet on the FDA drug-shortage database →
Scopolamine Transdermal System View full page →
Key facts about the Scopolamine Transdermal System shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Scopolamine Transdermal System may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Scopolamine Transdermal System shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
The scopolamine transdermal system (the motion-sickness patch) is currently on the FDA shortage list. I want to explain what that means for you so you can plan ahead calmly.
This shortage record covers the 1 mg patch, and that strength has no available source from the manufacturer that filed this report. The reason given is that the maker, Padagis US LLC, is discontinuing production of this product. Because this is a discontinuation rather than a temporary delay, the supply problem from this manufacturer may be permanent.
Importantly, this report reflects only one manufacturer. Other companies still make the same scopolamine patch, so your pharmacy may be able to find it from a different maker.
Here is what I suggest:
- Do not stop, skip, or change how you use your patch on your own.
- Ask your pharmacy to check their wholesalers and other manufacturers — the same medicine is listed as still on the market from makers such as Mylan, Baxter (Transderm Scop), Rhodes, Amneal, Zydus, and others. It may not be in local stock, but your pharmacy can try to source it.
- If your patch cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Scopolamine — SCOPOLAMINE 1 mg/3d
- Transderm Scop — SCOPOLAMINE 1 mg/3d
- Scopolamine — SCOPOLAMINE 1 mg/3d
- Scopolamine Transdermal System — SCOPOLAMINE 1 mg/1
- Scopolamine — SCOPOLAMINE 1.5 mg/1
- Scopolamine Trandermal System — SCOPOLAMINE 1 mg/1
- Scopolamine — SCOPOLAMINE 1 mg/3d
- Scopolamine — SCOPOLAMINE 1 mg/3d
- Scopolamine — SCOPOLAMINE 1 mg/3d
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 866-634-9120 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Scopolamine Transdermal System →
View Scopolamine Transdermal System on the FDA drug-shortage database →
Phenobarbital Tablet View full page →
Key facts about the Phenobarbital Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Phenobarbital Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Phenobarbital Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Phenobarbital tablets are currently on the FDA shortage list. If you take this medicine, please keep taking it as prescribed while we sort out supply — this is manageable, and there are steps we can take together.
All four tablet strengths on this record — 16.2 mg, 32.4 mg, 64.8 mg, and 97.2 mg — currently have no available source from the manufacturer that filed this report. The reason listed for each strength is that the maker (Endo Pharmaceuticals) is discontinuing production. Because this is a discontinuation, the shortage for these specific products may be permanent, so a conversation with your prescriber about a longer-term plan is the right next step.
Here is what I'd suggest, in order:
- Do not stop, skip, or change your doses on your own — stopping phenobarbital suddenly can be dangerous.
- Ask your pharmacy to check other suppliers. The same medicine is still listed from other makers (Hikma, Major, e5 Pharma), and your pharmacy may be able to source one, though it may not be in local stock right away.
- If your exact strength can't be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative or a different strength to make up your dose.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Phenobarbital — PHENOBARBITAL 60 mg/1
- Phenobarbital — PHENOBARBITAL 100 mg/1
- Phenobarbital — PHENOBARBITAL 15 mg/1
- Phenobarbital — PHENOBARBITAL 30 mg/1
- Phenobarbital — PHENOBARBITAL 32.4 mg/1
- Phenobarbital — PHENOBARBITAL 16.2 mg/1
- Phenobarbital — PHENOBARBITAL 32.4 mg/1
- Phenobarbital — PHENOBARBITAL 64.8 mg/1
- Phenobarbital — PHENOBARBITAL 97.2 mg/1
- Phenobarbital — PHENOBARBITAL 30 mg/1
- Phenobarbital — PHENOBARBITAL 60 mg/1
- Phenobarbital — PHENOBARBITAL 100 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 32.4 mg Discontinuation of the manufacture of the drug
- 97.2 mg Discontinuation of the manufacture of the drug
- 16.2 mg Discontinuation of the manufacture of the drug
- 64.8 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Endo Pharmaceuticals, Inc. 📞 800-828-9393 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Phenobarbital Tablet →
View Phenobarbital Tablet on the FDA drug-shortage database →
Moxifloxacin Injection View full page →
Key facts about the Moxifloxacin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Moxifloxacin Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Moxifloxacin Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Moxifloxacin Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The strength involved is 400mg per 250mL, and right now this is the only strength covered by this report. There is no available source listed for it at this time. The reason given is that the manufacturer, Fresenius Kabi USA, is discontinuing production of this product. Because the status is listed as "to be discontinued," this supply problem may be permanent rather than temporary, so a conversation with your prescriber is the right next step.
Please keep in mind this information comes from national, manufacturer-reported FDA data. It may not match what your local pharmacy actually has on its shelves.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check with wholesalers and other suppliers — the same medicine in this strength is also listed under Fresenius Kabi, and your pharmacy may be able to source it, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 400mg per 250mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Moxifloxacin Injection →
View Moxifloxacin Injection on the FDA drug-shortage database →
Pramlintide Acetate Injection View full page →
Key facts about the Pramlintide Acetate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Pramlintide Acetate Injection may not appear here at all, so this is not a picture of every available option. See the full Pramlintide Acetate Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Pramlintide acetate injection, sold as SymlinPen 60 and SymlinPen 120, is currently on the FDA drug-shortage list.
The one strength on this record is 1000 ug/1 mL, and it does not have an available source right now. The reason reported is that the manufacturer, AstraZeneca AB, is discontinuing production of the drug. Because this is a discontinuation rather than a temporary supply delay, this problem may be permanent, and there is no estimated recovery date. Only one manufacturer is listed on this record, so I can't point you to another maker of the same medicine in our data.
Please do not stop, skip, or adjust your doses on your own while you sort this out. Here is what I suggest:
- Talk with your prescriber or pharmacist soon about your options, since your strength is being discontinued and may not be found.
- Ask your pharmacy to check wholesalers for any remaining stock while it lasts, and to help plan next steps.
- For reference, the manufacturer's contact number is listed on this page, though pharmacies usually handle those calls.
This information comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock. It isn't individualized medical advice, so please let your care team guide your next step.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1000 ug/1 mL Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: AstraZeneca AB 📞 800-236-9933 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| SymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
| SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Pramlintide Acetate Injection →
View Pramlintide Acetate Injection on the FDA drug-shortage database →
Insulin Lispro Injection View full page →
Key facts about the Insulin Lispro Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Insulin Lispro Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Insulin Lispro Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Insulin Lispro Injection is currently on the FDA shortage list, and I want to walk you through what this means so you can plan ahead calmly.
The two products on this record — the U-100 Tempo Pen and the 100 [iU]/1 mL (Insulin Lispro Junior KwikPen) — both currently have no available source. Neither strength is showing supply on this report. Please note this record covers only the manufacturer that filed it, so it does not describe every maker of this medicine.
The reason listed is a business decision by Eli Lilly to discontinue these products, with distribution of the Junior KwikPen projected to end in June 2027. Because these items are being discontinued, this supply change may be permanent, which makes a conversation with your prescriber the right next step.
Here is what I suggest, in order:
- Do not stop, skip, or change your insulin doses on your own — that can be dangerous.
- Ask your pharmacy to check wholesalers and other manufacturers for the same medicine. Related insulin lispro products remain on the market, including Humalog KwikPen 200 [iU]/mL, Humalog Junior KwikPen 100 [iU]/mL, and Admelog 100 U/mL — though these may not be in local stock.
- Ask your prescriber or pharmacist about a clinician-chosen option that fits you.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- U-100 Tempo Pen A business decision was made to discontinue manufacture of the drug.
- 100 [iU]/1 mL A business decision was made to discontinue manufacture of the drug. Distribution projecte...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05) | — | A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance. | — | To Be Discontinued |
| Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Insulin Lispro Injection →
View Insulin Lispro Injection on the FDA drug-shortage database →
Busulfan Injection View full page →
Key facts about the Busulfan Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Busulfan Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Busulfan Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Busulfan Injection is currently on the FDA drug-shortage list. I know seeing this can feel unsettling, so let me walk you through what it means and what comes next.
This shortage report covers the 6 mg/1 mL strength, and right now that strength has no available source from the manufacturer who filed this report. The reason given is that the maker, Mylan Institutional (a Viatris Company), is discontinuing the manufacture of this product. Because this is listed as "to be discontinued," the supply problem from this manufacturer may be permanent — which makes a conversation with your care team the right next step.
I want to be clear that this report reflects only the one manufacturer who filed it. Other companies still make busulfan injection, so the medicine itself is not gone.
Here is what you can do:
- Do not stop, skip, or change any doses on your own.
- Ask your pharmacy or treatment center to check wholesalers and other makers — the same medicine (busulfan injection 6 mg/mL) is also listed from Hospira, Accord Healthcare, Sagent, Otsuka (Busulfex), Amneal, and Meitheal. It may not be in local stock, but they may be able to source it.
- If your exact product cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 6 mg/1 mL Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Busulfan Injection →
Insulin Glargine Injection View full page →
Key facts about the Insulin Glargine Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Insulin Glargine Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Insulin Glargine Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Insulin glargine injection is currently on the FDA shortage list, and I want to walk you through what this means for you.
The affected product is the Basaglar U-100 Tempo Pen, which right now has no available source reported. The manufacturer, Eli Lilly, has noted this specific pen is being discontinued as a business decision. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent — so a conversation with your prescriber is the right next step to plan ahead.
Please keep in mind this report reflects one manufacturer's decision about one product. Insulin glargine itself is still made by other companies. Here is what I suggest:
- Do not stop, skip, or change your insulin doses on your own — steady dosing matters for your safety.
- Ask your pharmacy to check wholesalers and other suppliers; they can see stock that this national report may not reflect.
- The same medicine, insulin glargine, is available from other makers as products like Basaglar Kwikpen, Lantus, Lantus Solostar, Toujeo, and Insulin Glargine U-300 Max. Your pharmacy may be able to source one, though it may not be in local stock, and your prescriber should choose what fits you.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- U-100 Tempo Pen A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Insulin Glargine Injection →
View Insulin Glargine Injection on the FDA drug-shortage database →
Insulin Lispro-Aabc Injection View full page →
Key facts about the Insulin Lispro-Aabc Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Insulin Lispro-Aabc Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Insulin Lispro-Aabc Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Insulin Lispro-Aabc (sold as Lyumjev) is currently on the FDA shortage list. Because this affects an insulin, I want to walk you through it carefully.
The affected products are the U-100 Tempo Pen and the U-100 Tempo Pen Sample. Neither has an available source reported right now. The manufacturer, Eli Lilly, has reported that a business decision was made to discontinue making these Tempo Pen products. Because they are being discontinued, this supply change may be permanent rather than a short-term gap, so planning ahead with your care team is the right step.
The same insulin (insulin lispro, Lyumjev) is still listed in other pen forms — the Lyumjev KwikPen in U-100 (100 units/mL) and U-200 (200 units/mL). These are the same medicine from the same maker in a different pen, though they may not be sitting on your pharmacy's shelf.
- Do not stop, skip, or change your insulin on your own.
- Ask your pharmacy whether a Lyumjev KwikPen can be ordered for you.
- If your Tempo Pen cannot be found, ask your prescriber or pharmacist which option fits you best.
A manufacturer contact number is listed on this page for reference; your pharmacy usually handles those calls. This is national, manufacturer-reported data and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- U-100 Tempo Pen Sample A business decision was made to discontinue manufacture of the drug.
- U-100 Tempo Pen A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Insulin Lispro-Aabc Injection →
View Insulin Lispro-Aabc Injection on the FDA drug-shortage database →
Tranylcypromine Sulfate Tablet View full page →
Key facts about the Tranylcypromine Sulfate Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Tranylcypromine Sulfate Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Tranylcypromine Sulfate Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Tranylcypromine sulfate tablets are currently on the FDA drug-shortage list. I want to walk you through what this means and what your next steps can be.
The affected strength is the 10 mg tablet, which is the only strength on this report, and right now there is no available source for it from the manufacturer who filed this notice. The reason listed is that this product is being discontinued, with supply expected to run out by December 31, 2025. Because this is marked "to be discontinued," this supply problem may be a lasting one for this maker — so a conversation with your prescriber is the right next step to plan ahead.
Please keep in mind that this is national, manufacturer-reported data and may not match what your local pharmacy actually has on hand.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine (tranylcypromine sulfate 10 mg) is reportedly still made by other companies, though it may not be in local stock.
- If your tablets cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls for you.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg Supply is expected to be depleted by 12/31/2025.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Parnate, Tablet, 10 mg (NDC 0591-5590-01) | — | Supply is expected to be depleted by 12/31/2025. | — | To Be Discontinued |
Full shortage page: Tranylcypromine Sulfate Tablet →
View Tranylcypromine Sulfate Tablet on the FDA drug-shortage database →
Oxaliplatin Injection View full page →
Key facts about the Oxaliplatin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Oxaliplatin Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Oxaliplatin Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Oxaliplatin Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
This shortage record covers both strengths, 5 mg/1 mL and 5 mg/mL, and neither has an available source from the manufacturers who filed this report. The reason listed is that three manufacturers — Sandoz, Sagent Pharmaceuticals, and Fresenius Kabi — have each made a business decision to discontinue their version of this product. Because the status here is "to be discontinued," this particular supply problem may be permanent for these makers, so a conversation with your care team is the right next step.
It's important to know this report reflects only those three companies. Oxaliplatin 5 mg/mL is still listed as being on the market from several other manufacturers, so the medicine itself is not gone.
Here is what I'd suggest:
- Do not stop, skip, or change any doses on your own — oxaliplatin is part of a planned cancer treatment.
- Ask your pharmacy or infusion center to check other manufacturers; the same medicine may be available from makers such as Winthrop, Accord, Baxter, Eugia, Apotex, Hospira, Mylan, BluePoint, Meitheal, Fosun, or NorthStar, though local stock can vary.
- Ask your prescriber or pharmacist about the best sourcing plan for your treatment.
Manufacturer contact numbers are listed on this page for reference; your care team usually handles those calls. This is general, national information and may not match your local supply.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
- Oxaliplatin — OXALIPLATIN 5 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg/1 mL Discontinuation of the manufacture of the drug · Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
- 5 mg/mL A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 847-550-2300 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co., Ltd. 📞 Sagent Pharmaceuticals: 866-625-1618 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-10) | — | Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-20) | — | Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Sandoz Inc. 📞 800-525-8747 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3315-70) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Oxaliplatin Injection →
View Oxaliplatin Injection on the FDA drug-shortage database →
Elbasvir; Grazoprevir Tablet View full page →
Key facts about the Elbasvir; Grazoprevir Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Elbasvir; Grazoprevir Tablet may not appear here at all, so this is not a picture of every available option. See the full Elbasvir; Grazoprevir Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Elbasvir-grazoprevir (the brand Zepatier) is currently on the FDA drug-shortage list. I want to walk you through what that means for the strength you take.
This product comes as a combined tablet, and both of its strengths are affected the same way. The 50 mg / 100 mg tablet has no available source reported right now, and there is no separately supplied strength that is unaffected.
The reason listed is that this product is being discontinued, with a date of December 1, 2025. Because this is a planned discontinuation rather than a temporary supply gap, this change may be permanent. For that reason, the most important next step is a conversation with the person who prescribes this medicine.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own — keep taking it as prescribed while you sort out next steps.
- Talk with your prescriber or pharmacist soon about a plan, since this product is set to be discontinued and our records show no other maker supplying the same medicine.
- For reference, the manufacturer's contact number is listed on this page, though your pharmacy usually handles those calls.
This information comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock. Your care team can guide you to the right plan for you.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg; 100 mg To be discontinued December 1, 2025
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Merck Sharp & Dohme LLC 📞 800-672-6372 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Zepatier, Tablet, 50 mg; 100 mg (NDC 0006-3074-02) | — | To be discontinued December 1, 2025 | — | To Be Discontinued |
Full shortage page: Elbasvir; Grazoprevir Tablet →
View Elbasvir; Grazoprevir Tablet on the FDA drug-shortage database →
Vigabatrin Oral Solution View full page →
Key facts about the Vigabatrin Oral Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Vigabatrin Oral Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Vigabatrin Oral Solution shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Vigabatrin oral solution is currently on the FDA shortage list, and I want to walk you through what this means for you.
The only strength on this record, 50 mg/1 mL, does not have an available source right now. The reason reported is that the manufacturer, Pyros Pharmaceuticals, is discontinuing production of its product (Vigpoder). Because this is listed as a discontinuation, this particular supply problem may be permanent — so a conversation with your prescriber is the right next step rather than something to handle alone.
The good thing to know is that this report reflects only one manufacturer. Several other companies make the same medicine, vigabatrin, in the same 50 mg/mL strength — for example products from Upsher-Smith, Actavis, Camber, Dr. Reddy's, Lundbeck (Sabril), and others. Your pharmacy may be able to source one of these, though it may not be in local stock today.
Here is what I'd suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for the same medicine.
- Talk with your prescriber or pharmacist about which option fits you, since this product is being discontinued.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Vigadrone — VIGABATRIN 50 mg/mL
- Vigabatrin — VIGABATRIN 50 mg/mL
- Vigabatrin For Oral Solution — VIGABATRIN 50 mg/mL
- Vigabatrin — VIGABATRIN 50 mg/mL
- Vigabatrin — VIGABATRIN 50 mg/mL
- Vigabatrin — VIGABATRIN 500 mg/1
- Sabril — VIGABATRIN 50 mg/mL
- Vigabatrin — VIGABATRIN 50 mg/mL
- Vigabatrin — VIGABATRIN 500 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pyros Pharmaceuticals, Inc. 📞 763-315-2000 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vigpoder, Oral Solution, 50 mg/1 mL (NDC 80789-117-50) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Vigabatrin Oral Solution →
View Vigabatrin Oral Solution on the FDA drug-shortage database →
Voriconazole Injection View full page →
Key facts about the Voriconazole Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Voriconazole Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Voriconazole Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Voriconazole Injection is currently on the FDA drug-shortage list. I want to walk you through what that means so you know what to do next.
The strength affected is the 10 mg/1 mL injection. Right now this strength has no available source under the record we have, because Pfizer (the maker of Vfend) has filed a notice to discontinue making it. That means this particular supply problem may be permanent for that one manufacturer's product.
Even so, this report only reflects the manufacturer who filed it — it does not mean every company has stopped making this medicine. Several other makers have the same medicine (voriconazole 10 mg/mL injection) on record, including Roerig, PAI Pharma, Sandoz, Camber, Fresenius Kabi, Meitheal, Fosun, and Civica. These are the same medicine, simply supplied by a different company.
Here is what I'd suggest:
- Do not stop, skip, or change your treatment on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for the same medicine from one of the makers listed above — though it may not be in local stock right away.
- Because this product is being discontinued, talk with your prescriber or pharmacist about the best path forward.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Vfend — VORICONAZOLE 10 mg/mL
- Voriconazole — VORICONAZOLE 10 mg/mL
- Voriconazole — VORICONAZOLE 10 mg/mL
- Voriconazole — VORICONAZOLE 10 mg/mL
- Voriconazole — VORICONAZOLE 10 mg/mL
- Voriconazole — VORICONAZOLE 200 mg/1
- Voriconazole — VORICONAZOLE 10 mg/mL
- Voriconazole — VORICONAZOLE 10 mg/mL
- Voriconazole — VORICONAZOLE 10 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vfend, Injection, 10 mg/1 mL (NDC 0049-3190-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Voriconazole Injection →
View Voriconazole Injection on the FDA drug-shortage database →
Pemetrexed Disodium Injection View full page →
Key facts about the Pemetrexed Disodium Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Pemetrexed Disodium Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Pemetrexed Disodium Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Pemetrexed Disodium Injection is currently on the FDA shortage list. This is a chemotherapy medicine, and I understand seeing it here can feel unsettling, so let me walk you through what the data shows.
Both strengths reported on this record — the 500 mg/20 mL and the 100 mg/4 mL — currently have no available source from the two manufacturers who filed this report (Sandoz and Eli Lilly). The reason given for both is discontinuation of manufacture, and the status is listed as "to be discontinued." Because this reflects a permanent stop by these two makers, a conversation with your care team is the right next step. Importantly, this report covers only these manufacturers — the same medicine may still be available from other companies.
What you can do:
- Do not stop, skip, or change your treatment on your own. Your oncology team manages this closely.
- Ask your pharmacy to check other manufacturers and wholesalers. The same medicine, pemetrexed disodium injection, is listed from several other makers, including Hospira, Accord, Sagent, Dr. Reddy's, and Solco — though these may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Pemetrexed — PEMETREXED DISODIUM 1 g/40mL
- Pemetrexed — PEMETREXED DISODIUM 100 mg/4mL
- Pemetrexed — PEMETREXED DISODIUM 500 mg/20mL
- Pemetrexed — PEMETREXED DISODIUM HEMIPENTAHYDRATE 100 mg/4mL
- Pemetrexed — PEMETREXED DISODIUM HEMIPENTAHYDRATE 500 mg/20mL
- Pemetrexed — PEMETREXED DISODIUM HEMIPENTAHYDRATE 1 g/40mL
- Pemetrexed — PEMETREXED DISODIUM HEMIPENTAHYDRATE 100 mg/4.2mL
- Pemetrexed — PEMETREXED DISODIUM HEMIPENTAHYDRATE 500 mg/20mL
- Pemetrexed — PEMETREXED DISODIUM HEMIPENTAHYDRATE 100 mg/1
- Pemetrexed Disodium — PEMETREXED DISODIUM 1 g/40mL
- Pemetrexed Disodium — PEMETREXED DISODIUM 100 mg/4mL
- Pemetrexed Disodium — PEMETREXED DISODIUM 500 mg/20mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500 mg/20 mL Discontinuation of the manufacture of the drug
- 100 mg/4 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Alimta, Injection, 500 mg/20 mL (NDC 0002-7623-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Alimta, Injection, 100 mg/4 mL (NDC 0002-7640-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Sandoz Inc. 📞 800-525-8747 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Pemetrexed Disodium, Injection, 100 mg/4 mL (NDC 0781-3518-76) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Pemetrexed Disodium, Injection, 500 mg/20 mL (NDC 0781-3519-90) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Pemetrexed Disodium Injection →
View Pemetrexed Disodium Injection on the FDA drug-shortage database →
Adalimumab-Afzb Injection View full page →
Key facts about the Adalimumab-Afzb Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Adalimumab-Afzb Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Adalimumab-Afzb Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Adalimumab-Afzb (the brand Abrilada) is currently on the FDA shortage list. The record shows this product is being discontinued by the manufacturer that filed the report, so this supply problem may be a permanent change rather than a temporary gap.
The only company on this record, Pfizer Inc., lists Abrilada in the injection kit form (NDC 0025-0325-01) as being discontinued. No separate strengths are reported on this record, so there is no other strength here that still has supply to point you toward. The reason given is simply that the manufacturer is stopping production of this drug.
Because this is a discontinuation, the most important next step is a conversation with your prescriber. Please do not stop, skip, or change your dose on your own.
Here is how I'd suggest handling it:
- Talk with your prescriber or pharmacist soon about your plan, since this product is being discontinued.
- Ask your pharmacy whether the same medicine, Abrilada, can still be sourced from Pfizer Laboratories — it may not be in local stock, but they can check.
- If it cannot be found, ask your prescriber about a clinician-chosen alternative that fits your needs.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- All / unspecified Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Abrilada, Injection, Kit (NDC 0025-0325-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Adalimumab-Afzb Injection →
View Adalimumab-Afzb Injection on the FDA drug-shortage database →
Omeprazole Delayed Release Capsule View full page →
Key facts about the Omeprazole Delayed Release Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Omeprazole Delayed Release Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Omeprazole Delayed Release Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Omeprazole delayed-release capsules are currently on the FDA drug-shortage list. This affects the medicine you may take for heartburn or acid-related conditions, and I want to walk you through what it means.
The report covers all three strengths — 10 mg, 20 mg, and 40 mg — and none of them currently has an available source from the manufacturer that filed this report. The reason listed for each strength is that the manufacturer, Sandoz Inc., is discontinuing its production. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent. Importantly, this report reflects only that one manufacturer, and the same medicine is still listed as being made by other companies.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort out supply.
- Because omeprazole delayed-release capsules are listed as available from other makers (for example Major Pharmaceuticals, NorthStar Rx, and AvPAK), ask your pharmacy whether it can source your strength from one of them; it may not be in local stock right away.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Omeprazole — OMEPRAZOLE 10 mg/1
- Omeprazole — OMEPRAZOLE 20 mg/1
- Omeprazole — OMEPRAZOLE 20 mg/1
- Omeprazole — OMEPRAZOLE 40 mg/1
- Omeprazole — OMEPRAZOLE 10 mg/1
- Omeprazole — OMEPRAZOLE 20 mg/1
- Omeprazole — OMEPRAZOLE 20 mg/1
- Omeprazole — OMEPRAZOLE 40 mg/1
- Omeprazole — OMEPRAZOLE 20 mg/1
- Omeprazole — OMEPRAZOLE 20 mg/1
- Omeprazole — OMEPRAZOLE 40 mg/1
- Omeprazole — OMEPRAZOLE 40 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg Discontinuation of the manufacture of the drug
- 10 mg Discontinuation of the manufacture of the drug
- 40 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Sandoz Inc. 📞 800-525-8747 10 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-31) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-31) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-92) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-10) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-31) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Omeprazole Delayed Release Capsule →
View Omeprazole Delayed Release Capsule on the FDA drug-shortage database →
Cobicistat Tablet View full page →
Key facts about the Cobicistat Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Cobicistat Tablet may not appear here at all, so this is not a picture of every available option. See the full Cobicistat Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Cobicistat (brand name Tybost) 150 mg tablets are currently on the FDA shortage list, and the status is listed as "to be discontinued."
The only strength involved is the 150 mg tablet, and right now no available source is reported for it. The manufacturer, Gilead Sciences, has stated it plans to sell through the end of February 2026 and is stopping production for business reasons. Because this is a planned discontinuation rather than a temporary supply gap, this change may be permanent. That makes a conversation with your prescriber the right next step so you can plan ahead.
Please keep this in mind, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed.
- While supply lasts, ask your pharmacy to order the 150 mg tablet; pharmacies can check wholesalers and other sources.
- Because this medicine is being discontinued, talk with your prescriber or pharmacist soon about a planned, clinician-chosen path forward.
- The manufacturer's contact number is listed on this page for reference, though pharmacies usually handle those calls.
This information comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock. It is general information, not individual medical advice.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 150 mg Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Gilead Sciences, Inc. 📞 800-445-3235 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Tybost, Tablet, 150 mg (NDC 61958-1401-1) | — | Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons. | — | To Be Discontinued |
Full shortage page: Cobicistat Tablet →
Paricalcitol Capsule View full page →
Key facts about the Paricalcitol Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Paricalcitol Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Paricalcitol Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Paricalcitol capsules are currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
Both strengths of the branded product, Zemplar — the 1 ug and the 2 ug capsules — have no available source from the manufacturer that filed this report (AbbVie). The reason given for both is discontinuation of manufacture. Because this is listed as a discontinuation, the supply problem from this maker may be permanent, which makes a conversation with your prescriber the right next step.
The good part of this picture is that this report reflects only one company. Paricalcitol capsules in the same 1 ug and 2 ug strengths are still listed from several other makers, so the medicine itself has not gone away.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine is listed from Time Cap Laboratories, Dr. Reddy's, Aurobindo, Bionpharma, and Bryant Ranch Prepack, though it may not be in local stock.
- If your pharmacy cannot source it, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Paricalcitol — PARICALCITOL 1 ug/1
- Paricalcitol — PARICALCITOL 2 ug/1
- Paricalcitol — PARICALCITOL 4 ug/1
- Paricalcitol — PARICALCITOL 1 ug/1
- Paricalcitol — PARICALCITOL 2 ug/1
- Paricalcitol — PARICALCITOL 4 ug/1
- Paricalcitol — PARICALCITOL 1 ug/1
- Paricalcitol — PARICALCITOL 2 ug/1
- Paricalcitol — PARICALCITOL 1 ug/1
- Paricalcitol — PARICALCITOL 2 ug/1
- Paricalcitol — PARICALCITOL 4 ug/1
- Paricalcitol — PARICALCITOL 1 ug/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 ug Discontinuation of the manufacture of the drug
- 2 ug Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: AbbVie Inc. 📞 800-633-9110 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Zemplar, Capsule, 2 ug (NDC 0074-9037-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Zemplar, Capsule, 1 ug (NDC 0074-9036-30) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Paricalcitol Capsule →
View Paricalcitol Capsule on the FDA drug-shortage database →
Hydrochlorothiazide; Quinapril Hydrochloride Tablet View full page →
Key facts about the Hydrochlorothiazide; Quinapril Hydrochloride Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Hydrochlorothiazide; Quinapril Hydrochloride Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Hydrochlorothiazide; Quinapril Hydrochloride Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Your combination blood pressure medicine, quinapril with hydrochlorothiazide (sold by Pfizer as Accuretic), is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The two strengths on this record — the 12.5 mg/10 mg tablet and the 12.5 mg/20 mg tablet — currently have no available source from the manufacturer that filed this report. The reason given is that Pfizer is discontinuing manufacture of these tablets. Because this is a discontinuation rather than a temporary delay, the supply problem from this maker may be permanent, and no estimated-recovery date applies. That said, this report reflects only Pfizer, and the same medicine is still listed by other makers, so it is not gone from the market entirely.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed.
- Ask your pharmacy whether they can source the same quinapril/hydrochlorothiazide combination from another maker, such as Lupin, Chartwell, Aurobindo, or Cipla — though it may not be in local stock right away.
- Because this product is being discontinued, please talk with your prescriber or pharmacist about your best long-term option.
Pfizer's contact number is listed on this page for reference; pharmacies usually handle these calls. This is general, national information and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Quinapril Hcl And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril Hcl And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril Hcl And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1
- Quinapril And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1
- Quinapril Hydrochloride/Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril Hydrochloride/Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril Hydrochloride/Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1
- Quinapril And Hydrochlorothiazide 10/12.5 — QUINAPRIL HYDROCHLORIDE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril And Hydrochlorothiazide 20/12.5 — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril And Hydrochlorothiazide 20/25 — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 12.5 mg; 10 mg Discontinuation of the manufacture of the drug
- 12.5 mg; 20 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Accuretic, Tablet, 12.5 mg; 20 mg (NDC 0071-5212-23) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Accuretic, Tablet, 12.5 mg; 10 mg (NDC 0071-3112-23) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Hydrochlorothiazide; Quinapril Hydrochloride Tablet →
View Hydrochlorothiazide; Quinapril Hydrochlo... on the FDA drug-shortage database →
Oseltamivir Phosphate Capsule View full page →
Key facts about the Oseltamivir Phosphate Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Oseltamivir Phosphate Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Oseltamivir Phosphate Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Oseltamivir phosphate capsules — the flu medicine sold under the brand name Tamiflu — are currently on the FDA shortage list.
The affected product is the 45 mg capsule, which has no available source reported right now. The reason listed is that the manufacturer, Genentech, is discontinuing the manufacture of this branded 45 mg capsule. Because this is a discontinuation rather than a temporary delay, this particular product may not come back. That said, this record reflects only one manufacturer's decision, and the same medicine is still made by other companies.
The good part to keep in mind is that oseltamivir 45 mg capsules are also listed as available from several other makers, including Lannett, Camber, and Macleods.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- If you have a current or upcoming need, ask your pharmacy to try ordering oseltamivir 45 mg from another manufacturer (Lannett, Camber, or Macleods); they can check wholesalers, though it may not be in local stock immediately.
- If your exact strength cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Tamiflu — OSELTAMIVIR PHOSPHATE 75 mg/1
- Tamiflu — OSELTAMIVIR PHOSPHATE 30 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 30 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 45 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 75 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 30 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 45 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 75 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 30 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 45 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 75 mg/1
- Oseltamivir Phosphate — OSELTAMIVIR PHOSPHATE 75 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 45 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Genentech, Inc 📞 800-551-2231 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Tamiflu, Capsule, 45 mg (NDC 0004-0801-85) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Oseltamivir Phosphate Capsule →
View Oseltamivir Phosphate Capsule on the FDA drug-shortage database →
Fondaparinux Sodium Injection View full page →
Key facts about the Fondaparinux Sodium Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Fondaparinux Sodium Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Fondaparinux Sodium Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Fondaparinux Sodium Injection is currently on the FDA drug-shortage list. I want to walk you through what this means so you know what to expect and what to do next.
This shortage report covers all four strengths: 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL. Right now, none of these strengths has an available source from the manufacturer that filed this report. The reported reason is that this manufacturer (distributed by Sandoz Inc.) is discontinuing its production. Because this is listed as a discontinuation, the supply problem from this maker may be permanent — which makes a conversation with your prescriber the right next step.
Keep in mind this report reflects only the manufacturer who filed it. Other companies still make this same medicine, so it may still be available elsewhere.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own — this medicine is important, and changes should be guided by a professional.
- Ask your pharmacy to check wholesalers and other makers. The same medicine (fondaparinux sodium) is also listed from Dr. Reddy's Laboratories and Eugia US LLC, though these may not be in your local pharmacy's stock.
- If your exact strength cannot be found, talk with your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's actual supply.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Fondaparinux Sodium — FONDAPARINUX SODIUM 2.5 mg/.5mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 5 mg/.4mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 7.5 mg/.6mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 10 mg/.8mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 2.5 mg/.5mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 5 mg/.4mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 7.5 mg/.6mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 10 mg/.8mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 2.5 mg/.5mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 5 mg/.4mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 7.5 mg/.6mL
- Fondaparinux Sodium — FONDAPARINUX SODIUM 10 mg/.8mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 7.5 mg/.6 mL Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
- 10 mg/.8 mL Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
- 2.5 mg/.5 mL Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
- 5 mg/.4 mL Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.) 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95) | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc. | — | To Be Discontinued |
| Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95) | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc. | — | To Be Discontinued |
| Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95) | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc. | — | To Be Discontinued |
| Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95) | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc. | — | To Be Discontinued |
Full shortage page: Fondaparinux Sodium Injection →
View Fondaparinux Sodium Injection on the FDA drug-shortage database →
Tafamidis Meglumine Capsule View full page →
Key facts about the Tafamidis Meglumine Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Tafamidis Meglumine Capsule may not appear here at all, so this is not a picture of every available option. See the full Tafamidis Meglumine Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Tafamidis meglumine (Vyndaqel) 20 mg capsules are currently on the FDA shortage list, and I want to walk you through what that means for you.
The affected product is the 20 mg soft gelatin capsule, sold in a blister card of 120 capsules. Right now there is no available source reported for this strength. The record lists it as to be discontinued — the manufacturer, Pfizer, plans to stop making it once current supply runs out, with a reported stop-sale in December 2025. Because this is a planned discontinuation rather than a temporary delay, the supply problem may be permanent, and our records do not show another maker of the same medicine at this time.
That makes a conversation with your care team the most important next step. Here is how I would prioritize it:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check wholesalers, since remaining supply may still be found while it lasts.
- Because this product is being discontinued, talk with your prescriber soon about a clinician-chosen plan going forward.
- For reference, the manufacturer's contact number is listed on this page, though pharmacies usually handle those calls.
This is national, manufacturer-reported data and may not match your local pharmacy's stock, so please confirm details with your pharmacist or prescriber.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg soft gelatin capsules; b... Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-879-3477 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-8730-30) | — | Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025. | — | To Be Discontinued |
Full shortage page: Tafamidis Meglumine Capsule →
View Tafamidis Meglumine Capsule on the FDA drug-shortage database →
Triazolam Tablet View full page →
Key facts about the Triazolam Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Triazolam Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Triazolam Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Triazolam 0.25 mg tablets are currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The strength affected here is the 0.25 mg tablet. The manufacturer on this record, Pfizer (its brand version is called Halcion), has reported that it is discontinuing this product. Because this is a discontinuation rather than a temporary delay, this particular supply may not return. That said, this report reflects only one manufacturer — other companies still make triazolam, so the medicine itself is not gone from the market.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort this out.
- Ask your pharmacy to check whether the same medicine, triazolam 0.25 mg, is available from another maker; several other companies are listed on this page. Your pharmacy can look through wholesalers, though it may not be in local stock right away.
- Because Pfizer's version is being discontinued, talk with your prescriber or pharmacist about your options going forward.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Triazolam — TRIAZOLAM .25 mg/1
- Triazolam — TRIAZOLAM .25 mg/1
- Triazolam — TRIAZOLAM .125 mg/1
- Triazolam — TRIAZOLAM .25 mg/1
- Triazolam — TRIAZOLAM .125 mg/1
- Triazolam — TRIAZOLAM .25 mg/1
- Triazolam — TRIAZOLAM .25 mg/1
- Triazolam — TRIAZOLAM .125 mg/1
- Triazolam — TRIAZOLAM .25 mg/1
- Triazolam — TRIAZOLAM .25 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .25 mg Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Halcion, Tablet, .25 mg (NDC 0009-0017-58) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Triazolam Tablet →
Irinotecan Hydrochloride Injection View full page →
Key facts about the Irinotecan Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Irinotecan Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Irinotecan Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Irinotecan Hydrochloride Injection is currently listed on the FDA drug-shortage list, and I want to walk you through what that means for you.
This shortage record covers two strengths — 40 mg/2 mL and 100 mg/5 mL — and neither has an available source from the two manufacturers on this report. Both companies (Ingenus Pharmaceuticals and Jiangsu Hengrui, distributed by Sagent) have made a business decision to discontinue their products. Because this is listed as "to be discontinued," the supply problem from these makers may be permanent rather than temporary.
That said, this report reflects only these two manufacturers. Irinotecan is an injectable medicine usually given in a clinic or hospital, and other companies still make the same ingredient in a 20 mg/mL solution — so your care team likely has ways to continue your treatment.
Here is what I suggest, in order:
- Do not stop, skip, or change your treatment on your own — talk with your care team first.
- Ask your pharmacy or infusion clinic to check wholesalers and other manufacturers; the same medicine is made by several other companies (for example Hikma, Fresenius Kabi, Hospira, Apotex, and others), though local stock can vary.
- If your exact product cannot be found, your prescriber or pharmacist can choose a suitable option for you.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Camptosar — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloride — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloride — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloride — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloride — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloride — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloride — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloride — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloride — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloide — IRINOTECAN HYDROCHLORIDE 20 mg/mL
- Irinotecan Hydrochloide — IRINOTECAN HYDROCHLORIDE 20 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 40 mg/2 mL A business decision was made to discontinue manufacture of the drug. · Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals
- 100 mg/5 mL Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals · A business decision was made to discontinue manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Ingenus Pharmaceuticals LLC 📞 866-321-5031 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
| Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02) | — | A business decision was made to discontinue manufacture of the drug. | — | To Be Discontinued |
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.) 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02) | — | Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals | — | To Be Discontinued |
| Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05) | — | Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals | — | To Be Discontinued |
Full shortage page: Irinotecan Hydrochloride Injection →
View Irinotecan Hydrochloride Injection on the FDA drug-shortage database →
Obeticholic Acid Tablet View full page →
Key facts about the Obeticholic Acid Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Obeticholic Acid Tablet may not appear here at all, so this is not a picture of every available option. See the full Obeticholic Acid Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Obeticholic acid tablets are currently on the FDA shortage list, and I want to walk you through what that means for you.
Both strengths of this medicine — the 5 mg and the 10 mg — currently have no available source reported. The manufacturer on this record, Intercept Pharmaceuticals, has listed the product as to be discontinued due to a business decision, with the note that these tablets will not be available after November 14, 2025. Because this is a discontinuation rather than a temporary manufacturing delay, the supply problem may be permanent, and no estimated recovery date has been given. This means a conversation with your prescriber is the most important next step.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own — keep taking your medicine as prescribed while you sort out next steps.
- Ask your pharmacy to check wholesalers and other suppliers, since national data may not match what is on a local shelf.
- Talk with your prescriber or pharmacist soon about your options, since this exact medicine is being discontinued. They can help choose a suitable plan for you.
- Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls.
This is general information from national data and is not individualized advice.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg Business decision. Products will not be available after November 14, 2025.
- 10 mg Business decision. Products will not be available after November 14, 2025.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Intercept Pharmaceuticals 📞 1-844-782-4278 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ocaliva, Tablet, 10 mg (NDC 69516-010-30) | — | Business decision. Products will not be available after November 14, 2025. | — | To Be Discontinued |
| Ocaliva, Tablet, 5 mg (NDC 69516-005-30) | — | Business decision. Products will not be available after November 14, 2025. | — | To Be Discontinued |
Full shortage page: Obeticholic Acid Tablet →
View Obeticholic Acid Tablet on the FDA drug-shortage database →
Pilocarpine Hydrochloride Tablet View full page →
Key facts about the Pilocarpine Hydrochloride Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Pilocarpine Hydrochloride Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Pilocarpine Hydrochloride Tablet shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Pilocarpine hydrochloride tablets are currently on the FDA drug-shortage list, and I want to walk you through what that means for the strength you take.
This report covers both the 5 mg and 7.5 mg tablets, and neither strength has an available source from the manufacturer that filed this report (Actavis Pharma, under the brand name Salagen). The reason listed for both strengths is that this maker is discontinuing production, so this particular supply problem may be permanent rather than temporary. This report reflects only the one manufacturer that filed it — it does not mean the medicine is gone from every company.
Please keep taking your medicine as prescribed. Do not stop, skip, or change your dose on your own. Here is how to move forward:
- Ask your pharmacy whether they can source pilocarpine hydrochloride tablets — the same medicine is listed as available from other makers, including Lannett, Aurobindo, Amneal, and Advanz Pharma (brand Salagen). Your pharmacy can check wholesalers, though a given maker may not be in local stock.
- Because the reporting manufacturer is discontinuing this product, talk with your prescriber or pharmacist about your options going forward.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. Actual local stock may differ from this national data.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 5 mg/1
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 7.5 mg/1
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 5 mg/1
- Salagen — PILOCARPINE HYDROCHLORIDE 5 mg/1
- Salagen — PILOCARPINE HYDROCHLORIDE 7.5 mg/1
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 5 mg/1
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 7.5 mg/1
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 5 mg/1
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 5 mg/1
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 5 mg/1
- Pilocarpine Hydrochloride — PILOCARPINE HYDROCHLORIDE 5 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 7.5 mg Discontinuation of the manufacture of the drug.
- 5 mg Discontinuation of the manufacture of the drug.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Actavis Pharma, Inc. 📞 800-545-8800 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Salagen, Tablet, 5 mg (NDC 0228-2801-11) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
| Salagen, Tablet, 7.5 mg (NDC 0228-2837-11) | — | Discontinuation of the manufacture of the drug. | — | To Be Discontinued |
Full shortage page: Pilocarpine Hydrochloride Tablet →
View Pilocarpine Hydrochloride Tablet on the FDA drug-shortage database →
Meperidine Hydrochloride Injection View full page →
Key facts about the Meperidine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Meperidine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Meperidine Hydrochloride Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Meperidine hydrochloride injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
All three strengths on this record — 25 mg/1 mL, 50 mg/1 mL, and 100 mg/1 mL — still have an available source right now. None of them are listed as having no supply. So the strength you take should still be obtainable.
Both manufacturers on this record are reporting available supply, and additional lots are scheduled to be made and released over time. This shortage has lasted more than a year, but it remains a lower-level supply issue rather than a full outage.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength; they can check wholesalers and both manufacturers on this record.
- The same medicine (meperidine hydrochloride injection) is also made under the brand Demerol, so your pharmacy may be able to source that, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about options, such as a different strength to make up your dose.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 25 mg/1 mL Additional lots are scheduled to be manufactured. Product will be made available as it is...
- 100 mg/1 mL Additional lots are scheduled to be manufactured. Product will be made available as it is...
- 50 mg/1 mL Additional lots are scheduled to be manufactured. Product will be made available as it is...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30) | Available | — | — | Current |
| Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30) | Available | — | — | Current |
| Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30) | Available | — | — | Current |
Full shortage page: Meperidine Hydrochloride Injection →
View Meperidine Hydrochloride Injection on the FDA drug-shortage database →
Bacitracin Ophthalmic Ointment View full page →
Key facts about the Bacitracin Ophthalmic Ointment shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Bacitracin Ophthalmic Ointment may not appear here at all, so this is not a picture of every available option. See the full Bacitracin Ophthalmic Ointment shortage page → for the still-marketed options we could find.
- Discontinuation of the manufacture of the drug
Do you take this medicine? What Should I Do?!
Bacitracin ophthalmic ointment is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The only strength on this record, the 3.5 g ointment, has no available source reported right now. There are no other strengths listed that still have supply, so for this medicine in particular, every listed product is marked unavailable at this time.
The reason given is that the manufacturer, Padagis US, has discontinued making this product. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent. The record notes the shortage is estimated to last about 24 months, and it has already lasted over a year. This report reflects only the one manufacturer who filed it, so I can't say it is unavailable from every maker.
Here is what I suggest, in order:
- Do not stop or change your medicine on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — local stock can differ from national data.
- Since this strength appears discontinued, talk with your prescriber or pharmacist about a clinician-chosen alternative that fits your needs.
A manufacturer contact number is listed on this page for reference, though pharmacies usually handle those calls. This is general information and not individualized medical advice.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 3.5 g Shortage is estimated for 24 months
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Padagis US LLC 📞 866-634-9120 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35) | Unavailable | Shortage is estimated for 24 months | Discontinuation of the manufacture of the drug | Current |
Full shortage page: Bacitracin Ophthalmic Ointment →
View Bacitracin Ophthalmic Ointment on the FDA drug-shortage database →
Methylphenidate Film, Extended Release View full page →
Key facts about the Methylphenidate Film, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Methylphenidate Film, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Methylphenidate Film, Extended Release shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Methylphenidate Film, Extended Release is currently listed on the FDA drug-shortage list. This is a medium-level supply concern, and it has been on the list for over a year.
The reassuring detail here is that all four strengths still have a reported source. The 10 mg, 15 mg, 20 mg, and 30 mg strengths are all marked as available, distributed by Padagis US LLC. None of the strengths is showing as having no available source at this time. This report reflects the one manufacturer that filed it, so listing here does not mean the medicine is impossible to find — it simply flags a supply concern to watch.
Here is how to approach it:
- Keep taking your medicine as prescribed — do not stop, skip, or change your dose on your own.
- Since your strength still shows supply, ask your pharmacy to order it; they can check wholesalers and other manufacturers, though local stock can vary day to day.
- If your exact strength ever becomes hard to find, ask your prescriber or pharmacist about options, such as a different strength to make up your dose or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually make these calls. This is national, manufacturer-reported information and may not match your local pharmacy's stock, so your pharmacist remains your best guide.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Methylphenidate — METHYLPHENIDATE 1.1 mg/h
- Methylphenidate — METHYLPHENIDATE 1.6 mg/h
- Methylphenidate — METHYLPHENIDATE 2.2 mg/h
- Methylphenidate — METHYLPHENIDATE 3.3 mg/h
- Daytrana — METHYLPHENIDATE 10 mg/9h
- Daytrana — METHYLPHENIDATE 15 mg/9h
- Daytrana — METHYLPHENIDATE 20 mg/9h
- Daytrana — METHYLPHENIDATE 30 mg/9h
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 15 mg Distributed by Padagis US LLC
- 30 mg Distributed by Padagis US LLC
- 10 mg Distributed by Padagis US LLC
- 20 mg Distributed by Padagis US LLC
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Noven Pharmaceuticals, Inc. 📞 800-455-8070 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65) | Available | Distributed by Padagis US LLC | — | Current |
| Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65) | Available | Distributed by Padagis US LLC | — | Current |
| Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65) | Available | Distributed by Padagis US LLC | — | Current |
| Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65) | Available | Distributed by Padagis US LLC | — | Current |
Full shortage page: Methylphenidate Film, Extended Release →
View Methylphenidate Film, Extended Release on the FDA drug-shortage database →
Hydroxocobalamin Injection View full page →
Key facts about the Hydroxocobalamin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Hydroxocobalamin Injection may not appear here at all, so this is not a picture of every available option. See the full Hydroxocobalamin Injection shortage page → for the still-marketed options we could find.
- Other (2 NDCs)
Do you take this medicine? What Should I Do?!
Hydroxocobalamin injection is currently on the FDA shortage list. This affects the two strengths differently, so let me point you to the one you take.
The 5 g/250 mL presentation (Cyanokit, from BTG International) still has an available source, though it is listed as limited availability. The 1000 mcg/mL, 30 mL multi-dose vial (from Teva) is currently unavailable, with an estimated recovery date not yet set. So one of the two strengths still has supply, and only one of the two manufacturers on this record is reporting a shortage on its product.
The reported reason is listed only as "Other," and this situation has lasted over a year. Even so, this report reflects only the two manufacturers who filed it, and supply can shift.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- If you use the 5 g/250 mL strength, ask your pharmacy to order it — pharmacies can check wholesalers and manufacturers, even when stock is limited.
- If you use the 30 mL vial that is currently unavailable, talk with your prescriber or pharmacist about your options.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 30 ML Multi-Dose Vial Estimated recovery: TBD
- 5 g/250mL Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SER...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: BTG International Inc. 📞 1 877 377 3784 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11) | Limited Availability | Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage. | Other | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30) | Unavailable | Estimated recovery: TBD | Other | Current |
Full shortage page: Hydroxocobalamin Injection →
View Hydroxocobalamin Injection on the FDA drug-shortage database →
Dextrose Monohydrate 70% Injection View full page →
Key facts about the Dextrose Monohydrate 70% Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dextrose Monohydrate 70% Injection may not appear here at all, so this is not a picture of every available option. See the full Dextrose Monohydrate 70% Injection shortage page → for the still-marketed options we could find.
- Other
Do you take this medicine? What Should I Do?!
Dextrose Monohydrate 70% Injection is currently listed on the FDA drug-shortage list. The good part to keep in view is that this product comes in a single strength, and that strength still has supply.
Only one strength exists here — 70 g/100 mL — and it is not out of stock. Two of the three manufacturers on this record are still reporting it as available, while one manufacturer's version is currently unavailable, with an estimated recovery date of September 2026. About a quarter of the listed product codes are marked unavailable, and the FDA-reported reason is simply listed as "Other." This situation has continued for over a year, but the overall supply risk is rated low.
Because your strength still has an available source, here is how to approach it:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order the 70 g/100 mL from a manufacturer that still has it — pharmacies can check wholesalers and other makers.
- If your pharmacy cannot locate it, ask your prescriber or pharmacist about the best next step for you.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 70 g/100 mL This product is distributed by ICU Medical. For questions regarding this product, please c... · Estimated recovery: September 2026
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50) | Available | — | — | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06) | Unavailable | Estimated recovery: September 2026 | Other | Current |
Manufacturer: Otsuka ICU Medical LLC 📞 1-866-829-9025 or [email protected] 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
Full shortage page: Dextrose Monohydrate 70% Injection →
View Dextrose Monohydrate 70% Injection on the FDA drug-shortage database →
Riluzole Oral Suspension View full page →
Key facts about the Riluzole Oral Suspension shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Riluzole Oral Suspension may not appear here at all, so this is not a picture of every available option. See the full Riluzole Oral Suspension shortage page → for the still-marketed options we could find.
- Requirements related to complying with good manufacturing practices
Do you take this medicine? What Should I Do?!
Riluzole oral suspension is currently on the FDA shortage list, so I want to walk you through what that means for you.
The two strengths are affected differently. The 5 mg/1 mL suspension is still available from the manufacturer, so if that is the one you take, supply is being reported. The 50 mg/10 mL suspension has no available source right now, and its estimated recovery date is not yet set.
The reason reported to the FDA is tied to requirements for following good manufacturing practices. One manufacturer is on this record, and it is still supplying the 5 mg/1 mL strength. This shortage has lasted more than a year, so it may take time to fully resolve.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- If you take the 5 mg/1 mL strength, ask your pharmacy to order it — pharmacies can check wholesalers and confirm current stock.
- If you take the 50 mg/10 mL strength and it cannot be found, ask your prescriber or pharmacist about options, such as using a different strength to make up your dose.
The manufacturer contact number is listed on this page for reference, though your pharmacy usually handles those calls.
This is general, national information and may not match your local pharmacy's stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg/10 mL Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) 📞 610-937-6172 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1) | Available | — | — | Current |
| Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1) | Available | — | — | Current |
| Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1) | Available | — | — | Current |
Full shortage page: Riluzole Oral Suspension →
View Riluzole Oral Suspension on the FDA drug-shortage database →
Technetium Tc-99M Pyrophosphate Kit Injection View full page →
Key facts about the Technetium Tc-99M Pyrophosphate Kit Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Technetium Tc-99M Pyrophosphate Kit Injection may not appear here at all, so this is not a picture of every available option. See the full Technetium Tc-99M Pyrophosphate Kit Injection shortage page → for the still-marketed options we could find.
- Other (2 NDCs)
- Shortage of an active ingredient
Do you take this medicine? What Should I Do?!
Technetium Tc-99M Pyrophosphate Kit Injection is currently on the FDA drug-shortage list. This is a specialized imaging agent, so I want to walk you through what the reported data shows.
The strengths affect supply differently. The 11.9 mg/10 mL and 3.2 mg/10 mL strength still has an available source, though it is being supplied on an allocation basis. The 12 mg/10 mL strength currently has no available source, with an estimated recovery time listed as to-be-determined.
The reported reasons are listed as "Other" and a shortage of an active ingredient. Two manufacturers appear on this record, and one is still reporting supply. This situation has lasted over a year, so some limited waiting may be involved.
Here is what I suggest:
- Do not stop, skip, or change how you use this medicine on your own.
- If your test uses the 11.9/3.2 mg strength, ask your imaging center or pharmacy to order it — they can check wholesalers and manufacturers, though it may not always be in local stock.
- If you need the 12 mg strength, talk with your prescriber or pharmacist about the best next step.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This reflects national, manufacturer-reported data and may not match local stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 12 mg/10 mL Estimated recovery: TBD
- 11.9 mg/10 mL; 3.2 mg/10 mL Available via allocation
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Curium US LLC 📞 888-744-1414 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20) | Limited Availability | Available via allocation | Shortage of an active ingredient | Current |
Manufacturer: Sun Pharmaceutical Industries, Inc. 📞 800-818-4555 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2) | Unavailable | Estimated recovery: TBD | Other | Current |
| CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1) | Unavailable | Estimated recovery: TBD | Other | Current |
Full shortage page: Technetium Tc-99M Pyrophosphate Kit Injection →
View Technetium Tc-99M Pyrophosphate Kit Inje... on the FDA drug-shortage database →
Promethazine Hydrochloride Injection View full page →
Key facts about the Promethazine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Promethazine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Promethazine Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Other (6 NDCs)
- Demand increase for the drug (3 NDCs)
Do you take this medicine? What Should I Do?!
Promethazine hydrochloride injection is currently on the FDA drug-shortage list. This is an injectable medicine, so it is usually given in a clinic or hospital setting rather than something you handle at home.
The two strengths are affected differently. The 25 mg/1 mL strength still has an available source from one manufacturer (XGen Pharmaceuticals), while the 50 mg/1 mL strength has no available source reported right now. The reasons given are increased demand and "other," and the shortage has lasted over a year. For the 50 mg/1 mL, additional lots are expected in the October 2026 timeframe, though the exact recovery date is listed as still to be determined.
Please do not stop, skip, or change how you receive this medicine on your own. Here are helpful steps:
- If you use the 25 mg/1 mL strength, ask your pharmacy or clinic to order it — they can check wholesalers and other manufacturers, since one maker still reports supply.
- If you use the 50 mg/1 mL strength, ask whether it can be sourced from another maker of the same medicine, keeping in mind it may not be in local stock.
- If your strength cannot be found, ask your prescriber or pharmacist about options, such as adjusting the strength used or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This information comes from national manufacturer-reported data and may not match your local supply.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg/1 mL This presentation is temporarily on backorder. Expected in October 2026 timeframe · Estimated recovery: TBD · Additional lots will be available in the October 2026 timeframe. Product will be made avai...
- 25 mg/1 mL Estimated recovery: TBD · Additional lots will be available in the October 2026 timeframe. Product will be made avai... · Additional lots are scheduled to be manufactured. Product will be made available as it is...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35) | Unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. | Other | Current |
| Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25) | Unavailable | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | Other | Current |
| Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25) | Unavailable | Estimated recovery: TBD | Other | Current |
| Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25) | Unavailable | Estimated recovery: TBD | Other | Current |
| Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35) | Unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. | Other | Current |
| Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25) | Unavailable | Estimated recovery: TBD | Other | Current |
| Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25) | Unavailable | This presentation is temporarily on backorder. Expected in October 2026 timeframe | Demand increase for the drug | Current |
Manufacturer: XGen Pharmaceuticals DJB, Inc. 📞 866-390-4411 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6) | Unvailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3) | Available | — | — | Current |
Full shortage page: Promethazine Hydrochloride Injection →
View Promethazine Hydrochloride Injection on the FDA drug-shortage database →
Cromolyn Sodium Concentrate View full page →
Key facts about the Cromolyn Sodium Concentrate shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Cromolyn Sodium Concentrate may not appear here at all, so this is not a picture of every available option. See the full Cromolyn Sodium Concentrate shortage page → for the still-marketed options we could find.
- Other (2 NDCs)
Do you take this medicine? What Should I Do?!
Cromolyn Sodium Concentrate is currently listed on the FDA drug-shortage list, but I want to reassure you right away: both strengths still have an available source, and the overall supply risk is low.
Here is how the two strengths stand today. Neither strength is completely out. The 100 mg/5 mL strength is still available from more than one supplier, though a few distributors report their versions are no longer being made, with some supplies remaining in the chain. The 20 mg/1 mL strength (Gastrocrom) is also reported as available. In short, all four manufacturers on this record are still reporting supply, and none of the currently listed products are marked unavailable.
The FDA lists the reason simply as "Other," and this situation has lasted over a year without leaving patients without a source. That steadiness is encouraging.
What you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength — pharmacies can check wholesalers and other manufacturers.
- If your usual product is hard to find, ask your prescriber or pharmacist about other suitable options.
- Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg/5 mL Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 · No longer manufactured, some supplies still available in supply chain. Distributed by Wood... · No longer manufactured, some supplies still available in supply chain. Distributed by Rite...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Ailex Pharmaceuticals 📞 Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or [email protected] 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96) | Limited Availability | No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300 | Other | Current |
| Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96) | Limited Availability | No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2 | Other | Current |
| Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96) | Available | Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 | — | Current |
Manufacturer: Micro Labs LTD 📞 (908) 484-7410 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52) | Available | — | — | Current |
Manufacturer: Mylan Specialty, a Viatris Company 📞 (800) 796-9526 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96) | Available | — | — | Current |
Manufacturer: Rising Pharma Holdings, Inc. 📞 (201) 961-9000 or [email protected] 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96) | Available | — | — | Current |
Full shortage page: Cromolyn Sodium Concentrate →
View Cromolyn Sodium Concentrate on the FDA drug-shortage database →
Propranolol Hydrochloride Injection View full page →
Key facts about the Propranolol Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Propranolol Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See the full Propranolol Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Shortage of an active ingredient
Do you take this medicine? What Should I Do?!
Propranolol Hydrochloride Injection is currently on the FDA drug-shortage list. This medicine comes in one strength, 1 mg/1 mL, and I want you to know that this exact strength still has an available source.
Two manufacturers are listed on this record. One (Hikma) reports its supply as unavailable, but the other (Fresenius Kabi) reports the 1 mg/1 mL injection as available. The reported cause is a shortage of an active ingredient, and this situation has lasted over a year. A firm recovery date has not been set, and pharmacies are advised to check wholesalers for inventory. Because one maker is still supplying, this remains a manageable situation rather than a complete gap.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Since your strength still has a supplier, ask your pharmacy to order it — pharmacies can check wholesalers and other manufacturers for stock.
- If your pharmacy cannot locate it locally, ask your prescriber or pharmacist about your options.
- Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls.
This information comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock, so please confirm with them directly.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mg/1 mL Estimated recovery: TBD · Check wholesalers for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10) | Unavailable | Estimated recovery: TBD | Shortage of an active ingredient | Current |
Full shortage page: Propranolol Hydrochloride Injection →
View Propranolol Hydrochloride Injection on the FDA drug-shortage database →
Methylphenidate Hydrochloride Tablet, Extended Release View full page →
Key facts about the Methylphenidate Hydrochloride Tablet, Extended Release shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Methylphenidate Hydrochloride Tablet, Extended Release may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Methylphenidate Hydrochloride Tablet, Extended Release shortage page → for the still-marketed options we could find.
- Demand increase for the drug (7 NDCs)
- Discontinuation of the manufacture of the drug (4 NDCs)
- Other (4 NDCs)
Do you take this medicine? What Should I Do?!
Methylphenidate hydrochloride extended-release tablets are currently on the FDA shortage list, and I want to walk you through what that actually means for the strength you take.
The reassuring part is that every strength still has an available source right now. All seven strengths — 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg, and 72 mg — are being supplied by at least one manufacturer. There is no strength that is completely unavailable at this time.
This shortage has lasted over a year, and the reported reasons include higher demand, one manufacturer discontinuing its version, and other factors. Five of the six manufacturers on this record still report supply, and some products have estimated recovery dates noted in 2026. So while some individual makers have limited supply, the medicine overall is still being produced.
Here is how to handle it:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength — they can check wholesalers and other manufacturers.
- The same medicine is made by more than one company, so your pharmacy may be able to source it from another maker, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually make these calls. This is national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 5 mg/1
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Methylphenidate Hydrochloride Extended-Release — METHYLPHENIDATE HYDROCHLORIDE 27 mg/1
- Methylphenidate Hydrochloride Extended-Release — METHYLPHENIDATE HYDROCHLORIDE 36 mg/1
- Methylphenidate Hydrochloride Extended-Release — METHYLPHENIDATE HYDROCHLORIDE 54 mg/1
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 5 mg/1
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Methylphenidate Hydrochloride — METHYLPHENIDATE HYDROCHLORIDE 18 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 54 mg Allocation to current contracted customers · Currently not marketed
- 27 mg Allocation to current contracted customers · Estimated recovery: November 2026 · Currently not marketed
- 63 mg Allocation to current contracted customers
- 18 mg Currently not marketed · Estimated recovery: September 2026 · Allocation to current contracted customers
- 36 mg Currently not marketed · Estimated recovery: September 2026 · Allocation to current contracted customers · Estimated recovery: November 2026
- 72 mg Allocation to current contracted customers
- 45 mg Allocation to current contracted customers
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Janssen Pharmaceuticals 📞 800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01) | Available | — | — | Current |
| Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01) | Available | — | — | Current |
| Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01) | Available | — | — | Current |
| Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01) | Available | — | — | Current |
Manufacturer: Lannett Company, Inc. 📞 844-834-0530 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37) | Limited Availability | Estimated recovery: November 2026 | Other | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37) | Available | — | — | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37) | Available | — | — | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37) | Limited Availability | Estimated recovery: November 2026 | Other | Current |
Manufacturer: Sun Pharmaceutical Industries, Inc. 📞 800-818-4555 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88) | Unavailable | Currently not marketed | Discontinuation of the manufacture of the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88) | Unavailable | Currently not marketed | Discontinuation of the manufacture of the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88) | Unavailable | Currently not marketed | Discontinuation of the manufacture of the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88) | Unavailable | Currently not marketed | Discontinuation of the manufacture of the drug | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01) | Available | — | — | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01) | Limited Availability | Estimated recovery: September 2026 | Other | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01) | Limited Availability | Estimated recovery: September 2026 | Other | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01) | Available | — | — | Current |
Manufacturer: Trigen Laboratories, LLC 📞 800-541-4802 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30) | Limited Availability | Allocation to current contracted customers | Demand increase for the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10) | Limited Availability | Allocation to current contracted customers | Demand increase for the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30) | Limited Availability | Allocation to current contracted customers | Demand increase for the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10) | Limited Availability | Allocation to current contracted customers | Demand increase for the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30) | Limited Availability | Allocation to current contracted customers | Demand increase for the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10) | Limited Availability | Allocation to current contracted customers | Demand increase for the drug | Current |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10) | Limited Availability | Allocation to current contracted customers | Demand increase for the drug | Current |
Manufacturer: Vertical Pharmaceuticals, LLC 📞 800-541-4802 11 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30) | Available | — | — | Current |
| Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30) | Available | — | — | Current |
Full shortage page: Methylphenidate Hydrochloride Tablet, Extended Release →
View Methylphenidate Hydrochloride Tablet, Ex... on the FDA drug-shortage database →
Liraglutide Injection View full page →
Key facts about the Liraglutide Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Liraglutide Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Liraglutide Injection shortage page → for the still-marketed options we could find.
- Delay in shipping of the drug (2 NDCs)
- Discontinuation of the manufacture of the drug
Do you take this medicine? What Should I Do?!
Liraglutide injection is currently on the FDA drug-shortage list. This medicine comes in one strength, 6 mg/1 mL, and that strength still has an available source right now — so there is no strength listed as completely unsupplied.
The situation looks manageable. This shortage has been ongoing for over a year, and the reported causes are a shipping delay and one manufacturer discontinuing its version. Even so, three of the four manufacturers on this record are still reporting supply of the 6 mg/1 mL strength. One point worth knowing: one brand version (Saxenda) is expected to remain available until it is discontinued in January 2027, which may make that particular product a longer-term concern.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order the 6 mg/1 mL strength — pharmacies can check wholesalers and different manufacturers for you.
- The same medicine is made by other companies, and your pharmacy may be able to source one of those, though it may not be in local stock right away.
- If your product is being discontinued, ask your prescriber or pharmacist about the best next step.
Manufacturer contact numbers are listed on this page for reference. This is general national data and may not match your pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 6 mg/1 mL Estimated shortage duration: TBD · Distributed by Teva · Product will be available until discontinuation in January 2027; Discontinuation of the ma... · Discontinuation of the manufacture of the drug · Product will be available until discontinuation in January 2027
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) | Available | — | — | Current |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) | Available | — | — | Current |
Manufacturer: Meitheal Pharmaceuticals, Inc. 📞 844-824-8426 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) | Available | — | — | Current |
| Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) | Available | — | — | Current |
Manufacturer: Novo Nordisk, Inc. 📞 833-493-4689 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) | Available | Distributed by Teva | — | Current |
| Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Limited Availability | Product will be available until discontinuation in January 2027 | Discontinuation of the manufacture of the drug | Current |
| Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | — | Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) | Available | Distributed by Teva | — | Current |
| Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) | Limited Availability | Estimated shortage duration: TBD | Delay in shipping of the drug | Current |
| Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) | Limited Availability | Estimated shortage duration: TBD | Delay in shipping of the drug | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 888-838-2872 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Liraglutide Injection →
View Liraglutide Injection on the FDA drug-shortage database →
Lisdexamfetamine Dimesylate Capsule View full page →
Key facts about the Lisdexamfetamine Dimesylate Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Lisdexamfetamine Dimesylate Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Lisdexamfetamine Dimesylate Capsule shortage page → for the still-marketed options we could find.
- Shortage of an active ingredient (26 NDCs)
- Other (7 NDCs)
- Delay in shipping of the drug
Do you take this medicine? What Should I Do?!
Lisdexamfetamine dimesylate capsules (the generic form of Vyvanse) are currently on the FDA shortage list. This has been a long-running situation, but the supply picture right now is fairly stable.
Every strength you might take — 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg — still has an available source. No strength is completely without supply at this time. The strength you take should be findable, though it may take a little effort at the pharmacy counter.
The reported reasons include a shortage of an active ingredient, shipping delays, and other factors. All 13 manufacturers on this record are still reporting supply, with several distributing on a controlled "allocation" basis. A firm recovery date has not been set for most strengths (one note lists an estimate of 9/25/26 for the 20 mg), but many makers list their products as simply available.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength — they can check wholesalers and multiple manufacturers.
- The same medicine may also be available from other makers, including Sandoz and Camber, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 10 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 20 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 30 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 40 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 50 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 60 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 70 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 10 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 20 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 30 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 40 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 50 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 70 mg Available on allocation · On allocation · Estimated recovery: TBD
- 10 mg On allocation · Available on allocation · Estimated recovery: TBD
- 30 mg On allocation · Estimated recovery: TBD · Available on allocation
- 40 mg Estimated recovery: TBD · Available on allocation · On allocation
- 20 mg Estimated recovery: 9/25/26 · Estimated recovery: TBD · On allocation · Available on allocation
- 60 mg Available on allocation · On allocation · Estimated recovery: TBD
- 50 mg Estimated recovery: TBD · On allocation · Available on allocation
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Alvogen 📞 844-842-8672 and email: [email protected] 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01) | Available | — | — | Current |
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09) | Available | — | — | Current |
Manufacturer: Apotex Corp. 📞 800-706-5575 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1) | Unavailable | Estimated recovery: 9/25/26 | Delay in shipping of the drug | Current |
Manufacturer: Elite Laboratories, Inc. 📞 888-852-6657 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25) | Limited Availability | Available on allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25) | Limited Availability | Available on allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25) | Limited Availability | Available on allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25) | Limited Availability | Available on allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25) | Limited Availability | Available on allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25) | Limited Availability | Available on allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25) | Limited Availability | Available on allocation | Shortage of an active ingredient | Current |
Manufacturer: Lannett Company, Inc. 📞 844-834-0530 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37) | Available | — | — | Current |
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 800-796-9526 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77) | Available | — | — | Current |
Manufacturer: Rhodes Pharmaceuticals L.P. 📞 888-827-0616 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
Manufacturer: Solco Healthcare US, LLC 📞 866-931-9829 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10) | Limited Availability | On allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10) | Limited Availability | On allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10) | Limited Availability | On allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10) | Limited Availability | On allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10) | Limited Availability | On allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10) | Limited Availability | On allocation | Shortage of an active ingredient | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10) | Limited Availability | On allocation | Shortage of an active ingredient | Current |
Manufacturer: SpecGx LLC 📞 800-325-8888 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01) | Available | — | — | Current |
Manufacturer: Sun Pharmaceutical Industries, Inc. 📞 800-818-4555 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88) | Limited Availability | Estimated recovery: TBD | Other | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88) | Limited Availability | Estimated recovery: TBD | Other | Current |
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88) | Limited Availability | Estimated recovery: TBD | Other | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88) | Limited Availability | Estimated recovery: TBD | Other | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88) | Limited Availability | Estimated recovery: TBD | Other | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 57664-048-88) | Limited Availability | Estimated recovery: TBD | Other | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88) | Limited Availability | Estimated recovery: TBD | Other | Current |
Manufacturer: Takeda Pharmaceuticals USA Inc. 📞 877-TAKEDA-7 (1-877-825-3327) 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vyvanse, Capsule, 60 mg (NDC 59417-106-10) | Available | — | — | Current |
| Vyvanse, Capsule, 20 mg (NDC 59417-102-10) | Available | — | — | Current |
| Vyvanse, Capsule, 40 mg (NDC 59417-104-10) | Available | — | — | Current |
| Vyvanse, Capsule, 70 mg (NDC 59417-107-10) | Available | — | — | Current |
| Vyvanse, Capsule, 50 mg (NDC 59417-105-10) | Available | — | — | Current |
| Vyvanse, Capsule, 10 mg (NDC 59417-101-10) | Available | — | — | Current |
| Vyvanse, Capsule, 30 mg (NDC 59417-103-10) | Available | — | — | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01) | Available | — | — | Current |
Full shortage page: Lisdexamfetamine Dimesylate Capsule →
View Lisdexamfetamine Dimesylate Capsule on the FDA drug-shortage database →
Lisdexamfetamine Dimesylate Tablet, Chewable View full page →
Key facts about the Lisdexamfetamine Dimesylate Tablet, Chewable shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Lisdexamfetamine Dimesylate Tablet, Chewable may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Lisdexamfetamine Dimesylate Tablet, Chewable shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Lisdexamfetamine dimesylate chewable tablets (the chewable form of the medicine also sold as Vyvanse) are currently on the FDA shortage list. Seeing your medicine on that list can be unsettling, so let me walk you through what the data actually shows.
The reassuring part is that all six strengths — 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg — still have an available source right now. None of these strengths is listed as having no supply. All three manufacturers on this record are reporting available product, even though the shortage has been open for over a year. In other words, whatever strength you take, it is currently listed as available from at least one maker.
Here is what I'd suggest:
- Do not stop, skip, or change your dose on your own.
- Since your strength still has supply, ask your pharmacy to order it — pharmacies can check wholesalers and different manufacturers to find stock.
- If your pharmacy has trouble, the same chewable medicine may be available from another maker (such as SpecGx or Teva), though it may not be in local stock.
- If your exact strength ever can't be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's shelves.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 10 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 20 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 30 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 40 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 50 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 60 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 10 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 20 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 30 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 40 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 50 mg/1
- Lisdexamfetamine Dimesylate — LISDEXAMFETAMINE DIMESYLATE 60 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Novadoz Pharmaceuticals LLC 📞 (855) 668-2369; [email protected] 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91) | Available | — | — | Current |
Manufacturer: Sun Pharmaceutical Industries, Inc. 📞 800-818-4555 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88) | Available | — | — | Current |
| Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88) | Available | — | — | Current |
Manufacturer: Takeda Pharmaceuticals USA Inc. 📞 877-TAKEDA-7 (1-877-825-3327) 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01) | Available | — | — | Current |
| Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01) | Available | — | — | Current |
| Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01) | Available | — | — | Current |
| Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01) | Available | — | — | Current |
| Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01) | Available | — | — | Current |
| Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01) | Available | — | — | Current |
Full shortage page: Lisdexamfetamine Dimesylate Tablet, Chewable →
View Lisdexamfetamine Dimesylate Tablet, Chew... on the FDA drug-shortage database →
Carboplatin Injection View full page →
Key facts about the Carboplatin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Carboplatin Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Carboplatin Injection shortage page → for the still-marketed options we could find.
- Other (11 NDCs)
- Discontinuation of the manufacture of the drug (7 NDCs)
- Demand increase for the drug (4 NDCs)
- Requirements related to complying with good manufacturing practices (2 NDCs)
- Delay in shipping of the drug
Do you take this medicine? What Should I Do?!
Carboplatin injection, a chemotherapy medicine given by infusion, is currently on the FDA drug-shortage list. Because it is given in a clinic or hospital, your care team manages the supply — but I want to explain what this means so you feel informed.
Several strengths still have an available source, including 80 mg/8 mL, 500 mg/50 mL, 600 mg/60 mL, 150 mg/15 mL, and 450 mg/45 mL from certain makers (some with limited supply). The strengths currently showing no available source are the 50 mg/5 mL, 150 mg/15 mL multiple-dose vial, 450 mg/45 mL multiple-dose vial, and 600 mg/60 mL multiple-dose vial. Find the one you receive above.
The FDA reports several causes, including manufacturing delays, increased demand, quality-standard requirements, and some manufacturers discontinuing their version. This shortage has lasted over a year, and 5 of 9 makers still report some supply. A few products marked "discontinued" mean that particular maker's version may not return.
Here is what I suggest:
- Do not skip or delay any scheduled treatment on your own — talk with your oncology team first.
- Ask your cancer center to check wholesalers and other manufacturers for your strength; several suppliers still list carboplatin, sometimes in a different vial size that can make up the same dose.
- If your exact product is discontinued, ask your prescriber about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; clinics usually handle those calls. This is national data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg/5 mL (10 mg/mL) Multiple... Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the m...
- 150 mg/15 mL (10 mg/mL) Multip... Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the m...
- 450 mg/45 mL (10 mg/mL) Multip... Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the m...
- 50mg/5mL Discontinued; Distributed by BPI Labs, LLC
- 600 mg/60 mL (10 mg/mL) Multip... Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the m...
- 450 mg/45 mL Discontinuation of the manufacture of the drug · On backorder. Recovery: late September 2026. Check wholesalers for inventory
- 600 mg/60 mL Discontinuation of the manufacture of the drug · Check wholesalers for inventory
- 10 mg/1 mL Estimated recovery: TBD · Estimated recovery: December 2028 · Next release November 2026. Check wholesalers for inventory. · Estimated recovery: February 2027 · Estimated recovery: January 2027 · Estimated recovery: September 2027
- 600 mg/60 mL (10 mg/mL) Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage p... · Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer:...
- 450 mg/45 mL (10 mg/mL) Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage p... · Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufactu...
- 600 mg/65 mL Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC
- 150mg/15mL Distributed by BPI Labs, LLC
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875, option 2 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31) | Unavailable | Estimated recovery: TBD | Discontinuation of the manufacture of the drug | Current |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33) | Unavailable | Estimated recovery: TBD | Discontinuation of the manufacture of the drug | Current |
Manufacturer: Avyxa Pharma, LLC 📞 877-595-7337; [email protected] 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50) | Available | — | — | Current |
| Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08) | Available | — | — | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) | Available | Check wholesalers for inventory | — | Current |
| Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) | Unavailable | On backorder. Recovery: late September 2026. Check wholesalers for inventory | Demand increase for the drug | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60) | Unavailable | Next release November 2026. Check wholesalers for inventory. | Delay in shipping of the drug | Current |
Manufacturer: Gland Pharma Limited 📞 Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) | Limited Availability | Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC | Demand increase for the drug | Current |
| Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) | Available | Distributed by BPI Labs, LLC | — | Current |
| Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) | Limited Availability | Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC | Demand increase for the drug | Current |
| Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) | Unavailable | Discontinued; Distributed by BPI Labs, LLC | Discontinuation of the manufacture of the drug | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05) | Unavailable | Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22) | Limited Availability | Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18) | Limited Availability | Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027 | Demand increase for the drug | Current |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18) | Unavailable | Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05) | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05) | Unavailable | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50) | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56) | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Manufacturer: Ingenus Pharmaceuticals LLC 📞 866-321-5031 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01) | Limited Availability | Estimated recovery: September 2027 | Other | Current |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01) | Unavailable | Estimated recovery: January 2027 | Other | Current |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01) | Limited Availability | Estimated recovery: February 2027 | Other | Current |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01) | Limited Availability | Estimated recovery: December 2028 | Other | Current |
Manufacturer: Teyro Labs 📞 Apotex Inc.: 800-706-5575 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Carboplatin Injection →
View Carboplatin Injection on the FDA drug-shortage database →
Sterile Water Irrigant View full page →
Key facts about the Sterile Water Irrigant shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Sterile Water Irrigant may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Sterile Water Irrigant shortage page → for the still-marketed options we could find.
- Discontinuation of the manufacture of the drug (4 NDCs)
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Sterile Water Irrigant is currently on the FDA shortage list, but supply remains reachable for both strengths. Both the 1 mL/1 mL and 100 mL/100 mL strengths still have an available source, so the size you use should be findable through your pharmacy. At this time, no strength is completely without a source.
Here is how it looks: the shortage record lists three manufacturers, and two are still reporting available supply. One maker (ICU Medical) has marked its 1 mL/1 mL product as unavailable, tied to a discontinuation, but B. Braun still lists the 1 mL/1 mL as available. For the 100 mL/100 mL size, Baxter lists both available and limited-availability items, with one estimated recovery in September 2026. The FDA-reported reasons are a manufacturing discontinuation by one company and increased demand.
A few practical steps:
- Do not stop, skip, or change how you use this product on your own.
- Ask your pharmacy to order your strength — pharmacies can check wholesalers and other manufacturers, since a source is still listed for both sizes.
- The same medicine is also made by another maker (B. Braun and Baxter), so your pharmacy may be able to source one of those, though it may not be in local stock right away.
Manufacturer contact numbers appear on this page for reference; your pharmacy usually handles those calls. This is general national information and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mL/1 mL Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by I...
- 100 mL/100 mL Estimated recovery: September 2026
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10) | Available | — | — | Current |
| Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00) | Available | — | — | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03) | Available | — | — | Current |
| Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02) | Available | — | — | Current |
| Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04) | Limited Availability | Estimated recovery: September 2026 | Demand increase for the drug | Current |
Manufacturer: Otsuka ICU Medical LLC 📞 1-866-829-9025 or [email protected] 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09) | Unavailable | Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | Discontinuation of the manufacture of the drug | Current |
| Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36) | Unavailable | Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | Discontinuation of the manufacture of the drug | Current |
| Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03) | Unavailable | Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | Discontinuation of the manufacture of the drug | Current |
| Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22) | Unavailable | Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | Discontinuation of the manufacture of the drug | Current |
Full shortage page: Sterile Water Irrigant →
View Sterile Water Irrigant on the FDA drug-shortage database →
Prazosin Hydrochloride Capsule View full page →
Key facts about the Prazosin Hydrochloride Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Prazosin Hydrochloride Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Prazosin Hydrochloride Capsule shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Prazosin hydrochloride capsules are currently on the FDA shortage list. The report you're seeing comes from the maker of the brand-name version, Minipress, and it applies to the 1 mg, 2 mg, and 5 mg strengths.
For this particular record, none of the three strengths have an available source. All three are listed as to be discontinued by this one manufacturer, with supply expected to run out during 2023. This means the shortage from this maker may be permanent rather than temporary. Even so, this reflects only the company that filed the report — prazosin is a common medicine, and other manufacturers still make it.
Please keep taking your medicine as prescribed. Do not stop, skip, or change your dose on your own while you sort this out.
Here are practical next steps:
- Ask your pharmacy whether they can source prazosin from another manufacturer. The same medicine in 1 mg, 2 mg, and 5 mg is listed from makers including Teva, Mylan, Major, and Marlex. Your pharmacy can check wholesalers, though it may not be in local stock right away.
- If your exact capsule can't be found, ask your prescriber or pharmacist about options, such as a different way to reach your dose.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 1 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 2 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 5 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 1 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 2 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 5 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 1 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 2 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 5 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 1 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 2 mg/1
- Prazosin Hydrochloride — PRAZOSIN HYDROCHLORIDE 5 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 20...
- 1 mg Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023
- 2 mg Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 20...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Pfizer Inc. 📞 800-533-4535 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Minipress, Capsule, 2 mg (NDC 0069-4370-71) | — | Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023 | — | To Be Discontinued |
| Minipress, Capsule, 1 mg (NDC 0069-4310-71) | — | Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023 | — | To Be Discontinued |
| Minipress, Capsule, 5 mg (NDC 0069-4380-71) | — | Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023 | — | To Be Discontinued |
Full shortage page: Prazosin Hydrochloride Capsule →
View Prazosin Hydrochloride Capsule on the FDA drug-shortage database →
Penicillin G Benzathine Injection View full page →
Key facts about the Penicillin G Benzathine Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Penicillin G Benzathine Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Penicillin G Benzathine Injection shortage page → for the still-marketed options we could find.
- Other (3 NDCs)
Do you take this medicine? What Should I Do?!
Penicillin G Benzathine injection is currently on the FDA shortage list. This is an antibiotic given as a shot, and I want to walk you through what the reported data shows so you can find the strength you use.
The one strength with no available source right now is the 600,000 unit/1 mL product. Three other strengths still have a source reported: 1,200,000 units/2 mL, 1,200,000 units/4 mL, and 2,400,000 units/4 mL. Both manufacturers on this record are still reporting supply, though some strengths are marked "limited availability." The reported reason involves a manufacturing delay, and this situation has lasted over a year, with recovery estimates extending into late 2027.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- If your strength still has supply, ask your pharmacy to order it — pharmacies can check wholesalers and both manufacturers on this record.
- The same medicine (penicillin G benzathine) may be available from another maker; your pharmacy may be able to source one, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as making up the dose with a different strength.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls. This is national, manufacturer-reported data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 600000 [iU]/1 mL Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer:...
- 1200000 [iU]/2 mL Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027;...
- 2400000 [iU]/4 mL Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027;...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Laboratorios Atral 📞 Mark Cuban Cost Plus Drug Company: 682-428-8081 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01) | Available | — | — | Current |
Manufacturer: Pfizer Inc. 📞 800-533-4535 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10) | Unavailable | Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10) | Limited Availability | Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10) | Limited Availability | Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Full shortage page: Penicillin G Benzathine Injection →
View Penicillin G Benzathine Injection on the FDA drug-shortage database →
Clindamycin Phosphate Injection View full page →
Key facts about the Clindamycin Phosphate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Clindamycin Phosphate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Clindamycin Phosphate Injection shortage page → for the still-marketed options we could find.
- Discontinuation of the manufacture of the drug (3 NDCs)
- Other (2 NDCs)
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Clindamycin phosphate injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for the strength you use.
The good part is that several strengths still have supply. These include the 12 mg/1 mL, 6 mg/1 mL, and 18 mg/1 mL premix bags, the 300 mg/50 mL and 900 mg/50 mL bags, and Cleocin Phosphate 600 mg/4 mL (150 mg/mL). The strengths with no available source right now are the smaller Cleocin vials — the 300 mg/2 mL, 600 mg/4 mL vials, and 900 mg/6 mL, along with the 600 mg/50 mL bag.
The reported reasons include one maker discontinuing certain vial sizes, a demand increase, and other factors. Importantly, all four manufacturers on this record still report some available supply, so this is not a case of the medicine disappearing entirely. Some of the discontinued vial sizes may not return, and one bag size (600 mg/50 mL) has an estimated recovery of October 2026.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other makers.
- The same medicine is made by others (for example, Hikma and Baxter); your pharmacy may source one, though it may not be in local stock.
- If your exact vial is discontinued, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference. This reflects national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Cleocin Phosphate — CLINDAMYCIN PHOSPHATE 150 mg/mL
- Clindamycin In 5 Percent Dextrose — CLINDAMYCIN 6 mg/mL
- Clindamycin In 5 Percent Dextrose — CLINDAMYCIN 12 mg/mL
- Clindamycin In 5 Percent Dextrose — CLINDAMYCIN 18 mg/mL
- Clindamycin Phosphate — CLINDAMYCIN PHOSPHATE 300 mg/50mL
- Clindamycin Phosphate — CLINDAMYCIN PHOSPHATE 600 mg/50mL
- Clindamycin Phosphate — CLINDAMYCIN PHOSPHATE 900 mg/50mL
- Clindamycin — CLINDAMYCIN PHOSPHATE 150 mg/mL
- Clindamycin Phosphate — CLINDAMYCIN PHOSPHATE 600 mg/50mL
- Clindamycin Phosphate — CLINDAMYCIN PHOSPHATE 900 mg/50mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 900 mg/6 mL (150 mg/mL); 6 mL... Discontinuation of the manufacture of the drug
- 300 mg/2 mL (150 mg/mL); 2 mL... Discontinuation of the manufacture of the drug
- 600 mg/4 mL (150 mg/mL); 4 mL... Discontinuation of the manufacture of the drug
- 600 mg/4 mL (150 mg/mL); 4 mL... Discontinuation of the manufacture of the drug
- 600 mg/50 mL Estimated recovery: October 2026
- 300 mg/2 mL (150 mg/mL); 2 mL... Discontinuation of the manufacture of the drug
- 900 mg/6 mL (150 mg/mL); 6 mL... Discontinuation of the manufacture of the drug
- Cleocin Phosphate 300 mg/2 mL... Next Delivery and Estimated Recovery: December 2028
- Cleocin Phosphate 900 mg/6 mL... Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- 12 mg/1 mL Civica Label
- 150 mg/1 mL Discontinuation of the manufacture of the drug · Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting pro...
- 18 mg/1 mL Civica Label
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Baxter Healthcare 📞 888-229-0001 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50) | Available | — | — | Current |
| Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50) | Available | — | — | Current |
| Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50) | Available | — | — | Current |
| Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50) | Unavailable | Estimated recovery: October 2026 | Other | Current |
| Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50) | Available | — | — | Current |
| Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50) | Available | — | — | Current |
Manufacturer: Pfizer Inc. 📞 800-533-4535 9 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26) | Unavailable | Next Delivery and Estimated Recovery: December 2028 | Demand increase for the drug | Current |
| Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26) | Available | — | — | Current |
| Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Sagent Pharmaceuticals 📞 866-625-1618 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02) | Limited Availability | Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line | Discontinuation of the manufacture of the drug | Current |
| Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06) | Limited Availability | Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line | Discontinuation of the manufacture of the drug | Current |
| Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
Manufacturer: Sandoz Inc. 📞 800-525-8747 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24) | Available | Civica Label | — | Current |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09) | Available | — | — | Current |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09) | Available | — | — | Current |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24) | Available | Civica Label | — | Current |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09) | Available | — | — | Current |
Full shortage page: Clindamycin Phosphate Injection →
View Clindamycin Phosphate Injection on the FDA drug-shortage database →
Methotrexate Sodium Injection View full page →
Key facts about the Methotrexate Sodium Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Methotrexate Sodium Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Methotrexate Sodium Injection shortage page → for the still-marketed options we could find.
- Other (5 NDCs)
- Demand increase for the drug (2 NDCs)
Do you take this medicine? What Should I Do?!
Methotrexate Sodium Injection is currently on the FDA shortage list. If this is the medicine you use, please know that every strength still has at least one manufacturer reporting available supply, so this is a manageable situation.
Right now, no strength is completely without a source. The 25 mg/1 mL, 50 mg/2 mL (25 mg/mL), 1 g, and 1 g/40 mL (25 mg/mL) all have at least one maker with supply. Some companies have listed their products as unavailable or limited, while others (including Hospira and Fresenius Kabi) report certain strengths as available — so the strength you take can likely still be found.
The FDA lists the reasons as increased demand and "other." Three of the five manufacturers on this record still report supply, and some others give estimated recovery dates ranging into 2026. This shortage has lasted over a year, but supply overall is holding.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength — they can check wholesalers and different manufacturers.
- The same medicine is made by several companies (Hospira, Fresenius Kabi, Teva, Accord, Hikma); your pharmacy may source one, though it may not be in local stock.
- If your exact product can't be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 25 mg/1 mL Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: TBD · Check wholesaler for inventory · Estimated recovery: late September 2026; Short dated inventory with expiry of 09/30/27 ava... · Estimated recovery: December 2026 · Additional lots will be available in the September 2026 timeframe. Product will be made av... · Estimated recovery: October 2026
- 1 g Check wholesaler for inventory · Additional lots will be available in the September 2026 timeframe. Product will be made av...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875, option 2 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) | Unavailable | Estimated recovery: late September 2026; Short dated inventory with expiry of 09/30/27 available | Other | Current |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) | Unavailable | Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: TBD | Other | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) | Available | Check wholesaler for inventory | — | Current |
| Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) | Available | Check wholesaler for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) | Unavailable | Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug | Current |
| Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) | Unavailable | Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) | Available | — | — | Current |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) | Available | — | — | Current |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) | Available | — | — | Current |
| Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10) | Available | — | — | Current |
| Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) | Available | — | — | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) | Limited Availability | Estimated recovery: October 2026 | Other | Current |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) | Limited Availability | Estimated recovery: October 2026 | Other | Current |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) | Limited Availability | Estimated recovery: December 2026 | Other | Current |
Full shortage page: Methotrexate Sodium Injection →
View Methotrexate Sodium Injection on the FDA drug-shortage database →
Clonazepam Tablet View full page →
Key facts about the Clonazepam Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Clonazepam Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Clonazepam Tablet shortage page → for the still-marketed options we could find.
- Other
Do you take this medicine? What Should I Do?!
Clonazepam tablets are currently on the FDA shortage list, but supply overall remains steady, so this news should not worry you.
All three strengths — 0.5 mg, 1 mg, and 2 mg — still have an available source right now. None of these strengths are listed as having no supply. In fact, all six manufacturers on this record are still reporting availability, and none of the currently listed products are marked unavailable. One maker (Teva) lists its 1 mg tablet as limited, with more supply estimated by August 2026, but other companies continue to supply that strength. The FDA lists the reason for this shortage simply as "Other," and it has been in place for over a year without cutting off access.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength; because supply exists, they can check wholesalers and other manufacturers.
- If your usual product is hard to get, the same medicine is made by several companies (including brand-name Klonopin), so your pharmacy may be able to source an equivalent, though it may not be in local stock.
- If any issue comes up, ask your prescriber or pharmacist about options before making changes.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Clonazepam — CLONAZEPAM .125 mg/1
- Clonazepam — CLONAZEPAM .25 mg/1
- Clonazepam — CLONAZEPAM .5 mg/1
- Clonazepam — CLONAZEPAM 1 mg/1
- Clonazepam — CLONAZEPAM 2 mg/1
- Clonazepam — CLONAZEPAM .5 mg/1
- Clonazepam — CLONAZEPAM 1 mg/1
- Clonazepam — CLONAZEPAM 2 mg/1
- Clonazepam — CLONAZEPAM 1 mg/1
- Clonazepam — CLONAZEPAM .5 mg/1
- Clonazepam — CLONAZEPAM .125 mg/1
- Clonazepam — CLONAZEPAM .25 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .5 mg Marketed by Advagen Pharma Ltd. · Marketed by Solco Healthcare · Marketed by H2-Pharma
- 1 mg Marketed by Advagen Pharma Ltd. · Marketed by Solco Healthcare · Estimated supply: August 2026 · Marketed by H2-Pharma
- 2 mg Marketed by Solco Healthcare · Marketed by Advagen Pharma Ltd. · Marketed by H2-Pharma
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875, option 2 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clonazepam, Tablet, 1 mg (NDC 16729-137-16) | Available | — | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 16729-138-16) | Available | — | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 16729-138-00) | Available | — | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 16729-136-16) | Available | — | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 16729-137-00) | Available | — | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 16729-136-00) | Available | — | — | Current |
Manufacturer: Aurobindo Pharma USA 📞 866-850-2876 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clonazepam, Tablet, .5 mg (NDC 59651-722-99) | Available | — | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 59651-722-01) | Available | — | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 59651-723-99) | Available | — | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 59651-724-01) | Available | — | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 59651-724-05) | Available | — | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 59651-723-01) | Available | — | — | Current |
Manufacturer: Cheplapharm Arzneimittel GmbH 📞 [email protected] 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Klonopin, Tablet, 1 mg (NDC 61269-610-10) | Available | Marketed by H2-Pharma | — | Current |
| Klonopin, Tablet, 2 mg (NDC 61269-620-10) | Available | Marketed by H2-Pharma | — | Current |
| Klonopin, Tablet, .5 mg (NDC 61269-605-10) | Available | Marketed by H2-Pharma | — | Current |
Manufacturer: Prinston Pharmaceutical, Inc. 📞 For orders, Solco Healthcare 866-931-9829 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clonazepam, Tablet, .5 mg (NDC 43547-406-10) | Available | Marketed by Solco Healthcare | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 43547-408-10) | Available | Marketed by Solco Healthcare | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 43547-407-50) | Available | Marketed by Solco Healthcare | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 43547-407-11) | Available | Marketed by Solco Healthcare | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 43547-406-50) | Available | Marketed by Solco Healthcare | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 43547-407-10) | Available | Marketed by Solco Healthcare | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 43547-408-50) | Available | Marketed by Solco Healthcare | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 43547-406-11) | Available | Marketed by Solco Healthcare | — | Current |
Manufacturer: Rubicon Research Private Limited 📞 [email protected] 11 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clonazepam, Tablet, .5 mg (NDC 72888-152-00) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 72888-154-30) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 72888-152-30) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 72888-154-01) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 72888-154-05) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 72888-153-01) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 72888-152-05) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 72888-153-05) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 72888-153-00) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 72888-153-30) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 72888-152-01) | Available | Marketed by Advagen Pharma Ltd. | — | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Clonazepam, Tablet, 1 mg (NDC 0093-3212-05) | Available | — | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 0093-3213-05) | Available | — | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 0093-0832-01) | Available | — | — | Current |
| Clonazepam, Tablet, .5 mg (NDC 0093-0832-05) | Available | — | — | Current |
| Clonazepam, Tablet, 2 mg (NDC 0093-3213-01) | Available | — | — | Current |
| Clonazepam, Tablet, 1 mg (NDC 0093-3212-01) | Limited Availability | Estimated supply: August 2026 | Other | Current |
Full shortage page: Clonazepam Tablet →
Rocuronium Bromide Injection View full page →
Key facts about the Rocuronium Bromide Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Rocuronium Bromide Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Rocuronium Bromide Injection shortage page → for the still-marketed options we could find.
- Delay in shipping of the drug (2 NDCs)
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Rocuronium Bromide Injection is currently on the FDA drug-shortage list. This is a medicine given in hospital and clinical settings, and the current supply picture is reassuring.
Every listed strength still has an available source right now — the 10 mg/1 mL, the 50 mg/5 mL (10 mg/mL), and the 100 mg/10 mL (10 mg/mL) all have at least one manufacturer reporting supply. No strength is completely without a source at this time. In fact, all 11 manufacturers on this record report available product, so whichever strength you or your loved one receives is covered.
The FDA lists the reasons as a delay in shipping and an increase in demand. A few individual lots are limited or on allocation, and one supplier notes a next release in October 2026 — but because so many makers still have product, this is rated a low supply risk.
Because this medicine is given by a healthcare provider, most of the steps below happen behind the scenes. Still, here is what helps:
- Do not stop, skip, or change any dose on your own.
- Ask your pharmacy or care team to order your strength; they can check wholesalers and other manufacturers.
- If your usual source is short, the same medicine may be available from another maker, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Rocuronium Bromide — ROCURONIUM BROMIDE 10 mg/mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 10 mg/mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 50 mg/5mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 100 mg/10mL
- Rocuronium — ROCURONIUM BROMIDE 10 mg/mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 10 mg/mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 50 mg/5mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 100 mg/10mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 10 mg/mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 10 mg/mL
- Rocuronium — ROCURONIUM BROMIDE 50 mg/5mL
- Rocuronium Bromide — ROCURONIUM BROMIDE 10 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg/10 mL On allocation · Tamarang is the application holder and X-Gen is the distributor/labeler · Check wholesalers for inventory
- 10 mg/1 mL Estimated recovery: TBD · Additional lots will be available. Product will be made available as it is released. · Next release October 2026. Check wholesalers for inventory. · Check wholesalers for inventory
- 50 mg/5 mL Tamarang is the application holder and X-Gen is the distributor/labeler · Check wholesalers for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Baxter Healthcare 📞 888-229-0001 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10) | Available | — | — | Current |
| Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10) | Available | — | — | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05) | Available | Check wholesalers for inventory | — | Current |
| Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10) | Available | Check wholesalers for inventory | — | Current |
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05) | Available | Check wholesalers for inventory | — | Current |
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10) | Available | Check wholesalers for inventory | — | Current |
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Delay in shipping of the drug | Current |
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10) | Available | Additional lots will be available. Product will be made available as it is released. | — | Current |
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10) | Available | Additional lots will be available. Product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10) | Available | — | — | Current |
| Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10) | Available | — | — | Current |
| Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10) | Available | — | — | Current |
| Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10) | Available | — | — | Current |
Manufacturer: Meitheal Pharmaceuticals, Inc. 📞 844-824-8426 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11) | Available | — | — | Current |
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06) | Available | — | — | Current |
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10) | Available | — | — | Current |
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05) | Available | — | — | Current |
Manufacturer: Piramal Critical Care Inc. 📞 800-414-1901 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41) | Available | — | — | Current |
| Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41) | Limited Availability | On allocation | Demand increase for the drug | Current |
Manufacturer: Sagent Pharmaceuticals 📞 866-625-1618 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05) | Available | — | — | Current |
Manufacturer: Sandoz Inc. 📞 800-525-8747 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92) | Available | — | — | Current |
| Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95) | Available | — | — | Current |
Manufacturer: XGen Pharmaceuticals DJB, Inc. 📞 866-390-4411 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6) | Available | Tamarang is the application holder and X-Gen is the distributor/labeler | — | Current |
| Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2) | Available | Tamarang is the application holder and X-Gen is the distributor/labeler | — | Current |
Full shortage page: Rocuronium Bromide Injection →
View Rocuronium Bromide Injection on the FDA drug-shortage database →
Quinapril Hydrochloride Tablet View full page →
Key facts about the Quinapril Hydrochloride Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Quinapril Hydrochloride Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Quinapril Hydrochloride Tablet shortage page → for the still-marketed options we could find.
- Shortage of an active ingredient (4 NDCs)
- Discontinuation of the manufacture of the drug (4 NDCs)
- Requirements related to complying with good manufacturing practices (4 NDCs)
Do you take this medicine? What Should I Do?!
Quinapril hydrochloride tablets are currently on the FDA drug-shortage list. If you take this blood pressure medicine, please know that all four strengths — 5 mg, 10 mg, 20 mg, and 40 mg — still have an available source, so there is a reasonable path to keeping you supplied.
Here is how it looks right now. Several manufacturers have reported their quinapril as unavailable, and the reasons include a shortage of an active ingredient, some makers discontinuing the product, and manufacturing-quality requirements. This situation has lasted over a year, and where a maker has stopped production there is no estimated return date. Even so, one manufacturer is still reporting all four strengths as available, which is why every strength shows a source.
Please do not let this news worry you into changing anything on your own.
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength; pharmacies can check wholesalers and other makers.
- The same medicine may be available from other manufacturers your pharmacy can source, though it may not be in local stock right away.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as a different strength to reach your dose.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Quinapril — QUINAPRIL HYDROCHLORIDE 10 mg/1
- Quinapril Hydrochloride — QUINAPRIL HYDROCHLORIDE 5 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 10 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 20 mg/1
- Quinapril Hydrochloride — QUINAPRIL HYDROCHLORIDE 40 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 20 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 10 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 5 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 40 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 5 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 10 mg/1
- Quinapril — QUINAPRIL HYDROCHLORIDE 20 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg Discontinuation of the manufacture of the drug · Estimated recovery: TBD · Not available. Long-term backorder for all NDCs. No estimated release date at this time.
- 40 mg Not available. Long-term backorder for all NDCs. No estimated release date at this time. · Discontinuation of the manufacture of the drug · Estimated recovery: TBD
- 5 mg Estimated recovery: TBD · Discontinuation of the manufacture of the drug · Not available. Long-term backorder for all NDCs. No estimated release date at this time.
- 20 mg Discontinuation of the manufacture of the drug · Estimated recovery: TBD · Not available. Long-term backorder for all NDCs. No estimated release date at this time.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Aurobindo Pharma USA 📞 866-850-2876 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
Manufacturer: Chartwell Molecular Holdings LLC 📞 845-268-5000 x 510 or Chartwell Customer service at [email protected] 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90) | Available | — | — | Current |
| Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90) | Available | — | — | Current |
| Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60) | Available | — | — | Current |
| Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90) | Available | — | — | Current |
Manufacturer: Lupin Pharmaceuticals, Inc. 📞 866-587-4617 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
Manufacturer: Pfizer Inc. 📞 800-533-4535 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Accupril, Tablet, 5 mg (NDC 0071-0527-23) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Accupril, Tablet, 20 mg (NDC 0071-0532-23) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Accupril, Tablet, 10 mg (NDC 0071-0530-23) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Accupril, Tablet, 40 mg (NDC 0071-0535-23) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Solco Healthcare US, LLC 📞 866-931-9829 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09) | Unavailable | Not available. Long-term backorder for all NDCs. No estimated release date at this time. | Shortage of an active ingredient | Current |
| Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09) | Unavailable | Not available. Long-term backorder for all NDCs. No estimated release date at this time. | Shortage of an active ingredient | Current |
| Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09) | Unavailable | Not available. Long-term backorder for all NDCs. No estimated release date at this time. | Shortage of an active ingredient | Current |
| Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09) | Unavailable | Not available. Long-term backorder for all NDCs. No estimated release date at this time. | Shortage of an active ingredient | Current |
Full shortage page: Quinapril Hydrochloride Tablet →
View Quinapril Hydrochloride Tablet on the FDA drug-shortage database →
Quinapril/Hydrochlorothiazide Tablet View full page →
Key facts about the Quinapril/Hydrochlorothiazide Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Quinapril/Hydrochlorothiazide Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Quinapril/Hydrochlorothiazide Tablet shortage page → for the still-marketed options we could find.
- Discontinuation of the manufacture of the drug (3 NDCs)
Do you take this medicine? What Should I Do?!
Quinapril/hydrochlorothiazide, the combination tablet used for blood pressure, is currently on the FDA shortage list. I want you to know that all three strengths still have a manufacturer reporting supply, so this does not mean your dose is gone.
Here is how the strengths break down. All three combinations — 12.5 mg/10 mg, 12.5 mg/20 mg, and 25 mg/20 mg — remain available from Chartwell Molecular Holdings. The same three strengths from Aurobindo Pharma USA are listed as unavailable because that company has discontinued making them. So no strength is completely without a source right now, though about half of the listed products are marked unavailable. This shortage has lasted over a year, and the reported reason is a manufacturer discontinuing production.
What you can do:
- Do not stop, skip, or change your dose on your own — your blood pressure medicine should continue as prescribed.
- Ask your pharmacy to order your strength; pharmacies can check wholesalers and other makers, including the supply reported as available.
- This same combination is also made by Lupin, Cipla, and Aurobindo Pharma Limited. Your pharmacy may be able to source one of these, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about equivalent options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national data and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Quinapril Hcl And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril Hcl And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril Hcl And Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1
- Quinapril Hydrochloride/Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril Hydrochloride/Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril Hydrochloride/Hydrochlorothiazide — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1
- Quinapril And Hydrochlorothiazide 10/12.5 — QUINAPRIL HYDROCHLORIDE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril And Hydrochlorothiazide 20/12.5 — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1
- Quinapril And Hydrochlorothiazide 20/25 — QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 12.5 mg; 20 mg Discontinuation of the manufacture of the drug
- 12.5 mg; 10 mg Discontinuation of the manufacture of the drug
- 25 mg; 20 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Aurobindo Pharma USA 📞 866-850-2876 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
Manufacturer: Chartwell Molecular Holdings LLC 📞 845-268-5000 x 510 or Chartwell Customer service at [email protected] 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90) | Available | — | — | Current |
| Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90) | Available | — | — | Current |
| Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90) | Available | — | — | Current |
Full shortage page: Quinapril/Hydrochlorothiazide Tablet →
View Quinapril/Hydrochlorothiazide Tablet on the FDA drug-shortage database →
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet View full page →
Key facts about the Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet shortage page → for the still-marketed options we could find.
- Shortage of an active ingredient (23 NDCs)
- Other (3 NDCs)
- Demand increase for the drug (3 NDCs)
Do you take this medicine? What Should I Do?!
Your combination amphetamine salts tablet — the mixed amphetamine product sold as generic Adderall — is currently on the FDA shortage list. I want to walk you through what that means for the strength you take.
The reassuring part is that every strength still has at least one supplier. This includes the 1.25 mg, 1.875 mg, 2.5 mg, 3.125 mg, 3.75 mg, 5 mg, and 7.5 mg tablets. No strength is completely without a source right now. Some makers list their supply as available, while others report limited availability or none at the moment, with estimated recovery dates ranging from September 2026 through April 2027.
The FDA lists the reasons as a shortage of an active ingredient, higher demand, and "other." Eight of eleven manufacturers on this record still report supply, which is why your pharmacy may be able to find your strength even if one company is short.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own — this medicine should be adjusted only with your prescriber or pharmacist.
- Ask your pharmacy to order your strength; they can check wholesalers and other manufacturers who still report supply.
- If your usual maker is short, your pharmacy may source the same medicine from another maker (such as Sunrise, Aurolife, or Lannett), though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber about options, such as combining strengths or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This information comes from national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 2.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; D
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 1.25 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 m
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 1.875 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 1.875
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 2.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 3.125 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 3.125
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 3.75 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 3.75 m
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; D
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 7.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 7.5 mg/
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 1.25 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 m
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 2.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Ampheta — DEXTROAMPHETAMINE SACCHARATE 3.75 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 3.75 m
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1.25 mg; 1.25 mg; 1.25 mg; 1.2... Estimated recovery: April 2027 · Estimated recovery: TBD · Estimated availability: October 2026 · Estimated recovery: October 2026
- 5 mg; 5 mg; 5 mg; 5 mg Estimated recovery: April 2027 · Estimated recovery: TBD · Estimated recovery: October 2026 · Estimated availability: October 2026
- 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg Estimated recovery: TBD · Estimated availability: October 2026 · Estimated recovery: October 2026 · Estimated recovery: April 2027
- 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg Estimated recovery: TBD · Estimated recovery: October 2026 · Estimated availability: October 2026 · Estimated recovery: April 2027
- 3.75 mg; 3.75 mg; 3.75 mg; 3.7... Estimated availability: October 2026 · Estimated recovery: TBD · Estimated recovery: September 2026 · Estimated recovery: October 2026 · Estimated recovery: April 2027
- 1.875 mg; 1.875 mg; 1.875 mg;... Estimated recovery: October 2026 · Estimated availability: October 2026
- 3.125 mg; 3.125 mg; 3.125 mg;... Estimated recovery: October 2026
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Alvogen 📞 844-842-8672 and email: [email protected] 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01) | Available | — | — | Current |
Manufacturer: Aurobindo Pharma USA 📞 (866) 850-2876 or [email protected] 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01) | Unavailable | Estimated availability: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01) | Unavailable | Estimated availability: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01) | Unavailable | Estimated availability: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01) | Unavailable | Estimated availability: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01) | Unavailable | Estimated availability: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01) | Unavailable | Estimated availability: October 2026 | Shortage of an active ingredient | Current |
Manufacturer: Elite Laboratories, Inc. 📞 888-852-6657 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01) | Available | — | — | Current |
Manufacturer: Epic Pharma, LLC 📞 (718) 276-8600 ext. 3 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01) | Limited Availability | Estimated recovery: TBD | Shortage of an active ingredient | Current |
Manufacturer: Granules Pharmaceuticals Inc. 📞 877-770-3183 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01) | Unavailable | Estimated recovery: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01) | Unavailable | Estimated recovery: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01) | Unavailable | Estimated recovery: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01) | Unavailable | Estimated recovery: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01) | Unavailable | Estimated recovery: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01) | Unavailable | Estimated recovery: October 2026 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01) | Unavailable | Estimated recovery: October 2026 | Shortage of an active ingredient | Current |
Manufacturer: Lannett Company, Inc. 📞 844-834-0530 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37) | Available | — | — | Current |
Manufacturer: Oryza Pharmaceuticals Inc. 📞 855-257-0292 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01) | Unavailable | Estimated recovery: April 2027 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01) | Unavailable | Estimated recovery: April 2027 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01) | Unavailable | Estimated recovery: April 2027 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01) | Unavailable | Estimated recovery: April 2027 | Shortage of an active ingredient | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01) | Unavailable | Estimated recovery: April 2027 | Shortage of an active ingredient | Current |
Manufacturer: Sandoz Inc. 📞 800-525-8747 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01) | Available | — | — | Current |
Manufacturer: SpecGx LLC 📞 800-325-8888 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01) | Limited Availability | Estimated recovery: TBD | Demand increase for the drug | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01) | Limited Availability | Estimated recovery: TBD | Demand increase for the drug | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01) | Limited Availability | Estimated recovery: TBD | Demand increase for the drug | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01) | Available | — | — | Current |
Manufacturer: Sunrise Pharmaceutical, Inc. 📞 732-382-6085 Monday to Friday 9 am to 3:45 pm 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01) | Available | — | — | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 14 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02) | Available | — | — | Current |
| Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01) | Unavailable | Estimated recovery: October 2026 | Other | Current |
| Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02) | Available | — | — | Current |
| Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01) | Available | — | — | Current |
| Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01) | Available | — | — | Current |
| Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02) | Limited Availability | Estimated recovery: TBD | Other | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02) | Limited Availability | Estimated recovery: September 2026 | Other | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02) | Available | — | — | Current |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02) | Available | — | — | Current |
| Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01) | Available | — | — | Current |
Full shortage page: Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet →
View Amphetamine Aspartate Monohydrate, Amphe... on the FDA drug-shortage database →
Etomidate Injection View full page →
Key facts about the Etomidate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Etomidate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Etomidate Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug (2 NDCs)
- Other
Do you take this medicine? What Should I Do?!
Etomidate injection is currently on the FDA drug-shortage list. Because this medicine is given in clinical settings such as hospitals and procedure areas, most of what follows is handled by your care team, but I want you to understand where supply stands.
The affected sizes are the 20 mg/10 mL and 40 mg/20 mL vials, which currently have no available source and are on backorder with a recovery time still to be determined. The smaller 2 mg/mL (also listed as 2 mg/1 mL) concentration still has supply reported from several makers, so the strength many patients receive is generally obtainable.
This shortage has lasted more than a year, and the reported reasons are increased demand and "other" factors. Importantly, 5 of 6 manufacturers still report available supply, so this is a limited-source issue rather than a full outage.
Here is what you can do:
- Do not skip or change any dose on your own — this medicine is dosed and given by your care team.
- If your setting uses the 2 mg/mL size, your pharmacy can order it and check wholesalers and other manufacturers.
- If the 10 mL or 20 mL vial you need cannot be found, your pharmacist or prescriber can discuss options, such as using an available concentration.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This is national, manufacturer-reported data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg/10 mL On backorder. Recovery: TBD. Check wholesalers for inventory
- 40 mg/20 mL On backorder. Recovery: TBD. Check wholesalers for inventory
- 2 mg/mL Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586 · Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer...
- 2 mg/1 mL Additional product will be made available as it is released. · Distributed by Civica · Novaplus label · Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.
- 2mg/1 mL Check wholesalers for inventory; Marketed by Fresenius Kabi
- 2mg/mL Check wholesalers for inventory; Marketed by Fresenius Kabi
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Caplin Steriles, Ltd. 📞 908-803-2586 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Etomidate, Injection, 2 mg/mL (NDC 72485-509-10) | Available | Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586 | — | Current |
| Etomidate, Injection, 2mg/mL (NDC 65219-447-20) | Available | Check wholesalers for inventory; Marketed by Fresenius Kabi | — | Current |
| Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10) | Available | Check wholesalers for inventory; Marketed by Fresenius Kabi | — | Current |
| Etomidate, Injection, 2 mg/mL (NDC 72485-508-10) | Available | Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586 | — | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
| Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
Manufacturer: Gland Pharma Limited 📞 833-291-9645 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10) | Available | Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645. | — | Current |
| Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10) | Available | Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645. | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10) | Available | Distributed by Civica | — | Current |
| Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10) | Available | Additional product will be made available as it is released. | — | Current |
| Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10) | Available | Novaplus label | — | Current |
| Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10) | Available | Novaplus label | — | Current |
| Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10) | Available | Distributed by Civica | — | Current |
| Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10) | Available | Additional product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01) | Available | — | — | Current |
| Amidate, Injection, 2 mg/mL (NDC 0409-6695-02) | Unavailable | Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20) | Available | — | — | Current |
| Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10) | Available | — | — | Current |
Full shortage page: Etomidate Injection →
View Etomidate Injection on the FDA drug-shortage database →
Flurazepam Hydrochloride Capsule View full page →
Key facts about the Flurazepam Hydrochloride Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Flurazepam Hydrochloride Capsule may not appear here at all, so this is not a picture of every available option. See the full Flurazepam Hydrochloride Capsule shortage page → for the still-marketed options we could find.
- Regulatory delay (2 NDCs)
Do you take this medicine? What Should I Do?!
Flurazepam hydrochloride capsules are currently on the FDA drug-shortage list. I want to walk you through what this means for the strength you take so you can plan ahead calmly.
Both strengths — 15 mg and 30 mg — still have an available source. Neither strength is completely out. The shortage record shows two manufacturers: one (Rising Pharma) has both strengths listed as unavailable, with supply anticipated in Q4 2026, while the other (Chartwell) reports both strengths as available. So even though about a third of the listed products are marked unavailable, the medicine itself can still be sourced.
The reported reason is a regulatory delay tied to manufacturing at a contract facility. This situation has lasted over a year, but supply from the second maker is helping fill the gap.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength from the manufacturer still reporting supply — pharmacies can check wholesalers and other makers.
- If your pharmacy cannot locate your exact capsule, ask your prescriber or pharmacist about options, such as a different strength to reach your dose.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This reflects national data and may not match your local stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 30 mg Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract ma...
- 15 mg Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract ma...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Chartwell Molecular Holdings LLC 📞 845-268-5000 Ext. 510 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30) | Available | — | — | Current |
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90) | Available | — | — | Current |
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90) | Available | — | — | Current |
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30) | Available | — | — | Current |
Manufacturer: Rising Pharma Holdings, Inc. 📞 1-844-874-7464 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01) | Unavailable | Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility. | Regulatory delay | Current |
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01) | Unavailable | Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility. | Regulatory delay | Current |
Full shortage page: Flurazepam Hydrochloride Capsule →
View Flurazepam Hydrochloride Capsule on the FDA drug-shortage database →
Streptozocin Powder, For Solution View full page →
Key facts about the Streptozocin Powder, For Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Streptozocin Powder, For Solution may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Streptozocin Powder, For Solution shortage page → for the still-marketed options we could find.
- Other
Do you take this medicine? What Should I Do?!
Streptozocin (also sold as Zanosar) is currently on the FDA drug-shortage list, and I want to walk you through what that means for the strength you take.
The two strengths are affected differently right now. The 1 g/10 mL strength still has an available source from one manufacturer, so if that is the one you use, supply is reported as available. The 100 mg/1 mL strength currently has no available source — the manufacturer that makes it reports it as unavailable, with an estimated recovery time listed as "to be determined." The reported reason is listed only as "Other." This situation has lasted more than a year.
Here is what you can do:
- Do not stop, skip, or change your dose on your own.
- If you take the 1 g/10 mL strength, ask your pharmacy to order it — pharmacies can check wholesalers and manufacturers for current stock.
- If your exact strength (100 mg/1 mL) cannot be found, talk with your prescriber or pharmacist about options, such as using a different strength to make up the dose or a clinician-chosen alternative.
- Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
This is national, manufacturer-reported data and may not match your local pharmacy's actual stock, so please confirm with them.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg/1 mL Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: ESTEVE PHARMACEUTICALS, S.A. 📞 [email protected] 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01) | Available | — | — | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01) | Unavailable | Estimated recovery: TBD | Other | Current |
Full shortage page: Streptozocin Powder, For Solution →
View Streptozocin Powder, For Solution on the FDA drug-shortage database →
Remifentanil Hydrochloride Injection View full page →
Key facts about the Remifentanil Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Remifentanil Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Remifentanil Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug (2 NDCs)
- Delay in shipping of the drug
Do you take this medicine? What Should I Do?!
Remifentanil Hydrochloride Injection is currently on the FDA shortage list. This is a hospital medicine, so most people receive it during a procedure or in a care setting rather than filling it at a pharmacy counter.
Not every strength is in short supply. The 2 mg per vial and 1 mg per vial sizes have no available source right now, with estimated recovery listed as to-be-determined. However, several strengths still have supply: 1 mg/1 mL, 2 mg, 5 mg, and 5 mg per vial are reported as available from manufacturers.
The reported reasons are higher demand and a shipping delay. This shortage has lasted over a year, but all three manufacturers on this record are still supplying at least some products, and one notes additional lots of the 5 mg per vial will be released as they become available. That is a reassuring sign.
Here is what you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your care team or pharmacy to order a strength that still has supply; they can check wholesalers and other manufacturers.
- The same medicine is available from more than one maker, so your team may be able to source it—though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2 mg per vial Estimated recovery: TBD
- 1 mg per vial Estimated recovery: TBD
- 1 mg/1 mL Next release September 2026. Check wholesalers for inventory. · Check wholesalers for inventory
- 5 mg per vial Additional lots will be available. Product will be made available as it is released.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10) | Available | Check wholesalers for inventory | — | Current |
| Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03) | Available | Check wholesalers for inventory | — | Current |
| Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Delay in shipping of the drug | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10) | Available | Additional lots will be available. Product will be made available as it is released. | — | Current |
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ultiva, Injection, 2 mg (NDC 72078-035-02) | Available | — | — | Current |
| Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01) | Available | — | — | Current |
| Ultiva, Injection, 5 mg (NDC 72078-036-05) | Available | — | — | Current |
Full shortage page: Remifentanil Hydrochloride Injection →
View Remifentanil Hydrochloride Injection on the FDA drug-shortage database →
Sufentanil Citrate Injection View full page →
Key facts about the Sufentanil Citrate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Sufentanil Citrate Injection may not appear here at all, so this is not a picture of every available option. See the full Sufentanil Citrate Injection shortage page → for the still-marketed options we could find.
- Other (3 NDCs)
Do you take this medicine? What Should I Do?!
Sufentanil Citrate Injection is currently on the FDA drug-shortage list. This is an injectable pain medicine used in medical settings, so it is usually handled and administered by your care team rather than kept at home.
The two listings on this record are the same strength described two ways. The 50 mcg/1 mL product from Hikma Pharmaceuticals is listed as unavailable and not currently manufactured. The 50 ug/1 mL product from Hospira (a Pfizer company) is listed as available. "ug" and "mcg" mean the same measurement, so the same-strength product is still being supplied by one manufacturer even though another has stopped making it.
The reported reason is simply listed as "Other," and this shortage has continued for more than a year. Even so, one of the two manufacturers is still reporting supply.
Here is what you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy or care team to order the strength that still has supply; pharmacies can check wholesalers and other manufacturers, though it may not be in local stock right away.
- If your exact product cannot be found, ask your prescriber or pharmacist about clinician-chosen options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mcg/1 mL Not currently manufactured
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05) | Unavailable | Not currently manufactured | Other | Current |
| Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02) | Unavailable | Not currently manufactured | Other | Current |
| Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01) | Unavailable | Not currently manufactured | Other | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21) | Available | — | — | Current |
Full shortage page: Sufentanil Citrate Injection →
View Sufentanil Citrate Injection on the FDA drug-shortage database →
Conivaptan Hydrochloride Injection View full page →
Key facts about the Conivaptan Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Conivaptan Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See the full Conivaptan Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Delay in shipping of the drug
Do you take this medicine? What Should I Do?!
Conivaptan Hydrochloride Injection is currently on the FDA drug-shortage list. I want to walk you through what this means so you know what to expect and what steps make sense.
The one strength on this record, 20 mg/100 mL, has no available source reported right now. This is the only strength listed, and there are no other strengths showing supply at this time. The reported reason is a delay in shipping of the drug, and only one manufacturer is on this record. An estimated recovery date has not yet been set (listed as TBD), and this shortage has lasted more than a year.
Even so, this report reflects only the manufacturer that filed it, so it does not mean every supplier is out. Here is what you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers, since this is a hospital-administered injection and local availability can differ from national data.
- If your dose cannot be found, ask your prescriber or pharmacist about options they can choose for you.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls.
This is general, manufacturer-reported information and may not match your local stock, so please lean on your care team for guidance.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg/100 mL Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Cumberland Pharmaceuticals Inc. 📞 800-706-5575 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
Full shortage page: Conivaptan Hydrochloride Injection →
View Conivaptan Hydrochloride Injection on the FDA drug-shortage database →
Dextrose Monohydrate 10% Injection View full page →
Key facts about the Dextrose Monohydrate 10% Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dextrose Monohydrate 10% Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dextrose Monohydrate 10% Injection shortage page → for the still-marketed options we could find.
- Other
- Discontinuation of the manufacture of the drug
Do you take this medicine? What Should I Do?!
Dextrose Monohydrate 10% Injection is currently on the FDA shortage list, but all three strengths still have at least one supplier. If you or the person you care for uses this product, the strength you need can most likely still be found.
Here is where each strength stands:
- 100 g/1000 mL — available (one product code is temporarily unavailable, with estimated recovery in September 2026, but other codes of this strength are in supply)
- 10 g/100 mL — available (note: one product code from ICU Medical has been discontinued, but others in this strength remain available)
- 100 mg/1 mL — available (manufacturer suggests checking wholesalers for inventory)
The reasons reported to the FDA include "other" and the discontinuation of one specific product code. Even so, all four manufacturers on this record are still reporting supply, so the overall risk is low. This is a hospital and clinic injection, so your care team usually manages ordering.
What you can do:
- Do not stop or change how this product is used on your own.
- Ask your pharmacy or care team to order your exact strength — they can check wholesalers and other makers.
- The same medicine is also listed from Becton Dickinson; your pharmacy may be able to source it, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference. This information comes from national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 g/1000 mL Estimated recovery: September 2026
- 10 g/100 mL This product is distributed by ICU Medical. For questions regarding this product, please c... · Product discontinued. This product is distributed by ICU Medical. For questions regarding...
- 100 mg/1 mL Check wholesalers for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20) | Available | — | — | Current |
| Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00) | Available | — | — | Current |
| Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10) | Available | — | — | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03) | Available | — | — | Current |
| Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04) | Available | — | — | Current |
| Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02) | Unavailable | Estimated recovery: September 2026 | Other | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74) | Available | Check wholesalers for inventory | — | Current |
| Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76) | Available | Check wholesalers for inventory | — | Current |
| Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Otsuka ICU Medical LLC 📞 1-866-829-9025 or [email protected] 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19) | Unavailable | Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | Discontinuation of the manufacture of the drug | Current |
| Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
Full shortage page: Dextrose Monohydrate 10% Injection →
View Dextrose Monohydrate 10% Injection on the FDA drug-shortage database →
Dextrose Monohydrate 5% Injection View full page →
Key facts about the Dextrose Monohydrate 5% Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dextrose Monohydrate 5% Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dextrose Monohydrate 5% Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Dextrose Monohydrate 5% Injection is currently on the FDA shortage list, but supply overall looks steady. This one appears because demand for the product went up, not because it has run out.
Every strength on this record still has an available source. That includes the 50 mg/1 mL, 5 g/100 mL, 50 g/1000 mL, and 2.5 g/50 mL sizes. Right now, no strength is listed as having no source — all four are being reported as available. Four different manufacturers are still supplying this medicine, which is why the supply risk is rated low even though the listing has lasted more than a year. Some records simply note that wholesalers should be checked for inventory.
Because this product is given in clinics and hospitals, here is what helps most:
- Do not stop or change any part of your treatment on your own.
- Since your strength still has supply, your pharmacy or care team can order it and check wholesalers and other manufacturers.
- The same medicine is also made by other companies on this record, so your pharmacy may be able to source one of those, though it may not be in local stock right away.
- If your exact size cannot be found, ask your prescriber or pharmacist about the best option for you.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This is general, nationwide information and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Dextrose — DEXTROSE MONOHYDRATE 50 mg/mL
- Dextrose — DEXTROSE MONOHYDRATE 50 g/1000mL
- Dextrose — DEXTROSE MONOHYDRATE 5 g/100mL
- Dextrose — DEXTROSE MONOHYDRATE 2.5 g/50mL
- Dextrose — DEXTROSE MONOHYDRATE 5 g/100mL
- Dextrose — DEXTROSE MONOHYDRATE 2.5 g/50mL
- Dextrose — DEXTROSE MONOHYDRATE 50 mg/mL
- Dextrose — DEXTROSE MONOHYDRATE 5 g/100mL
- Dextrose — DEXTROSE MONOHYDRATE 50 mg/mL
- Dextrose — DEXTROSE MONOHYDRATE 50 mg/mL
- Dextrose — DEXTROSE MONOHYDRATE 2500 mg/50mL
- Dextrose — DEXTROSE MONOHYDRATE 5000 mg/100mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50 mg/1 mL Check wholesalers for inventory · Check wholealers for inventory
- 5 g/100 mL This product is distributed by ICU Medical. For questions regarding this product, please c...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32) | Available | — | — | Current |
| Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20) | Available | — | — | Current |
| Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31) | Available | — | — | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 16 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18) | Available | — | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10) | Available | — | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60) | Available | Check wholealers for inventory | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50) | Available | Check wholesalers for inventory | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20) | Available | Check wholesalers for inventory | — | Current |
| Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10) | Available | Check wholesalers for inventory | Demand increase for the drug | Current |
| Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Otsuka ICU Medical LLC 📞 1-866-829-9025 or [email protected] 10 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
Full shortage page: Dextrose Monohydrate 5% Injection →
View Dextrose Monohydrate 5% Injection on the FDA drug-shortage database →
Metronidazole Injection View full page →
Key facts about the Metronidazole Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Metronidazole Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Metronidazole Injection shortage page → for the still-marketed options we could find.
- Other (2 NDCs)
- Discontinuation of the manufacture of the drug
Do you take this medicine? What Should I Do?!
Metronidazole Injection is currently on the FDA drug-shortage list. This is the intravenous form of the antibiotic, and I want to walk you through what the national data shows so you can find the strength you use.
There is only one strength involved, 500 mg/100 mL, and it still has an available source. No strength of this product is completely without supply right now. Two of the three manufacturers on this record are still reporting supply, and one of those (Sagent/InfoRLife) lists limited availability. One company has reported it is discontinuing its version of the product, with an estimated recovery note of August 2026. The reported reasons are listed as "Other" and a manufacturer's decision to stop making its own product — not a safety problem with the medicine itself.
Because this is a hospital and clinic injection, here is how to approach it:
- Do not stop or change your treatment on your own.
- Ask your pharmacy or care team to order the 500 mg/100 mL that still has supply — they can check wholesalers and other makers.
- The same medicine is available from other manufacturers, including Baxter, WG Critical Care, Civica, and Amneal; your pharmacy may be able to source one, though it may not be in local stock.
- If your supply cannot be found, ask your prescriber about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500 mg/100 mL Labeler: Hospira Inc. · Discontinuation of the manufacture of the drug · Estimated recovery: August 2026; Marketed by Sagent Pharmaceuticals
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Baxter Healthcare 📞 888-229-0001 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48) | Available | — | — | Current |
Manufacturer: Gland Pharma Limited 📞 Distributed by Sun Pharma 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
Manufacturer: InfoRLife SA 📞 Sagent: 866-625-1618 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82) | Limited Availability | Estimated recovery: August 2026; Marketed by Sagent Pharmaceuticals | Other | Current |
| Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24) | Limited Availability | Labeler: Hospira Inc. | Other | Current |
Full shortage page: Metronidazole Injection →
View Metronidazole Injection on the FDA drug-shortage database →
Dextrose Monohydrate 50% Injection View full page →
Key facts about the Dextrose Monohydrate 50% Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dextrose Monohydrate 50% Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dextrose Monohydrate 50% Injection shortage page → for the still-marketed options we could find.
- Other
Do you take this medicine? What Should I Do?!
Dextrose Monohydrate 50% Injection is currently on the FDA drug-shortage list, and I want to walk you through what this means for the strength you use.
The 25 g/50 mL strength still has an available source — in fact, both manufacturers on this record report supply for it, though one is filling from limited stock. So if this is your strength, your pharmacy should be able to obtain it. Separately, the 50% Dextrose Injection 0.5 g/mL (ABBOJECT® Glass Syringe) form currently has no available source and is reported as discontinued, which means that supply problem may be permanent.
The FDA lists the reason as "Other," and one supplier notes a manufacturing delay with delivery expected around November–December 2026. Here is how to move forward:
- Do not stop, skip, or change your dose on your own.
- If you use the 25 g/50 mL strength, ask your pharmacy to order it — they can check wholesalers and both listed makers.
- The same medicine is also made by ICU Medical and RemedyRepack; your pharmacy may be able to source one of these, though it may not be in local stock.
- If you rely on the discontinued ABBOJECT syringe, talk with your prescriber or pharmacist about an appropriate option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 50% Dextrose Injection 0.5 g/m... Discontinuation of the manufacture of the drug
- 25 g/50 mL Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amphastar Pharmaceuticals, Inc. 📞 800-423-4136 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1) | Available | — | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16) | Available | — | — | Current |
| Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02) | Limited Availability | Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Dextrose Monohydrate 50% Injection →
View Dextrose Monohydrate 50% Injection on the FDA drug-shortage database →
Rifampin Capsule View full page →
Key facts about the Rifampin Capsule shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Rifampin Capsule may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Rifampin Capsule shortage page → for the still-marketed options we could find.
- Discontinuation of the manufacture of the drug (4 NDCs)
Do you take this medicine? What Should I Do?!
Rifampin capsules are currently listed on the FDA drug-shortage list, and I want to walk you through what that means for you.
Both strengths — 150 mg and 300 mg — still have an available source right now. Neither one is completely out. What is happening is that one maker (Epic Pharma) has discontinued several of its rifampin products, which is why some packages show as unavailable. But another manufacturer (Lupin) still reports both the 150 mg and 300 mg capsules as available, so a supply path remains open even though this listing has continued for over a year.
Because the affected items are marked as discontinued, that portion of the supply may not return. That is not a reason to worry — it simply means your pharmacy may need to order from a maker that still has stock.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own — rifampin works best when taken exactly as prescribed.
- Ask your pharmacy to order your strength; they can check wholesalers and other makers, including Lupin and others such as Chartwell, American Health Packaging, or Major Pharmaceuticals, though these may not be in local stock.
- If your exact capsule can't be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 300 mg Discontinuation of the manufacture of the drug
- 150 mg Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Epic Pharma, LLC 📞 (718) 276-8600 ext. 3 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rifampin, Capsule, 300 mg (NDC 42806-799-05) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Rifampin, Capsule, 300 mg (NDC 42806-799-01) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Rifampin, Capsule, 300 mg (NDC 42806-799-30) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Rifampin, Capsule, 300 mg (NDC 42806-799-60) | Available | — | — | Current |
| Rifampin, Capsule, 150 mg (NDC 42806-801-01) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Rifampin, Capsule, 150 mg (NDC 42806-801-30) | Available | — | — | Current |
Manufacturer: Lupin Pharmaceuticals, Inc. 📞 866-587-4617 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rifampin, Capsule, 150 mg (NDC 68180-658-06) | Available | — | — | Current |
| Rifampin, Capsule, 300 mg (NDC 68180-659-07) | Available | — | — | Current |
| Rifampin, Capsule, 300 mg (NDC 68180-659-06) | Available | — | — | Current |
Full shortage page: Rifampin Capsule →
Methylprednisolone Acetate Injection View full page →
Key facts about the Methylprednisolone Acetate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Methylprednisolone Acetate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Methylprednisolone Acetate Injection shortage page → for the still-marketed options we could find.
- Other (5 NDCs)
- Demand increase for the drug (5 NDCs)
- Shortage of an active ingredient (3 NDCs)
Do you take this medicine? What Should I Do?!
Methylprednisolone acetate injection is currently on the FDA shortage list. This is a widely used medicine, and I want to reassure you upfront: every strength still has an available source.
All three strengths — 20 mg/mL, 40 mg/mL, and 80 mg/mL — have at least one manufacturer reporting supply right now. None of them are without a source. That said, some manufacturers report limited or backordered supply, so your local pharmacy may need to check around to find the strength you take.
The FDA lists a few reasons for this shortage: increased demand, a shortage of an active ingredient, and other manufacturing delays. Three of the five manufacturers on this record are still reporting supply, and estimated recovery notes range from mid-2026 to later dates for the affected batches. The shortage has lasted over a year, so some patience with sourcing may be needed.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own — this medicine should always be managed with your care team.
- Ask your pharmacy to order your strength; pharmacies can check wholesalers and other manufacturers for stock.
- The same medicine is made by other companies (such as Sandoz, Endo, Amneal, and others); your pharmacy may be able to source one, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference. This information comes from national, manufacturer-reported data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Depo-Medrol — METHYLPREDNISOLONE ACETATE 80 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 80 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 40 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 40 mg/mL
- Depo-Medrol — METHYLPREDNISOLONE ACETATE 80 mg/mL
- Depo-Medrol — METHYLPREDNISOLONE ACETATE 40 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 40 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 80 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 40 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 80 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 80 mg/mL
- Methylprednisolone Acetate — METHYLPREDNISOLONE ACETATE 40 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 40 mg/1 mL Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026;... · Estimated recovery: November 2026 · Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer:... · On backorder. Estimated recovery: late July · On backorder. Recovery: TBD. Check wholesalers for inventory · Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage p... · Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026 · Next Delivery: October 2026; Estimated Recovery: December 2026
- 80 mg/1 mL Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026 · On backorder. Recovery: TBD. Check wholesalers for inventory · Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expir... · Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1) | Available | — | — | Current |
| Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5) | Available | — | — | Current |
| Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5) | Available | — | — | Current |
| Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1) | Limited Availability | On backorder. Estimated recovery: late July | Other | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
| Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
Manufacturer: Par Health, USA LLC 📞 800-828-9393 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01) | Unavailable | Estimated recovery: TBD | Other | Current |
Manufacturer: Pfizer Inc. 📞 844-646-4398 13 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22) | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026 | Demand increase for the drug | Current |
| Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01) | Limited Availability | Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026 | Demand increase for the drug | Current |
| Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02) | Available | — | — | Current |
| Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02) | Available | — | — | Current |
| Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03) | Available | — | — | Current |
| Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01) | Available | — | — | Current |
| Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03) | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12) | Available | — | — | Current |
| Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51) | Available | — | — | Current |
| Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01) | Limited Availability | Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026 | Demand increase for the drug | Current |
| Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23) | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03) | Limited Availability | Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52) | Available | — | — | Current |
Manufacturer: Sagent Pharmaceuticals 📞 866-625-1618 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05) | Unavailable | Estimated recovery: November 2026 | Shortage of an active ingredient | Current |
| Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05) | Limited Availability | Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry | Shortage of an active ingredient | Current |
| Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10) | Unavailable | Estimated recovery: November 2026 | Shortage of an active ingredient | Current |
Full shortage page: Methylprednisolone Acetate Injection →
View Methylprednisolone Acetate Injection on the FDA drug-shortage database →
Sterile Water Injection View full page →
Key facts about the Sterile Water Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Sterile Water Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Sterile Water Injection shortage page → for the still-marketed options we could find.
- Other
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Sterile Water Injection is currently listed on the FDA drug-shortage report, and the overall supply risk is low. All three strengths on this record still have at least one source, so the type you use should be findable.
Every strength — 1 mL/1 mL, 10 mL/10 mL, and 1000 mL/1000 mL — currently has an available source, and none is marked with no supply at all. For the 1 mL size, one maker reports only a small amount of inventory, and another notes a next release in September 2026, but other manufacturers still report this size as available. All five manufacturers on this record are still reporting supply. The reported reasons are increased demand and "other," and while this listing has lasted over a year, that reflects tight supply rather than a full outage.
Here is what I suggest:
- Do not stop, skip, or change how you use this product on your own.
- Ask your pharmacy to order your strength; they can check wholesalers and other manufacturers.
- The same medicine is made by several other companies (for example B. Braun, Baxter, American Regent, and ICU Medical). Your pharmacy may be able to source one of these, though it may not be in local stock.
- If your exact size can't be found, ask your pharmacist or prescriber about options.
Manufacturer contact numbers are on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match your local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Sterile Water — WATER 1 mL/mL
- Sterile Water — WATER 100 mL/100mL
- Sterile Water — WATER 1 mL/mL
- Sterile Water — WATER 1 mL/mL
- Sterile Water — WATER 1 mL/mL
- Sterile Water — WATER 1 mL/mL
- Sterile Water — WATER 1000 mL/1000mL
- Sterile Water — WATER 1000 mL/1000mL
- Sterile Water — WATER 1 mL/mL
- Water — WATER 1 mL/mL
- Sterile Water — WATER 1 mL/mL
- Sterile Water — WATER 1 mL/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mL/1 mL Small amount of inventory available with 12/31/2026 dating · Additional lots will be scheduled for manufacturing. Product will be made available as it... · Check wholesalers for inventory · Next release September 2026. Check wholesalers for inventory.
- 1000 mL/1000 mL Check wholesalers for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76) | Available | Check wholesalers for inventory | — | Current |
| Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
| Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50) | Available | Check wholesalers for inventory | — | Current |
| Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10) | Available | Additional lots will be scheduled for manufacturing. Product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03) | Available | — | — | Current |
| Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50) | Available | — | — | Current |
| Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20) | Available | — | — | Current |
| Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10) | Available | — | — | Current |
| Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99) | Available | — | — | Current |
Manufacturer: Medefil, Inc. 📞 630-682-4600 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30) | Available | — | — | Current |
Manufacturer: Nephron Pharmaceuticals Corporation 📞 800-443-4313 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01) | Limited Availability | Small amount of inventory available with 12/31/2026 dating | Other | Current |
Full shortage page: Sterile Water Injection →
View Sterile Water Injection on the FDA drug-shortage database →
Triamcinolone Hexacetonide Injection View full page →
Key facts about the Triamcinolone Hexacetonide Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Triamcinolone Hexacetonide Injection may not appear here at all, so this is not a picture of every available option. See the full Triamcinolone Hexacetonide Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Triamcinolone hexacetonide injection is currently on the FDA drug-shortage list. I know that can feel unsettling, so let me walk you through what the data actually shows.
The single strength on this record, 40 mg/2 mL, currently has an available source. No strength of this medicine is listed as unavailable right now. So the version you take is being reported as in supply.
This shortage has been in place for over a year, and one manufacturer, Medexus, is on the record and reporting its product (brand name Hexatrione, 40 mg/2 mL) as available. The overall supply risk is listed as medium. No estimated-recovery date is provided, but the fact that the strength still has a source is a reassuring sign.
Here is what you can do:
- Do not stop, skip, or change your dose on your own.
- Because your strength still has supply, ask your pharmacy to order it — pharmacies can check wholesalers and other manufacturers.
- If your pharmacy cannot locate it, ask your prescriber or pharmacist about the best next step for you.
- The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls.
This is national, manufacturer-reported information and may not match your local pharmacy's stock or your personal situation.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Medexus 📞 1-855-336-3322 Option 9 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01) | Available | — | — | Current |
Full shortage page: Triamcinolone Hexacetonide Injection →
View Triamcinolone Hexacetonide Injection on the FDA drug-shortage database →
Desmopressin Acetate Spray View full page →
Key facts about the Desmopressin Acetate Spray shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Desmopressin Acetate Spray may not appear here at all, so this is not a picture of every available option. See the full Desmopressin Acetate Spray shortage page → for the still-marketed options we could find.
- Requirements related to complying with good manufacturing practices (3 NDCs)
Do you take this medicine? What Should I Do?!
Desmopressin Acetate Spray is currently on the FDA shortage list, and I want to walk you through what that means for the strength you use.
The picture depends on which strength you take. The 10 ug spray is still available from a manufacturer right now. Three other strengths do not have an available source at this time: the 1.5 mg/1 mL spray (Stimate), the .1 ug/1 mL spray (Ddavp), and the 10 ug/.1 mL spray. For each of those, the estimated recovery is listed as to-be-determined.
The reported reason involves requirements tied to good manufacturing practices. One of the two manufacturers on this record is still supplying, and this shortage has lasted over a year, so it may take time to fully resolve.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- If you use the 10 ug spray, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
- If your strength is one of the unavailable ones, ask your prescriber or pharmacist about options, such as adjusting to reach your dose or a clinician-chosen alternative.
- Manufacturer contact numbers are listed on this page for reference; your pharmacy usually makes these calls.
This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1.5 mg/1 mL Estimated recovery: TBD
- .1 ug/1 mL Estimated recovery: TBD
- 10 ug/.1 mL Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Apotex Corp. 📞 800-706-5575 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0) | Available | — | — | Current |
Manufacturer: Ferring 📞 888-337-7464 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
Full shortage page: Desmopressin Acetate Spray →
View Desmopressin Acetate Spray on the FDA drug-shortage database →
Rifampin Injection View full page →
Key facts about the Rifampin Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Rifampin Injection may not appear here at all, so this is not a picture of every available option. See the full Rifampin Injection shortage page → for the still-marketed options we could find.
- Other
- Demand increase for the drug
- Discontinuation of the manufacture of the drug
Do you take this medicine? What Should I Do?!
Rifampin Injection is currently on the FDA drug-shortage list. This affects the injectable form, and the situation differs by strength, so let me point you to the one that matters for you.
The 600 mg strength still has an available source, though supply is limited and pharmacies may need to check wholesalers for inventory. The 600 mg/10 mL strength has no available source right now, as the maker reporting it has discontinued that product. Because a discontinuation is involved, that particular presentation may not return.
The reasons reported to the FDA include increased demand, a discontinuation, and other factors. Of the three manufacturers on this record, one is still reporting supply of the 600 mg strength, and one recovery estimate points to late 2026. This shortage has lasted over a year.
Here is what I suggest:
- Do not stop, skip, or change how this medicine is given on your own.
- If you use the 600 mg strength, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
- If your strength cannot be found or is discontinued, ask your prescriber or pharmacist about a clinician-chosen option.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is national, manufacturer-reported data and may not match your local pharmacy's stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 600 mg/10 mL Discontinuation of the manufacture of the drug
- 600 mg Check wholesalers for inventory · Estimated recovery: Q4 2026 · Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rifampin, Injection, 600 mg (NDC 63323-351-20) | Limited Availability | Check wholesalers for inventory | Other | Current |
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rifampin, Injection, 600 mg (NDC 67457-445-60) | Unavailable | Estimated recovery: Q4 2026 | Demand increase for the drug | Current |
Manufacturer: Sanofi-Aventis U.S. LLC 📞 800-633-1610 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Rifadin, Injection, 600 mg (NDC 0068-0597-01) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Full shortage page: Rifampin Injection →
Valproate Sodium Injection View full page →
Key facts about the Valproate Sodium Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Valproate Sodium Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Valproate Sodium Injection shortage page → for the still-marketed options we could find.
Do you take this medicine? What Should I Do?!
Valproate Sodium Injection is currently listed on the FDA drug-shortage list. I want to reassure you at the start: both strengths still have a manufacturer reporting supply, so this listing does not mean the medicine is gone.
Here is how the strengths look right now. The 500 mg/5 mL strength is reported as available, with additional lots being released over time. The 100 mg/1 mL strength is also reported as available, and pharmacies are advised to check wholesalers for inventory. Neither strength has zero source at this time — both manufacturers on this record are still supplying.
This shortage has lasted over a year, but the overall supply risk is rated low. Two of two manufacturers are still reporting stock, which is a good sign for finding what you need.
What you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength; they can check wholesalers and other manufacturers for you.
- The same medicine may also be available from other makers (Hikma, Sagent, or Fresenius Kabi); your pharmacy may be able to source one, though it may not be in local stock.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This reflects national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 500 mg/5 mL Additional lots will be available. Product will be made available as it is released.
- 100 mg/1 mL Checkwholesalers for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05) | Available | Checkwholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10) | Available | Additional lots will be available. Product will be made available as it is released. | — | Current |
Full shortage page: Valproate Sodium Injection →
View Valproate Sodium Injection on the FDA drug-shortage database →
Azacitidine Injection View full page →
Key facts about the Azacitidine Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Azacitidine Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Azacitidine Injection shortage page → for the still-marketed options we could find.
- Other (2 NDCs)
- Demand increase for the drug
- Discontinuation of the manufacture of the drug
Do you take this medicine? What Should I Do?!
Azacitidine injection is currently on the FDA drug-shortage list. This is an injectable cancer medicine, so it is usually given to you by a healthcare team rather than something you fill yourself — but I want you to understand where supply stands.
Not every strength is affected the same way. The 100 mg vial (including 100 mg and 100 mg/30 mL forms) still has an available source from more than one manufacturer, though some suppliers list it as available to existing customers only. The 100 mg/4 mL strength currently has no available source and is on backorder, with recovery listed as to-be-determined. One maker has also chosen to discontinue its 100 mg/30 mL product, so that particular version may not return. Overall, 6 of 9 manufacturers on this record still report supply. Reported reasons include increased demand and one company's decision to stop making its version.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own — your care team manages the timing and dose.
- Ask your pharmacy or clinic to order the 100 mg vial form, which still has supply; they can check wholesalers and other makers.
- Several other companies still list the same medicine, so your pharmacy may be able to source it, though it may not be in local stock right away.
- If your exact form can't be found, ask your prescriber about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls. This is national, manufacturer-reported data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
- Azacitidine — AZACITIDINE 100 mg/1
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mg/4 mL On backorder. Recovery: TBD. Check wholesalers for inventory
- 100 mg/30 mL Discontinuation of the manufacture of the drug
- 100 mg Available to existing customers · Estimated recovery: TBD
- 100 mg/ Vial Additional lots are scheduled for manufacturing to meet demand. Product will be made avail...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875, option 2 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Azacitidine, Injection, 100 mg (NDC 16729-306-10) | Available | — | — | Current |
Manufacturer: Armas Pharmaceuticals Inc 📞 732-637-1971 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Azacitidine, Injection, 100 mg (NDC 72485-201-01) | Limited Availability | Estimated recovery: TBD | Other | Current |
Manufacturer: Bristol Myers Squibb Co. 📞 1-888-423-5436 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Vidaza, Injection, 100 mg (NDC 59572-102-01) | Available | — | — | Current |
Manufacturer: Dr. Reddy's Laboratories, Inc. 📞 866-732-3952 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Azacitidine, Injection, 100 mg (NDC 43598-305-62) | Available | Available to existing customers | — | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 1-888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 1-800-631-2174 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01) | Available | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
Manufacturer: Meitheal Pharmaceuticals, Inc. 📞 844-824-8426 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30) | Available | — | — | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Azacitidine, Injection, 100 mg (NDC 68001-313-56) | Unavailable | Estimated recovery: TBD | Other | Current |
Full shortage page: Azacitidine Injection →
View Azacitidine Injection on the FDA drug-shortage database →
Amino Acid Injection View full page →
Key facts about the Amino Acid Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Amino Acid Injection may not appear here at all, so this is not a picture of every available option. See the full Amino Acid Injection shortage page → for the still-marketed options we could find.
- Shortage of an active ingredient (2 NDCs)
- Shortage of an inactive ingredient component
Do you take this medicine? What Should I Do?!
Amino Acid Injection is currently on the FDA shortage list. This is a broad category with several different products, and most of them still have supply, so I want to help you find the one you use.
Right now, the two products with no available source are Aminosyn-PF 10% and Aminosyn-PF 7%. Their estimated recovery is listed as "to be determined." Most other products in this group remain available, including Premasol 10% Sulfite Free, Clinisol 15%, Aminosyn II 10% and 15%, TrophAmine 10%, and Plenamine. One Travasol product is marked unavailable with an estimated recovery of December 2026, but other Travasol supply is available.
The reported reasons are a shortage of an active ingredient and a shortage of an inactive ingredient. All three manufacturers on this record are still reporting some available supply, which is encouraging.
Here is what I suggest:
- Do not stop or change how this medicine is given on your own.
- If your product still has supply, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
- If your exact product is one of the unavailable ones, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is national data and may not match your local pharmacy's stock.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- Aminosyn-PF 10% Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regardi...
- Aminosyn-PF 7% Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regardi...
- 2.07 g/100 mL; 1.15 g/100 mL;... Estimated recovery: December 2026
- Aminosyn II 10% In Plastic Con... This product is distributed by ICU Medical. For questions regarding this product, please c...
- Aminosyn II 15% In Plastic Con... This product is distributed by ICU Medical. For questions regarding this product, please c...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Plenamine, Injection, 0.15 (NDC 0264-4500-05) | Available | — | — | Current |
| TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10) | Available | — | — | Current |
| Plenamine, Injection, 0.15 (NDC 0264-4500-00) | Available | — | — | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 9 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0 | Available | — | — | Current |
| Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03) | Available | — | — | Current |
| PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg | Available | — | — | Current |
| Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0 | Unavailable | Estimated recovery: December 2026 | Shortage of an inactive ingredient component | Current |
| Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06) | Available | — | — | Current |
| Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04) | Available | — | — | Current |
| Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06) | Available | — | — | Current |
| Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0 | Available | — | — | Current |
| Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03) | Available | — | — | Current |
Manufacturer: Otsuka ICU Medical LLC 📞 1-866-829-9025 or [email protected] 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03) | Unavailable | Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | Shortage of an active ingredient | Current |
| Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17) | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — | Current |
| Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05) | Unavailable | Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | Shortage of an active ingredient | Current |
Full shortage page: Amino Acid Injection →
View Amino Acid Injection on the FDA drug-shortage database →
Dexmedetomidine Hydrochloride Injection View full page →
Key facts about the Dexmedetomidine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dexmedetomidine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dexmedetomidine Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Other (4 NDCs)
- Delay in shipping of the drug (2 NDCs)
- Discontinuation of the manufacture of the drug (2 NDCs)
- Demand increase for the drug (2 NDCs)
Do you take this medicine? What Should I Do?!
Dexmedetomidine Hydrochloride Injection is currently on the FDA drug-shortage list. This is a medicine given in hospital and clinical settings, and the overall supply risk is rated low.
The reassuring part for you is that every strength on this record still has an available source — all 20 strengths are covered, and 13 of 17 manufacturers are reporting supply. That includes the common concentrations such as 80 mcg/20 mL, 100 mcg/1 mL, 200 mcg/50 mL, and 400 mcg/100 mL. Some individual manufacturers list certain lots as unavailable (for example, one 200 ug/50 mL product with an estimated recovery of September 2026), but other makers still carry those same strengths.
The FDA lists several reasons, including shipping delays, higher demand, and one manufacturer discontinuing its version. Because this is an injectable used in care settings, your care team manages the supply directly.
Here is what to keep in mind:
- Do not stop or change any treatment on your own — this medicine is given and adjusted by clinicians.
- If a specific product is short, the pharmacy can check wholesalers and other manufacturers, since the same medicine is available from several makers (such as Hikma, Sagent, Sun, Amneal, Piramal, and others listed here).
- If your exact product cannot be found, your prescriber or pharmacist can choose an appropriate option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Dexmedetomidine Hydrochloride — DEXMEDETOMIDINE HYDROCHLORIDE 4 ug/mL
- Precedex — DEXMEDETOMIDINE HYDROCHLORIDE 4 ug/mL
- Dexmedetomidine Hydrochloride In 0.9% Sodium Chloride — DEXMEDETOMIDINE HYDROCHLORIDE 4 ug/mL
- Dexmedetomidine Hydrochloride — DEXMEDETOMIDINE HYDROCHLORIDE 4 ug/mL
- Dexmedetomidine Hydrochloride — DEXMEDETOMIDINE HYDROCHLORIDE 200 ug/50mL
- Dexmedetomidine Hydrochloride — DEXMEDETOMIDINE HYDROCHLORIDE 400 ug/100mL
- Dexmedetomidine Hydrochloride — DEXMEDETOMIDINE HYDROCHLORIDE 100 ug/mL
- Dexmedetomidine — DEXMEDETOMIDINE HYDROCHLORIDE 200 ug/2mL
- Dexmedetomidine Hydrochloride — DEXMEDETOMIDINE HYDROCHLORIDE 4 ug/mL
- Dexmedetomidine Hydrochloride In Sodium Chloride — DEXMEDETOMIDINE HYDROCHLORIDE 4 ug/mL
- Dexmedetomidine Hydrochloride — DEXMEDETOMIDINE HYDROCHLORIDE 4 ug/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 200 ug/2 mL Marketed by Piramal Critical Care Inc.: 800-414-1901
- 100 ug/1 mL Discontinuation of the manufacture of the drug · Estimated recovery: TBD · Marketed by WG Critical Care · Product temporarily on backorder. Additional lots will be available in the September 2026... · Check wholesalers for inventory · Please check wholesalers for inventory
- 4 ug/1 mL Estimated recovery: TBD · Estimated recovery: TBD; Please check wholesalers for inventory · Marketed by WG Critical Care · Distributed by DRL · Expected recovery: TBD · Inventory available 4 to 5 month as per current demand. Next supply: week of 06/29/2026 · Check wholesalers for inventory · Discontinuation of the manufacture of the drug
- 80 mcg/20 mL Marketed by Sandoz Inc.; Customer service: 800-525-8747
- 400 mcg/100 mL Marketed by Sandoz Inc.; Customer service: 800-525-8747
- 400 mcg/100 mL (4 ug/1 mL) Distributed by Civica · Distributed by Wilshire Pharmaceuticals, Inc.
- 200 ug/50 mL Estimated recovery: September 2026
- 200 mcg/50 mL Marketed by Sandoz Inc.; Customer service: 800-525-8747
- 200 mcg/50 mL (4 ug/1 mL) Distributed by Wilshire Pharmaceuticals, Inc. · Distributed by Civica
- 200 mcg/2 mL Distributed by Avenacy; Contact information: 877-283-6229
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875, option 2 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1) | Available | — | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1) | Available | — | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8) | Available | Inventory available 4 to 5 month as per current demand. Next supply: week of 06/29/2026 | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7) | Available | — | — | Current |
Manufacturer: Azurity Pharmaceuticals, Inc 📞 877-495-6856 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08) | Available | Distributed by Wilshire Pharmaceuticals, Inc. | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10) | Available | Distributed by Civica | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10) | Available | Distributed by Wilshire Pharmaceuticals, Inc. | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08) | Available | Distributed by Civica | — | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24) | Available | — | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12) | Available | — | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12) | Available | — | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24) | Unavailable | Estimated recovery: September 2026 | Other | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10) | Available | Check wholesalers for inventory | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02) | Available | Check wholesalers for inventory | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00) | Unavailable | Expected recovery: TBD | Delay in shipping of the drug | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20) | Unavailable | Expected recovery: TBD | Other | Current |
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
Manufacturer: Gland Pharma Limited 📞 Distributed by DRL 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58) | Available | Distributed by DRL | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58) | Available | Distributed by DRL | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42) | Available | Marketed by Piramal Critical Care Inc.: 800-414-1901 | — | Current |
Manufacturer: HQ Specialty Pharma 📞 WG Critical Care 888-493-0861 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04) | Available | Marketed by WG Critical Care | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04) | Available | Marketed by WG Critical Care | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24) | Available | Marketed by WG Critical Care | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24) | Available | Marketed by WG Critical Care | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25) | Unavailable | Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe. | Demand increase for the drug | Current |
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 See Related Information section below for customer service information 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02) | Available | Distributed by Avenacy; Contact information: 877-283-6229 | — | Current |
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co., Ltd. 📞 See Related Information section below for customer service information 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95) | Available | Marketed by Sandoz Inc.; Customer service: 800-525-8747 | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95) | Available | Marketed by Sandoz Inc.; Customer service: 800-525-8747 | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95) | Available | Marketed by Sandoz Inc.; Customer service: 800-525-8747 | — | Current |
Manufacturer: Meitheal Pharmaceuticals, Inc. 📞 844-824-8426 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03) | Available | — | — | Current |
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02) | Available | — | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50) | Available | — | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10) | Available | — | — | Current |
Manufacturer: Par Health, USA LLC 📞 800-828-9393 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20) | Unavailable | Estimated recovery: TBD; Please check wholesalers for inventory | Other | Current |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10) | Unavailable | Estimated recovery: TBD; Please check wholesalers for inventory | Other | Current |
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25) | Available | Please check wholesalers for inventory | — | Current |
Manufacturer: Pfizer Inc. 📞 844-646-4398 14 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01) | Available | — | — | Current |
| Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20) | Available | — | — | Current |
| Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12) | Available | — | — | Current |
| Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24) | Available | — | — | Current |
| Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24) | Available | — | — | Current |
| Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20) | Available | — | — | Current |
| Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01) | Available | — | — | Current |
| Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20) | Available | — | — | Current |
| Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02) | Available | — | — | Current |
| Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02) | Available | — | — | Current |
| Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50) | Available | — | — | Current |
| Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10) | Available | — | — | Current |
| Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10) | Available | — | — | Current |
| Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10) | Available | — | — | Current |
Manufacturer: Slayback Pharma 📞 800-461-7449 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Somerset Therapeutics, LLC 📞 732-554-1037 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04) | Available | — | — | Current |
| Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04) | Available | — | — | Current |
Full shortage page: Dexmedetomidine Hydrochloride Injection →
View Dexmedetomidine Hydrochloride Injection on the FDA drug-shortage database →
Furosemide Injection View full page →
Key facts about the Furosemide Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Furosemide Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Furosemide Injection shortage page → for the still-marketed options we could find.
- Other (5 NDCs)
- Discontinuation of the manufacture of the drug (3 NDCs)
- Requirements related to complying with good manufacturing practices (3 NDCs)
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Furosemide injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for the strength you use.
Most strengths still have a source right now, including the 10 mg/1 mL, 40 mg/4 mL, 100 mg/10 mL, and the 2 mL presentation. The strength that has no available source at the moment is the 20 mg/2 mL, which is on backorder with recovery listed as "to be determined." One version of the 10 mg/1 mL from Sagent Pharmaceuticals is also listed as a discontinued product, but several other makers still report supply of that strength.
The reported reasons include increased demand, manufacturing requirements and delays, and one discontinuation. This shortage has lasted over a year, but 6 of 8 manufacturers on this record still report available supply — so this is a supply-chain issue, not a sign the medicine is gone.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
- The same medicine is made by other companies (such as Hikma, Baxter, Fresenius Kabi, Meitheal, and Amneal); your pharmacy may source one, though it may not be in local stock.
- If your exact strength can't be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference. This is national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Furosemide — FUROSEMIDE 10 mg/mL
- Furosemide — FUROSEMIDE 10 mg/mL
- Furosemide — FUROSEMIDE 10 mg/mL
- Furosemide — FUROSEMIDE 10 mg/mL
- Furosemide — FUROSEMIDE 10 mg/mL
- Furosemide — FUROSEMIDE 10 mg/mL
- Furosemide — FUROSEMIDE 100 mg/10mL
- Furosemide — FUROSEMIDE 20 mg/2mL
- Furosemide — FUROSEMIDE 40 mg/4mL
- Furosemide — FUROSEMIDE 10 mg/mL
- Furosemide — FUROSEMIDE 10 mg/mL
- Furosemide — FUROSEMIDE 10 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 20 mg/2 mL On backorder. Recovery: TBD. Check wholesalers for inventory
- 10 mg/1 mL Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug · Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product · Check wholesalers for inventory · Estimated recovery: TBD · Estimated recovery: End October 2026; Manufacturing delay
- 40 mg/4 mL Check wholesalers for inventory
- 20 mg/2 mL (10 mg/1 mL) Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufactur...
- 100 mg/ 10mL (10 mg/1 mL) Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- 40 mg/4 mL (10 mg/1 mL) Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufactur...
- 100 mg/10 mL Check wholesalers for inventory
- 2 mL Check wholesalers for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
Manufacturer: Avet Pharmaceuticals, Inc. 📞 855-228-9470 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41) | Available | — | — | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42) | Unavailable | Estimated recovery: End October 2026; Manufacturing delay | Other | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44) | Unavailable | Estimated recovery: End October 2026; Manufacturing delay | Other | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25) | Available | — | — | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25) | Available | — | — | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25) | Available | — | — | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25) | Available | Check wholesalers for inventory | — | Current |
| Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
| Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10) | Available | Check wholesalers for inventory | — | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04) | Available | Check wholesalers for inventory | — | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Gland Pharma Limited 📞 866-625-1618 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02) | Unavailable | Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product | Discontinuation of the manufacture of the drug | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10) | Unavailable | Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product | Discontinuation of the manufacture of the drug | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04) | Unavailable | Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product | Discontinuation of the manufacture of the drug | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10) | — | Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02) | — | Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04) | — | Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26) | Unavailable | Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25) | Unavailable | Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04) | Available | — | — | Current |
| Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10) | Available | — | — | Current |
| Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02) | Available | — | — | Current |
Manufacturer: Meitheal Pharmaceuticals, Inc. 📞 844-824-8426 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03) | Available | Check wholesalers for inventory | — | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11) | Available | Check wholesalers for inventory | — | Current |
| Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05) | Available | Check wholesalers for inventory | — | Current |
Full shortage page: Furosemide Injection →
View Furosemide Injection on the FDA drug-shortage database →
Midazolam Hydrochloride Injection View full page →
Key facts about the Midazolam Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Midazolam Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Midazolam Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug (11 NDCs)
- Other (2 NDCs)
- Delay in shipping of the drug
Do you take this medicine? What Should I Do?!
Midazolam Hydrochloride Injection is currently on the FDA shortage list. This is a hospital and clinical injection, and because it is given by trained staff, your care team is already tracking supply closely.
Several strengths still have a source. These include 50 mg/10 mL (5 mg/mL), 2 mg/2 mL (1 mg/mL), 5 mg/1 mL, and 1 mg/1 mL. The strengths reported with no available source right now are 10 mg/10 mL (1 mg/mL), 5 mg/5 mL (1 mg/mL), 10 mg/2 mL (5 mg/mL), the 5 mg/mL vial, one 2 mg/2 mL product, and 25 mg/5 mL (5 mg/mL). Please match the strength you use to these lists.
The reported reasons include higher demand, a shipping delay, and other factors. Five of six manufacturers still report some supply, and recovery estimates for the affected strengths range from September through December 2026. This has been an ongoing shortage, so steady supply may take time.
Here is what you can do:
- Do not stop, skip, or change any dose on your own.
- If your strength still has supply, ask your pharmacy to order it — pharmacies can check wholesalers and other makers.
- The same medicine is made by other companies (such as Hikma, Fresenius Kabi, and others), so your pharmacy may be able to source one, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about clinician-chosen options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls. This national data may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Midazolam In Sodium Chloride — MIDAZOLAM HYDROCHLORIDE 1 mg/mL
- Midazolam — MIDAZOLAM HYDROCHLORIDE 1 mg/mL
- Midazolam — MIDAZOLAM HYDROCHLORIDE 5 mg/mL
- Midazolam — MIDAZOLAM HYDROCHLORIDE 5 mg/mL
- Midazolam In Sodium Chloride — MIDAZOLAM HYDROCHLORIDE 1 mg/mL
- Midazolam Hydrochloride — MIDAZOLAM HYDROCHLORIDE 5 mg/mL
- Midazolam Hydrochloride — MIDAZOLAM HYDROCHLORIDE 1 mg/mL
- Midazolam — MIDAZOLAM HYDROCHLORIDE 1 mg/mL
- Midazolam — MIDAZOLAM HYDROCHLORIDE 2 mg/2mL
- Midazolam — MIDAZOLAM HYDROCHLORIDE 5 mg/5mL
- Midazolam — MIDAZOLAM HYDROCHLORIDE 2 mg/2mL
- Midazolam — MIDAZOLAM HYDROCHLORIDE 1 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg/10 mL (1 mg/mL) Next Delivery and Estimated Recovery: December 2026
- 5 mg/5 mL (1 mg/mL) Next Delivery: October 2026; Estimated Recovery: December 2026
- 10 mg/2 mL (5 mg/mL) Next Delivery and Estimated Recovery: September 2026
- 5 mg/mL (5 mg/mL) Next Delivery and Estimated Recovery: December 2026
- 2 mg/2 mL Next release October 2026. Check wholesalers for inventory.
- 25 mg/5 mL (5 mg/mL) Next Delivery and Estimated Recovery: September 2026
- 2 mg/2mL (1 mg/mL) Next Estimated Delivery and Estimated Recovery: December 2026 · Next Delivery and Estimated Recovery: December 2026
- 5 mg/1 mL Next release October 2026. Check wholesalers for inventory. · Additional lots are scheduled to be manufactured. Product will be made available as it is... · Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals · Check wholesalers for inventory · Estimated recovery: TBD
- 1 mg/1 mL Please check wholesalers and distributors for inventory. · Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals · Additional lots are scheduled to be manufactured. Product will be made available as it is... · Estimated recovery: TBD · Check wholesalers for inventory · Estimated recovery: 9/25/2026
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Avet Pharmaceuticals, Inc. 📞 855-228-9470 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41) | Limited Availability | Estimated recovery: 9/25/2026 | Demand increase for the drug | Current |
| Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42) | Available | — | — | Current |
| Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41) | Available | — | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25) | Available | Check wholesalers for inventory | — | Current |
| Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
| Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02) | Available | Check wholesalers for inventory | — | Current |
| Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12) | Available | Check wholesalers for inventory | — | Current |
| Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
| Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
Manufacturer: Gland Pharma Limited 📞 Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10) | Unavailable | Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals | Other | Current |
| Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02) | Unavailable | Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals | Other | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25) | Limited Availability | Next Delivery and Estimated Recovery: December 2026 | Demand increase for the drug | Current |
| Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05) | Available | — | — | Current |
| Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03) | Unavailable | Next Delivery and Estimated Recovery: September 2026 | Demand increase for the drug | Current |
| Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01) | Unavailable | Next Delivery and Estimated Recovery: December 2026 | Demand increase for the drug | Current |
| Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02) | Unavailable | Next Delivery and Estimated Recovery: September 2026 | Demand increase for the drug | Current |
| Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05) | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026 | Demand increase for the drug | Current |
| Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05) | Unavailable | Next Delivery and Estimated Recovery: December 2026 | Demand increase for the drug | Current |
| Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25) | Limited Availability | Next Estimated Delivery and Estimated Recovery: December 2026 | Demand increase for the drug | Current |
Manufacturer: WG Critical Care 📞 888-493-0861 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10) | Available | Please check wholesalers and distributors for inventory. | — | Current |
| Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10) | Available | Please check wholesalers and distributors for inventory. | — | Current |
Full shortage page: Midazolam Hydrochloride Injection →
View Midazolam Hydrochloride Injection on the FDA drug-shortage database →
Echothiophate Iodide Ophthalmic Solution View full page →
Key facts about the Echothiophate Iodide Ophthalmic Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Echothiophate Iodide Ophthalmic Solution may not appear here at all, so this is not a picture of every available option. See the full Echothiophate Iodide Ophthalmic Solution shortage page → for the still-marketed options we could find.
- Other
Do you take this medicine? What Should I Do?!
Echothiophate iodide ophthalmic solution (also sold as Phospholine Iodide) is currently on the FDA drug-shortage list. This has been an ongoing situation for over a year, but the medicine does still have an available source, so I want to walk you through what that means for you.
The only strength involved here is the 0.125% eye drops, and that strength does have supply. There is no strength of this medicine that is completely without a source right now. One manufacturer is reporting available stock, distributed in a limited way through Walgreens Specialty Pharmacy. The reason on file is listed only as "Other," and there is no recovery date attached because supply is currently flowing through that specialty channel rather than typical wholesalers.
Because this drug moves through limited distribution, your regular pharmacy may not have it on the shelf and may need to direct your prescription to the specialty pharmacy.
Here are the steps I'd suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order the 0.125% strength, which still has supply.
- Since it's limited distribution, your pharmacy may route it through Walgreens Specialty Pharmacy.
- If it can't be filled, ask your prescriber or pharmacist about your options.
A manufacturer contact number is listed on this page for reference; pharmacies usually make these calls.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 0.125% Available through limited distribution by Walgreens Specialty Pharmacy.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fera Pharmaceuticals 📞 516-277-1449 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05) | Available | Available through limited distribution by Walgreens Specialty Pharmacy. | Other | Current |
Full shortage page: Echothiophate Iodide Ophthalmic Solution →
View Echothiophate Iodide Ophthalmic Solution on the FDA drug-shortage database →
Dexamethasone Sodium Phosphate Injection View full page →
Key facts about the Dexamethasone Sodium Phosphate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dexamethasone Sodium Phosphate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dexamethasone Sodium Phosphate Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug (2 NDCs)
Do you take this medicine? What Should I Do?!
Dexamethasone Sodium Phosphate Injection is currently listed on the FDA drug-shortage list, but I want to point out right away that both strengths still have an available source, so this is a manageable situation.
Here is how the strengths break down: the 4 mg/mL and the 10 mg/mL both still have an available supply from manufacturers. Neither strength is without a source right now. In fact, all five manufacturers on this record are reporting available product, and none of the listed items are marked unavailable.
The FDA reason on file is simply an increase in demand for the medicine. Because this is a hospital-administered injection, supply can be tight at times, and several makers note that more product will be released as it becomes ready. There is no firm recovery date, but multiple companies continue to supply.
What you can do:
- Do not stop, skip, or change your dose on your own.
- If your strength is running low locally, ask your pharmacy or care team to order it — they can check wholesalers and other manufacturers.
- The same medicine (Dexamethasone Sodium Phosphate injection) is also made by other companies, so your pharmacy may be able to source one, though it may not be in local stock.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 100 mg/10mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL
- Dexamethasone Sodium Phosphate — DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 mg/1 mL Check wholesalers for inventory · Product will be made available as it is released. · 3 month expiry available on request. Next release not available at this time.
- 4 mg/1 mL Additional product will be made available as it is released. · Check wholesalers for inventory · Checkwholesalers for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Eugia US LLC 📞 888-238-7880 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 9 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10) | Limited Availability | 3 month expiry available on request. Next release not available at this time. | Demand increase for the drug | Current |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10) | Limited Availability | 3 month expiry available on request. Next release not available at this time. | Demand increase for the drug | Current |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10) | Available | Check wholesalers for inventory | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05) | Available | Check wholesalers for inventory | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10) | Available | Check wholesalers for inventory | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30) | Available | Check wholesalers for inventory | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10) | Available | Checkwholesalers for inventory | — | Current |
| Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01) | Available | Check wholesalers for inventory | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25) | Available | Additional product will be made available as it is released. | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25) | Available | Product will be made available as it is released. | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25) | Available | Additional product will be made available as it is released. | — | Current |
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12) | Available | — | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10) | Available | — | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30) | Available | — | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54) | Available | — | — | Current |
Manufacturer: Somerset Therapeutics, LLC 📞 732-554-1019 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25) | Available | — | — | Current |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10) | Available | — | — | Current |
Full shortage page: Dexamethasone Sodium Phosphate Injection →
View Dexamethasone Sodium Phosphate Injection on the FDA drug-shortage database →
Lorazepam Injection View full page →
Key facts about the Lorazepam Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Lorazepam Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Lorazepam Injection shortage page → for the still-marketed options we could find.
- Other (6 NDCs)
- Demand increase for the drug (4 NDCs)
Do you take this medicine? What Should I Do?!
Lorazepam injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for the strength you use.
The picture depends on the strength. The 2 mg/1 mL vials and the 2 mg/1 mL syringes still have an available source — supply is limited, but three of the four listed manufacturers are reporting stock, and some report a next release around September 2026. The 4 mg/1 mL strength currently has no available source from the manufacturers on this record, with recovery listed as to-be-determined.
This shortage has lasted more than a year, and the reported reasons are increased demand and "other." Because more than one company still makes this medicine, that limited supply may be found by working with your pharmacy.
Here is what I suggest:
- Do not stop, skip, or adjust your dose on your own. This medicine should only be changed with a clinician's guidance.
- If you use the 2 mg/1 mL vial or syringe, ask your pharmacy to order it — they can check wholesalers and other makers.
- The same medicine is also listed from other manufacturers (Hikma, Fresenius Kabi, RemedyRepack, and Civica); your pharmacy may be able to source one, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national, manufacturer-reported data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 4 mg/1 mL Estimated recovery: TBD
- 2 mg/1 mL Estimated recovery: TBD · Next release September 2026. Check wholesalers for inventory.
- 2 mg/1 mL Syringes Limited Supply Available. Next Delivery and Estimated Recovery: September 2026
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amphastar Pharmaceuticals, Inc. 📞 800-423-4136 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1) | Available | — | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10) | Unavailable | Estimated recovery: TBD | Other | Current |
| Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25) | Limited Availability | Estimated recovery: TBD | Demand increase for the drug | Current |
| Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25) | Unavailable | Estimated recovery: TBD | Other | Current |
| Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10) | Unavailable | Estimated recovery: TBD | Other | Current |
| Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10) | Unavailable | Estimated recovery: TBD | Other | Current |
| Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10) | Unavailable | Estimated recovery: TBD | Other | Current |
| Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25) | Limited Availability | Estimated recovery: TBD | Demand increase for the drug | Current |
| Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25) | Unavailable | Estimated recovery: TBD | Other | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30) | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: September 2026 | Demand increase for the drug | Current |
Full shortage page: Lorazepam Injection →
View Lorazepam Injection on the FDA drug-shortage database →
Ropivacaine Hydrochloride Injection View full page →
Key facts about the Ropivacaine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ropivacaine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ropivacaine Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Other (7 NDCs)
- Demand increase for the drug (4 NDCs)
- Delay in shipping of the drug (4 NDCs)
Do you take this medicine? What Should I Do?!
Ropivacaine hydrochloride injection is currently on the FDA drug-shortage list. This is a numbing medicine used mainly during procedures and for pain control, and the overall supply risk here is low.
All four strengths — 2 mg/mL, 5 mg/mL, 7.5 mg/mL, and 10 mg/mL — still have at least one manufacturer reporting an available source. No strength is completely without supply right now. Some specific products are limited or on backorder, but across all five manufacturers on this record, each strength can still be sourced.
The FDA lists the reasons as increased demand, a shipping delay, and "other." Several makers note their supply is limited and suggest checking wholesalers, and some recovery dates are still to be determined. Because this medicine is given by a clinician during care, your team usually manages the supply side for you.
If you or someone you care for is scheduled to receive this medicine:
- Do not skip or change any part of your treatment on your own — talk with your care team first.
- Ask your pharmacy or facility to check wholesalers and other manufacturers, since your strength still has a source.
- The same medicine is made by other companies (for example Hikma and Fresenius Kabi's Naropin); your pharmacy may be able to source one, though it may not be in local stock.
- If your exact product cannot be found, your prescriber or pharmacist can discuss options.
Manufacturer contact numbers are listed on this page for reference. This is general national information and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 2 mg/mL
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 5 mg/mL
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 2 mg/mL
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 5 mg/mL
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 7.5 mg/mL
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 10 mg/mL
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 2 mg/mL
- Naropin — ROPIVACAINE HYDROCHLORIDE 2 mg/mL
- Naropin — ROPIVACAINE HYDROCHLORIDE 5 mg/mL
- Naropin — ROPIVACAINE HYDROCHLORIDE 10 mg/mL
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 2 mg/mL
- Ropivacaine Hydrochloride — ROPIVACAINE HYDROCHLORIDE 5 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg/1 mL Limited supply; Check wholesalers for inventory; Marketed by Baxter · Marketed by Sagent Pharmaceuticals · Estimated recovery: TBD · Check wholesalers for inventory · Check wholesalers for inventory; Marketed by Baxter
- 2 mg/1 mL Estimated recovery: TBD · On backorder. Recovery: TBD. Check wholesalers for inventory · Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals · Check wholesalers for inventory · Check wholesalers for inventory; Marketed by Baxter · Marketed by Sagent Pharmaceuticals · Check wholesaler for inventory
- 7.5 mg/1 mL On backorder. Recovery: TBD. Check wholesalers for inventory · Check wholesalers for inventory · Estimated recovery: TBD
- 10 mg/1 mL Check wholesalers for inventory; Marketed by Baxter · Check wholesalers for inventory · Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Caplin Steriles, Ltd. 📞 888-229-0001 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10) | Available | Check wholesalers for inventory; Marketed by Baxter | — | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10) | Limited Availability | Check wholesalers for inventory; Marketed by Baxter | Other | Current |
| Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10) | Available | Check wholesalers for inventory; Marketed by Baxter | — | Current |
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10) | Limited Availability | Limited supply; Check wholesalers for inventory; Marketed by Baxter | Other | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10) | Available | Check wholesalers for inventory | — | Current |
| Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20) | Available | Check wholesalers for inventory | — | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99) | Available | Check wholesalers for inventory | — | Current |
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20) | Available | Check wholesalers for inventory | — | Current |
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30) | Available | Check wholesalers for inventory | — | Current |
| Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 22 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35) | Available | Check wholesalers for inventory | — | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13) | Available | Check wholesaler for inventory | — | Current |
| Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00) | Available | — | — | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61) | Unavailable | Estimated recovery: TBD | Other | Current |
| Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
| Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11) | Available | — | — | Current |
| Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
| Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21) | Available | — | — | Current |
| Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23) | Available | Check wholesalers for inventory | — | Current |
| Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63) | Available | — | — | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10) | Available | — | — | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65) | Available | Check wholesalers for inventory | — | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20) | Available | — | — | Current |
| Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21) | Available | Check wholesalers for inventory | — | Current |
| Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
| Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23) | Available | — | — | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20) | Unavailable | Estimated recovery: TBD | Other | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63) | Unavailable | Estimated recovery: TBD | Other | Current |
| Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64) | Available | — | — | Current |
Manufacturer: InfoRLife SA 📞 Sagent: 866-625-1618 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87) | Available | Marketed by Sagent Pharmaceuticals | — | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82) | Available | Marketed by Sagent Pharmaceuticals | — | Current |
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87) | Available | Marketed by Sagent Pharmaceuticals | — | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66) | Limited Availability | Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals | Other | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67) | Unavailable | Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals | Other | Current |
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82) | Available | Marketed by Sagent Pharmaceuticals | — | Current |
Manufacturer: Somerset Therapeutics, LLC 📞 732-554-1037 10 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25) | Available | — | — | Current |
| Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25) | Available | — | — | Current |
Full shortage page: Ropivacaine Hydrochloride Injection →
View Ropivacaine Hydrochloride Injection on the FDA drug-shortage database →
Ketorolac Tromethamine Injection View full page →
Key facts about the Ketorolac Tromethamine Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Ketorolac Tromethamine Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Ketorolac Tromethamine Injection shortage page → for the still-marketed options we could find.
- Other (9 NDCs)
- Demand increase for the drug (6 NDCs)
- Delay in shipping of the drug (3 NDCs)
Do you take this medicine? What Should I Do?!
Ketorolac tromethamine injection is currently on the FDA drug-shortage list. I want to walk you through what that means so you can find the strength you use.
Here is how the strengths break down right now. Three strengths — 15 mg/1 mL, 30 mg/1 mL, and 60 mg/2 mL — still have at least one manufacturer reporting available supply. The one strength listed with no available source at the moment is the 60 mg/2 mL (30 mg/mL) presentation from one manufacturer. So the strength you take may well still be reachable through your pharmacy.
The FDA-reported reasons include increased demand, a shipping delay, and manufacturing delays. This shortage has lasted over a year, but it's important to know that 4 of the 7 manufacturers on this record still report supply, and recovery estimates vary by product (some as early as late 2026).
What you can do:
- Do not stop, skip, or change your dose on your own.
- If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
- The same medicine may be available from another maker your pharmacy can source, though it may not be in local stock.
- If your exact strength can't be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 15 mg/mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 30 mg/mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 60 mg/2mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 15 mg/mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 30 mg/mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 60 mg/2mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 30 mg/mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 15 mg/mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 60 mg/2mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 15 mg/mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 30 mg/mL
- Ketorolac Tromethamine — KETOROLAC TROMETHAMINE 15 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 60 mg/2 mL (30 mg/mL) Next Estimated Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer:...
- 15 mg/1 mL Estimated recovery: late September 2026 · Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufactur... · Estimated recovery: TBD · Check wholesalers for inventory · Estimated recovery: November 2026
- 30 mg/1 mL Next release October 2026. Check wholesalers for inventory. · Estimated recovery: TBD · Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645. · Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing... · Estimated recovery: November 2026
- 60 mg/2 mL Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Alembic Pharmaceuticals 📞 908-393-9604 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25) | Available | — | — | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25) | Available | — | — | Current |
| Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25) | Available | — | — | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25) | Unavailable | Estimated recovery: November 2026 | Demand increase for the drug | Current |
| Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10) | Unavailable | Estimated recovery: November 2026 | Demand increase for the drug | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10) | Unavailable | Estimated recovery: TBD | Other | Current |
| Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20) | Unavailable | Estimated recovery: TBD | Other | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Delay in shipping of the drug | Current |
| Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01) | Available | Check wholesalers for inventory | — | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10) | Unavailable | Estimated recovery: TBD | Other | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Delay in shipping of the drug | Current |
Manufacturer: Gland Pharma Limited 📞 833-291-9645 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01) | Available | — | — | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25) | Available | Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645. | Demand increase for the drug | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25) | Available | Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645. | Demand increase for the drug | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01) | Available | — | Demand increase for the drug | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02) | Available | — | Demand increase for the drug | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25) | Unavailable | Estimated recovery: TBD | Other | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25) | Unavailable | Estimated recovery: TBD | Other | Current |
| Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25) | Unavailable | Estimated recovery: TBD | Other | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-25) | Unavailable | Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-25) | Unavailable | Next Estimated Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-25) | Unavailable | Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Manufacturer: Sagent Pharmaceuticals 📞 866-625-1618 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01) | Available | — | — | Current |
| Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02) | Available | — | — | Current |
| Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01) | Limited Availability | Estimated recovery: late September 2026 | Delay in shipping of the drug | Current |
Full shortage page: Ketorolac Tromethamine Injection →
View Ketorolac Tromethamine Injection on the FDA drug-shortage database →
Bupivacaine Hydrochloride Injection View full page →
Key facts about the Bupivacaine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Bupivacaine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Bupivacaine Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Discontinuation of the manufacture of the drug (5 NDCs)
- Other (2 NDCs)
- Demand increase for the drug (2 NDCs)
- Delay in shipping of the drug
Do you take this medicine? What Should I Do?!
Bupivacaine Hydrochloride Injection, a local anesthetic given during procedures, is currently on the FDA shortage list. Most strengths remain available, so this note is meant to help you find the one you use.
Only one form has no available source right now: the spinal preparation, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25%, with a reported next delivery in October 2026 and estimated recovery in December 2026. Every other strength — including the common 2.5 mg/mL, 5 mg/mL, and 7.5 mg/mL vials and the Marcaine products — still has a reported source. Seven of eight manufacturers are still supplying, and 17 of 18 strengths are covered.
The reported reasons include a manufacturing delay, a demand increase, a shipping delay, and one company discontinuing its version. Because several makers remain in the market, this mainly affects certain products, not the medicine as a whole.
Here is what you can do:
- Do not stop, skip, or change any dose on your own.
- If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
- The same medicine may be available from other makers, such as Hikma or B. Braun; your pharmacy may be able to source one, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about clinician-chosen options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Bupivacaine Hydrochloride — BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL
- Bupivacaine Hydrochloride — BUPIVACAINE HYDROCHLORIDE 5 mg/mL
- Bupivacaine Hydrochloride — BUPIVACAINE HYDROCHLORIDE 7.5 mg/mL
- Bupivacaine Hydrochloride With Dextrose — BUPIVACAINE HYDROCHLORIDE 7.5 mg/mL
- Bupivacaine Hydrochloride — BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL
- Bupivacaine Hydrochloride — BUPIVACAINE HYDROCHLORIDE 5 mg/mL
- Marcaine — BUPIVACAINE HYDROCHLORIDE 150 mg/30mL
- Marcaine — BUPIVACAINE HYDROCHLORIDE 7.5 mg/mL
- Marcaine — BUPIVACAINE HYDROCHLORIDE 25 mg/10mL
- Marcaine — BUPIVACAINE HYDROCHLORIDE 50 mg/10mL
- Marcaine — BUPIVACAINE HYDROCHLORIDE 75 mg/30mL
- Bupivacaine Hydrochloride — BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 0.75% 15 mg/2 mL (7.5 mg/mL) i... Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer:...
- 7.5 mg/1 mL Discontinuation of the manufacture of the drug · Check wholesalers for inventory · Meitheal Pharmaceuticals is distributor/labeler · Estimated recovery: TBD
- 5 mg/1 mL Check wholesalers for inventory · Meitheal Pharmaceuticals is distributor/labeler · Estimated recovery: TBD · Discontinuation of the manufacture of the drug
- 225 mg/30 mL Historical NDC: 0409-1582-29
- 2.5 mg/1 mL Discontinuation of the manufacture of the drug · Distributed by Fosun Pharma USA Inc. · Check wholesalers for inventory · Meitheal Pharmaceuticals is distributor/labeler · Estimated recovery: TBD
- 250 mg/50 mL Historical NDC: 0409-1610-50
- Marcaine 225 mg/30 mL (7.5 mg/... Historical NDC: 0409-1582-29
- Bupivacaine Spinal 15 mg/2 mL... Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage p...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Aspiro Pharma Limited 📞 732-529-0430, [email protected] 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34) | Available | — | — | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30) | Available | Check wholesalers for inventory | — | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30) | Available | Check wholesalers for inventory | — | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50) | Available | Check wholesalers for inventory | — | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50) | Available | Check wholesalers for inventory | — | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10) | Available | Check wholesalers for inventory | — | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10) | Available | Check wholesalers for inventory | — | Current |
| Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30) | Available | Check wholesalers for inventory | — | Current |
| Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 10 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
| Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 20 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01) | Available | — | — | Current |
| Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01) | Available | — | — | Current |
| Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01) | Available | — | — | Current |
| Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01) | Available | — | — | Current |
| Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01) | Available | — | — | Current |
| Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10) | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01) | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01) | Available | — | — | Current |
| Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01) | Available | Historical NDC: 0409-1582-29 | — | Current |
| Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1165-01) | Available | — | — | Current |
| Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25) | Available | Historical NDC: 0409-1610-50 | — | Current |
| Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02) | Available | — | — | Current |
| Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25) | Available | Historical NDC: 0409-1582-29 | — | Current |
Manufacturer: Huons Co., Ltd 📞 +82-2-854-4700 or via email [email protected] 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
Manufacturer: Kindos Pharmaceuticals Co. Ltd. 📞 844-824-8426 10 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52) | Limited Availability | Meitheal Pharmaceuticals is distributor/labeler | Discontinuation of the manufacture of the drug | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52) | Limited Availability | Meitheal Pharmaceuticals is distributor/labeler | Discontinuation of the manufacture of the drug | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32) | Limited Availability | Meitheal Pharmaceuticals is distributor/labeler | Discontinuation of the manufacture of the drug | Current |
| Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32) | Limited Availability | Meitheal Pharmaceuticals is distributor/labeler | Discontinuation of the manufacture of the drug | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32) | Limited Availability | Meitheal Pharmaceuticals is distributor/labeler | Discontinuation of the manufacture of the drug | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: ONESOURCE SPECIALTY PTE LTD 📞 888-217-8103 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10) | Available | Distributed by Fosun Pharma USA Inc. | — | Current |
Manufacturer: Somerset Therapeutics, LLC 📞 732-554-1037 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25) | Available | — | — | Current |
| Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10) | Available | — | — | Current |
Full shortage page: Bupivacaine Hydrochloride Injection →
View Bupivacaine Hydrochloride Injection on the FDA drug-shortage database →
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection View full page →
Key facts about the Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection shortage page → for the still-marketed options we could find.
- Other (6 NDCs)
- Delay in shipping of the drug
Do you take this medicine? What Should I Do?!
Bupivacaine hydrochloride with epinephrine injection — the local anesthetic used during procedures — is currently on the FDA's drug-shortage list. This is a hospital and clinic medicine, so your care team manages the supply directly, but it helps to understand what is happening.
The shortage does not affect every version. Several branded forms remain available, including Marcaine with Epinephrine (as the bitartrate) in 250 mg/50 mL, 75 mg/30 mL, and 25 mg/10 mL, and several Sensorcaine concentrations (7.5 mg/1 mL and 2.5 mg/1 mL). The strengths currently showing no available source are the generic bupivacaine-and-epinephrine 250 mg/50 mL, 125 mg/50 mL, 25 mg/10 mL, 75 mg/30 mL, 50 mg/10 mL, and 150 mg/30 mL, along with one Sensorcaine 5 mg/1 mL presentation.
Both manufacturers on this record are still supplying some products. The reported reasons are a manufacturing delay and a shipping delay. For the unavailable generic strengths, the maker lists an estimated recovery of December 2028; some Sensorcaine timing is listed as to-be-determined.
- Do not stop or change how you are treated on your own — this is given by your care team.
- If your product still has supply, your clinic can ask its wholesaler or the other maker to source it.
- The same medicine from another maker may be an option, though it may not be in local stock.
- If your form can't be found, your prescriber can choose a suitable alternative.
Manufacturer contact numbers are listed on this page for reference; clinics usually handle those calls.
This is national, manufacturer-reported information and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Marcaine With Epinephrine — BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mL
- Marcaine With Epinephrine — BUPIVACAINE HYDROCHLORIDE 5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mL
- Sensorcaine Mpf — BUPIVACAINE HYDROCHLORIDE 5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL
- Sensorcaine Mpf — BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 250 mg/50 mL (5 mg/mL) Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- 125 mg/50 mL (2.5 mg/mL) Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- 25 mg/10 mL (2.5 mg/mL) Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- 75 mg/30 mL (2.5 mg/mL) Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- 50 mg/10 mL (5 mg/mL) Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- 150 mg/30 mL (5 mg/mL) Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- 5 mg/1 mL; .005 mg/1 mL Estimated recovery: TBD · Check wholesaler for inventory · Check wholesalers for inventory
- 7.5 mg/1 mL; .005 mg/1 mL Check wholesaler for inventory
- 2.5 mg/1 mL; .005 mg/1 mL Check wholesalers for inventory · Check wholesaler for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37) | Available | Check wholesaler for inventory | — | Current |
| Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57) | Available | Check wholesaler for inventory | — | Current |
| Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17) | Available | Check wholesalers for inventory | — | Current |
| Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57) | Available | Check wholesaler for inventory | — | Current |
| Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37) | Available | Check wholesaler for inventory | — | Current |
| Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31) | Unavailable | Estimated recovery: TBD | Delay in shipping of the drug | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 12 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50) | Available | — | — | Current |
| Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29) | Available | — | — | Current |
| Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10) | Available | — | — | Current |
| Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10) | Available | — | — | Current |
| Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30) | Available | — | — | Current |
| Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50) | Available | — | — | Current |
| Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Full shortage page: Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection →
View Bupivacaine Hydrochloride, Epinephrine B... on the FDA drug-shortage database →
Bumetanide Injection View full page →
Key facts about the Bumetanide Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Bumetanide Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Bumetanide Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Bumetanide Injection is currently on the FDA shortage list, but supply overall remains strong, so this should have little effect on your care.
Here is the part that matters most for finding what you take: every strength on this record still has an available source. That includes the 0.25 mg/mL vials in the 4 mL, 10 mL, and 2.5 mg/10 mL sizes, as well as the 1 mg/4 mL size. No strength is currently listed with no source at all. One manufacturer marked a single lot as temporarily unavailable, with additional lots expected around September 2026, but four other makers still report the same medicine as available.
The reported reason is simply higher demand. All five manufacturers on this record are still supplying, and more lots are scheduled to be made.
What you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength — they can check wholesalers and other manufacturers, since supply exists.
- If your usual product is briefly out, this same medicine is available from other makers your pharmacy may be able to source, though it may not be in local stock.
- If a specific product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .25 mg/1 mL Check wholesalers for inventory · Additional lots will be available in the September 2026 timeframe. Product will be made av... · Additional lots are scheduled for manufacturing to meet demand. Product will be made avail...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10) | Available | Check wholesalers for inventory | — | Current |
| Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10) | Available | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
| Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10) | Unavailable | Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug | Current |
Manufacturer: MSN Laboratories Private Limited 📞 855-668-2369; [email protected] 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07) | Available | — | — | Current |
| Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01) | Available | — | — | Current |
| Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07) | Available | — | — | Current |
| Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01) | Available | — | — | Current |
Manufacturer: Mullan Pharmaceutical Inc. 📞 800-673-9839 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2) | Available | — | — | Current |
| Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2) | Available | — | — | Current |
Manufacturer: Sagent Pharmaceuticals 📞 866-625-1618 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10) | Available | — | — | Current |
| Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04) | Available | — | — | Current |
Full shortage page: Bumetanide Injection →
View Bumetanide Injection on the FDA drug-shortage database →
Heparin Sodium Injection View full page →
Key facts about the Heparin Sodium Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Heparin Sodium Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Heparin Sodium Injection shortage page → for the still-marketed options we could find.
- Other (3 NDCs)
Do you take this medicine? What Should I Do?!
Heparin Sodium Injection is currently on the FDA shortage list. I want to reassure you at the outset: the overall supply risk here is low, and every strength on this record still has an available source.
To help you find the one you take: all three listed strengths — 200 units/100 mL, 1,000 units/500 mL, and 2,000 units/1,000 mL — still have at least one manufacturer reporting supply. Right now, no strength has zero available source. All four manufacturers on this record are still supplying. A few individual product codes are marked unavailable or limited, and one specific package is not expected to release again until September 2026, but other makers cover the same strength.
The reported reason is listed simply as "Other," with some manufacturing delays noted. Because supply is spread across several companies, this has stayed manageable even though it has lasted over a year.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own. This medicine works best when taken exactly as prescribed.
- Ask your pharmacy to order your strength; they can check wholesalers and other manufacturers.
- The same medicine is also available from another maker (Baxter Healthcare), so your pharmacy may be able to source it, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 200 [USP'U]/100 mL Check wholesalers for inventory · Estimated recovery: TBD; Manufacturing delays · Next release September 2026. Check wholesalers for inventory.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00) | Limited Availability | Estimated recovery: TBD; Manufacturing delays | Other | Current |
| Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10) | Limited Availability | Estimated recovery: TBD; Manufacturing delays | Other | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04) | Available | — | — | Current |
| Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03) | Available | — | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12) | Available | — | — | Current |
| Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20) | Available | — | — | Current |
Full shortage page: Heparin Sodium Injection →
View Heparin Sodium Injection on the FDA drug-shortage database →
Dobutamine Hydrochloride Injection View full page →
Key facts about the Dobutamine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dobutamine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dobutamine Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Other
Do you take this medicine? What Should I Do?!
Dobutamine Hydrochloride Injection is currently on the FDA shortage list. This is a hospital-administered medicine, and the overall supply risk is low, so I want to walk you through where things stand without alarm.
The reassuring detail here is that every strength on this record still has an available source. All eight strengths — including the 500 mg/250mL, 250 mg/20mL (12.5 mg/mL), 100 mg/100 mL, 1,000 mg/250mL, 250 mg/250mL, 400 mg/100 mL, and 200 mg/100 mL — are being supplied by manufacturers right now. No strength is completely out. One specific package of the 250 mg/20mL from Hospira is listed as unavailable with an estimated recovery of December 2027 due to a manufacturing delay, but the same strength remains available in other packages and from another supplier.
All three manufacturers on this record report available supply. The FDA reason is listed only as "Other," and this situation has continued for over a year.
Here is what you can do:
- Do not stop, skip, or change your treatment on your own.
- Ask your care team or pharmacy to order your strength; they can check wholesalers and multiple manufacturers.
- The same medicine is also available from Hikma Pharmaceuticals and Slate Run Pharmaceuticals, so your pharmacy may source one of these, though it may not be in local stock.
- If a specific package cannot be found, ask your prescriber or pharmacist about equivalent options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This is general, national information and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 250 mg/20mL (12.5 mg/1 mL) Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufactur...
- 250 mg/20 mL Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Baxter Healthcare 📞 888-229-0001 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02) | Available | — | — | Current |
| Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02) | Available | — | — | Current |
| Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02) | Available | — | — | Current |
Manufacturer: Hainan Poly Pharm. Co., Ltd. 📞 Slate Run Pharmaceuticals, LLC: 844-529-8988 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80) | Available | Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988 | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88) | Unavailable | Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10) | Available | — | — | Current |
| Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10) | Available | — | — | Current |
| Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02) | Available | — | — | Current |
| Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01) | Available | — | — | Current |
| Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10) | Available | — | — | Current |
Full shortage page: Dobutamine Hydrochloride Injection →
View Dobutamine Hydrochloride Injection on the FDA drug-shortage database →
Dopamine Hydrochloride Injection View full page →
Key facts about the Dopamine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Dopamine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Dopamine Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug (2 NDCs)
- Other
Do you take this medicine? What Should I Do?!
Dopamine Hydrochloride Injection is currently on the FDA drug-shortage list, and most of its strengths still have a supply source. Because this is an injectable medicine, it is almost always given in a clinic or hospital, so the care team managing it will track supply closely.
Here is how the strengths break down right now. Most are still available from a manufacturer: 200 mg/5 mL (40 mg/1 mL), 400 mg/10 mL (40 mg/1 mL), 400 mg/250 mL, 80 mg/100 mL, 160 mg/100 mL, and 800 mg/250 mL. Two strengths currently have no available source: 40 mg/1 mL and 800 mg/500 mL (1.6 mg/1 mL).
The FDA lists the reasons as increased demand and manufacturing delays. Two of the three makers on this record are still shipping product, so this affects certain strengths rather than the medicine as a whole. Recovery notes point to later dates for the affected strengths (October 2026 and February 2027 for 40 mg/1 mL, and December 2027 for 800 mg/500 mL).
- Do not stop or change any dose on your own.
- If your strength still has supply, ask your pharmacy or care team to order it—they can check wholesalers and other makers.
- The same medicine is available from other makers in different strengths; your team may be able to source one, though local stock varies.
- If your exact strength cannot be found, ask your prescriber about options, such as a different strength to reach the same dose.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls.
This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 40 mg/1 mL Product temporarily on backorder. Additional lots will be available in the February 2027 t... · Additional lots will be available in the October 2026 timeframe. Product will be made avai...
- 800 mg/500 mL (1.6 mg/1 mL) Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufactur...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Baxter Healthcare 📞 888-229-0001 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02) | Available | — | — | Current |
| Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02) | Available | — | — | Current |
| Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03) | Available | — | — | Current |
| Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03) | Available | — | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25) | Unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug | Current |
| Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25) | Unavailable | Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe. | Demand increase for the drug | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12) | Available | — | — | Current |
| Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24) | Unavailable | Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12) | Available | — | — | Current |
| Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20) | Available | — | — | Current |
| Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01) | Available | — | — | Current |
Full shortage page: Dopamine Hydrochloride Injection →
View Dopamine Hydrochloride Injection on the FDA drug-shortage database →
Morphine Sulfate Injection View full page →
Key facts about the Morphine Sulfate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Morphine Sulfate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Morphine Sulfate Injection shortage page → for the still-marketed options we could find.
- Other (6 NDCs)
- Demand increase for the drug (2 NDCs)
- Discontinuation of the manufacture of the drug
Do you take this medicine? What Should I Do?!
Morphine Sulfate Injection is currently on the FDA drug-shortage list. This report covers 16 strengths, and 14 of them still have a source, so the specific strength you use may not be affected.
Only two strengths currently have no available source: the 5 mg/1 mL vial and the 10 mg/1 mL Syringes. Many others remain available, including 2 mg/1 mL, 10 mg/1 mL, 4 mg/1 mL, 1 mg/1 mL, 25 mg/1 mL, 50 mg/1 mL, and the larger 200 mg/20 mL and 500 mg/20 mL solutions, among others.
The reported reasons include higher demand, manufacturing issues, and one product being discontinued. All five listed manufacturers are still reporting some available supply, and several note additional lots are planned through late 2026. Note that the 10 mg/1 mL Syringes are being discontinued, so that supply gap may be lasting.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
- The same medicine is made by several companies on this record, so your pharmacy may be able to source another maker's version, though it may not be in local stock.
- If your exact strength is discontinued or cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Morphine Sulfate — MORPHINE SULFATE 4 mg/mL
- Morphine Sulfate — MORPHINE SULFATE 10 mg/mL
- Morphine Sulfate — MORPHINE SULFATE 2 mg/mL
- Morphine Sulfate — MORPHINE SULFATE 4 mg/mL
- Morphine Sulfate — MORPHINE SULFATE 8 mg/mL
- Morphine Sulfate — MORPHINE SULFATE 4 mg/mL
- Morphine Sulfate — MORPHINE SULFATE 8 mg/mL
- Morphine Sulfate — MORPHINE SULFATE 10 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 5 mg/1 mL Estimated recovery: TBD
- 10 mg/1 mL Syringes Discontinuation of the manufacture of the drug
- 2 mg/1 mL Next release September 2026. Check wholesalers for inventory. · Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026;...
- 10 mg/1 mL Additional lots are scheduled to be manufactured. Product will be made available as it is... · Additional lots will be available in the October 2026 timeframe. Product will be made avai... · Check wholesalers for inventory
- .5 mg/1 mL Additional lots are scheduled to be manufactured. Product will be made available as it is...
- 4 mg/1 mL Next release September 2026. Check wholesalers for inventory. · Next release October 2026. Check wholesalers for inventory. · Additional lots are scheduled to be manufactured. Product will be made available as it is...
- 50 mg/1 mL Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Ma...
- 1 mg/1 mL Additional lots are scheduled to be manufactured. Product will be made available as it is...
- 25 mg/1 mL Additional lots are scheduled to be manufactured. Product will be made available as it is...
- 8 mg/1 mL Additional lots are scheduled to be manufactured. Product will be made available as it is...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amphastar Pharmaceuticals, Inc. 📞 800-423-4136 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1) | Available | — | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01) | Available | Check wholesalers for inventory | — | Current |
| Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Other | Current |
| Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 7 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25) | Unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug | Current |
| Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12) | Available | — | — | Current |
| Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01) | Available | — | — | Current |
| Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01) | Available | — | — | Current |
| Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01) | Available | — | — | Current |
| Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12) | Available | — | — | Current |
| Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23) | Limited Availability | Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20) | Unavailable | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Manufacturer: Piramal Critical Care Inc. 📞 800-414-1901 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02) | Available | — | — | Current |
| Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02) | Available | — | — | Current |
Full shortage page: Morphine Sulfate Injection →
View Morphine Sulfate Injection on the FDA drug-shortage database →
Hydromorphone Hydrochloride Injection View full page →
Key facts about the Hydromorphone Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Hydromorphone Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Hydromorphone Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Other (11 NDCs)
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Hydromorphone Hydrochloride Injection is currently on the FDA shortage list. I want to walk you through what this means so you can find the strength you use and know your next steps.
Most strengths still have an available source. These include the 10 mg/1 mL, 500 mg/50 mL (10 mg/mL), 2 mg/1 mL, 4 mg/1 mL, several prefilled syringe forms (1 mg, 2 mg, and 4 mg per 1 mL), the 0.5 mg/0.5 mL NexJect single-dose syringe, and the 50 mg/5 mL. The strengths reported with no available source right now are the 1 mg/1 mL vial, the 0.2 mg/1 mL, and the 0.25 mg/0.5 mL NexJect syringe.
The reported reasons are increased demand and other manufacturing factors. This has been an ongoing situation for over a year, but all four manufacturers on this record still report some supply, and some products list restock dates ranging from late 2026 into early 2027.
Here are your next steps:
- Do not stop, skip, or change your dose on your own.
- If your strength still shows supply, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
- The same medicine may be available from another maker; your pharmacy can try to source one, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as a different strength or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Hydromorphone Hydrochloride — HYDROMORPHONE HYDROCHLORIDE 1 mg/mL
- Hydromorphone Hydrochloride — HYDROMORPHONE HYDROCHLORIDE 2 mg/mL
- Hydromorphone Hydrochloride — HYDROMORPHONE HYDROCHLORIDE 1 mg/mL
- Hydromorphone Hydrochloride — HYDROMORPHONE HYDROCHLORIDE .5 mg/.5mL
- Hydromorphone Hydrochloride — HYDROMORPHONE HYDROCHLORIDE .2 mg/mL
- Dilaudid — HYDROMORPHONE HYDROCHLORIDE 1 mg/mL
- Dilaudid — HYDROMORPHONE HYDROCHLORIDE 2 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1 mg/1 mL Next release September 2026. Check wholesalers for inventory. · Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Ma... · Next release October 2026. Check wholesalers for inventory.
- .2 mg/1 mL Next release November 2026. Check wholesalers for inventory.
- 0.25 mg/ 0.5 mL NexJect™ Singl... Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufactur...
- 10 mg/1 mL Check wholesaler for inventory · Check wholesalers for inventory · Estimated recovery: TBD
- 2 mg/1 mL Next release not available at this time. Check wholesalers for inventory. · Next release September 2026. Check wholesalers for inventory. · Additional lots are scheduled for manufacturing to meet demand. Product will be made avail... · Product temporarily on backorder. Additional lots will be available in the September 2026... · Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Sho...
- 4 mg/1 mL Check wholesalers for inventory
- 0.5 mg/0.5 mL NexJect™ Single-... Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 10 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11) | Unavailable | Next release November 2026. Check wholesalers for inventory. | Other | Current |
| Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Other | Current |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50) | Available | Check wholesalers for inventory | — | Current |
| Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Other | Current |
| Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10) | Available | Check wholesalers for inventory | — | Current |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10) | Available | Check wholesalers for inventory | — | Current |
| Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11) | Unavailable | Next release not available at this time. Check wholesalers for inventory. | Other | Current |
| Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15) | Available | Check wholesaler for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01) | Unavailable | Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe. | Demand increase for the drug | Current |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25) | Available | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 11 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01) | Unavailable | Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01) | Available | — | — | Current |
| Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05) | Available | — | — | Current |
| Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01) | Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026 | Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36) | Limited Availability | Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10) | Available | — | — | Current |
| Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31) | Available | — | — | Current |
| Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37) | Unavailable | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30) | Available | — | — | Current |
| Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31) | Available | — | — | Current |
| Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50) | Available | — | — | Current |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01) | Available | — | — | Current |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03) | Available | — | — | Current |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03) | Limited Availability | Estimated recovery: TBD | Other | Current |
Full shortage page: Hydromorphone Hydrochloride Injection →
View Hydromorphone Hydrochloride Injection on the FDA drug-shortage database →
Sodium Bicarbonate Injection View full page →
Key facts about the Sodium Bicarbonate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Sodium Bicarbonate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Sodium Bicarbonate Injection shortage page → for the still-marketed options we could find.
- Other (3 NDCs)
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Sodium Bicarbonate Injection is currently on the FDA drug-shortage list. This is a national, manufacturer-reported status, so it may not match what your local pharmacy actually has on hand.
Most strengths still have an available source. The 84 mg/1 mL (0.5 mEq/mL) and 42 mg/1 mL (1 mEq/mL) strengths are reported as available from more than one maker. The one strength with no current source is the 75 mg/1 mL, which one manufacturer has marked as discontinued — meaning that particular product may not return.
The reported reasons are a mix of higher demand and some manufacturers ending production of certain items. Even so, all five manufacturers on this record still report supply for at least some strengths, and a couple list future delivery and recovery dates. This shortage has lasted more than a year, so patience may be needed.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own. For an injectable medicine like this, your care team manages supply directly.
- If you use the 84 mg or 42 mg strength, your pharmacy can check wholesalers and other makers to order it.
- The same medicine is made by several other companies; your pharmacy may be able to source one, though it may not be in local stock.
- If your exact strength is unavailable or discontinued, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Sodium Bicarbonate — SODIUM BICARBONATE 84 mg/mL
- Sodium Bicarbonate — SODIUM BICARBONATE 84 mg/mL
- Sodium Bicarbonate — SODIUM BICARBONATE 84 mg/mL
- Sodium Bicarbonate — SODIUM BICARBONATE 84 mg/mL
- Sodium Bicarbonate — SODIUM BICARBONATE 84 mg/mL
- Sodium Bicarbonate — SODIUM BICARBONATE 84 mg/mL
- Sodium Bicarbonate — SODIUM BICARBONATE 84 mg/mL
- Sodium Bicarbonate — SODIUM BICARBONATE 84 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 75 mg/1 mL Discontinuation of the manufacture of the drug
- 84 mg/1 mL Check wholesalers for inventory · Discontinuation of the manufacture of the drug · Available on allocation
- 0.5 mEq/mL) Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manuf... · Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage p...
- 42 mg/1 mL Discontinuation of the manufacture of the drug · Check wholesalers for inventory.
- 1 mEq/mL) Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Ma...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amphastar Pharmaceuticals, Inc. 📞 800-423-4136 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1) | Limited Availability | Available on allocation | Demand increase for the drug | Current |
Manufacturer: Exela Pharma Sciences, LLC 📞 828-758-5474 ext. 154 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4) | Available | — | — | Current |
| Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4) | Available | — | — | Current |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5) | Available | — | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05) | Available | Check wholesalers for inventory. | — | Current |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02) | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35) | Unavailable | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14) | Available | — | — | Current |
| Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01) | Unavailable | Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14) | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Long Grove Pharmaceuticals LLC 📞 833-268-5559 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3) | Available | — | — | Current |
Full shortage page: Sodium Bicarbonate Injection →
View Sodium Bicarbonate Injection on the FDA drug-shortage database →
Sodium Acetate Injection View full page →
Key facts about the Sodium Acetate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Sodium Acetate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Sodium Acetate Injection shortage page → for the still-marketed options we could find.
- Other (2 NDCs)
Do you take this medicine? What Should I Do?!
Sodium Acetate Injection is currently on the FDA drug-shortage list, but supply overall remains steady. This product is given through an IV in a clinical setting, so any adjustments are handled by your care team rather than by you at home.
Every strength on this record still has an available source. That includes the 40 mEq/20 mL, 100 mEq/50 mL, 200 mEq/100 mL, and 400 mEq/100 mL (all 2 or 4 mEq/mL versions), as well as the 164 mg/mL and 4 mEq/100 mL products. No strength is completely without a source right now. A few items are tighter than others — the 400 mEq/100 mL is listed as limited with recovery still to be determined, and one 200 mEq/100 mL lot has an estimated recovery of September 2026 — but other makers still supply these sizes.
The FDA lists the reason simply as "Other," and all five manufacturers on this record are still reporting available supply. That is a reassuring sign.
Here is what I suggest:
- Do not skip or change any dose on your own; your care team manages this medicine.
- Ask your pharmacy to order your strength — they can check wholesalers and other manufacturers.
- The same medicine is also made by Amneal (164 mg/mL); your pharmacy may be able to source it, though it may not be in local stock.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 100 mEq/50mL (2 mEq/mL) Additional lots will be available. Product will be made available as it is released.
- 40 mEq/20mL (2 mEq/mL) Additional lots will be available. Product will be made available as it is released.
- 200 mEq/100 mL (2 mEq/mL) Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufactu...
- 400 mEq/100mL (4 mEq/mL) Estimated recovery: TBD
- 4 meq/100 mL Check wholesalers for inventory
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01) | Available | Additional lots will be available. Product will be made available as it is released. | — | Current |
| Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01) | Available | Additional lots will be available. Product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25) | Available | — | — | Current |
| Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25) | Available | — | — | Current |
| Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26) | Available | — | — | Current |
| Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73) | Available | — | — | Current |
| Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05) | Available | — | — | Current |
| Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06) | Limited Availability | Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Manufacturer: Milla Pharmaceuticals 📞 833-251-8463 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10) | Limited Availability | Estimated recovery: TBD | Other | Current |
| Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10) | Available | — | — | Current |
| Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10) | Available | — | — | Current |
| Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10) | Available | — | — | Current |
Manufacturer: Somerset Therapeutics, LLC 📞 732-554-1037 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25) | Available | — | — | Current |
| Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20) | Available | — | — | Current |
Full shortage page: Sodium Acetate Injection →
View Sodium Acetate Injection on the FDA drug-shortage database →
Cefotaxime Sodium Powder, For Solution View full page →
Key facts about the Cefotaxime Sodium Powder, For Solution shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Cefotaxime Sodium Powder, For Solution may not appear here at all, so this is not a picture of every available option. See the full Cefotaxime Sodium Powder, For Solution shortage page → for the still-marketed options we could find.
- Demand increase for the drug (4 NDCs)
Do you take this medicine? What Should I Do?!
Cefotaxime sodium (the powder used to make an injectable solution) is currently on the FDA drug-shortage list. If you or someone you care for uses this medicine, here is what the manufacturer-reported data shows.
The picture depends on which strength you use. The 1 g and 2 g strengths still have an available source through one manufacturer (SteriMax). The 10 g and 500 mg strengths do not have an available source right now. The reason listed is an increase in demand for the drug, and estimated recovery is not yet set. This shortage has continued for over a year, but it involves two manufacturers, and one is still supplying the 1 g and 2 g sizes.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- If you use the 1 g or 2 g strength, ask your pharmacy to order it—they can check wholesalers and other manufacturers, even if it is not on the local shelf today.
- If you use the 10 g or 500 mg strength, ask your prescriber or pharmacist about options, such as using a different strength to make up the dose.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.
This is national data and may not match your local pharmacy's actual stock, so please confirm with your pharmacist.
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 10 g Estimated recovery: TBD
- 500 mg Estimated recovery: TBD
- 1 g Estimated recovery: TBD
- 2 g Estimated recovery: TBD
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
Manufacturer: SteriMax, Inc. 📞 800-881-3550 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02) | Available | — | — | Current |
| Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02) | Available | — | — | Current |
Full shortage page: Cefotaxime Sodium Powder, For Solution →
View Cefotaxime Sodium Powder, For Solution on the FDA drug-shortage database →
Lidocaine Hydrochloride Injection View full page →
Key facts about the Lidocaine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Lidocaine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Lidocaine Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Demand increase for the drug (16 NDCs)
- Other (4 NDCs)
Do you take this medicine? What Should I Do?!
Lidocaine Hydrochloride Injection is currently on the FDA drug-shortage list. This product is given as an injection in clinical settings, so most of the sourcing work happens through your pharmacy or care team, but here is what the national data shows.
Most strengths still have an available source. That includes the common concentrations such as 10 mg/mL, 20 mg/mL, the 1% and 2% plastic-container bags (for example 200 mg/20 mL and 400 mg/20 mL), and the dextrose combinations. Right now, three specific presentations have no available source: the 15 mg/1 mL, and the two "For Cardiac Use Only" ABBOJECT glass syringes (50 mg/5 mL and 100 mg/5 mL). The two ABBOJECT syringes are reported as discontinued by their manufacturer, so that supply gap may be permanent.
The main reason listed is a rise in demand. Encouragingly, 8 of 10 manufacturers still report supply, and several have more lots scheduled, with some releases noted for September and October 2026.
- Do not stop, skip, or change any dose on your own.
- If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other makers.
- The same medicine is available from other manufacturers (such as Hikma, Hospira, Eugia, B. Braun, or Avenacy); your pharmacy may source one, though it may not be in local stock.
- If your exact presentation is discontinued or unavailable, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Lidocaine — LIDOCAINE HYDROCHLORIDE 10 mg/mL
- Lidocaine — LIDOCAINE HYDROCHLORIDE 20 mg/mL
- Lidocaine Hydrochloride — LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL
- Lidocaine Hydrochloride And Dextrose — LIDOCAINE HYDROCHLORIDE 4 mg/mL
- Lidocaine Hydrochloride — LIDOCAINE HYDROCHLORIDE 10 mg/mL
- Lidocaine Hydrochloride — LIDOCAINE HYDROCHLORIDE 10 mg/mL
- Lidocaine Hydrochloride — LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL
- Lidocaine Hydrochloride — LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mL
- Lidocaine Hydrochloride — LIDOCAINE HYDROCHLORIDE 10 mg/mL
- Lidocaine Hydrochloride — LIDOCAINE HYDROCHLORIDE 20 mg/mL
- Xylocaine — LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL
- Xylocaine — LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 15 mg/1 mL Estimated recovery: TBD
- USP (For Cardiac Use Only) 50... Discontinuation of the manufacture of the drug
- USP (For Cardiac Use Only) 10... Discontinuation of the manufacture of the drug
- 10 mg/1 mL Check wholesalers for inventory · Estimated recovery: TBD · Next release October 2026. Check wholesalers for inventory. · On backorder. Recovery: late September 2026. Check wholesalers for inventory · Additional lots are scheduled for manufacturing to meet demand. Product will be made avail... · On backorder. Recovery: TBD. Check wholesalers for inventory
- 20 mg/1 mL Available on allocation · Next release October 2026. Check wholesalers for inventory. · Additional lots are scheduled for manufacturing to meet demand. Product will be made avail... · Estimated recovery: TBD · Check wholesalers for inventory · On backorder. Recovery: October 2026. Check wholesalers for inventory · Additional lots are scheduled to be manufactured. Product will be made available as it is... · Next release September 2026. Check wholesalers for inventory.
- 20 mg/mL Check wholesalers for inventory · On backorder. Recovery: TBD. Check wholesalers for inventory
- 200 mg/20 mL Distributed by Avenacy, LLC
- 10 mg/mL Check wholesalers for inventory · On backorder. Recovery: TBD. Check wholesalers for inventory
- 5 mg/1 mL Estimated recovery: TBD · Check wholesalers for inventory
- 500 mg/50 mL Distributed by Avenacy, LLC
- 20 mg/2 mL Distributed by Avenacy, LLC
- 250 mg/50 mL (0.5%; 5 mg/mL) Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Amphastar Pharmaceuticals, Inc. 📞 800-423-4136 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1) | Limited Availability | Available on allocation | Demand increase for the drug | Current |
Manufacturer: Anthea Pharma 📞 Avenacy, LLC: 877-283-6229 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05) | Available | Distributed by Avenacy, LLC | — | Current |
| Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30) | Available | Distributed by Avenacy, LLC | — | Current |
| Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10) | Available | Distributed by Avenacy, LLC | — | Current |
| Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02) | Available | Distributed by Avenacy, LLC | — | Current |
| Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50) | Available | Distributed by Avenacy, LLC | — | Current |
| Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20) | Available | Distributed by Avenacy, LLC | — | Current |
Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20) | Available | — | — | Current |
| Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10) | Available | — | — | Current |
| Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20) | Available | — | — | Current |
Manufacturer: Baxter Healthcare 📞 888-229-0001 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03) | Available | — | — | Current |
| Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02) | Available | — | — | Current |
Manufacturer: Eugia US LLC 📞 888-238-7880 11 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
| Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05) | Available | Check wholesalers for inventory | — | Current |
| Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
| Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
| Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30) | Available | Check wholesalers for inventory | — | Current |
| Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02) | Available | Check wholesalers for inventory | — | Current |
| Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20) | Available | Check wholesalers for inventory | — | Current |
| Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05) | Unavailable | On backorder. Recovery: October 2026. Check wholesalers for inventory | Demand increase for the drug | Current |
| Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02) | Unavailable | On backorder. Recovery: late September 2026. Check wholesalers for inventory | Demand increase for the drug | Current |
| Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20) | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug | Current |
| Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 20 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27) | Available | Check wholesalers for inventory | — | Current |
| Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
| Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Other | Current |
| Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
| Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
| Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05) | Unavailable | Next release October 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
| Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10) | Available | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
| Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25) | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — | Current |
| Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25) | Available | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
| Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10) | Available | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 18 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32) | Available | — | — | Current |
| Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02) | Available | — | — | Current |
| Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05) | Available | — | — | Current |
| Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02) | Available | — | — | Current |
| Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02) | Available | — | — | Current |
| Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05) | Available | — | — | Current |
| Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01) | Available | — | — | Current |
| Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01) | Available | — | — | Current |
| Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01) | Available | — | — | Current |
| Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05) | Available | — | — | Current |
| Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01) | Available | — | — | Current |
| Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01) | Available | — | — | Current |
| Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02) | Available | — | — | Current |
| Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02) | Available | — | — | Current |
| Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01) | Available | — | — | Current |
| Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)" | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)" | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Huons Co., Ltd. (South Korea) 📞 [email protected] 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2) | Unavailable | Estimated recovery: TBD | Demand increase for the drug | Current |
Manufacturer: Spectra Medical Devices, LLC 📞 978-657-0889 ext. 5231 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1) | Unavailable | Estimated recovery: TBD | Other | Current |
Full shortage page: Lidocaine Hydrochloride Injection →
View Lidocaine Hydrochloride Injection on the FDA drug-shortage database →
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection View full page →
Key facts about the Epinephrine Bitartrate, Lidocaine Hydrochloride Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Epinephrine Bitartrate, Lidocaine Hydrochloride Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Epinephrine Bitartrate, Lidocaine Hydrochloride Injection shortage page → for the still-marketed options we could find.
- Other (9 NDCs)
- Demand increase for the drug (3 NDCs)
Do you take this medicine? What Should I Do?!
Lidocaine with epinephrine injection (also sold under the name Xylocaine) is currently on the FDA shortage list. This is a combination medicine used mainly for numbing during procedures, and both manufacturers who filed this report still have some strengths available.
Several strengths remain in supply, including the 1% (500 mg/50 mL) and 2% (400 mg/20 mL) concentrations, along with several Xylocaine strengths such as the 10 mg/mL products. The strengths reported with no available source right now include the 0.5% (2.5 g/50 mL), the 1% (300 mg/30 mL and 200 mg/20 mL), the 1.5% (75 mg/5 mL), the 2% (400 mg/20 mL at 1:100,000), and a few smaller Xylocaine vials.
The reasons given are increased demand and manufacturing delays. This shortage has lasted more than a year, and some restocking dates run into 2026, with one product noted as far out as 2028. Because this is a professionally administered injection, your care team manages sourcing on your behalf.
What you can do:
- Do not skip or change any planned treatment on your own — talk with your clinician first.
- Ask your pharmacy or provider to check wholesalers, since two manufacturers still list available strengths.
- If your exact strength is unavailable, ask your prescriber about a suitable alternative concentration or product.
Manufacturer contact numbers are listed on this page for reference. This reflects national data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Lidocaine Hydrochloride And Epinephrine — LIDOCAINE HYDROCHLORIDE 10 mg/mL; EPINEPHRINE 10 ug/mL
- Lidocaine Hydrochloride And Epinephrine — LIDOCAINE HYDROCHLORIDE 20 mg/mL; EPINEPHRINE 10 ug/mL
- Lidocaine Hydrochloride And Epinephrine — LIDOCAINE HYDROCHLORIDE 15 mg/mL; EPINEPHRINE 5 ug/mL
- Xylocaine — LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mL; EPINEPHRINE BITARTRATE .01 mg/mL
- Xylocaine — LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL; EPINEPHRINE BITARTRATE .01 mg/mL
- Xylocaine Mpf — LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL
- Xylocaine Mpf — LIDOCAINE HYDROCHLORIDE ANHYDROUS 15 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL
- Xylocaine Mpf — LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL
- Xylocaine — LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL; EPINEPHRINE BITARTRATE .01 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 2.5 g/50 mL (0.5%; 1:200 Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer...
- 300 mg/30 mL (1%; 1:100 Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer...
- 75 mg/5 mL (1.5%; 1:200 Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer...
- 200 mg/20 mL (1%; 1:100 Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer:...
- .005 mg/1 mL; 5 mg/1 mL Next release September 2026. Check wholesalers for inventory.
- 400 mg/20 mL (2%; 1:100 Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufactur...
- .005 mg/1 mL; 15 mg/1 mL Next release September 2026. Check wholesalers for inventory. · Check wholesalers for inventory
- .005 mg/1 mL; 20 mg/1 mL Next release September 2026. Check wholesalers for inventory. · Check wholesalers for inventory
- .005 mg/1 mL; 10 mg/1 mL Check wholesalers for inventory
- 600 mg/30 mL (2%; 1:100 Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage...
- .01 mg/1 mL; 20 mg/1 mL Check wholesalers for inventory
- .01 mg/1 mL; 10 mg/1 mL Check wholesalers for inventory · Next release September 2026. Check wholesalers for inventory.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 12 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17) | Available | Check wholesalers for inventory | Demand increase for the drug | Current |
| Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37) | Available | Check wholesalers for inventory | — | Current |
| Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
| Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Demand increase for the drug | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 10 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03) | Limited Availability | Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01) | Available | — | — | Current |
| Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01) | Unavailable | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02) | Limited Availability | Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03) | Available | — | — | Current |
| Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01) | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01) | Unavailable | Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01) | Available | — | — | Current |
| Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02) | Unavailable | Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01) | Unavailable | Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Full shortage page: Epinephrine Bitartrate, Lidocaine Hydrochloride Injection →
View Epinephrine Bitartrate, Lidocaine Hydroc... on the FDA drug-shortage database →
Atropine Sulfate Injection View full page →
Key facts about the Atropine Sulfate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Atropine Sulfate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Atropine Sulfate Injection shortage page → for the still-marketed options we could find.
- Requirements related to complying with good manufacturing practices (3 NDCs)
- Discontinuation of the manufacture of the drug (2 NDCs)
- Other
Do you take this medicine? What Should I Do?!
Atropine Sulfate Injection is currently on the FDA drug-shortage list. This has been an ongoing situation for over a year, and I want to walk you through where supply stands so you can find the strength you take.
Several strengths still have an available source right now, including 1 mg/10 mL (0.1 mg/mL) syringes, 1 mg/1 mL, 0.1 mg/1 mL, 0.4 mg/1 mL (and .4 mg/1 mL), and 0.25 mg/5 mL (0.05 mg/mL) syringes. A few strengths have no available source at this time: the .05 mg/1 mL, the Adult 0.5 mg/5 mL LifeShield ABBOJECT glass syringe, and the Adult 1 mg/10 mL LifeShield ABBOJECT glass syringe.
The reported reasons include manufacturing and good-manufacturing-practice requirements, and some products being discontinued. Encouragingly, all eight manufacturers on this record still report supply. For products marked as discontinued, that particular supply may be permanent, so a prescriber conversation is the right next step.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own. If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other manufacturers. If your exact strength is discontinued or cannot be found, ask your prescriber or pharmacist about options, such as a different strength to make up the dose or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This is national, manufacturer-reported data and may not match your local pharmacy's stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
- Atropine Sulfate — ATROPINE SULFATE 1 mg/mL
- Atropine Sulfate — ATROPINE SULFATE .05 mg/mL
- Atropine Sulfate — ATROPINE SULFATE .1 mg/mL
- Atropine Sulfate — ATROPINE SULFATE .1 mg/mL
- Atropine Sulfate — ATROPINE SULFATE .1 mg/mL
- Atropine Sulfate — ATROPINE SULFATE .1 mg/mL
- Atropine Sulfate — ATROPINE SULFATE .4 mg/mL
- Atropine Sulfate — ATROPINE SULFATE .4 mg/mL
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- .05 mg/1 mL Discontinuation of the manufacture of the drug
- (Adult) 0.5 mg/5 mL (0.1 mg/mL... Discontinuation of the manufacture of the drug
- (Adult)1 mg/10 mL (0.1 mg/mL)... Discontinuation of the manufacture of the drug
- 1 mg/10 mL (0.1 mg/mL) Syringe... Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer:...
- 1 mg/1 mL Estimated recovery: TBD
- .4 mg/1 mL Check wholesalers for inventory · Estimated recovery: mid-September 2026 · Estimated recovery: TBD
- .1 mg/1 mL Discontinuation of the manufacture of the drug
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875, option 2 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45) | Available | — | — | Current |
| Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03) | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Current |
| Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
| Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08) | Unavailable | Estimated recovery: mid-September 2026 | Requirements related to complying with good manufacturing pr... | Current |
| Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08) | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... | Current |
Manufacturer: American Regent, Inc. 📞 800-645-1706 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25) | Available | — | — | Current |
| Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25) | Available | — | — | Current |
Manufacturer: Amphastar Pharmaceuticals, Inc. 📞 800-423-4136 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1) | Available | — | — | Current |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10) | Available | — | — | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 4 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05) | Available | — | — | Current |
| Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10) | Unavailable | Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
| Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)" | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
| Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)" | — | Discontinuation of the manufacture of the drug | — | To Be Discontinued |
Manufacturer: Medefil, Inc. 📞 630-682-4600 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91) | Available | — | — | Current |
Manufacturer: Somerset Therapeutics, LLC 📞 732-554-1037 3 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10) | Available | — | — | Current |
| Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25) | Available | — | — | Current |
| Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25) | Available | — | — | Current |
Full shortage page: Atropine Sulfate Injection →
View Atropine Sulfate Injection on the FDA drug-shortage database →
Fentanyl Citrate Injection View full page →
Key facts about the Fentanyl Citrate Injection shortage
About these numbers: they describe only the manufacturers reporting this shortage to the FDA — companies that told the FDA they have a supply problem. Other makers of Fentanyl Citrate Injection may not appear here at all, so this is not a picture of every available option. See potential alternatives below or the full Fentanyl Citrate Injection shortage page → for the still-marketed options we could find.
- Other (5 NDCs)
- Demand increase for the drug
Do you take this medicine? What Should I Do?!
Fentanyl Citrate Injection is currently on the FDA drug-shortage list. Because this is an injectable medicine given in clinics and hospitals, this note is mostly for your awareness — the care team that gives it to you will handle sourcing.
The reassuring detail here is that every listed strength still has an available source. All 8 strengths — including 50 mcg/1 mL (.05 mg/1 mL), 100 mcg/2 mL, 250 mcg/5 mL, 500 mcg/10 mL, 1000 mcg/20 mL, and 2500 mcg/50 mL — have at least one manufacturer reporting supply. Some individual product lots are marked unavailable, but no strength is completely out of stock, and all three manufacturers on this record are still supplying.
The reported reasons are increased demand and other manufacturing factors. A few specific presentations have future release dates noted (around September 2026, and one line with recovery estimated December 2026), but other supply remains available now. The overall supply risk is rated low.
- Do not stop, skip, or change your medicine on your own.
- Ask your pharmacy or care team to order your strength — they can check wholesalers and other makers.
- The same medicine is also made by Hospira, Hikma, Fresenius Kabi, Civica, and Phlow; your pharmacy may be able to source one of these, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls. This is national, manufacturer-reported data and may not match local stock.
From our NDC records, these are still-marketed products of the same medicine (same active ingredient, dosage form & route). They may not be in stock at your pharmacy, and only your prescriber or pharmacist can decide what's right for you:
General information from national, manufacturer-reported FDA data — not your local pharmacy's stock, and not medical advice. Please don't stop or change a medicine on your own; talk to your pharmacist or prescriber.
- 1000 mcg/20 mL (50 ug/1 mL) Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026;...
- 50 ug/1 mL Inventory available in vial presentations. · Check wholesalers for inventory
- 50 mcg/1 mL Additional lots will be available September 2026 timeframe. Product will be made available... · Additional lots will be scheduled for manufacturing to meet demand. Product will be made a...
- .05 mg/1 mL Check wholesalers for inventory · Next release September 2026. Check wholesalers for inventory.
A rule-based estimate of national supply risk — not your local pharmacy's stock, and alternatives may not be interchangeable. Medicaid use (CMS SDUD, available through 2025) is a proxy for how widely a drug is used — Medicaid patients only, not the whole U.S. Reference only — not medical advice.
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 6 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05) | Available | Check wholesalers for inventory | — | Current |
| Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50) | Available | Check wholesalers for inventory | — | Current |
| Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11) | Available | Check wholesalers for inventory | — | Current |
| Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01) | Available | Check wholesalers for inventory | — | Current |
| Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02) | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other | Current |
| Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20) | Available | Check wholesalers for inventory | — | Current |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 8 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25) | Available | Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
| Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05) | Unavailable | Inventory available in vial presentations. | Other | Current |
| Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10) | Unavailable | Inventory available in vial presentations. | Other | Current |
| Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01) | Available | Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
| Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25) | Available | Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
| Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25) | Available | Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. | — | Current |
| Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25) | Unavailable | Additional lots will be available September 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug | Current |
| Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10) | Unavailable | Inventory available in vial presentations. | Other | Current |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 5 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28) | Available | — | — | Current |
| Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61) | Available | — | — | Current |
| Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22) | Available | — | — | Current |
| Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25) | Available | — | — | Current |
| Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31) | Limited Availability | Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other | Current |
Full shortage page: Fentanyl Citrate Injection →
View Fentanyl Citrate Injection on the FDA drug-shortage database →
Peginterferon Alfa-2A Injection View full page →
Manufacturer: pharmaand GmbH (pharma&) 📞 800-506-8501, email: [email protected] 2 NDCS click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4) | — | — | — | Resolved |
| Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1) | — | — | — | Resolved |
Full shortage page: Peginterferon Alfa-2A Injection →
View Peginterferon Alfa-2A Injection on the FDA drug-shortage database →
Albuterol Sulfate Solution View full page →
Manufacturer: Nephron Pharmaceuticals Corporation 📞 800-443-4313 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30) | — | — | — | Resolved |
Manufacturer: Rising Pharma Holdings, Inc. 📞 201-961-9000 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03) | — | — | — | Resolved |
Manufacturer: Ritedose Pharmaceuticals, LLC 📞 803-806-3300 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01) | — | — | — | Resolved |
Full shortage page: Albuterol Sulfate Solution →
View Albuterol Sulfate Solution on the FDA drug-shortage database →
Triamcinolone Acetonide Injection View full page →
Manufacturer: Harrow Eye, LLC 📞 (615) 733-4734 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01) | — | — | — | Resolved |
Full shortage page: Triamcinolone Acetonide Injection →
View Triamcinolone Acetonide Injection on the FDA drug-shortage database →
Rifapentine Tablet, Film Coated View full page →
Manufacturer: Sanofi-Aventis U.S. LLC 📞 800-633-1610 Option 7 1 NDC click to expand
| NDC / product | Availability | Related information | Reason | Status |
|---|---|---|---|---|
| Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24) | — | — | — | Resolved |
Full shortage page: Rifapentine Tablet, Film Coated →
View Rifapentine Tablet, Film Coated on the FDA drug-shortage database →
No drugs match the current filter.
A transparent, rule-based rating. We check 5 things: (1) can every strength or pack size still be sourced, (2) is more than one manufacturer still supplying, (3) how many NDCs are unavailable, (4) how long it’s lasted (we count a shortage as long-running once it passes about 3 months, one calendar quarter), and (5) how widely it’s made, plus Medicaid demand where available. The level is the number of those checks that are currently a risk factor, shown as a tier: 1-2 = Low, 3 = Medium, 4-5 = High. One exception: a complete outage — no affected strength or pack size can be sourced and only one manufacturer remains — always rates 5 of 5, even when the shortage is new. It’s a national signal, not your local pharmacy’s stock; alternatives may not be clinically interchangeable.
What FDA’s shortage terms meanstatuses & the reasons you’ll see
Status & availability
- Currently in shortage
- Demand (or projected demand) for the drug in the U.S. exceeds supply.
- Resolved
- FDA determined supply is no longer exceeded by demand. Kept here for history.
- To be discontinued
- The manufacturer has notified FDA it will permanently stop making this product (a section 506C discontinuation notice). Informational only.
- Available
- The manufacturer’s most current report that a product is in supply — not an FDA determination that the shortage is resolved.
Reason for shortage
Under section 506E of the FD&C Act, a shortage may be attributed to:
- Requirements related to complying with good manufacturing practices
- Regulatory delay
- Shortage of an active ingredient
- Shortage of an inactive ingredient component
- Discontinuation of the manufacture of the drug
- Delay in shipping of the drug
- Demand increase for the drug
- Other — the manufacturer’s reason doesn’t fit a category above
Therapeutic category describes where a drug is commonly used (e.g. Pediatrics); it does not reflect FDA-approved status. All product, availability and reason details are provided by the manufacturer (via FDA) and can change daily.
Drug shortage FAQs
What does it mean when a drug is “in shortage”?
Why do drug shortages happen?
A medicine I take is on the list. What should I do?
Does “in shortage” mean my pharmacy is out of it?
What does “to be discontinued” mean?
What is the Supply-Risk rating on each drug?
What does the Medicaid use figure represent?
How often is this page updated?
Where does the data come from?
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates, grouped by FDA active ingredient then manufacturer. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data (SDUD) (per 100k uses 2023 U.S. Census population). Utilization shown is Medicaid only (CMS State Drug Utilization Data). It has reporting gaps and under-represents drugs used mainly outside Medicaid — treat it as a relative signal, not total U.S. use. Reference only — confirm current status with the manufacturer or FDA before acting on it.